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Abstract 
HIV-1 in the United Kingdom: population dynamics and genetic evolution 
Background: Phylogenetic characterisation of local HIV-1 epidemics can be used 
to understand emerging transmission networks. We analysed subtype-unassigned 
sequences in the UK HIV Drug Resistance Database (UK HIV DRD) to map the 
emergence and origin of genetically diverse recombinant strains using phylogenetic 
analyses, near full-length sequencing of plasma HIV-1 and CD4 cell count decline. 
Methods: 55,556 genotyped pol sequences (protease amino acids 1-99, RT amino 
acids 1-234) were analysed for evidence of recombination. Near full-length single 
genome sequencing of plasma HIV-1 was performed on stored specimens from six 
patients with a putative A1/D novel recombinant strain. Recombination and 
phylogenetic analyses were performed using RIP, PhyML, jpHMM, Simplot, 
SCUEAL and FastTree v2.3.1. Evolutionary analysis of putative novel recombinants 
was performed using Bayesian Evolutionary Analysis by Sampling Trees (BEAST). 
Geographic screening for additional instances of recombinant structures was 
performed using HIV BLAST and the Los Alamos National HIV database. 
Demographic data were available for 50/72 patients. CD4 cell count decline was 
assessed using linear regression. 
Results: The proportion of subtype-unassigned HIV-1 strains in the UK HIV DRD 
increased significantly during 1999-2008 (p=<0.01). 2,030 putative B-recombinant 
sequences were analysed for evidence of transmission of novel recombinant 
strains; 15 novel recombinant clusters comprising 94 individuals were identified. The 
proportion of intravenous drug users (IVDU), males and people of white ethnicity 
was significantly higher among novel recombinant clusters than among people 
infected with pure subtypes and recognised CRFs. Geographic screening showed 
co-circulation of novel strains in seven countries over three continents and import 
and export of novel strains from the UK was identified.  
Near full-length sequencing of six plasma specimens showed five patients sharing 
an identical A1/D strain; this was registered as CRF50_A1D and 67 further 
instances in the UK HIV DRD were identified. Geographic analysis showed close 
relation of component subtype A1 and D regions to East African strains; 
monophyletic clustering indicated a single introduction of this variant into the UK. 
Time scaled analysis showed a time to most recent common ancestor of 
approximately 1992. Demographic data showed the earliest CRF50 transmissions 
were confined to men who have sex with men (MSM), with subsequent 
transmissions to heterosexuals and IVDUs.  Analysis of the sixth, complex, 
sequence demonstrated onward recombination of CRF50 with a subtype B strain 
(median divergence year 2000). CD4 cell count analysis suggested infections with 
CRF50 progressed in a similar manner to subtype B infections. 
Conclusions: Significant increasing genetic diversity of HIV-1 in the UK is linked to 
both UK and international transmissions among multiple exposure routes. These 
findings highlight the changing dynamics of HIV transmission in the UK and the 
converging of the two previously distinct MSM and heterosexual epidemics.    
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Chapter 1: Introduction 
1.1 The HIV virus and how it causes infection 
Human Immunodeficiency Virus (HIV), a lentivirus from the Retroviridae family, is a 
diploid, positive sense, single stranded RNA virus (Baltimore classification VI) 
(Baltimore, 1971; Jetzt et al., 2000). HIV is divided into two types: HIV-1 and HIV-2. 
Of these, HIV-1 is more widespread globally than HIV-2, which is mainly found in 
West Africa, and causes a less severe disease (Marlink et al., 1994). HIV-1 is 
further subdivided into four groups: M, N, O and P (Keele et al., 2006; Plantier et al., 
2009; Sharp et al., 2005).  This review and the following investigation is primarily 
concerned with HIV-1 group M viruses, although other virus types within HIV are 
occasionally relevant and mentioned. 
The RNA genome of HIV consists of 9749 nucleotides and comprises three 
structural genes – gag, pol and env – and several non-structural genes including tat, 
rev, nef, vpr and vpu (vpx in HIV-2). Of the structural genes, gag codes for the gag 
polyprotein which is involved in viral encapsidation, assembly and budding of viral 
particles, and the organisation of the envelope protein on the virion surface 
(reviewed in Hill et al., 1996). The pol, or polymerase, gene codes for the viral 
enzymes reverse transcriptase (RT), RNase H, integrase and protease; the env 
gene codes for the precursor protein gp160 which undergoes cleavage into two 
proteins which are active in viral entry: gp120, which binds to the CD4 receptor, and 
gp41, which is the fusion fragment (Allan et al., 1985; Frey et al., 2010).  
Of the non-structural genes, vif enhances the infectivity of viral particles and is 
essential for productive HIV-1 infection of natural target cells, and vpu is active in 
viral release (Gupta et al., 2009; Hinz et al., 2010; Wieland et al., 1997). Tat and rev 
are accessory genes which are unique to lentiviruses and are believed to be 
responsible for these viruses’ ability to maintain a chronic persistent infection even 
in the presence of a pronounced host immune response (Ranki et al., 1994). Nef 
plays a role in virus infectivity. The long terminal repeat regions (LTR) located at 
each end of the genome have regulatory functions (Kent et al., 2001). 
Entry of HIV-1 into target cells is mediated through binding of the gp120 envelope 
glycoprotein to the CD4 receptor and a chemokine co-receptor, which is commonly 
CCR5 on macrophages and a subset of memory CD4 T-cells, and CXCR4 on many 
cell types including CD4 T-cells and macrophages (Esté and Telenti, 2007). 
Sequential binding of the gp120 to the CD4 receptor and co-receptor (CCR5 or 
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CXCR4) induces conformational changes which trigger the dissociation of gp120 
and a refolding of the gp41 protein (Frey et al., 2010; Harrison, 2008). This 
irreversible refolding of gp41 triggers the fusion of viral and target cell membranes 
(Frey et al., 2010).  
Following fusion, the viral core enters the cytoplasm and the viral RNA (vRNA) acts 
as the template for double stranded proviral DNA synthesis by the virus-encoded 
reverse transcriptase (RT) enzyme. The DNA migrates to the nucleus, where the 
viral integrase mediates integration into the host cell genome. The initial 
transcription and translation of mRNA and proteins within activated cells is then 
governed by host cell functions (Hinz et al., 2010).  
The process of viral entry, expression, assembly and budding can be disrupted by a 
number of host restriction factors, notably the apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 3 (APOBEC3) family of proteins that delaminate 
C to U residues during transcription; tripartite motif 5 alpha (TRIM5α), which 
interferes with viral uncoating and blocks reverse transcription and subsequent 
transport to the nucleus, and tetherin, an antiviral protein which blocks virus release 
(Gupta and Towers, 2009; Huthoff et al., 2009; Jern et al., 2009; McNatt et al., 
2009; Perez-Caballero et al., 2005; Sauter et al., 2009; Stremlau et al., 2005). 
These selected restriction factors highlight the complexity of host-virus interactions 
in HIV infections, however, many other such factors exist that govern this process in 
individuals. 
Individual host genetics also affect how readily HIV can cause and prolong infection, 
particularly Human Leukocyte Antigen (HLA). Individuals with HLA type B-27 or B-
57 tend to have infections that progress more slowly than individuals with different 
HLA profiles. An association has been described between protective HLA alleles 
and lower viral replication capacities, suggesting that the targeting of HLA 
responses at functionally important epitopes in gag results in escape variants that 
have undergone a fitness cost (Wright et al., 2010). The TL9 epitope in gag (p24) is 
an immunodominant epitope which is restricted by HLA B-7 supertype alleles, of 
which HLA type B*81:01 appears to exert the greatest selective pressure on the 
virus, at least in the first 18 months post-infection (Ntale et al., 2012). Other host 
genetic factors that can act to restrict HIV-1 are CCR5 deletions and KIR receptors 
(Mothe et al., 2009).  
Finally, the HIV-1 infection and replication process can also be disrupted by 
antiretroviral agents, of which the main classes are: reverse transcriptase inhibitors 
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(nucleos(t)ide reverse transcriptase inhibitors (NRTI) and non-nucleoside reverse 
transcriptase inhibitors (NNRTI)), which prevent synthesis of double stranded viral 
DNA; protease inhibitors (PI), which prevent the cleavage of protein precursors; 
entry inhibitors, which target the ‘prehairpin intermediate’ conformation of gp41; 
integrase inhibitors, which block the integration of linear viral cDNA, and  CCR5 
antagonists which inhibit viral binding to CCR5-expressing cells (Buzón et al., 2010; 
Esté and Telenti, 2007; Frey et al., 2010; Harrison, 2008). The widespread use of 
highly active antiretroviral therapy (HAART) in the treatment of HIV-1 has led to the 
emergence of antiretroviral resistance to classes of antiretroviral agents (Tang and 
Pillay, 2004), which has had consequences for both individuals and populations. 
1.2 In-host viral diversity in HIV infections 
Transmission of HIV-1 usually results from virus exposure at mucosal surfaces 
followed by viral replication in submucosal and loco-regional lymphoid tissues 
subsequent to overt systemic infection (Salazar-Gonzalez et al., 2009). In its early 
phase after transmission, an HIV-1 infection is characterised by extreme levels of 
viral replication and a high peak viraemia, coupled with massive depletion of CD4 T-
cells in the gastrointestinal tract. As the infection moves from the acute into chronic 
phase, viraemia is lowered by 2-4 logs, which is accompanied by progressive loss 
of CD4 cells and eventual progression to AIDS (reviewed in (Fischer et al., 2012)).  
Both humoral and cell-mediated immune responses are mounted to HIV-1 infection; 
however, these are eventually evaded by HIV-1 replication and adaptation to the 
host environment (Jost and Altfeld, 2012; Lemey et al., 2007; Wei et al., 2003). The 
lowering of viraemia by 2-4 logs during the move from the acute to the chronic stage 
of infection is primarily due to host immune responses such as the production of 
neutralising antibodies and the cytotoxic T cell response (Karlsson et al., 2007; Wei 
et al., 2003). Wei noted that the viral inhibitory activity of neutralising antibodies in 
early HIV-1 infection resulted in a complete replacement of neutralising antibody-
sensitive virus with populations of neutralising antibody-resistant virus (2003).  
Although neutralising antibodies impose a strong selective pressure on the env 
gene of HIV-1, they do not control viral replication; partial control of HIV-1 replication 
(and therefore a lowering of HIV-1 viral load) is associated with the appearance of 
HIV-1-specific cytotoxic T cell responses (Koup et al., 1994; Lemey et al., 2007). 
Natural killer cells expressing the KIR3DS1 receptor can also inhibit HIV-1 replication 
in vitro; however, HIV-1 accessory proteins seem to have evolved in particular to 
counteract NK cell responses (reviewed in Jost and Altfeld, 2012). The various host 
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immune responses to HIV-1 infection mean that during the nonsymptomatic phase 
preceding progression to AIDS, there is great variation in the level of circulating 
virus in the plasma (Fellay et al., 2007). 
Viral population fluctuations are recurrent in HIV-1 natural infections, and they have 
important consequences for viral evolution (Lorenzo-Redondo et al., 2011). When 
only one variant establishes productive infection (the founder virus), this produces a 
population bottleneck. During the massive population expansion that subsequently 
occurs, a swarm of mutants is generated. This swarm has been described as 
comprising a viral quasispecies, a concept first introduced by Eigen and Schuster in 
1979 (Eigen and Schuster, 1979; Lauring and Andino, 2010; Lorenzo-Redondo et 
al., 2011); however, it should be acknowledged that this definition is not universally 
accepted, and that observation of intra-patient genetic variation is not necessarily 
sufficient evidence to demonstrate quasispecies behaviour (reviewed in Holmes, 
2010).  
The extreme levels of genetic diversity displayed in HIV infections are in keeping 
with other lentiviruses (Artenstein et al., 1995; Buonaguro et al., 2007; Geretti, 2006; 
Jetzt et al., 2000; Keele and Derdeyn, 2009; Robertson et al., 1995; Shriner et al., 
2004; Vessière et al., 2010). This in-host viral diversity is due to: a) the error-prone 
nature of the RT enzyme, which lacks proofreading ability; this leads to point 
mutations, insertions and deletions in progeny genomes, with an estimated error 
rate of ~3x10-5 per nucleotide base per cycle of replication; b) high rates of 
replication, with ~1010 virus particles produced daily; c) the mutagenic activity of 
APOBEC3 and other host factors; d) a high tendency to genetic recombination due 
to the ability of RT to switch templates during reverse transcription; e) immune 
pressure; f) repair mechanisms (Allen et al., 2000; Archer et al., 2008; Huthoff et al., 
2009; Jetzt et al., 2000; Karlsson et al., 2007; Lemey et al., 2007; Salazar-Gonzalez 
et al., 2009).  
a) The error prone nature of the RT enzyme 
The error-prone nature of the HIV-1 RT enzyme has been described several times; 
in addition, there are also several other sources of retroelement mutation: RNA 
polymerase II errors, RNA editing, and spontaneous decay of RNA or DNA 
(Bebenek et al., 1989; Holland et al., 1991; Preston et al., 1988; reviewed in Preston 
and Dougherty, 1996). Since then, Lauring and Andino proposed that the intrinsic 
error rate of the viral replicase determines the mutation rate for the virus and 
therefore the range of genetic variation on which natural selection can act (2010). Of 
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the errors that occur in progeny genomes, G-to-A mutations (not APOBEC-
mediated) are the most common RT-mediated error (Jern et al., 2009).  
b) High rates of viral replication 
HIV-1 has highly productive replication in vivo, with, on average, a turnover of half of 
the plasma virions every two days (Ho et al., 1995) and a mean replication rate of 
0.68+/- 0.13x109 virions per day. Nearly the entirety of the circulating plasma virus 
comes from recently infected cells (Ho et al., 1995). 
c) Mutagenic activity of host factors 
In vivo viral evolution can also be mediated by host factors. APOBEC proteins can 
induce lethal mutagenesis of HIV through widespread deamination of the HIV 
genome during reverse transcription (Jern et al., 2009; Lauring and Andino, 2010). 
The fact that HIV replicates close to the error threshold makes it particularly 
sensitive to slight increases in mutational load (Lauring and Andino, 2010); 
however, it should be noted that this may be solely a function of the high replication 
rates of HIV-1, rather than HIV-1 replicating closer to the error threshold than other 
organisms.   
Low levels of APOBEC3-mediated mutagenesis have also affected long-term, inter-
host HIV-1 evolution, leading to enhanced rates of variation at sites (Jern et al., 
2009). 
d) Genetic recombination due to RT template switching 
Genetic recombination is a source of viral diversity for many RNA viruses (Beemon 
et al., 1974; Coffin, 1979; Hu and Temin, 1990). As a retrovirus, HIV contains two 
copies of its RNA genome in each virion (Hu and Temin, 1990). Viral diversity in 
RNA viruses as a result of homologous recombination as opposed to reassortment 
of genome segments has been described since the early 1970s (Beemon et al., 
1974), however, the precise method of retroviral recombination was initially 
unknown. The two main theories concerning mechanisms of retroviral 
recombination were the copy choice model and the strand displacement model 
(Coffin, 1979; Skalka et al., 1982). The copy choice model proposed that only one 
provirus would result from each cellular infection event, whilst the strand 
displacement model postulated that two copies of DNA would be produced from 
each virion, and that recombination would occur during plus-strand DNA synthesis 
due to displacement of DNA and assimilation into the DNA synthesised by the 
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second template (Coffin, 1979; Junghans et al., 1982). Hu and Temin showed in 
1990 that single recombinant proviruses were the progeny of heterozygous virions, 
supporting the copy choice model. 
The copy-choice model originally proposed that the RT enzyme switched templates 
when it encountered breaks in RNA, however this was broadened to include 
recombination occurring during minus-strand DNA synthesis without the 
requirement of breaks in viral RNA. The low processivity of RT causes the enzyme 
to dissociate from the template, allowing the short DNA-RNA hybrid to be disrupted 
so that the growing DNA strand is displaced to the other RNA template (Huber et 
al., 1989; Jetzt et al., 2000). 
The estimated mean rate of HIV-1 recombination in vivo is 1.38 x 10-4 recombination 
events/adjacent sites/generation, which is 5.5 fold greater than the reported point 
mutation rate of 2.5x10-5/site/generation (Shriner et al., 2004). This recombination 
between RNA strands mainly occurs during minus-strand DNA synthesis (Jetzt et 
al., 2000; Zhuang et al., 2002). Unlike other aspects of HIV-1 replication, 
recombination is not error-prone (Zhang and Temin, 1994), and the combination of 
polymorphisms into a new genome in a single round of replication enables viruses 
to rapidly access a greater sequence space than is possible by the stepwise 
accumulation of point mutations (Simon-Loriere et al., 2010). The net effect of this is 
to facilitate the combination of advantageous mutations within highly fit genomes 
and the removal of deleterious mutations from the viral population (Galli et al., 2010; 
Simon-Loriere et al., 2010). The effect of recombination on viral evolution within an 
HIV-1 infected individual is of the same order of magnitude as point mutational 
change and is therefore a major evolutionary force (Shriner et al., 2004); however, it 
is important to note that, unlike point mutational change, recombination does not 
necessarily result in increased genetic diversity within an infected individual. 
 e) Immune pressure 
Early cytotoxic T cell responses have been shown to influence genetic variation in 
HIV-1 infections (Allen et al., 2000; Karlsson et al., 2007; Salazar-Gonzalez et al., 
2009). Karlsson found that HIV-1 undergoes a continuous dynamic development of 
cytotoxic T cell responses that was associated with viral escape and increased in-
host viral diversity (2007). Cytotoxic T cell responses tend to target epitopes in the 
viral gag and nef genes (Lemey et al., 2007). HIV-1 is also able to evade 
neutralising antibody responses by accumulating multiple amino acid changes, 
particularly in the hypervariable regions of env (Lemey et al., 2007). 
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 f) Repair mechanisms 
In vitro, HIV-1 has been shown to undergo fitness recovery of debilitated clones 
following multiple large-population passages (Lorenzo-Redondo et al., 2010). 
Following 20 passages of debilitated viral clones, Lorenzo-Redondo observed that 
24 mutations were fixed at passage 11 (with a dominance of synonymous changes), 
but 79 mutations were fixed after passage 21 (with a dominance of non-
synonymous changes), indicating that fitness recovery is a multistage process in 
which non-synonymous mutations are indicative of the influence of selective 
pressures and generate increasing viral heterogeneity (2010).  
HIV-1 also exploits host cellular DNA repair mechanisms, triggering the DNA repair 
machinery of infected cells during the integration process (Smith and Daniel, 2006). 
1.3 HIV recombination and consequences for population-level genetic 
diversity  
A critical feature of recombination as an evolutionary force is that of allowing 
reshuffling of genetic information carried by distantly related viral strains (Simon-
Loriere et al., 2010). The existence of an HIV infection is not protective against 
super- or co-infection with another HIV strain (Artenstein et al., 1995), and it is 
possible for a cell to become infected with two different viruses and for a plus-strand 
RNA from each virus to be packaged into a new virion (Harris et al., 2002; Jetzt et 
al., 2000).  Although the rate of recombination between two partially identical 
molecules is less than that between two identical RNA molecules (Zhang and 
Temin, 1994), recombination between highly divergent viral strains is possible 
(Robertson et al. 1995). Therefore, should the above scenario occur, the strand 
switching activity of the RT can create intra- or intersubtype or inter-group 
recombinants (Harris et al., 2002; Jetzt et al., 2000; Simon-Loriere et al., 2009).  
In order to understand how the ready generation of intra- and inter-subtype 
recombinants effects both the properties that lead to one virus variant 
predominating over others, and overall trends in the HIV-1 epidemic, an 
understanding of the emergence of HIV subtypes and recombinants is essential 
(Balotta et al., 2001; Holguín et al., 2008). 
HIV-1 infections are now accepted to have arisen from at least four separate cross-
species transmissions of Simian Immunodeficiency Virus (SIV) from primates to 
humans: two involving transmission from Pan troglodytes troglodytes (Ptt) of SIV 
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chimpanzee (SIVcpzPtt) in the early 20
th Century, creating HIV groups M and N 
(Keele et al., 2006; Sharp et al., 2005; Vidal et al., 2000), and one, HIV group P, 
from a cross-species transmission involving gorillas (SIVgor) (Plantier et al., 2009); 
although HIV group O was traditionally considered to have arisen following 
transmission of SIVcpz, emerging evidence suggests this group is more closely 
related to SIVgor (D'arc et al., CROI 2014, Abstract 51; Figure 1_1).  The origins of 
HIV groups M and N have been defined using phylogeography, which identified two 
regions in Cameroon that appear to contain the wild Ptt populations infected with 
the source SIV viruses (Keele et al., 2006). Groups O and N have remained largely 
confined to Cameroon and Central Africa, but Group M has not (Lemey et al., 2004). 
Although the precise reasons why HIV-1 group M is solely responsible for the global 
pandemic have not been elucidated, it has been proposed that it is the ability, 
restricted to group M viruses, to use the vpu gene to antagonise the host cellular 
antiviral factor tetherin that has allowed this (Gupta and Towers, 2009). 
 
 
Figure 1_1. HIV origins. Maximum likelihood tree displaying the phylogenetic relationships 
of SIVcpz, HIV-1, and SIVgor strains for a region of the pol gene (HXB2 coordinates 3887–
4778). SIVcpz sequences are shown in black, SIVgor sequences are shown in green, HIV-1 
group M is shown in red, HIV-1 group N in light blue, HIV-1 group O in dark blue and HIV-1 
group P in brown, respectively. Black circles indicate the four branches where cross-species 
transmission-to-humans has occurred; white circles indicate two possible alternative 
branches on which chimpanzee-to-gorilla transmission occurred. The close relationship of 
HIV-1 group O sequences to HIV-1 group P sequences adds weight to recent evidence that 
HIV-1 group O also resulted from a cross-species transmission from gorillas. The scale bar 
shows 0.05 nucleotide substitutions per site. Figure taken from Sharp and Hahn, 2011. 
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From Cameroon, HIV-1 group M (via infected individuals) travelled south to 
Kinshasa in the Democratic Republic of Congo (DRC), where the growth of sub-
Saharan African cities allowed for the rapid expansion of HIV-1 infections and the 
birth of the modern HIV-1 pandemic (Keele et al., 2006; Worobey et al., 2008). 
Worldwide dissemination of the virus was initiated by multiple ‘founder events’, 
whereby individual HIV-1 lineages moved to new regions and established 
epidemics, sometimes recombining in the process, and creating a globally diverse 
epidemic comprised of multiple subtypes and recombinant forms (Pybus and 
Rambaut, 2009). 
HIV-1 group M variants can be subdivided into phylogenetically distinct genetic 
subtypes and recombinant forms (Artenstein et al., 1995; Buonaguro et al., 2007; 
Geretti, 2006; Jetzt et al., 2000; Keele and Derdeyn, 2009; Robertson et al., 2000; 
Vessière et al., 2010). Currently, there are nine "pure" subtypes (A-D, F-H, J and K); 
some subtypes can be further divided into sub-subtypes, for example A1-A5 
(Peeters, 2001; Vidal et al., 2009). The idea of subtypes was originally proposed 
because many sequences of Group M fall into discrete clades that are 
approximately equidistantly related to each other across the entire genome 
(Peeters, 2001). This distance varies both within and between genes: for example, 
whilst gag and pol are relatively conserved, env is less so, with an average distance 
of 10-13% from a common ancestral node; within env itself, the hypervariable 
regions have less than 25% conservation of amino acids (Leitner et al., 1995; 
Simmonds et al., 1990). Importantly, the subtype classification system reflects only 
the order in which strains were classified, rather than the evolutionary history of the 
virus (Vidal et al., 2009). Equally, some subtypes, most notably D and B, are so 
similar that they would be more accurately classified as sub-subtypes of each other; 
that they are not is due to reasons for wishing to preserve the historical link with 
previous literature and classification (Geretti, 2006; Peeters, 2001).   
The mechanisms of viral recombination described earlier have also led to the 
identification of at least 54 circulating recombinant forms (CRFs) of HIV-1, and one 
of HIV-2 (http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html), 
alongside several unique recombinant forms (URFs). When the same inter-subtype 
recombinant is transmitted between multiple individuals (typically at least three 
subjects not immediately epidemiologically related), and therefore has the potential 
to be of epidemiological significance, it is termed a CRF. Members of a CRF should 
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resemble each other over the entire genome and share identical breakpoints 
reflecting common ancestry from the same recombination event (Peeters, 2001; 
Robertson et al., 2000). Unique recombinant forms, or URFs, have a more limited 
distribution, and are found in either fewer individuals or in epidemiologically-linked 
circumstances such as a single household.  
 
Intersubtype recombination may have occurred in approximately 20% of lineages 
evolving over a period of 30 years in early group M sequences from Kinshasa, DRC, 
confirming that intersubtype recombination was a substantial force in generating 
HIV-1 group M diversity (Ward et al., 2013). Since then, CRFs have spread globally 
alongside the pure subtypes of the group M viruses, and in some areas of the world, 
form the predominant variant (Easterbrook et al., 2010; Simon-Loriere et al., 2009; 
Vidal et al., 2009).  
The most widely noted impact of recombination on the genetic diversification of HIV 
is the frequent natural occurrence of inter-subtype recombinants in parts of the 
world where multiple subtypes co-circulate (Simon-Loriere et al., 2009). Dual 
infection was posited to affect the global HIV-1 epidemic as early as 1995, and 
continues to play a major role in the creation of new HIV-1 variants, particularly in 
Africa and other regions that experience high levels of co-circulation (Artenstein et 
al., 1995; Robertson et al., 1995; Vidal et al., 2013). For example, a study 
performed in Cameroon found a dual infection rate of approximately 22% (Vidal et 
al., 2013), and a recent study among men who have sex with men (MSM) in San 
Diego found an intrasubtype B dual infection rate of 14.4% (Wagner et al., 2013); 
these levels of dual infection vastly increase the chances of inter-strain in-host 
recombination, and therefore onward transmission of new strains to the newly 
infected.     
1.4 Distribution of HIV-1 subtypes 
Whilst all group HIV-1 group M subtypes can be found in Central Africa, consistent 
with this area being the source of the pandemic, the remainder of the world has an 
unequal distribution of subtypes (Arnold et al., 1995; Vidal et al., 2000). Globally the 
main variant is subtype C, which predominates in south and east Africa, followed by 
subtype A and CRF02_AG in west and west-central Africa (Easterbrook et al., 
2010). Subtype A is also predominant in central and eastern Africa and in Eastern 
European countries of the former Soviet Union (Buonaguro et al., 2007). 
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In contrast to Africa, infections with subtype B have dominated the HIV-1 epidemic 
in Western Europe and North America (Balotta et al., 2001; Geretti, 2006). Although 
this strain of HIV-1 has often dominated the headlines, on a global scale, infections 
with subtype B cause approximately 12% of infections, compared with 
approximately 48% caused by subtype C (Geretti et al., 2009). However, given its 
predominance in so many countries, it can be argued that subtype B is the most 
widespread of the HIV-1 variants (Gilbert et al., 2007).  
Historically, subtype B likely moved from Africa to Haiti in approximately 1966, 
where it spread for some years before dispersing elsewhere (Gilbert et al., 2007). A 
pandemic clade encompassing the vast majority of subtype B infections in the 
United States and elsewhere around the world subsequently emerged after a single 
foundation event out of Haiti in or around 1969, creating the basis of the Western 
epidemic (Gilbert et al., 2007). However, an increase in co-circulation of multiple 
HIV-1 strains in Western countries occurred following immigration from sub-Saharan 
Africa, Asia and Eastern Europe, leading to parallel epidemics comprised of 
different strains segregated according to ethnicity and risk group (Geretti et al., 
2009). In Western countries, subtype B is predominantly observed in white MSM 
while non-B subtypes circulate among heterosexual man and women of other ethnic 
groups (Geretti et al., 2009). Although increasing migration toward Europe is 
changing the predominantly B pattern and increasing non-B infections, and the 
overall HIV-1 epidemic is becoming more homogenous, highly compartmentalised 
epidemics are still in evidence (Abecasis et al., 2013; Ciccozzi et al., 2012; Gifford 
et al., 2007). 
A conservative estimate places the global prevalence of intersubtype recombinant 
forms at approximately 20% of the total infections worldwide (Galli et al., 2010). A 
high proportion of HIV-1 strains in both Uganda and Kenya are subtype A/D 
recombinants (Dowling et al., 2002; Harris et al., 2002). In Uganda, 24% of the HIV-
1 strains analysed in Rakai were unique A/D recombinants (Harris et al., 2002). 
Interestingly, the proportion of each subtype within recombinants differs between, 
and within, each country: whereas subtype D is the most important component of 
the HIV-1 strains in Rakai (Harris et al., 2002), 50% of vif genes in a different region 
of Uganda were subtype A (Wieland et al., 1997), and subtype A also predominates 
in Kenya (Dowling et al., 2002), demonstrating that regional dependency is also 
exhibited by local recombinant networks.     
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1.5 Risk group and geography vs. recombination 
Along with the inherent genetic plasticity of the virus, the range of different risk 
factors for HIV-1 infection contributes differing distribution pressures across 
geographic regions; the introduction of a new variant into a high risk population can 
lead to rapid spread and the establishment of that variant as the dominant subtype, 
e.g. subtype B in MSM in Europe and North America, and CRF01_AE in 
intravenous drug users (IVDU) in Asia (Arnold et al., 1995; Sanders-Buell et al., 
2007; Vidal et al., 2009).  
The rate at which HIV-1 spreads in a host population also affects the evolutionary 
rate of HIV-1 in that population (Berry et al., 2007). Differences in genetic diversity 
of HIV-1 strains exist both between and within risk groups, for example, subtype A 
spreading heterosexually in Africa had an evolutionary rate that was 8.4 times 
higher than the spread of subtype A among IVDUs in the former Soviet Union (Berry 
et al., 2007). IVDUs have been shown to both do and do not have differing intra-
host HIV evolution rates (Berry et al., 2007). In South and Southeast Asia, rapid 
growth of HIV-1 infections was first observed among Thai IVDUs in 1988, mainly 
involving subtypes B and B’ (Berry et al., 2007). Spread of CRF01_AE among 
female sex workers introduced this recombinant to the IVDU risk group, resulting in 
a mixed epidemic of CRF01_AE and B’ infections in a complicated transmission 
network between sex workers and IVDUs (Berry et al., 2007). 
In a heterosexual epidemic, where HIV-1 is transmitted from person to person as 
new contacts are formed, there is an evolutionary rate at the population level that 
corresponds to the intra-host evolutionary rate or (due to convergent bottleneck 
effects) a rate slightly slower than this. However, in an IVDU epidemic, HIV-1 
spreads from person to person in the first stage of infection, leading to a fast spread 
of very similar viruses (Berry et al., 2007). Although some research has found that 
transmitted variants have less diversity than currently circulating variants in the 
infecting partner and are more closely related to ancestral strains (Sagar et al., 
2009), more recent research indicates that sexually transmitted founder viruses 
cannot be directly predicted through analysis of donor quasispecies (Frange et al., 
2013). At this stage, further research to determine the viral traits that accord the 
capacity to establish infection is needed.   
Once the dominance of a variant is established in a population, the homogeneity of 
the epidemic increases the difficulty in measuring the degree of contribution of 
recombination to genetic diversity (Harris et al., 2002). However, in situations where 
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there is either a genetically diverse epidemic, a well-defined high-risk population, or 
where a new variant is in the process of becoming established, the frequency of 
viral recombination and the effect on viral pathogenesis can be assessed (Geretti, 
2006; Harris et al., 2002; Sanders-Buell et al., 2007; Vidal et al., 2009).   
1.6 The UK HIV-1 epidemic  
The UK epidemic, although historically dominated by subtype B infections in white 
MSM, has always displayed a diverse range of subtypes in non-MSM infected 
individuals (Arnold et al., 1995; Balotta et al., 2001; Geretti, 2006). The subtype B 
epidemic has been phylogenetically characterised and is thought to have arisen 
from at least six separate introductions into the UK population, which argues for the 
existence of distinct, non-overlapping sexual networks within the predominant MSM 
group (Hué et al., 2005). Similarly, most non-B infections in the UK have been 
characterised as resulting from separate introductions and at least 36 
geographically distinct HIV-1 strains have been identified in the UK epidemic, 
including a Ugandan subtype D and subtype A strains associated with East and 
West Africa (Gifford et al., 2007). 
Although parallel epidemics exist in the UK (MSM = subtype B; heterosexual = non-
B), HIV-1 distribution and diversity is a highly dynamic process (Geretti, 2006; 
Gifford et al., 2007; Peeters, 2001; Vidal et al., 2009), and non-B infections have 
been appearing in the UK MSM community for a number of years. There has also 
been a change in the manner of acquisition of HIV-1 in the UK (HPA, 2012). 
Previously, whilst MSM infections were largely acquired in-country, heterosexual 
infections were mainly imported (Geretti et al., 2009; HPA, 2012). However, this has 
now changed, such that infections acquired in-country now outnumber imported 
infections, indicating increasing onwards transmission within the UK (Easterbrook et 
al., 2010; Geretti et al., 2009; HPA, 2012; Hughes et al., 2009). Additionally, in both 
the UK and in Europe, MSM and heterosexual epidemics in the post-HAART era 
have begun to increase again, following a period showing a decrease in the number 
of new infections (Easterbrook et al., 2010; HPA, 2012; van Sighem et al., 2012). 
Taken together, this indicates that indigenously-acquired infections are likely to 
increase in importance in the coming years.  
HIV-1 recombinant forms have not traditionally been predominant in either the MSM 
or heterosexual UK HIV-1 epidemics. However, a study which investigated the 
genetic diversity of HIV-1 in the UK identified a number of sequences that could not 
be definitively assigned to a subtype or recognised HIV-1 CRF; further investigation 
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of these showed that many were recombinant in origin, indicating that the number of 
these strains in the UK is increasing (Gifford et al., 2006). As HIV-1 circulates in 
localised epidemics, and as new variants have the potential to be rapidly 
established in high risk populations, investigation of unrecognised recombinant 
forms is likely to offer insights into current population dynamics and routes of 
infection. 
 
1.7 Using phylogenetic analyses to classify novel HIV-1 CRFs and reconstruct 
HIV-1 epidemics 
As noted previously, the generation of novel CRFs and URFs is especially likely in 
areas or communities where there is co-circulation of strains within the same 
transmission networks, particularly in high-risk populations, where multiple 
exposures may be more frequent (Artenstein et al., 1995; Balotta et al., 2001; 
Buonaguro et al., 2007; Peeters, 2001; Sanders-Buell et al., 2007). The origin and 
temporal spread of these strains can be reconstructed using phylogenetic methods 
(An et al., 2012; Drummond et al., 2006), which, at their most accurate, use full-
length HIV-1 genomes. 
1.7.1 Classification of HIV-1 based on full genome sequencing 
The original designation of HIV-1 subtypes was based on the sub-genomic 
characterisation of a few individual genes (Buonaguro et al., 2007; Harris et al., 
2002; Robertson et al., 2000). This is also the case for the majority of the work 
performed regarding the spread and distribution of subtypes, which is most 
commonly measured using partial pol sequencing (Balotta et al., 2001). A 
consequence of this is that the presence of recombination, and, by extension, 
CRFs, may have been underestimated (Balotta et al., 2001; Harris et al., 2002). 
However, advancements in sequencing methods have meant that HIV-1 
phylogenetic classifications are currently based on either sequences derived from 
multiple sub-genomic regions or full-length genomic sequence analysis (Buonaguro 
et al., 2007; Harris et al., 2002). 
Although the advent of full-length analysis was a dramatic step forward in 
characterising HIV-1 genomes, the methods used are not without inherent 
problems, especially with respect to detecting and classifying recombination. Firstly, 
the majority of reported sequences are obtained from either PBMC-derived proviral 
15 
 
DNA or from plasma RNA with reverse-transcription PCR (RT-PCR) followed by 
cloning (Nadai et al., 2008). PBMC proviral DNA is easier to work with than plasma 
RNA, but it does not reflect the actively replicating virus in the same way as 
sequences captured from plasma RNA, as the half life of plasma virions is only a 
few hours (Ho et al., 1995; Nadai et al., 2008). Also, bulk PCR methods and cloning 
are prone to introducing methodological artefacts in the amplified virus (Jansen and 
Ledley, 1990; Marton et al., 1991; Meyerhans et al., 1990; Salazar-Gonzalez et al., 
2008). Another method, the heteroduplex assay (HTA), only allows for qualitative 
assessments of subgenomic structure (reviewed in Salazar-Gonzalez et al., 2008). 
To circumvent these problems, the single genome sequencing (SGS) approach was 
developed by Palmer and colleagues, and was extended by Salazar-Gonzalez and 
colleagues to encompass full-length viral genome analysis (Palmer et al., 2005; 
Salazar-Gonzalez et al., 2008). This method allows the obtainment of DNA 
sequences derived from many single viral genomes in a sample, and has low 
reported error rate of 0.03% (Palmer et al., 2005; Salazar-Gonzalez et al., 2008). 
The theory is based on the statistical premise of Poisson’s distribution, which states 
that a limiting dilution of cDNA that results in 30% of reactions being positive will 
have had a reaction input of one cDNA molecule 80% of the time (Palmer et al., 
2005; Nadai et al., 2008). The lack of in vitro recombination when using SGS 
techniques makes this approach ideally suited to obtaining sequences that 
correspond to the in vivo circulating plasma virus, which is essential when 
investigating viral pathogenesis and evolution (Nadai et al., 2008; Salazar-Gonzalez 
et al., 2008).     
1.7.2 Recombination analyses  
Recombination events can be identified most clearly in the context of phylogenetic 
analyses, and are indicated when phylogenetic relationships for different parts of the 
genome are discordant (Robertson et al., 1995).  
Analysis of recombinant HIV sequences is traditionally performed using sliding 
window analyses, followed by phylogenetic classification of putative non-
recombinant fragments of the genome (Kosakovsky Pond et al., 2009; Salminen et 
al., 1995). This method involves bootscanning, which involves aligning the 
sequence of interest with related sequences and computing phylogenies locally over 
the alignment, usually over a sequence length of 200-500 nucleotides (Salminen et 
al., 1995). When combined with informative sites analysis, a statistical assessment 
regarding the placement of a breakpoint (the genomic location where a 
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recombination event occurred) at a particular position can be made (Robertson et 
al., 1995).   
A number of automated and semi-automated algorithms based on statistical 
probability models, profile hidden markov models, likelihood-based models and 
comparison to standardised reference alignments have been developed, but these 
can give contradictory results (Holguín et al., 2008; Kosakovsky Pond et al., 2009; 
Lole et al., 1999; Oliveira et al., 2005; Pond et al., 2006; Schultz et al., 2006; 
Truszkowski and Brown, 2011). Additionally, difficulties exist in locating exact 
breakpoints between subtypes, since different subtypes are often highly conserved 
in some sequence regions (Gifford et al., 2006; Truszkowski and Brown, 2011).  
Given that discrepancies between automated subtyping methods are common, 
Pond proposes that a phylogeny-based method is adopted for accurate subtyping. 
The programme Subtype Classification Using Evolutionary Algorithms (SCUEAL), 
which uses a phylogeny-based method, has a reported breakpoint recovery of 
88.3% for sequences with 5% or greater divergence between parental strains and a 
length of 200 nucleotides or longer (Kosakovsky Pond et al., 2009).  
1.7.3 Epidemic reconstruction 
Phylogenetic analyses can be used as a molecular epidemiological strategy to 
characterise epidemics on the basis of the genetic interrelatedness of DNA 
sequences (Brenner et al., 2013; Drummond et al., 2006; Hué et al., 2004; Korber et 
al., 2000). It can be used to discern the introduction and dissemination of HIV-1 viral 
subtypes in different regional settings, including the transmission patterns of 
heterosexual, MSM and IVDU epidemics, the role of disease stage in transmission 
dynamics and underlying trends in regional epidemics; these can all be important in 
the selection of control interventions to limit HIV-1 transmission (Brenner et al., 
2013).   
Phylodynamics describes infectious disease behaviour that arises from a 
combination of evolutionary and ecological processes, and commonly use molecular 
clock models to represent the relationship between genetic distance and time 
(Pybus and Rambaut, 2009). Early models assumed a constant rate of genetic 
variation, but later, relaxed, models contain the ability to incorporate rate variation 
either between strains or through time (Pybus and Rambaut, 2009).  
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A common program used in phylodynamic analyses is BEAST (Bayesian 
Evolutionary Analysis by Sampling Trees), which uses Markov chain Monte Carlo 
(MCMC) probability distributions to provide a framework for analysing molecular 
sequence data through parameter estimation and hypothesis testing of evolutionary 
models (Drummond and Rambaut, 2007). In this program, an evolutionary model 
(nucleotide substitution, rate model among nucleotide sites and tree branches), the 
phylogenetic tree (which models the phylogenic relationships of the sequences) and 
the tree prior (a distribution for the node heights and tree topology) are used to infer 
a time scaled phylogeny from nucleotide sequence data, enabling epidemic 
reconstruction (Drummond and Rambaut, 2007). Different evolutionary models can 
be compared by calculating the Bayes Factor, which is a ratio of the marginal 
likelihoods between the models (Drummond and Rambaut, 2007). To ensure 
statistical sufficiency of results from these methods, it is advised to use multiple long 
BEAST runs and combine them (Ho and Phillips, 2009). 
The process of epidemic reconstruction can be enhanced by using methods such as 
the coalescent, which links patterns of genetic diversity to processes such as 
changing population size and population structure, and is typically used to infer past 
rates of population growth. This tool has been successfully used to reconstruct both 
HIV-1 and hepatitis C populations (Pybus and Rambaut, 2009; Pybus et al., 2001). 
Evolutionary and spatial change can also be considered by applying 
phylogeography tools, which use time scaled phylogenies and geographic data to 
infer the geographic origin of emerging infections, the route of transmission and the 
rate of geographic spread (Afonso et al., 2012; Lemey et al., 2009, 2010; Mbisa et 
al., 2012; Pybus and Rambaut, 2009). This can be particularly interesting in the 
context of the emergence of recombinants, such as in Rwanda, where it was found 
that the HIV-1 epidemic in Kigali was characterised by the emergence of A1/C 
recombinants and was phylogenetically distinct from the HIV-1 epidemic in 
neighbouring countries (Paraskevis et al., 2004; Rusine et al., 2012; Tee et al., 
2009). Local infections with non-B subtypes in B-dominated regions have also been 
identified by phylogenetic linkage of individuals diagnosed with primary HIV-1 
infection (Brenner et al., 2007). 
In order to reconstruct epidemic histories, nucleotide sequence data is required. 
Full-length HIV-1 genomes are preferred for this, as undetected recombination 
could contribute to errors made in dating HIV-1 phylogenies by increasing the 
apparent variation in rates among nucleotide sites and reducing the genetic 
distances between sequences (Rambaut et al., 2004; Schierup and Hein, 2000; 
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Worobey and Holmes, 2001).  However, drug resistance programmes, introduced in 
the 2000s, have provided large pol (protease/RT) sequence datasets which can be 
used for analysis of transmission trends in regional epidemics; using pol only has 
been found to be sufficient for epidemic reconstruction, notwithstanding the 
presence of undetected recombination that may exist in the unsequenced regions of 
the genome (Hué et al., 2004; Lewis et al., 2008; van Sighem et al., 2012). 
1.8 Individual-level consequences of HIV-1 genetic diversity 
There is great variation in the clinical outcome following HIV-1 infection (Fellay et 
al., 2007; Langford et al., 2007). As such, individual-level effects of genetic diversity, 
such as disease progression associated with different subtypes and strains, exist. 
One of the strongest predictors of disease progression is T cell activation (Ormsby 
et al., 2012). During the steady state (when CD4 lymphocyte production and 
destruction are balanced), the population of CD4 lymphocytes turns over every 15 
days (Ho et al., 1995). As HIV-1 infection advances and escapes immune pressures 
from the host, the immunological state of the infected individual deteriorates (Lemey 
et al., 2007; Ormsby et al., 2012). Progression to AIDS in humans is characterised 
by high levels of immune activation associated with accelerated T cell turnover rates 
and apoptotic death (Langford et al., 2007; Schindler et al., 2006). As such, CD4 
cell decline can be used as a proxy for disease progression in individuals (Badri et 
al., 2008; Phillips et al., 2010).  
Other predictors of HIV-1 disease progression include plasma HIV-1 RNA viral load, 
which has been classed as the best single predictor of HIV-1 disease progression 
(Mellors et al., 1997). Plasma viral load is predictive of subsequent CD4 cell decline 
and can discriminate risk at different levels of CD4 count, but the most accurate 
predictor of HIV-1 disease progression comes from the use of plasma HIV-1 viral 
load and CD4 cell count in combination (Mellors et al., 1997). HIV-1 proviral DNA 
viral load is also a predictor of disease progression (independent of plasma RNA 
viral load and CD4 cell count), particularly in the first six months of infection 
(Rouzioux et al., 2005). Although HIV-1 proviral DNA viral loads are not commonly 
measured during routine clinical monitoring, it may be that a combination of all three 
measurements would provide the best overall monitoring of HIV-1 disease 
progression (Rouzioux et al., 2005). 
There is some evidence to indicate that the rate of HIV-1 disease progression varies 
depending on the subtype of infection, and whether the infection was caused by a 
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multi-subtype recombinant. In both Kenya and Uganda, infections with viruses 
classed as subtype D based upon envelope sequences were found to carry a 
significantly higher increase in the risk of death, and a faster rate of CD4 cell decline 
and disease progression than subtype A infections, despite similar HIV-1 plasma 
viral loads (Baeten et al., 2007; Kaleebu et al., 2002; Kiwanuka et al., 2010). This 
was also seen in a study conducted in London, where subtype D infections were 
associated with significantly faster rate of CD4 decline when compared with 
subtypes B, A and C (Easterbrook et al., 2010). An earlier switch to using the 
CXCR4 co-receptor for viral entry may explain subtype D infections’ faster 
progression (Easterbrook et al., 2010). In other studies, subtype A and C have been 
shown to have slower disease progressions relative to subtype B infections (Klein et 
al., 2011). 
 A further study in the Rakai district of Uganda assessed A/D recombinants, and 
found subtype A and A/D infections were transmitted at a higher rate than subtype 
D infections, although the A/D recombinant figure was not statistically significant 
(Kiwanuka et al., 2009). This suggests that over time the rate of subtype D 
infections may decrease relative to the rate of subtype A infections, and is perhaps 
reflected in the lesser worldwide distribution of subtype D (Abecasis et al., 2007; 
Kiwanuka et al., 2010). This has been seen in Rakai, where an 8-year study found a 
significant decrease in subtype D viruses from 71% to 63% and an increase in A 
viruses from 15% to 20% (Kiwanuka et al., 2009).  
1.9 Aims and Objectives 
The aim of this PhD project was to conduct a comprehensive investigation into HIV-
1 recombination in the UK, focusing on the following research questions: 
1. Is the composition of the UK HIV-1 landscape changing on a genetic level?  
2. Are there novel HIV-1 CRFs circulating in the UK? 
3. What are the origin and likely pathogenesis of these novel strains? 
Question 1 (Chapter 3) was addressed by assessing the degree and nature of 
subtype unclassified recombination present in the UK as captured by the UK HIV 
Drug Resistance Database (UK HIV DRD), followed by phylogenetic identification of 
clusters of strains likely to be novel HIV-1 CRFs. Clusters comprised of strains likely 
to be of epidemiological importance were subjected to phylodynamic analysis, 
including geographic investigations.  
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Although Question 2 (Chapters 4 and 5) was partially answered through the 
investigation performed for Question 1, confirmation of one strain identified through 
this process as a novel HIV-1 CRF was sought. In order to perform detailed 
characterisation and analyses of one strain likely to be a novel HIV-1 CRF, a 
method for near full-length, single genome sequencing of HIV-1 RNA was 
developed and optimised. Stored plasma samples from six patients sharing a similar 
breakpoint in the pol gene were retrieved and characterised, and the recombination 
breakpoints identified. Identification of both the recombinant breakpoint locations 
and the classification of parental subtypes was performed using both a traditional 
sliding window analysis with phylogenetic reconstruction of non-recombinant 
fragments and a probabilistic jumping profile hidden markov model (jpHMM) (Lole et 
al., 1999; Schultz et al., 2006, 2009). Following characterisation, the registration of 
CRF50_A1D and one B/CRF50_A1D URF was reported.  
Question 3 (Chapters 6 and 7) was answered through a reconstruction of the 
epidemic history of CRF50_A1D in the UK using phylogeography and Bayesian 
skyline analysis, an investigation into the global origin of the component parental A1 
and D subtypes, and a preliminary analysis of the likely pathogenesis of 
CRF50_A1D infections conducted using CD4 decline slopes from patients not yet 
on antiretroviral treatment. 
 
 
 
 
 
 
 
 
 
 
 
21 
 
Chapter 2: Methods 
2.1 Access to HIV drug resistance testing sequences and associated clinical 
data 
The UK Collaborative Group on HIV Drug Resistance (UK CHIC) 
(http://www.ukchic.org.uk/) and the UK HIV Drug Resistance Database (UK HIV 
DRD) (http://www.hivrdb.org.uk/) provided access to stored HIV reverse 
transcriptase and protease sequences produced at the time of drug resistance 
testing in routine practice and, where available, relevant clinical and demographic 
data. These bodies are coordinated by the Medical Research Council Clinical Trials 
Unit (MRC-CTU) (http://www.ctu.mrc.ac.uk/). Additional demographic data for some 
patients were obtained through an agreement between the Health Protection 
Agency (HPA) and the UK HIV DRD. 
2.1.1 UK CHIC 
The UK collaborative group on HIV Drug Resistance was established in 2001 and 
collects clinical (including treatment) data from patients undergoing care at 15 
collaborating centres across the UK (http://www.ukchic.org.uk/). The earliest 
available data are from 1996, and, as of 2012, the CHIC database contained over 
45,000 records. The data retrieved from UK CHIC for this project were date of birth, 
gender, risk group (route of HIV exposure), country of origin, ethnicity, date of HIV-1 
diagnosis, CD4 cell counts with dates, plasma HIV-1 RNA loads with dates, and 
antiretroviral treatment (ART) history. 
2.1.2 The UK HIV DRD 
The UK HIV Drug Resistance database is a repository of pol  gene sequences 
(protease and reverse transcriptase) obtained by Sanger population sequencing in a 
large number of HIV-infected patients undergoing drug resistance testing in the UK 
(http://www.hivrdb.org.uk/). Sequences submitted by contributing centres are 
genotyped by the database steering committee using the Rega and SCUEAL 
methodologies at approximately 2-year intervals (Kosakovsky Pond et al., 2009; 
Oliveira et al., 2005). Both these methods classify HIV-1 sequences into pure or 
CRF HIV-1 subtypes. Sequences that are not recognised by Rega as a pure 
subtype or a known CRF are designated 'unassigned', whereas SCUEAL suggests 
a putative recombinant structure for these sequences, given as both a 'simplified 
subtype' and a 'detailed subtype'.  The ‘detailed subtype’ field includes both intra- 
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and inter-subtype recombination and is often quite complex (e.g. 
B,B,B,B,CRF14,D,G inter-subtype recombinant), whereas the simplified subtype 
field shows a basic recombinant structure only (e.g. B,G recombinant). 
Following genotyping, the accessible database download is referred to by the year 
of genotyping e.g. 2007, 2010 or 2012. This project used both the 2007 and 2010 
database downloads; the database download used in each project section is clearly 
indicated within the text. Although SCUEAL results are usually reported using the 
nucleotide position from the beginning of the sequence length, e.g. 212, for ease of 
understanding, all results in this report were converted to standard HXB2 
numbering. 
The 2007 UK HIV DRD database download contained 34,469 sequences, and the 
2010 download contained 55,556 sequences. As sequences were collected from 
both treatment-naive and treatment-experienced patients, the database contained 
multiple sequences from some patients (baseline and failure resistance test/s). 
Accordingly, the 2007 download contained 25,631 unique patient records, and the 
2010 download contained 43,002 unique records (Andrew Leigh Brown, personal 
communication, 2010; Hughes et al., 2009). For patients captured only in the UK 
HIV DRD and not by UK CHIC or HPA surveillance, the demographic information 
available for each sequence comprised the sample date and a geographical 
identifier for an aggregated group of HIV clinics.   
2.1.3 HPA data 
The Health Protection Agency is an independent body that collects epidemiological 
and surveillance data on UK HIV infections (http://www.hpa.org.uk/). As part of an 
agreement with the UK HIV DRD, access to some demographic data was available 
for those patients not captured by UK CHIC. As of 2012, the HPA database held 
approximately 19,500 records containing date of birth, gender, risk group, country of 
origin and date of HIV-1 diagnosis. 
2.1.4 Project proposals and ethical approval 
Access to data contained in UK CHIC and the UK HIV DRD is decided by the 
steering committee on a project-by-project basis.  Two proposals were submitted 
and accepted for this project.  
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2.1.4.1 UK HIV DRD project proposal for the analysis of unassigned 
sequences 
This proposal requested access to sequence data stored in the UK HIV DRD for the 
purposes of analysing subtype-unassigned sequences and identifying potential 
recombinant specimens of interest (Appendix 2_1). Ethics approval was gained 
from the Royal Free Hospital Ethics Committee for the anonymised study of up to 
15 recombinant specimens. The MRC-CTU assisted with the anonymised retrieval 
of six specimens from three HIV centres in London and Northwest England. Plasma 
specimens were retrieved from routine storage and transferred to the virology 
department of the Royal Free Hospital, London, where the laboratory work took 
place.  
2.1.4.2 UK CHIC proposal for CD4 cell slope analysis 
A proposal was submitted to UK CHIC to access HIV-1 RNA viral loads, CD4 cell 
counts and ART data for 19 patients with recombinant HIV-1 infections (Appendix 
2_2). These data were used to analyse the rate of HIV-1 disease progression as 
estimated from CD4 cell decline. 
2.2 Near full-length amplification and sequencing of HIV-1 from plasma RNA 
Following specimen retrieval, characterisation of patient specimens was performed 
using single genome, near full-length amplification and sequencing of HIV-1. This 
process involved: extraction of HIV-1 RNA (vRNA) from plasma; reverse 
transcription of  vRNA into cDNA; limiting dilution of cDNA; amplification of near full-
length HIV-1 DNA using nested PCR and Sanger sequencing of resulting PCR 
products. Each stage of the process was extensively optimised.   
2.2.1 Sample preparation 
140µl of plasma was normalised to contain 20,000 copies of vRNA. In specimens 
with low HIV viral loads, the appropriate volume of plasma was centrifuged for 90 
minutes, 20,000xg, 4°C, and the supernatant removed to obtain a final volume of 
140µl.  The viral pellet was resuspended in the remaining plasma supernatant 
before proceeding to vRNA extraction. In cases where the combination of HIV-1 
viral load and the volume of plasma received was too low to contain 20,000 virus 
copies, the entire available plasma volume was concentrated to 140µl using the 
above centrifugation protocol to obtain the maximum number of viral copies 
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available. This pre-extraction step was used prior to extraction using the QiAmp 
Viral RNA Mini Kit. 
2.2.2 Extraction and reverse transcription of viral RNA from plasma 
2.2.2.1 Viroseq extractions  
Viroseq extractions were used during the optimisation of the Nadai et al. protocol for 
near full-length amplification of HIV-1. These were performed according to the 
manufacturer’s instructions.  Briefly, 500µl thawed plasma was placed in an 1.5ml 
Eppendorf and centrifuged for 1 hour, 22,000xg, 4°C to pellet virions, after which the 
supernatant was removed. The pellet was resuspended in 600µl lysis buffer and 
incubated at room temperature for 10 minutes. 600µl isopropanol was added and 
the mixture centrifuged at 13,000xg, 5 minutes. Samples were aspirated to dryness; 
1ml chilled 70% ethanol was added, and the mixture spun at 13,000xg, 5 minutes. 
After a final aspiration, the pellets were air-dried and 50µl cold RNA diluent added to 
resuspend the extracted RNA.  
2.2.2.2 EasyMAG extractions 
Automated nucleic acid extractions were performed using the NucliSENS EasyMAG 
(Biomerieux, Marcy l'Etoile, France). 1ml of thawed plasma was used in the generic 
on board extraction protocol, according to the manufacturer's instructions. Following 
incubation of plasma with 2ml of Lysis Buffer for 10 minutes at room temperature, 
140µl of magnetic silica solution was added to the sample cartridge. Nucleic acids 
were eluted in 25µl Elution Buffer. 
2.2.2.3 QiAmp Viral RNA Mini kit 
To extract vRNA, the QiAmp Viral RNA Mini kit (Qiagen, Hilden, Germany) was 
used according to the manufacturer’s instructions, with a modified final elution 
volume of 65µl rather than 60µl. Briefly, 140µl of prepared sample and 560µl Buffer 
AVL with carrier RNA were combined and incubated at room temperature for 10 
minutes. 560µl absolute ethanol was added, and the entire mixture was applied to a 
spin column in two 630µl steps, using two spins at 6,000xg, 1 minute. 500µl of 
Buffer AW1 was added, and the mixture centrifuged at 6,000xg, 1 minute, after 
which 500µl Buffer AW2 was added and the column centrifuged at 14,000xg, 3 
minutes. An extra spin was performed using an empty spin column to ensure 
complete removal of buffer. RNA was eluted using 65µl AVE buffer, followed by 
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incubation at room temperature for 1 minute, and centrifugation at 6,000xg, 1 
minute.    
An identical extraction process using nuclease-free water as the input was 
performed simultaneously to provide a contamination control in subsequent 
downstream analyses. This is henceforth referred to as the negative control. 
2.2.3 Reverse Transcription 
All extracted RNA was immediately transcribed in four separate reactions using the 
Superscript III First Strand Synthesis Supermix Kit (Life Technologies, Paisley, UK) 
using the following protocol per reaction: 0.63µl of a 20µM solution (0.25µM final 
concentration) of reverse primer 1.R3.B3R 5’-
ACTACTTGAAGCACTCAAGGCAAGCTTTATTG (CHAVI-MBSC 2009, 
unpublished) was combined with 1.87µl nuclease free water and 2.5µl Annealing 
Buffer in a nucleic acid free environment on ice. 15µl (5,000 copies) RNA template 
was added, and the resulting mixture denatured at 65°C for 5 minutes. PCR tubes 
were removed and placed on ice for at least 1 minute before adding 25µl of 
2xReaction Mixture and 5µl of Enzyme Mixture (Superscript III and M-MLV-RT).  
Reactions were heated to 50°C for 90 minutes, paused, and 2µl of Superscript III 
RT Enzyme added, after which reactions were incubated at 55°C for a further 90 
minutes, then 85°C for 5 minutes. The resulting cDNA was combined, and either 
frozen at -80°C or used immediately as input into a nested PCR reaction. 
2.2.4 cDNA dilution and nested PCR protocol 
A two step cDNA dilution protocol was used to ensure single genome amplification. 
The first step was a limiting dilution to find the dilution at which 30% of the PCR 
reactions were positive. When a Poisson distribution is assumed, this 30% positive 
level is understood to contain a single copy of amplified DNA in 80% of cases. 96 
nested PCR reactions were set up, of which there was one no template control 
(NTC), one negative control, six reactions using undiluted cDNA, 24 wells at a 1:10 
cDNA dilution and 64 wells at 1:100 cDNA dilution. This plate was primarily a control 
to assess that the cDNA was amplifying at rates suggesting near-ideal extraction 
and reverse transcription conditions, i.e. that the undiluted cDNA contained 100 
copies/µl. Following acceptable results from the limiting dilution plate, a further 96 
nested PCR reactions were performed. These reactions comprised one NTC 
reaction and 95 template reactions at a 1:200 cDNA dilution (a theoretical input of 1 
copy/reaction). In circumstances where there was a reduced viral load, or the 
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limiting dilution plate suggested that the sample was amplifying suboptimally, the 
dilutions were adjusted accordingly. The PCR amplicons from this second 
amplification reaction were those used in subsequent Sanger sequencing.   
All PCR reactions were set up on ice. Both first round and nested PCR reactions 
used the Platinum PCR Supermix High Fidelity Kit (Life Technologies, Paisley, UK). 
The first round per reaction volumes were 45µl PCR supermix, 1.25µl each (0.25µM 
each final concentration) of forward primer 1.U5.B1F 
5’CCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGT and reverse primer 
1.R3.B3R, 0.5µl nuclease free water and 2µl cDNA. Cycling conditions were 94°C 2 
minutes, followed by 40 cycles of 94°C 15s, 60°C 30s, 68°C 9.5 m, and a final 
extension at 68°C 20 minutes. 
The nested PCR reaction was identical to the first round PCR, except that the 
primers used were 2.U5.B4F 5’-AGTAGTGTGTGCCCGTCTGTTGTGTGACTC 
(forward) and 2.R3.B6R 5’-TGAAGCACTCAAGGCAAGCTTTATTGAGGC 
(reverse). The template input was 2µl of the first-round reaction. Cycling conditions 
were 94°C 2 minutes, followed by 45 cycles of 94°C 15s, 60°C 30s, 68°C 9.5 m, 
and a final extension at 68°C 20 minutes. The resulting ~9kb product spanned 
HXB2 nucleotides 552-9636. 
2.2.5 Agarose gel electrophoresis and preparation of DNA for Sanger 
sequencing 
Positive nested PCR reactions were identified using agarose gel electrophoresis on 
a 1% agarose gel with a 5µl DNA input. PCR products were prepared for Sanger 
sequencing using Milipore filters (Watford, UK). Post-filtration, cleaned PCR 
products were quantified using agarose gel electrophoresis, whereby the intensity of 
the DNA band was compared to that of a quantified DNA ladder (Hyperladder I, 
Bioline, London, UK) and diluted with molecular biology grade water such that the 
subsequent sequencing reactions produced signal intensity within the parameters of 
the ABI 3730xl sequencing instrument (Life Technologies). Diluted PCR products 
were pooled for sequencing analysis as a quality control measure. 
2.2.6 DNA sequencing 
Prepared PCR products were directly sequenced using fluorescently labelled 
dideoxy chain terminators (BigDye Terminator v3.1 Cycle Sequencing Assay, Life 
Technologies) and an automated 3730xl sequencer in a 20µl sequencing reaction 
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containing 1.7µl Big Dye, 9.3µl nuclease free water, 1µl of primer (0.5µM final 
concentration) and 8µl template. Sequencing primers were sourced from in-house 
protocols obtained from the Molecular biology and Sequencing core at the Centre 
for HIV/AIDS Vaccine Immunology (CHAVI), published protocols in Van Laethem et 
al., 2005, 2006; Nadai et al., 2008 and designed using Primer3 version 4.0 
(available at http://frodo.wi.mit.edu/primer3). A total of 100 primers were used to 
sequence the full HIV genome (Appendix 2_3). Sequencing reactions were 
repeated until near full bi-directional coverage was obtained.  
2.2.7 Sequence assembly and quality control 
Sequences were assembled using SeqScape version 2.6 software (Life 
Technologies). During sequence assembly, the fragment sequences from individual 
sequencing primers were examined for the presence of mixed bases, which could 
potentially indicate the amplification of >1 target molecule. The electropherograms 
and raw data from all positions showing evidence of this were examined; cases 
where the mixed base was due to low sequencing intensity were repeated using the 
individual primer; for cases in which the mixed base appeared genuine the 
specimen was re-amplified from scratch. There were isolated cases for which there 
was consistently low sequencing signal at a particular base, even after repeat 
sequencing. In these cases, the mixed base was allowed to stand rather than 
manually edit the sequence.  
2.3 Phylogenetic analyses 
Phylogenetic analyses were used in the following tasks: assessing the number of 
subtype-unassigned and complex sequences present in the UK HIV DRD; cluster 
analyses of unassigned and complex sequences; recombination analyses of 
unassigned and complex sequences and the amplified full-length patient 
specimens; identification of further individuals carrying the novel CRF50_A1D strain; 
phylogeographic determination of the emergence and spread of CRF50_A1D in the 
UK and an investigation into the likely geographic region from which the 
CRF50_A1D parental strains originated.  
A variety of different methods were used to perform the phylogenetic analyses in 
this thesis. For sequence alignment, MUSCLE was chosen in preference to more 
widely used alignment programmes such as Clustal W due to the faster alignment 
time, especially when aligning full-length sequences (Edgar, 2004; Nuin et al., 
2006). Bio-Edit was selected for manual adjustments to automated sequence 
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alignments due to the flexibility of the program and the ability to convert files into a 
variety of formats (Hall, 1999).  
To construct phylogenetic trees, three programmes were used: FastTree, PhyML 
and BEAST (Drummond and Rambaut, 2007; Guindon et al., 2005; Price et al., 
2009). FastTree was used to analyse alignments with large numbers of sequences 
(>100) due to the speed of the programme; PhyML was used to perform maximum 
likelihood analysis when classifying the putative pure regions of full-length 
sequences, and BEAST was used for more complex analyses such as time-scaled 
phylogenies and phylogeographic analysis. PhyML was used in preference to 
BEAST during subtyping classification because it was considered that maximum 
likelihood analysis was a sufficiently robust methodology to perform subtyping 
classifications and that the high computational requirements of Bayesian analysis 
were best saved for intensive, time-scaled analyses. 
Recombination analyses were performed using four methods: RIP, SCUEAL, 
jpHMM and Simplot (Kosakovsky Pond et al., 2009; Lole 1999, Schultz et al., 2006; 
Siepel et al., 1995). RIP was used as a 'quick look' programme to gain a rough 
understanding of the likely recombinant structure of a sequence and Simplot was 
used to run manual screens of sequences; this was especially useful when 
classifying novel recombinants as the programme allowed the use of a user-defined 
reference sequence when performing a similarity scan. jpHMM and SCUEAL were 
used for the bulk of recombinant classification. SCUEAL was chosen in preference 
to Rega (another widely used subtyping method) due to its incorporation of 
evolutionary analyses into its algorithm through the measurement of branch lengths 
for MRCA and the use of statistical criteria (the Bayesian Information Criterion) to 
calculate the fitness of each proposed structural model; in contrast, Rega tests its 
subtyping classification using a sliding window approach and a measurement of 
phylogenetic signal only. jpHMM was chosen because of the probabilistic approach 
to assigning subtype classifications and recombinant breakpoints: local segments of 
the query are aligned to the segments of the reference alignment that are the most 
similar to them. It was considered that concordant recombination results from 
jpHMM and SCUEAL had a high possibility of accuracy, given the differences in the 
construction of the algorithms used.  
In terms of workflow, from a starting point of unaligned sequences, MUSCLE and 
Bio-Edit were used to create an alignment. For downstream analyses involving 
cluster identification, FastTree was used to build an approximate maximum 
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likelihood tree, followed by measurement of genetic distances and subtyping 
classification using SCUEAL and jpHMM; following screening, BEAST was used to 
build trees and time-scaled phylogenies of the identified clusters. For downstream 
analyses involving recombinant classification, RIP, Simplot and jpHMM were used 
to predict the likely recombinant structure; after slicing the alignment into regions of 
putative pure subtypes, PhyML was used for maximum likelihood classification of 
these regions. Subsequently, BEAST was used for evolutionary analyses such as 
time-scaled phylogenies, prediction of tMRCA and phylogeographic analysis. 
2.3.1 Creation of a near full-length HIV-1 reference alignment 
A near full-length HIV-1 reference alignment was constructed for use in 
recombination and phylogenetic analyses.  Sequences covering the HXB2 region 
552 - 9636 (the region amplified using the near full-length sequencing protocol) 
were downloaded from the Los Alamos HIV Sequence Database (LANL) 
(http://www.hiv.lanl.gov/components/sequence/HIV/search/search.html). Sequences 
were downloaded in subtype- and sub-subtype-specific groups of A1, A2, B, C, D, 
F1, F2 G, H, J and K. To reduce computational requirements, the implementation of 
MUSCLE housed at the European Bioinformatics Institute (EBI) website 
(http://www.ebi.ac.uk/Tools/muscle; Edgar, 2004) was used to make subtype-
specific alignments, which were then manually edited using BioEdit version 7.0.5.3 
(Hall, 1999). The genetic distance between the sequences in each subtype 
alignment was measured using a Tamura Nei 93 (TN93) pairwise distance matrix 
implemented in HyPhy (distancematrix.bf), and sequences with less than 6% 
genetic distance were discarded (Poon et al., 2009; Tamura and Nei, 1993). The 
6% genetic distance was chosen for two reasons: firstly, because a distance of 6% 
would allow the capture of the range of genetic variation that is present within 
individual subtype groupings; second, to keep consistency with the conditions that 
were used when the original SCUEAL reference alignment was created 
(Kosakovsky Pond et al., 2009).  
The final subtype-specific alignments were combined with the Los Alamos 2008 
subtype reference alignment, re-aligned using MUSCLE, edited with Bio-Edit, and 
genetic distances measured using the above parameters. At this stage, the V1 and 
V2 hypervariable regions of env were stripped from the alignment owing to 
excessive sequence variability across subtypes.  Finally, the remaining sequences 
were tested for recombination using the Recombinant Identification Program (RIP) 
at the Los Alamos HIV Sequence Database 
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(http://www.hiv.lanl.gov/content/sequence/RIP/RIP.html) with a window size of 400 
base pairs (bp), gap stripped, and a confidence level of 90%; any sequences 
showing evidence of recombination were discarded. As the resulting alignment was 
heavily weighted with subtype B and C sequences, several of these were stripped to 
provide a more manageable and relevant alignment. The final reference alignment 
contained 78 sequences comprising 10 A1, 1 A2, 19 B, 24 C, 4 D, 6 F1, 4 F2, 5 G, 3 
H, 1 J and 1 K sequences. This alignment was used for all subsequent analyses 
where the program implementation did not provide its own reference alignment, and 
is henceforth referred to as the ‘reference alignment’. 
2.3.2 Contribution of recombination to the UK HIV-1 epidemic 
The 2010 download of the UK HIV DRD was used to investigate the contribution of 
recombinant HIV-1 strains to the UK HIV-1 epidemic.  This investigation had two 
parts: a) an assessment of the proportion of recombinant HIV-1 strains present in 
the UK HIV DRD (both as CRFs and as non-CRF recombinants), and b) whether 
any of the non-CRF strains present had been transmitted to sufficient people to 
constitute novel CRF strains.   
The SCUEAL subtype classification from the 2010 UK HIV DRD download was 
used to classify sequences as pure or recombinant strains of HIV-1 for part a) of this 
investigation. To perform the work for part b), however, both the subtype 
classification and the location of any recombination breakpoints was essential data. 
Owing to restrictions in storage capacity, the stored subtype classification in the UK 
HIV DRD did not include recombinant breakpoint locations. Therefore, for part b) of 
this investigation, the sequences studied for the cluster analysis had recombination 
breakpoints determined using two methods: the SCUEAL implementation housed 
on the Datamonkey server (http://www.datamonkey.org), and the jpHMM 
implementation at the GOBICS server (http://jphmm.gobics.de/). The jpHMM 
program provided a schematic of the likely recombinant structure, subtype 
designations for each genomic region, breakpoint locations with 95% confidence 
intervals, and an indication of regions of subtyping uncertainty. Large 95% 
confidence intervals at breakpoint locations indicated uncertainty within the model, 
and suggested that further analysis was required to designate a precise location 
(Schultz et al., 2006, 2009). 
The results from these analyses were used in all downstream analyses. To 
differentiate between the two sets of SCUEAL results, the terms 'SCUEAL 2010' 
and 'SCUEAL 2012' were used throughout.  
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2.3.2.1 Definition of ‘non-CRF recombinant’, ‘unassigned’ and ‘complex’ 
sequences, and ‘clusters’ 
Both ‘non-CRF recombinant’ and ‘unassigned’ sequences were defined as those 
sequences that had been classified as recombinant strains of HIV-1 but were not a 
recognised CRF HIV-1 strain. ‘Complex’ sequences were defined as sequences 
comprising four or more subtype strains that did not share the defined recombinant 
structure of a recognised HIV-1 CRF. For the purposes of this document, all three 
sequence types have been referred to using the term 'unassigned sequence', which 
was defined to include any recombinant HIV-1 strain not included in the Los Alamos 
HIV CRF guide   
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html#CRF55) as of 
December 2012.  
It should be noted that this project did not seek to determine transmission direction 
among individuals sharing similar recombinant HIV-1 strains. The term 'cluster' is 
used throughout to refer to groups of related HIV-1 strains that have met particular 
phylogenetic criteria.  
 
2.3.2.2 Number of unassigned/recombinant sequences present in the UK HIV 
DRD by year 
To assess the degree of recombination in the UK HIV-1 epidemic (as captured by 
the UK HIV DRD) the 55,556 sequences in the UK HIV DRD were stratified by year 
of sampling; further stratification used the SCUEAL subtype classification to classify 
sequences into pure subtypes, recognised CRFs, and unassigned. Duplicate 
sequences from the same patient were excluded. The total number of unassigned 
sequences and the total number of all recombinant sequences (unassigned + 
recognised CRFs) per year were compared to the total number of sequences per 
year.  The SCUEAL simplified subtype field was used for sequence classification. 
Statistical significance was assessed using the Chi squared test and the Chi 
squared trend. The years 1996 and 2009 were excluded from statistical analysis 
due to the low number of sequences captured in 1996 and incomplete data from 
2009 (6 months only). 
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2.3.3 Identification of clusters of unassigned sequences 
Following the investigation into the degree of recombination present in the UK HIV-1 
epidemic, the specific recombinant structures present in the 'subtype-unassigned' 
fraction of the UK HIV DRD were characterised and clusters of identical structures 
were identified. The purpose of this was to identify potential new CRFs that were 
circulating in Britain, rather than specifically examining transmission clusters. 
Subtype B-containing recombinants were selected for this analysis as this subtype 
was traditionally restricted almost exclusively to the MSM risk group, and it was 
hypothesised that any emerging novel population dynamics would be identified 
more readily from this higher risk group as opposed to the lower risk heterosexual 
community.  
2.3.3.1 Subtyping classification of sequences in UK HIV DRD. 
The 2010 detailed SCUEAL subtype was used to capture all potential B-
recombinant sequences in the UK HIV DRD. There were two reasons for choosing 
the detailed subtype field rather than the simplified subtype field as the starting point 
for this analysis. Firstly, the speed of HIV-1 evolution makes the analysis of complex 
recombinant sequences notoriously difficult (Oliveira et al., 2005), and secondly, 
criteria with a wide latitude were desirable in order to capture all possible 
recombinants in the database.  The sequences were analysed for breakpoints and 
subtype classification using SCUEAL and jphMM as detailed previously. The results 
were examined for concordance using the SCUEAL detailed subtype, SCUEAL 
simplified subtype and the jpHMM results. Statistical significance was assessed 
using Fisher’s exact test (two tailed), and a p value of 0.05 was the cut-off for 
statistical significance. 
 2.3.3.2 Approximate maximum likelihood analyses 
Unassigned sequences belonging to subtype B were selected and aligned with the 
reference alignment. FastTree v2.1.3 was used to perform approximate maximum 
likelihood analyses using the Generalised Time Reversible (GTR) +CAT model 
(available from http://meta.microbesonline.org/fasttree/). 
2.3.3.3 Cluster screening  
The topology of the approximate maximum likelihood tree (but not the approximate 
likelihood values) was used to determine potential clusters of unassigned 
recombinants. Jukes-Cantor maximum genetic distances were calculated over the 
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entire tree using a Perl script written by J. Ambrose in the HIV, HBV and HCV 
pathogenesis group at the University of Liverpool. The usual cluster criteria when 
working with data from UK HIV DRD was a genetic distance of 4.5% or less and a 
bootstrap support of 95% (internal criteria set by the steering committee of the UK 
HIV DRD). However, these criteria were created to identify transmission clusters 
rather than novel CRFs; consequently, relaxed criteria were used for this analysis to 
ensure that all potentially related recombinant structures were captured. 
A maximum genetic distance of 10% was used to screen for clusters within the 
approximate maximum likelihood tree. The distance of 10% was chosen in order to 
capture groups of related recombinant structures e.g. groups of sequences with the 
same overall recombinant structure but that may have slightly different breakpoint 
locations. The distribution of the genetic distances of the clusters was measured 
using the D'Agostino-Pearson omnibus normality test. Clusters comprised of pairs 
and clusters containing pure subtype reference sequences were excluded. 
Following this, the SCUEAL 2012 and jpHMM subtype classifications were used to 
exclude clusters containing any sequences that had been previously classified as B-
recombinant (SCUEAL 2010) but were now classified as pure subtype B. Some 
sequences were now classified as belonging to pure subtypes other than B; clusters 
containing these sequences were excluded.  
Clusters remaining following this screening were screened using recombinant 
breakpoint locations. Owing to the variability inherent in the analysis of recombinant 
sequences, both the SCUEAL 2012 and the jpHMM results were used in this 
screening. If a cluster contained sequences showing similar breakpoint locations 
and subtype classifications in either SCUEAL 2012 or jpHMM then it was taken 
forward for further analysis. Finally, as neither SCUEAL nor jpHMM included all 
recognised CRFs in their algorithms, the Los Alamos CRF guide was consulted to 
ensure the remaining clusters were not comprised of sequences from a previously 
described CRF.   
 2.3.3.4 BEAST analyses 
To be considered a potential novel CRF, sequences in each of the identified 
clusters were required to also exhibit clustering when broken down into component 
subtype regions. This was investigated using Bayesian Evolution using Sampling 
Trees (BEAST) version 1.8.0.  
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In order to use the full range of subtype diversity for these analyses, the reference 
alignment was expanded to include selected sequences from the Los Alamos 2010 
HIV subtype reference alignment 
(http://www.hiv.lanl.gov/content/sequence/NEWALIGN/align.html#ref). To reduce 
computational requirements, only sequences relevant to the putative recombinant 
structure were included; due to the close relation between subtypes B and D, 
subtype D sequences were also included. The final alignment for each cluster 
comprised: the sequences under investigation; relevant pure subtype reference 
sequences; reference sequences from all recognised CRFs with similar subtype 
compositions, and an appropriate outgroup for the putative recombinant structure.  
Following the completion of each reference alignment, sequences were sliced into 
component subtype regions according to the identified SCUEAL and jpHMM 
breakpoints. Where conflict existed among the identified breakpoints for the cluster, 
the cluster was split into segments reflecting each conflicting set of breakpoints and 
analysed multiple times. 3xMCMC runs of 1x108 states were run for each alignment 
segment using a strict molecular clock, no tip dates, the Hasegawa, Kishino and 
Yano (HKY) nucleotide model, and a Bayesian Skyline coalescent with 10 groups. 
Trees were visualised using FigTree version 3.1 (available from 
http://tree.bio.ed.ac.uk/software/figtree/).  If the sequences under investigation 
clustered monophyletically in each component tree, with a posterior prior of at least 
0.7, they were considered to be a potential novel CRF.   
2.3.3.5 Demographic analysis 
Risk group analysis was conducted on the clusters that passed all the above criteria 
using the recorded risk groups (where available) in the UK HIV DRD and HPA data. 
The geographic location of each sequence was investigated using the aggregated 
centre data captured by the UK HIV DRD (this gave a general geographic region 
only, e.g. London and Southeast England or Northwest England).  
HIV BLAST at the Los Alamos National Database 
(http://www.hiv.lanl.gov/content/sequence/BASIC_BLAST/basic_blast.html) was 
used to conduct an initial investigation into further instances of the recombinant 
structures beyond the UK HIV DRD, using every sequence in a putative cluster as a 
reference sequence for a BLAST search. To be included in downstream analyses, a 
BLAST match was required to be one of the 10 most related sequences for at least 
75% of the sequences in a cluster. 
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Clusters with interesting demographic properties or geographic links were re-
analysed using time-scaled phylogenies in BEAST v1.8.0 using the conditions 
above (with tip dates) in order to elucidate further linkages. 
2.3.4 Analysis of near full-length sequences 
Following near full-length sequencing of specimens of interest, the following 
phylogenetic analyses were used: 
2.3.4.1 Recombination analyses using RIP 
Following sequence assembly of a query specimen, the sequence was submitted to 
the online RIP program using window size of 400bp, gap stripped, and a confidence 
level of 90% to have a ‘quick look’ at the likely recombination profile. Sequences 
were first submitted against the entire reference alignment of pure subtypes, and 
then subsequently submitted using a reduced profile containing only those subtypes 
showing the highest similarity scores. As this program does not identify 
recombination breakpoints, it was used to gain an overall idea of the likely 
recombinant structure. Specimens showing a recombination profile that warranted 
further breakpoint identification were analysed using two different methods: a) 
jpHMM, and b) sliding window and bootscanning analysis using Simplot.  
2.3.4.2 Recombination analyses using jpHMM 
Query sequences were submitted to the online jpHMM implementation at the 
GOBICS web server (http://jphmm.gobics.de). The identified breakpoints and 
subtype classifications were compared to the breakpoints and subtype 
classifications from the Simplot and maximum likelihood analyses.  
2.3.4.3 Recombination analyses using Simplot 
To perform sliding window and bootscan analyses using Simplot, the query 
sequence(s) were added to the full-length reference alignment. Query sequence(s) 
were added to the reference FASTA file, and this file was aligned using MUSCLE 
with manual editing using BioEdit as described previously. Sliding window analyses 
were performed using Simplot version 3.5.1 (Lole et al., 1999). A 400bp window 
was set with a step size of 20bp. Sequences were gap stripped, and Kimura 2-
parameter genetic distances were used to find the 50% consensus. The 
transition/transversion ratio was set at 2.0. The results from the similarity screening 
were used to select the subtype groups for bootscan analysis.  
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Bootscanning of the query sequence was performed using subtypes A1, B, D, and 
F2 with informative sites analysis. The analysis parameters were as for the similarity 
screening, and 100 bootscan replicates were performed using neighbour-joining 
tree building. Recombination breakpoints were set using the highest statistically 
significant x2 value around the 50% crossover point between subtypes. The 
statistical significance of the identified breakpoints was assessed using Fisher’s 
exact test. Following breakpoint assignment, slices of the alignment corresponding 
to the putative pure subtype regions between each breakpoint were created and 
saved for downstream analyses.  
2.3.4.4 Likelihood mapping and maximum likelihood genotyping of putative 
non-recombinant fragments 
Prior to maximum likelihood analysis, each slice of the alignment was assessed 
using likelihood mapping to determine whether sufficient phylogenetic signal was 
present for robust phylogenetic analysis. Likelihood mapping was performed using 
Tree-puzzle (Schmidt et al., 2002). Ungrouped sequences were analysed for 10,000 
neighbour-joining quartets, using the HKY model of nucleotide substitution. 
Transition/transversion and nucleotide frequency parameters were estimated from 
each dataset, and uniform rate heterogeneity was assumed. Results were viewed 
using EPS Viewer (available from http://epsviewer.org/), and the percentage of un- 
and partly-resolved quartets counted. 
The Entropy tool at the Los Alamos database (available from 
http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.html) was used to 
investigate the variation between subtypes B and D over the genomic region 
covered by alignment slice 4 (HXB2 2101-2503, pol gene). The subtype B and D 
alignments used in the full-length reference alignment were submitted to the tool, 
and the consensus sequence for each subtype produced from this was submitted to 
the EMBOSS pairwise alignment at the European Bioinformatics Institute website 
(http://www.ebi.ac.uk/Tools/emboss/align). Following this, the number of informative 
sites was counted over the length of the region in question.   
Following likelihood mapping, the likelihood parameters for each putatively pure 
subtype region of the HIV-1 genome were estimated using PAUP version 4.0 
(Sinauer Associates, Massachusetts, USA).  HKY85 distance and neighbour-joining 
trees were used to estimate the transition/transversion ratio, nucleotide base 
frequencies, and among-site rate variation under a gamma distribution. These 
parameter estimates were used for maximum likelihood analysis using the 
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Phylogenetic Estimation Using Maximum Likelihood (PhyML) implementation 
housed at the ATGC server (http://www.atgc-montpellier.fr/phyml/; Guindon et al., 
2005), with 1000 bootstrapping replicates, with the exception of alignment slice 5, 
which was too long for 1000 replicates to be performed. In this case, 100 bootstrap 
replicates were considered sufficient. To restrict computational requirements, the 
alignment used for the PhyML analysis was restricted to subtypes A1, B, D and K; 
subtypes A1 and D were chosen as the closest matches to the query sequences, 
subtype B due to its genomic similarity to subtype D, and subtype K as an outgroup.  
Regions of the genome not showing clear identification with one subtype after this 
process (paraphyletic clustering or bootstrap support <70%) were resubmitted to 
PhyML using a greater range of subtypes from the reference alignment (A1, A2, B, 
C, D, F1, F2 and K).   
The phylogenetic trees produced from the maximum likelihood analysis were 
visualised using Dendroscope version 2.3 (available from http://ab.inf.uni-
tuebingen.de/data/software/dendroscope3/download/welcome.html). Schematics of 
finalised recombinant structures were drawn using the Recombinant HIV-1 Drawing 
Tool (RDT) from the Los Alamos website (available from 
http://www.hiv.lanl.gov/content/sequence/DRAW_CRF/recom_mapper.html).   
2.3.5 Confirmation and registration of a novel HIV-1 CRF 
2.3.5.1 Observation of clustering across the entire genome 
Full-length sequencing was performed on six specimens in total. These specimens 
were selected following a two-stage process. Originally, a cluster analysis was 
performed on the 2007 download of the UK HIV DRD by colleagues at the Rega 
Institute in Belgium. This process identified five sequences that could not be 
assigned to a definite subtype. At this stage, ethics approval for full-length 
sequencing of up to 15 specimens was obtained, and the Rega Institute transferred 
the project to University College London and the Royal Free Hospital. Following 
this, 4/5 specimens were obtained from three different clinics in London. These four 
specimens (33365, 8179, 40534 and 34567) were subjected to full-length 
sequencing and the pol regions of the sequences were used to identify further 
instances of the same recombinant structure in the UK HIV DRD.  Additional 
specimens were sought for further full-length sequencing, but due to reasons of 
preserving patient anonymity, it was decided to only attempt to obtain specimens 
from clinics with greater than 10 patients sharing the novel recombinant structure. 
Following record de-linking performed at the UK HIV DRD headquarters, it became 
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apparent that only one clinic, located in Northwest England, had sufficient numbers 
of these patients. This clinic was contacted, and stored samples from two patients 
were available, bringing the total number of specimens obtained for full-length 
sequencing to six.  
To confirm clustering of the A1/D recombinant specimens across the entire HIV-1 
genome, the sequences from all six recombinant specimens were added to the full-
length reference alignment, and sliced into the pure subtype regions indicated by 
the breakpoint analysis. Each alignment slice was analysed using FastTree version 
2.1. Approximate maximum likelihood trees were generated using the GTR+CAT 
model on nucleotide alignments. Trees were visualised using FigTree version 3.1. 
Each tree was examined for evidence that the A1/D recombinant sequences 
clustered with each other within the pure subtype group across the entire HIV-1 
genome.  
2.3.5.2 Comparison with the Los Alamos HIV CRF register 
Following breakpoint identification and subtype assignment of the HIV-1 infections 
of interesting patients, the identified structures were compared with the list of 
registered CRFs on the Los Alamos website 
(http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). CRFs containing 
the same subtypes as identified recombinants were compared to the breakpoints of 
the novel recombinant to confirm the novel recombinant structure had not been 
previously identified as a CRF. 
2.3.5.3 Global BLAST analysis of full-length and individual gene regions 
The full-length structure of recombinants and individual genetic regions of the gag, 
pol and env genes were submitted to Basic Local Alignment Search Tool (BLAST) 
at NCBI (http://blast.ncbi.nlm.nih.gov/) in order to identify any submitted HIV-1 
sequences with similar subtype and breakpoint patterns.  Sequences returned as 
matches were scanned for evidence of recombination using RIP and jpHMM. 
2.3.6 Identification of additional cases of CRF50_A1D in the UK HIV DRD 
2.3.6.1 BLAST, SCUEAL and jpHMM analysis 
To capture additional cases of CRF50_A1D that were not identified during the 
original analysis, a three stage process was used. Firstly, the pol sequences of 
three specimens were used as reference sequences for a local BLAST search of 
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the UK HIV DRD. Following this, the top 500 closest matches to each sequence 
were subtyped using SCUEAL and jpHMM, and the breakpoint locations (and 
statistical confidence intervals) used to identify possible matches.  
Possible matches were confirmed using the following criteria: a) a matching 
SCUEAL breakpoint location, or a breakpoint that included the SCUEAL breakpoint 
in the 95% confidence interval; b) a matching jpHMM breakpoint location, or a 
nearby breakpoint location that included the jpHMM breakpoint in the 95% 
confidence interval.  
In addition to matching breakpoint locations, potential additional cases were 
required to show a matching recombinant structure.  Both B/A1 and D/A1 structures 
were admitted as possible matches owing to the similarity of subtypes D and B in 
pol (see Shannon Entropy results below).   
Following this initial determination, sequences were confirmed as additional cases  
by building an approximate maximum likelihood tree using FastTree to confirm 
monophyletic clustering. Multiple sequences from the same patient were excluded 
using UK CHIC ID and demographic information. 
2.3.6.1.2 Entropy analysis 
Shannon entropy testing was performed using the Shannon Entropy tool located at 
the LANL HIV database 
(http://www.hiv.lanl.gov/content/sequence/ENTROPY/entropy.html). Subtypes B 
and D were compared between HXB2 positions 2253 and 3572.  
 
2.3.7 Emergence and distribution of CRF50_A1D in the UK 
The time to Most Recent Common Ancestor (tMRCA) of CRF50_A1D in the UK was 
determined using time scaled phylogenies in BEAST v1.6.1.  All CRF50_A1D 
sequences (both full-length and pol only) were aligned with the following reference 
sequences: 4 full-length subtype A sequences; 4 full-length subtype D sequences; 
the 3 closest full-length sequence matches to CRF50_A1D in BLAST; 4 subtype C 
sequences (outgroup – chosen from the full-length reference alignment). The 
alignment was performed using HIV align 
(http://www.hiv.lanl.gov/content/sequence/VIRALIGN/viralign.html) and manually 
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edited using Bioedit. The month of sampling (sequence date) was converted into 
decimal to assume sampling in the middle of the month using the formula: 
                   
           
  
  
2.3.7.1 Model selection 
Find Model at the Los Alamos National database was used to predict the best 
nucleotide substitution model for use 
(http://www.hiv.lanl.gov/content/sequence/findmodel/findmodel.html). In each case, 
the initial tree was constructed using PAUP Jukes Cantor/Neighbour Joining and the 
reduced set of possible models was used. The model with the lowest Akaike 
Information Criterion (AIC) score was considered the best model. 
Strict and relaxed molecular clocks and GTR and HKY nucleotide substitution 
models were tested. A Bayesian Skyline coalescent was used throughout. Three 
runs of 1x108 states were performed for each set of model conditions.  To ease 
computational requirements the multiple tree and log files were combined using Log 
Combiner (available from http://beast.bio.ed.ac.uk/LogCombiner) with a resampling 
rate of 10,000 and a burn-in of 10%. Maximum clade credibility trees were 
annotated using Tree Annotator (available from 
http://beast.bio.ed.ac.uk/TreeAnnotator) and viewed using FigTree. Bayes factors 
were calculated using Tracer (available from http://beast.bio.ed.ac.uk/Tracer). 
2.3.7.2 Time scaled phylogenies 
Time scaled phylogenies were performed to investigate the likely emergence date of 
CRF50 using all identified CRF50 sequences, the subtype A region, subtype D 
region and the concatenated A/D region of pol.  
Time scaled phylogenies in BEAST v1.6.1 were performed using three runs of 1x108 
states, a relaxed uncorrelated log normal molecular clock, the GTR nucleotide 
substitution model, tip dates and a Bayesian Skyline coalescent with 10 groups and 
a constant expansion. No other priors were set. Multiple runs were combined using 
Log Combiner with a resampling rate of 10,000 and a burn-in of 10%. All Effective 
Sample Sizes (ESS) were required to be greater than 200 for run acceptance. 
To confirm the tMRCA, the five full-length sequences were used to analyse subtype 
A1 and D regions of gag, pol and env. Due to the small number of sequences, a 
simpler model and a longer run length were used for this analysis. Six runs of 
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2.5x108 states, a relaxed uncorrelated log normal molecular clock, the HKY 
nucleotide substitution model and a Bayesian skyline coalescent with two groups 
and a constant expansion were used. A gamma distribution prior was set on the 
covariance. Multiple runs were combined using Log Combiner as described above. 
The regions  of each gene used for analysis were dictated by the recombinant 
structure of CRF50, and were as follows (numbers represent HXB2 nucleotide 
positions):   
Subtype A: 
 gag: 552-1274 
 pol: 2504-3256 
 env: 6612-7248 
Subtype D: 
 gag: 1274-1884 
 pol: 2253-2504 
 env: 8568-7248 
 
The final characterised full-length sequence was a CRF50/B URF. In order to 
ascertain whether this recombinant was a product of onward recombination, or 
whether this sequence was the source of CRF50, the time scaled phylogenies were 
performed both with and without this sequence.   
2.3.7.2.1 Bayesian skyline reconstruction 
The demographic history of CRF50_A1D infections in the UK was reconstructed 
using a Bayesian skyline coalescent. A stepwise (constant) skyline variant was used 
to model the skyline population and group sizes to estimate the number of effective 
CRF50_A1D  infections. 
2.3.7.3 Phylogeographic analysis  
2.3.7.3.1 Geographic locations of CRF50_A1D patients 
Geographic locations of patients were determined using aggregated centre data as 
detailed above. A midpoint longitude/latitude point was used to create an arbitrary 
geographic location within each group of aggregated clinics. 
2.3.7.3.2 Discrete phylogeographic analysis using BEAST 
The combined tree file from the time-scaled emergence analysis was resampled to 
contain 1,000 trees and used as the input tree for discrete phylogeographic analysis 
in BEAST v1.6.1.  The .xml files from the emergence analysis were edited according 
to the instructions at http://beast.bio.ed.ac.uk/Discrete_Phylogeographic_Analysis in 
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order to estimate the path of CRF50 geographic spread across the UK. 2xMCMC 
runs of 2.5x108 states were performed and combined using Log Combiner as 
detailed above. Trees were annotated and visualised using Tree Annotator and 
FigTree as detailed above. 
2.3.7.3.3 Google Earth analysis 
Following the BEAST phylogeographic analysis, the tree files were converted to 
.kml format and converted for visualisation in Google Earth. CamStudio 
(http://camstudio.org/) was used to capture the Google Earth rendering on video. 
 
2.3.8 Global origin of CRF50_A1D  
The likely global origin of the A1 and D strains comprising CRF50_A1D was 
investigated. Gag, pol and env A1 and D regions of CRF50 were investigated 
separately. 
2.3.8.1 Construction of global alignments 
Alignments of A1 and D sequences were constructed using publicly available 
sequences downloaded from the LANL database, using the geography search. 
Sequences were initially downloaded from East African countries, as this region 
traditionally contains the highest number of subtype A, subtype D and A/D 
recombinant infections. Additional sequences were obtained from the LANL 
database by selecting all countries that had a prevalence in the LANL database of 
A1 or D sequences of 10% or more. UK sequences were included wherever 
possible; in practice this was only in the pol region. All pure A1 and D UK 
sequences lodged in the UK HIV DRD were included in the pol analysis. The list of 
countries searched was: Angola, Belarus, Botswana, Burundi, Cameroon, Central 
African Republic (CAR), Chad, DRC, Ethiopia, Gabon, Georgia, Ghana, India, 
Kenya, Latvia, Tanzania, Russian Federation, Rwanda, Ukraine, Uganda, and the 
UK. 
Potential reference sequences were screened by year and genetic distance. 
Sequences predating the earliest sequence in the UK HIV DRD were used in order 
to try and ascertain whether the recombinant was imported into the UK as a 
recombinant or whether the recombination event occurred in the UK.   
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Genetic distance screening was used to reduce the number of sequences in each 
alignment, and therefore ease computational requirements. Due to the difference in 
genetic variation present in different HIV-1 genes, a different genetic distance cut-off 
was used for each gene. Different cut-offs were also used for subtype A and 
subtype D in the pol gene due to the number of sequences available. The cut-offs 
used were: gag: 6%; pol: 14% (subtype A1) and 6% (subtype D), env: 20%. 
The number of sequences contained in the trees were too many to allow tip dates to 
be used in the analysis, or to list each reference sequence used. Therefore, the 
phylogenetic trees from this analysis have been presented with branches coloured 
by either country of origin or geographic region; the relevant accession numbers of 
reference sequences have been included where appropriate.  
2.3.8.1.1 Selection of A1 and D regions 
The sequence regions used for analysis were those used in the time scaled 
phylogenies detailed in section 2.3.7.2 above. 
2.3.8.2 Approximate maximum likelihood analysis  
Approximate maximum likelihood analysis was performed using the FastTree 
conditions detailed previously. The following criteria were used to assess the origin 
of the CRF50 A1 and D strains: 
 Clustering with of both A1 and D CRF50 strains with exclusively UK A1 and 
D sequences indicated that CRF50 arose from a recombination event in the 
UK (possible for the pol gene trees only); 
 Clustering with strains from other countries in the presence of UK A1 and D 
strains indicated likely recombination in another country followed by 
importation into the UK as a recombinant structure.  
2.4 Statistical analyses 
An estimation of the likely speed of progression of CRF50_A1D infections was 
performed using CD4 decline slopes as a proxy for disease progression.   
2.4.1 ID of CRF50_A1D patients in the CHIC database 
CRF50_A1D patients who had clinical and demographic data captured as part of 
UK CHIC were identified. The anonymised CHIC ID reference numbers were 
transferred to the MRC-CTU, de-anonymised at source, and the new reference IDs 
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were transferred to Professor Caroline Sabin at CHIC. Professor Sabin extracted 
the data and linked it to the original anonymised reference identifiers. No linkable 
patient identifiable information was transferred outside UK CHIC. 
  
The CHIC inclusion criteria were: age over 16; entered the cohort between January 
1, 1998 and June 2010; known HIV-1 subtype and at least two CD4+ T-lymphocyte 
counts within one year while ART naive.  CD4 cell counts, HIV-1 RNA viral loads 
and ART history were extracted from the CHIC database for each patient that met 
the criteria. 
 
Once data were received, post-treatment HIV-1 RNA viral loads and CD4 cell 
measurements were excluded. Patients were also excluded from further analysis if 
there were less than three pre-treatment CD4 counts available.  
 
2.4.2 Transformation of data and statistical analysis over time 
To calculate CD4 cell count decline per year, CD4 cell measurement dates were 
normalised by subtracting the first date of measurement for each individual 
(baseline) from each subsequent measurement date for that individual. This 
associated each CD4 cell measurement with a 'days from baseline' value; dividing 
the 'days from baseline' by 365.25 scaled these values to 'years from baseline'. 
Following normalisation, the square root of each CD4 cell measurement was taken 
and simple linear regression was performed for each patient. Due to the low number 
of patients involved the slope for each patient was studied individually. 
2.4.3 Comparison to subtype B slopes 
The CD4 count slopes for patients were compared to the CD4 count slopes for 
subtype B patients that were estimated by Klein in 2010 (CROI 2011, Abstract B-
131).  
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Chapter 3: Contribution of viral recombination to the UK HIV-
1 epidemic. 
3.1 Proportion of recombinant HIV sequences in the UK HIV DRD 
3.1.1 Genotyping the UK HIV DRD: Rega and SCUEAL results 
The 2010 UK HIV DRD SCUEAL and Rega genotyping results were obtained from 
the UK HIV DRD steering committee. Sequences were initially categorised 
according to whether a subtype could be assigned. Categorisation of the results into 
sequences that were subtype–assigned and those that were subtype-unassigned 
showed that SCUEAL returned significantly more unassigned results than Rega 
(6,076 vs. 3,801, p=<0.001; Table 3_1). Both methods identified the same number 
of Group O sequences in the database; Rega identified one HIV-2 sequence, 
whereas SCUEAL categorised this sequence as unknown. The SCUEAL method 
had 73 subtyping failures. No failures were recorded with the Rega method. 
Classification Rega SCUEAL 
Assigned 51,733 49,405 
Unassigned 3,821 6,076 
HIV-2 1 0 
Group O 1 1 
Unknown 0 1 
Failed 0 73 
Total 55,556 55,556 
Table 3_1. Classification of UK HIV DRD records using two different genotyping 
methods. The 55,556 sequences in the 2010 download of the UK HIV DRD were stratified 
into subtype-assigned, subtype-unassigned, failed and unknown using Rega and SCUEAL 
genotyping methods. 
 
3.1.2 Proportion of unassigned/recombinant sequences in the UK HIV DRD 
After removing any duplication, stratifying the UK HIV DRD sequences by year of 
sample showed that the number of unassigned sequences in the database 
increased from 0 in 1996 to 1140 (12.6%) in 2008, the last complete year of 
sampling (p = <0.001; Table 3_2). The chi squared test for trend over the same time 
period was also significant (p = <0.001).  One year (2004 - 2005) showed a 
statistically significant year-on-year increase (p = <0.01). The total number of 
recombinant records (unassigned sequences + recognised CRF) increased from 0 
in 1996 to 1,377 in 2008 (p = <0.001; chi squared test for trend p = <0.001); two 
years showed statistically significant year-on-year increases: 2004 - 2005 (p = 
<0.01) and 2006 - 2007 (p = 0.02).   
46 
 
During this same period, the proportion of recognised CRFs increased from 0% in 
1996 to 2.6% in 2008 (Figure 3_1). Unassigned sequences increased more rapidly 
than CRFs, demonstrating that the increase in recombinants as captured by the UK 
HIV DRD was independent of the increase in CRF circulation.  
 
Year Total 
records 
Unassigned 
records 
% 
Unassigned 
p Recombinant 
records 
% 
Recombinant 
p 
1996 7 0 0.0  0 0.0  
1997 334 17 5.1  21 6.3  
1998 464 19 4.1 0.64 21 4.5 0.38 
1999 588 26 4.4 0.92 30 5.1 0.79 
2000 855 50 5.8 0.31 61 7.1 0.18 
2001 1326 89 6.7 0.50 109 8.2 0.44 
2002 1795 128 7.1 0.72 163 9.1 0.48 
2003 2396 184 7.7 0.57 225 9.4 0.80 
2004 3886 332 8.5 0.29 420 10.8 0.11 
2005 5975 642 10.7 <0.01 801 13.4 <0.01 
2006 7474 849 11.4 0.33 1038 13.9 0.50 
2007 7938 987 12.4 0.07 1226 15.4 0.02 
2008 9053 1140 12.6 0.80 1377 15.2 0.73 
2009 906 124 13.7  153 16.9  
Table 3_2. Unassigned and total recombinant sequences stratified by year. 
Unassigned records include non-CRF recombinants; total recombinant records include non-
CRF + CRF recombinants. P values were calculated using Chi-squared with Yates’ 
correction and represent year-on-year increases. 
 
 
Figure 3_1. Unassigned and recombinant records as a proportion of total records in 
the UK HIV DRD.  Non-recombinant, CRF recombinant and unassigned recombinant 
sequences as a proportion of the total UK HIV DRD records. Non-recombinant sequences 
are coloured purple, CRF-recombinant records are coloured red and unassigned-
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recombinant records are coloured blue. The proportion of unassigned-recombinant records 
increased more than the proportion of CRF-recombinant records. 
 
3.2 Identification of clusters of complex sequences 
Following confirmation that the contribution of subtype-unassigned sequences to the 
UK HIV-1 epidemic was increasing, the nature of these unassigned sequences was 
investigated. As indigenous HIV transmission in the UK has been traditionally 
composed of subtype B infections transmitted among MSMs, we focused the 
investigation on unassigned sequences that contained subtype B in their mosaic 
structure. This was in order to draw inferences regarding whether population mixing 
between different risk groups was driving the increase in unassigned recombinant 
sequences.        
3.2.1 Subtyping classification of sequences in UK HIV DRD 
 2,030 sequences were classified as unassigned subtype B-recombinant in the 2010 
SCUEAL genotyping results. All 2,030 sequences were submitted to SCUEAL 2012 
and jpHMM for breakpoint analysis and the results between all three methods were 
compared. 
3.2.1.1 Comparison of SCUEAL 2010 and SCUEAL 2012 
The comparison first compared the SCUEAL 2010 and SCUEAL 2012 results. 
Using the SCUEAL detailed subtype field, 268/2,030 (13.2%) of subtyping results 
were concordant. The proportion of concordant results increased when using the 
SCUEAL simplified subtype field (1,174/2,030, 57.8%), but were still less than would 
generally be expected for two sets of results from the same method. 
Of the 858 non-concordant sequences (when using the simplified subtype field), 
409/858 (47.8%) were sequences that had been classified as subtype B-
recombinant by SCUEAL 2010 but were classified as pure subtype B by SCUEAL 
2012. To investigate these 409 sequences the jpHMM result was used to try and 
gain a consensus. Overall, 365/409 (89.2%) sequences were also classified as pure 
subtype B by jpHMM. Of the remaining 44/409 discrepant sequences, 27/44 
(61.2%) were sequences that contained gaps; and 26/27 (96.3%) contained an 
erroneous A2 classification by jpHMM (Figure 3_2). If the misclassified gap 
sequences were discarded, the concordance between jpHMM and SCUEAL 2012 
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for those sequences classified as subtype B-recombinant by SCUEAL 2010 but 
pure subtype B by SCUEAL 2012 was 95.3% (365/383). 
 
 
                       
Figure 3_2. Erroneous jpHMM A2 classification in sequences with gaps. Example of a 
jpHMM result for a sequence with a gap between HXB2 2549 and 2705. A gap (i.e. a region 
for which no nucleotides could be determined) in this position is typical of sequencing results 
from the Trugene genotyping assay. Small regions on either side of the sequence gap have 
been misclassified by jpHMM as subtype A2, suggesting that sequence with gaps should be 
genotyped using an alternative method.  
 
Of the remaining 449 sequences that showed discrepant results from the two 
SCUEAL runs, 183/449 (40.1%) were not truly discrepant but showed minor 
typographic differences in the displayed results displayed, 130/449 (29.0%) were 
sequences that were recombinant (e.g. G/D/B/K) by one set of results but classified 
as complex by the other, 29/449 (6.5%) were sequences originally classified as pure 
subtype B by SCUEAL 2010 but as subtype B-recombinant by SCUEAL 2012, and 
31/449 (6.9%) were sequences that were subtype B-recombinant by SCUEAL 2010 
but pure non-B subtypes by SCUEAL 2012. The remaining 76/449 (16.9%) 
sequences showed discrepant recombinant structures.  
If the 183 sequences showing typographical differences were classified as 
concordant, then the proportion of concordant results increased to 1,357/2,030 
(66.8%) for the simplified subtype results. If those sequences classified as 
recombinant by one genotyping run and complex by another were also included as 
concordant, the proportion further increased to 1,487/2,030 (73.2%).  
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3.2.1.2 Comparison of SCUEAL 2010, SCUEAL 2012 and jpHMM 
The breakdown of the SCUEAL 2010 results was as such: 
• 2,030 B-recombinant sequences (detailed subtype field) 
– 1176 B-recombinant (simplified subtype field) 
–  854 pure subtype B (simplified subtype field) 
Owing to the variability observed in the detailed subtyping results in this previous 
section, the simplified subtype field was used to investigate the concordance 
between all three sets of genotyping results. Firstly, all sequences that were pure 
subtype B in the simplified subtype classification were removed. This left 1,176 
SCUEAL 2010 subtype B-recombinant sequences. The jpHMM results for these 
sequences showed 609/1176 (51.8%) pure subtype B, 120/1176 (10.2%) non-B 
subtypes, 444/1176 (37.8%) subtype B-recombinant, and 3/1176 (0.26%) were 
subtyping failures.  
The SCUEAL 2012 results for the 1,176 SCUEAL 2010 subtype B-recombinant 
sequences showed 409/1176 (34.8%) pure subtype B, 68/1176 (57.8%) non-B 
subtypes, and 699/1176 (59.4%) subtype B-recombinants. Sequences that were 
classified as subtype B-recombinant by jpHMM were not necessarily classified as 
subtype B-recombinant by SCUEAL 2012. jpHMM showed a significantly higher 
proportion of pure subtype B results than SCUEAL 2012 (51.8% vs. 34.8%, 
p=<0.01) and a significantly higher proportion of non-B results (10.2% vs. 5.8%, 
p=<0.01). Overall, 379 sequences were subtype B-recombinant sequences by all 
three methods (Table 3_3). 
 
Method B Non-B B-recombinant Failures Total 
jpHMM 609 120 444 3 1176 
SCUEAL 2012 409 68 699 0 1176 
Table 3_3. Comparison of jpHMM and SCUEAL 2012 results to SCUEAL 2010 results 
using the SCUEAL simplified subtype classification. 1176 SCUEAL 2010 B-recombinant 
sequences were genotyped using SCUEAL 2012 and jpHMM.  jpHMM showed the lowest 
number of B-recombinant results and the highest number of pure subtype B results. jpHMM 
also showed the highest number of results that did not include subtype B.   
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3.2.2 Approximate maximum likelihood analyses 
The comparison between the three subtyping methods showed that, even when 
using the simplified subtype classification, a high degree of non-concordance was 
observed between the three subtyping methods. Therefore, all 2,030 sequences 
identified by the detailed SCUEAL 2010 results as subtype B-recombinant were 
carried over to the approximate maximum likelihood analysis that was the first stage 
of cluster identification (Figure 3_3). 
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Figure 3_3. Approximate maximum likelihood analysis of 2,030 putative B-
recombinant sequences.  2,030 sequences classified as B-recombinant by SCUEAL 2010 
were aligned with 78 pure subtype reference sequences and analysed using FastTree v2.1. 
The tree is mid-point rooted. Pure subtype sequences were coloured as follows: A = red; B = 
0.03
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teal, C = blue, D = turquoise, F1 = yellow, F2 = mustard, G = pink, H/J/K = purple.  The 
2,030 query sequences are coloured black. A high proportion of sequences were located in 
branches containing subtype B reference sequences.   
 
The tree showed the majority of the sequences distributed among the subtype B 
reference sequences, which was expected given the high number of pure subtype B 
subtyping results in the SCUEAL 2012 and jpHMM analyses. The tree topology 
indicated potential novel CRFs in three regions. The first of these was near the 
subtype G reference sequences, where several branches were located between the 
subtype B and subtype G reference sequences (Figure 3_4). These branches 
indicated the presence of B/G recombinant sequences; six of these branches 
contained greater than three sequences, suggesting novel CRFs. 
 
 
 
Figure 3_4.  Putative subtype B/G recombinant CRF sequences. Enlarged section of 
Figure 3_3 showing the region surrounding the subtype G reference sequences (in pink). 
Several branches were located between the subtype B and subtype G references, indicating 
the presence of B/G recombinant sequences. Numbers 1-6 indicate branches with sufficient 
sequences to be potential novel CRFs.  
 
 
The second region of interest was located near the subtype F reference sequences 
(Figure 3_5), where the tree showed five branches with sufficient sequences to 
comprise novel CRFs.  
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Figure 3_5. Putative subtype B/F recombinant CRF sequences. Enlarged section of 
Figure 3_3 showing the branches surrounding the subtype F reference sequences (F1 = 
yellow, F2 = mustard). Several branches are located between the subtype B and subtype F 
references, indicating the presence of B/F recombinant sequences. Numbers 1-5 indicate 
branches with sufficient sequences to be potential novel CRFs.  
 
The final region was located at the base of the tree (Figure 3_6). This region 
showed seven branches with sufficient sequences to be novel CRFs. Three regions 
were located between the subtype B reference sequences and the remainder of the 
reference sequences, one region was located close to the subtype A sequences, 
and the remaining three regions were located close to the subtype C sequences.  
Regions one, two and six contained sizeable numbers of sequences (58, 27 and 14, 
respectively), which, if confirmed as novel CRFs, could indicate a significant 
population impact. 
 
 
 
 
 
 
 
 
0.03
1 
2 
3 
4 
5 
54 
 
 
Figure 3_6. Putative novel CRF branches. Enlarged section of Figure 3_3 showing the 
region below the subtype B reference sequences. Seven branches indicated potential novel 
CRF clusters. Branches 1-3 were located between the subtype B sequences and the 
remainder of the reference sequences, branch 4 was located close to the subtype A 
sequences (in red), branches 5, 6 and 7 were located close to the subtype C sequences (in 
blue).  H/J/K reference sequences were coloured purple, and subtype D sequences were 
coloured turquoise.  
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 3.2.3 Cluster screening  
Cluster screening was performed on the whole tree and was reviewed alongside the 
SCUEAL 2012 and jpHMM genotyping results in order to identify groups of closely 
related sequences with identical recombinant structures. Maximum genetic distance 
measurements of the approximate maximum likelihood tree showed 2088 clusters 
with GDs ranging from 0 to 15.9%. The D'Agostino-Pearson K2 value was 182.0, 
indicating that the GD of the clusters were not normally distributed. Overall, 1959 of 
these had a maximum GD of 10% or less; 658 clusters were comprised of two 
sequences and 139 clusters contained a pure subtype reference sequence. After 
further screening using the SCUEAL 2012 and jpHMM results to exclude those 
clusters containing sequences now classified as pure subtype B strains and 
sequences now classified as other pure subtype strains, 281 clusters remained. 
These 281 clusters were screened according to recombinant breakpoint location 
and subtype classification; following this process 28 clusters remained. The 
maximum genetic distance in any cluster was 9.0% (Table 3_4). Some clusters 
displayed recombinant structures similar (but not identical) to recognised CRF 
structures, notably clusters 3 and 4 (CRF 24-like), 8 (CRF17, 38, 39, 44-like), 10 
(CRF03), and 19 and 20 (CRF31-like), respectively. The sequences identified as 
part of Cluster 9 contained some sequences that belonged to an already-classified 
CRF (CRF50; see subsequent chapters for details of the identification of 
CRF50_A1D). In order to confirm that Cluster 9 did not contain sequences from two 
very closely related (but separate) CRFs, the CRF50 sequences were excluded 
from Cluster 9 and the remaining sequences were subjected to the same analysis 
process as the other clusters.    
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Cluster number Recombinant 
Structure 
Max GD (%) No. of members 
1 G/B 8.6 26 
2 G/B 7.4 15 
3 G/B 7.4 12 
4 G/B 3.0 6 
5 G/B 1.2 4 
6 G/F/B 0.5 3 
7 F/B 4.9 4 
8 F/B 5.9 14 
9 D/A 6.8 60 
10 D/A 5.2 12 
11 D/A/B 1.6 3 
12 01/B 6.5 5 
13 A/B 6.5 8 
14 B/A/J/G 2.8 6 
15 B/C 0.3 5 
16 B/C 5.0 4 
17 B/G/B 3.0 7 
18 B/01 2.1 3 
19 C/B/C 3.2 7 
20 B/C/B 1.5 5 
21 B/U 1.1 4 
22 B/A 4.4 4 
23 B/A 3.6 3 
24 B/A 1.5 5 
25 B/A/B 8.1 21 
26 C/B/C 6.4 5 
27 C/B/C 1.2 4 
28 G_complex 9.0 23 
Table 3_4. Potential CRF clusters identified through recombinant structure and 
maximum genetic distance screening. 28 potential clusters were identified and selected 
for phylogenetic analysis of putative pure subtype regions using BEAST. Genetic distance 
measurements and recombinant structure were based on partial pol sequences captured by 
the UK HIV DRD. 
 
3.2.4 Phylogenetic and demographic analyses 
Phylogenetic screening was performed using the putative pure subtype regions of 
each cluster suggested by the jpHMM and SCUEAL genotyping results. Please note 
that in the following cluster descriptions, the full breakpoint results refer to 
sequences definitively identified as belonging to a cluster, not the complete list of 
putative cluster members listed in Table 3_4. 
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Following phylogenetic analysis, BEAST analysis identified 15 confirmed clusters 
comprised of sequences with novel recombinant structures, comprising 94 
individuals in total (Table 3_5). Relating the confirmed clusters back to the original 
approximate maximum likelihood tree (Figure 3_3) showed that Cluster 1 was group 
2 in Figure 3_4, Cluster 2 was group 6 in Figure 3_4, Cluster 3 was group 1 in 
Figure 3_4, Cluster 5 was group 4 in Figure 3_6, Cluster 6 was group 1 in Figure 
3_5, Cluster 15 was group 7 in Figure 3_6, Cluster 19 was group 6 in Figure 3_6, 
Cluster 25a was group 3 in Figure 3_6, Cluster 25b was group 2 in Figure 3_6 and 
Cluster 25c was located in group 1 in Figure 3_6. Cluster 27 was group 5 in Figure 
3_6. The remaining identified clusters were located in un-enlarged branches.  
The largest cluster contained 23 members; 1/15 (6.7%) clusters contained 10 and 
eight members, respectively, 2/15 (13.3%) contained six members, 4/15 (26.6%) 
contained five members, 3/15 (20%) contained four members and 3/15 (20%) 
clusters contained three members. The genetic distance range was 0.2-5%.  
Overall, 58/94 (61.7%) of cluster members were male, 14/94 (14.9%) were female, 
16/94 (17.0%) were IVDU, 36/94 (38.3%) were MSM and 15/94 (16.0%) were 
heterosexual. 58/94 (61.7%) cluster members were white, 10/94 (10.6%) were 
Black-African and 1/94 (1.1%) was Black-Caribbean.  When compared to the 
proportions seen among individuals infected with pure subtypes and recognised 
CRFs, the proportion of males in clusters was significantly higher (61.7% vs. 39.5%, 
p= <0.01), as was the proportion of IVDUs (17.0% vs. 1.5%, p= <0.01) and people 
of white ethnicity (61.7% vs. 31.4%, p= <0.01). 
The proportion of females in clusters was not significantly different compared to 
individuals infected with pure subtypes and recognised CRFs (14.9% vs. 15.3%, 
p=0.93), as was the proportion of MSMs (38.5% vs. 28.7%, p= 0.17), the proportion 
of heterosexuals (16.0% vs. 23.0%, p= 0.23), the proportion of Black-Africans 
(10.6% vs. 16.3%, p= 0.25) or the proportion of Black-Caribbeans (1.1% vs. 1.9%, 
p= 0.85).  
Overall, 3/15 (20%) of clusters showed exposure profiles composed of >1 exposure 
route.  One cluster was mixed IVDU/heterosexual, composed exclusively of white 
ethnicity and contained both males and females (Cluster 3). One cluster (6.7%) was 
mixed Heterosexual/MSM and was composed exclusively of white men (Cluster 15). 
Two clusters were comprised exclusively of sequences from heterosexuals (Cluster 
2 and Cluster 14); both clusters contained both male and female members. Cluster 
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2 was comprised exclusively of people of white ethnicity, and Cluster 14 showed 
Black-African members only. Cluster 14 had a complex recombinant structure that 
did not allow for evolutionary analysis prior to full-length sequencing. 
Overall, 2/4 sequences in Cluster 2 belonged to white heterosexual men and 2/4 
sequences belonged to white heterosexual women. The geographic region 
identified with these sequences was exclusively Southwest England/Wales. 
Eight  clusters were comprised exclusively of MSM sequences, of which 5/8 were 
exclusively white, 2/8 were mixed white/Black-African and one was mixed 
white/Black-African/Black-Caribbean; 1/5 white MSM cluster, comprising 10 
members, was located in London/Southeast England and Northwest England 
(cluster 25a). Another white MSM cluster containing three members was located in 
London/SE England and Scotland; 1/5 white MSM clusters were located in 
Northwest England (Cluster 5), and a further 1/5 white MSM cluster was located in 
both Northwest England and Scotland (Cluster 25b). The remaining white MSM 
cluster was located in East Anglia, a region of the UK immediately north of London. 
Of the three MSM clusters showing mixed ethnicity, 2/3 were located exclusively in 
London (Clusters 13 and 19); the remaining MSM cluster with mixed ethnicity was 
located in SW England and Wales (Cluster 18). 
Finally, extra-UK geographic links were found in 5/15  (33.4%) (Clusters 1, 2, 15, 
25, 19).  
Please see below for the detailed cluster analysis. Following this analysis, full-
genome sequencing of the identified clusters was required to confirm the 
recombinant structures as novel CRF strains of HIV-1.  
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Cluster No.  Max GD 
(%) 
Structure Breakpoint 
location 
(HXB2) 
Risk 
group 
Gender 
 
Ethnicity Location 
1 23 3.5 G/B 2985 IVDU, 
MSM, Het 
M/F White/ 
mixed 
London/ 
SE 
England 
2 4 0.2 G/B 2406 Het M/F White SW 
England/
Wales 
3 5 2.8 CRF14/B 2563 IVDU, Het M/F White SW 
England/
Wales 
5 4 1.2 G/?B 3049 MSM M White NW 
England 
6 3 0.5 G(or 
related)/F/
B 
2500/2698 IVDU M/F White East 
Anglia 
13 6 0.87 A1/B 2716 MSM M White/ Black 
African/ 
Black 
Caribbean 
London/ 
SE 
England 
14 6 2.8 B/AE/J/ 
CRF18 
2354/2815/ 
3093 
Het M/F Black-
African 
London/ 
SE 
England 
15 5 0.3 B/C 2589 Het, MSM M White London/ 
SE 
England 
and NW 
England 
16 4 5.0 CRF07/C 3079 MSM M White East 
Anglia 
18 3 2.1 B/AE 3231 MSM M White/ 
Black-
African 
SW 
England/
Wales 
19 5 1.8 C/B/C 2726/3089 MSM M White/ 
Black-
African 
London/ 
SE 
England 
25a 10 2.1 B/CRF50/
B 
2555/3048 MSM M White London/ 
SE 
England 
25b 8 1.5 B/CRF50/
B 
2545/2941 MSM M White Scotland/
NW 
England 
25c 3 0.4 CRF50/B 2632/2943 MSM M White London/ 
SE 
England 
27 5 4 C/B/C 2377/2719 U U U Mixed 
Table 3_5. Summary table of likely novel CRF clusters identified through BEAST 
phylogenetic analysis. 15 clusters were identified that may comprise novel CRFs. Further 
confirmation using full-genome screening is necessary before cluster sequences can be 
registered as novel CRFs.  
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3.2.4.1 Cluster 1 (G/B) 
Cluster 1 had 26 members and a maximum genetic distance of 8.6% (Table 3_4). 
The alignment slice was placed at HXB2 2985, the most commonly predicted 
breakpoint (jpHMM, 19/26 sequences). 
The tree for slice 1 showed 24/26 sequences clustering monophyletically with a 
posterior probability of 1 (Figure 3_7a). The sequences clustered closest to subtype 
G/CRF14.  Slice 2 showed 24/26 sequences clustering monophyletically with a 
posterior probability of 0.85. One of the non-clustering sequences was the same 
sequence as in slice 1 and one was different; when these were excluded from the 
cluster, the posterior probability decreased to 0.73 (Figure 3_7b). None of the three 
non-clustering sequences had a predicted breakpoint at HXB2 2985. The 24 
sequences clustered closest to subtype B with moderate support (0.63).  The three 
sequences that did not exhibit consistent monophyletic clustering were excluded 
from the cluster; this reduced the maximum genetic distance to 3.5%.  
Figure 3_7. Cluster 1: G and B fragments. Maximum clade credibility trees of putative 
pure subtype regions. The breakpoint was placed at HXB2 2985. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red. Sequences 
that do not exhibit monophyletic clustering are highlighted in green. a) Slice 1; b) Slice 2.      
 
The full breakpoint results showed that jpHMM identified 22/23 sequences as G/B 
recombinant and 1/23 as B/G/B recombinant (Table 3_6). The breakpoint 
predictions were consistent and had an interval of 40 nucleotides (HXB2 2956 – 
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HXB2 2996). SCUEAL 2012 consistently predicted 3 breakpoints: HXB2 2585-2630; 
HXB2 2705-2827 and HXB2 2956-2959.  
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No. jpHMM 
GT 
jpHMM breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 G/B 2985 (2942-3028) G/B CRF14/CRF24/CRF14/ 
B/B 
2585 (2584-2586) 2719 (2718-2720) 2956 (2955-2957) 3226 (3224-3228) 
2 G/B 2968 (2941-2995) G/B CRF14/B/G/B 2605 (2591-2619) 2723 (2722-2724) 2959 (2957-2961)  
3 B/G/B 2717 (2669-2765) 
2979 (2942-3016) 
G/B G/G/B  2759 (2747-2771) 2956 (2955-2957)  
4 G/B 2996 (2943-3049) G/B CRF14/G/CRF14/B/ 
CRF20/B 
2605 (2604-2606) 
 
2705 (2704-2706) 2959 (2958-2960) 3223 (3222-3224) 
3381 (3380-3382) 
5 G/B 2983 (2941-3024) G/B CRF14/B/G/B/B 2605 (2588-2622)  2759 (2758-2760) 2959 (2958-2960) 3382 (3381-3383) 
6 G/B 2985 (2941-3029) G/B G/B/G/B 2611 (2598-2624) 2729 (2727-2730) 2959 (2958-2960)  
7 G/B 2985 (2942-3028) G/B G/G/B 2630 (2610-2650) 2830 (2829-2831)   
8 G/B 2985 (2942-3028) G/B CRF14/G/CRF14/B 2605 (2598-2600) 2705 (2699-2711) 2959 (2958-2960)  
9 G/B 2957 (2940-2974) G/B G/CRF28/G/B 2605 (2593-2617) 2723 (2722-2724) 2959 (2958-2960)  
10 G/B 2985 (2942-3028) G/B CRF14/B/G/B/CRF20/B 2605 (2604-2606)  2723 (2722-2724) 2959 (2958-2960) 3205 (3203-3207) 
3381 (3375-3387) 
11 G/B 2985 (2942-3028) G/B CRF14/CRF28/G/B/B 2605 (2586-2624)  2723 (2722-2724) 2959 (2958-2960) 3382 (3381-1130) 
12 G/B 2965 (2940-2989) G/B G/CRF28/G/B 2558 (2551-2565) 2723 (2721-2725) 2959 (2958-2960)  
13 G/B 2956 (2941-2971) G/B G/B/G/B 2605 (2601-2609) 2759 (2758-2760) 2959 (2958-2960)  
14 G/B 2985 (2942-3028) G/B CRF14/B/G/B 2520 (2519-2521) 2723 (2722-2724)  3004 (2999-3009) 
15 G/B 2985 (2942-3028) G/B G/B/G/B/B/B 2558 (2557-2559)  2729 (2728-2730) 2959 (2958-2960) 3170 (3149-3193) 
3381 (1127-3382) 
16 G/B 2971 (2927-3015) G/B G/G/CRF14/B 2605 (2600-2610) 2705 (2704-2706) 2959 (2956-2962)  
17 G/B 2985 (2942-3028) G/B CRF14/B/G/B 2520 (2516-2524) 2723 (2721-2725) 2959 (2958-2960)  
18 G/B 2985 (2942-3028) CRF23-like CRF23/G/B  2720 (2696-2744) 2959 (2957-2961)  
19 G/B 2985 (2942-3028) G/B G/B/B  2827 (2826-2828)  3064 (3047-3081) 
20 G/B 2985 (2942-3028) G/B G/B   2959 (2955-2963)  
21 G/B 2985 (2942-3028) G/B CRF14/G/CRF14/B/CRF20 2605 (2602-2608) 2705 (2704-2706) 2959 (2955-2963) 3226 (3225-3227) 
22 G/B 2967 (2922-3012) G/B CRF14/CRF24/G/B/CRF20 2585 (2584-2586) 2720 (2719-2721) 2959 3145 (3144-3146) 
23 G/B 2980 (2942-3018) G/B G/B/G/B 2597 (2587-2607) 2729 (2728-2730) 2959 (2958-2960)  
Table 3_6. Full breakpoint results for Cluster 1. jpHMM and SCUEAL 2012 breakpoint results for Cluster 1. 20/23 and 23/23 sequences, 
respectively, had a SCUEAL or jpHMM predicted breakpoint in the region of HXB2 2956-2985.
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The 23 remaining members of the cluster showed a mixed exposure profile, 
comprising 15/23 (65.2%) IVDU (11/15 male, 4/15 female), 2/23 (8.7%) MSM, and 
2/23 (8.7%) female heterosexuals.  Overall, 20/23 (87.0%) members were white and 
1/23 (4.3%) showed a mixed ethnicity. Available geographic information showed the 
cluster was concentrated in London and Southeast England (21/23, 87.0%), with 
one member in Scotland and one in Southwest England/Wales. 
Six additional sequences with identical recombination structures and a breakpoint at 
HXB2 2985 were identified using HIV BLAST; 5/6 were from Portugal and 1/6 was 
from Spain. MCMC analysis showed a time to most recent common ancestor 
(tMRCA) in the UK of 1999.72 (95% highest posterior density (HPD) = 1997.70 -
2002.05); branches with other G/B recombinant sequences from Portugal and Spain 
showed tMRCA of 1989.14 (95% HPD = 1984.14 - 1994.92) and possible import of 
this recombinant structure into the UK from this region (Figure 3_8). 
The results suggested a novel recombinant spreading primarily in white IVDU with 
MSM and female heterosexual involvement, which was imported into the UK from 
Spain or Portugal.  
 
 
Figure 3_8. Time scaled phylogeny of Cluster 1, a mixed MSM, IVDU and heterosexual 
cluster. MCMC analysis of a UK-based novel subtype G/B recombinant cluster, plus strains 
showing identical recombination profiles from Portugal and Spain. Sequences from the UK 
are shown in red, sequences from Portugal are shown in blue, and sequences from Spain 
are shown in green. Subtype reference B, G and CRF14 sequences are shown in black. 
Later tMRCAs of the UK sequences relative to the Spanish and Portuguese sequences 
indicate possible import into the UK from this region.  
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3.2.4.2 Cluster 2 (G/B) 
Cluster 2 had 15 members and a maximum genetic distance of 7.4%. 9/15 
sequences had a breakpoint at HXB2 2406 and the alignment slice was placed at 
this position. The trees of slices 1 and 2 showed 4/15 sequences that consistently 
clustered together with a posterior probability of 1 in each tree (Figure 3_9a and 
3_9b). In slice 1 this was closest to subtype G (posterior probability = 0.62) and in 
slice 2 this was closest to subtype B (posterior probability = 0.81). Restricting the 
cluster to these four specimens reduced the genetic distance of the cluster to 0.2% 
 
 
Figure 3_9. Cluster 2: G and B fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoint was placed at HXB2 2406. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red. Sequences 
that do not exhibit monophyletic clustering are highlighted in green. a) Slice 1; b) Slice 2.      
 
The full breakpoint results showed no clear consensus in the jpHMM results, with 
2/4 sequences showing an uncertain subtype classification, and no clear consensus 
regarding breakpoint location (Table 3_7). The SCUEAL 2012 results showed 
closely related breakpoints in 3/4 sequences, and matching simplified subtypes in 
3/4 cases.  
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No. jpHMM 
GT 
jpHMM 
breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% 
CI) 
1 U/B 2334 
(2253-2415) 
G/B G/B 2427 
(2395-2459) 
 
2 G/B 2396 
(2369-2423) 
G/B G/B 2377 
(2322-2432) 
 
3 G/B 2401 
(2368-2434) 
G/B G/B/CRF29 2425 
(2423-2427) 
2582 
(2566-2598) 
4 UB 2344 
(2253-2435) 
F2/B F2/B/CRF29 2437 
(2426-2448) 
2564 
(2257-2571) 
Table 3_7. Full breakpoint results for Cluster 2. The SCUEAL 2012 breakpoints show a 
consistent breakpoint close to position HXB2 2427 in 3/4 sequences. This is not reflected in 
the jpHMM results, which show uncertain classification in 2/4 sequences and no clear 
consensus on breakpoint location.   
 
2/4 sequences in Cluster 2 belonged to white heterosexual men and 2/4 sequences 
belonged to white heterosexual women. The geographic region identified with these 
sequences was exclusively Southwest England/Wales. 
The HIV BLAST search identified four sequences sharing a recombinant structure 
and breakpoint location; 3/4 were from Portugal and 1/4 from Luxembourg. The 
time-scaled phylogeny showed a tMRCA for the UK sequences of 2004.78 (95% 
HPD = 2003.97-2011.41) (Figure 3_10). The tMRCA for the Portuguese and 
Luxembourgish sequences was 2004.60 (95% HPD = 2004.56-2011.08); the almost 
identical tMRCAs suggested co-circulation of this potential novel CRF in the UK, 
Portugal and Luxembourg. 
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Figure 3_10. Time scaled phylogeny of Cluster 2, a heterosexual cluster. MCMC 
analysis of a novel subtype G/B recombinant cluster, plus strains showing identical 
recombination profiles from Portugal and Luxembourg. Sequences from the UK are shown in 
red, sequences from Portugal are shown in blue, sequences from Luxembourg are shown in 
green. Subtype reference B and G sequences are shown in black. Branches showing almost 
identical tMRCAs of this recombinant in the UK and Portugal indicates co-circulation of this 
recombinant strain in three distinct geographic locations, with probable import from an 
unknown third location.  
 
3.2.4.3 Cluster 3 (G/B) 
Cluster 3 had 12 members and a maximum genetic distance of 7.4%. The alignment 
slice was placed at position HXB2 2563. 5/12 sequences clustered together 
consistently in slices 1 and 2 (Figure 3_11a and 3_11b). In slice 1 this was closest 
to CRF14 (posterior probability = 0.71) and in slice 2 it was closest to subtype B 
(posterior probability = 0.86). The posterior probability for the clustered sequences 
was 1 in both trees. Restricting the cluster to these sequences reduced the GD to 
2.8%. 
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Figure 3_11. Cluster 3: G and B fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoint was placed at HXB2 2563. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red. Sequences 
that do not exhibit monophyletic clustering are highlighted in green. a) Slice 1; b) Slice 2.      
 
Full breakpoint results showed consistent predicted recombinant structure and 
breakpoint locations in both the jpHMM and SCUEAL 2012 results, with a 
breakpoint located between HXB2 2504 and 2552 (Table 3_8). 
 
No. jpHMM 
GT 
jpHMM 
breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 G/B 2516 
(2503-2529) 
G/B CRF14/B 2552 
(2540-2564) 
 
2 G/B 2528 
(2504-2552) 
G/B G/B 2505 
(2483-2527) 
 
3 G/B 2504 
(2435-2573) 
G/B G/B/B 2530 
(2525-2535) 
3154 
(3151-3157) 
4 G/B 2528 
(2504-2552) 
G/B G/B 2505 
(2484-2526) 
 
5 G/B 2524 
(2503-2545) 
G/B CRF14/B/B/B 2539 
(2537-2541) 
2843 
(2833-2853) 
3364 
(3363-3365) 
 Table 3_8. Full breakpoint results for Cluster 3. A clear consensus on recombinant 
structure is shown by both SCUEAL 2012 and jpHMM results. The SCUEAL breakpoints are 
located at positions HXB2 2505, HXB2 2530, HXB2 2539 and HXB2 2552, consistent with 
the jpHMM breakpoints.  
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There were 3/5 sequences with demographic information available; 1/3 sequences 
was from a white heterosexual woman and 2/3 were from white male IVDU. 
Available geographical information showed the cluster was concentrated in 
Southwest England and Wales. 
The HIV BLAST search did not locate any matching recombinant structures. These 
results suggested that this cluster formed a novel recombinant spreading primarily 
in white male IVDU with white female heterosexual involvement, with no evidence of 
extra-UK circulation. 
3.2.4.4 Cluster 4 (G/B) 
Cluster 4 was composed entirely of sequences that were analysed as part of cluster 
3. These sequences did not exhibit consistent clustering. 
3.2.4.5 Cluster 5 (G/B) 
Cluster 5 had four members and a maximum genetic distance of 1.2%. Overall, 3/4 
sequences had an identical SCUEAL breakpoint at HXB2 3049; accordingly, the 
slice position was placed there. All four sequences clustered consistently in slices 1 
and 2 with a posterior probability of 1 (Figure 3_12a and 3_12b). In slice 1 the 
sequences clustered closest to subtype G and related CRFs (posterior probability = 
1), but the tree of slice 2 showed weak support for clustering with subtype B with a 
posterior probability of 0.55. This may have been related to the short fragment 
length of slice 2 of 240 nucleotides.      
 
69 
 
 
Figure 3_12. Cluster 5: G and B fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoint was placed at HXB2 3049. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red. a) Slice 1; 
b) Slice 2.      
 
Full breakpoint results showed consistent predicted recombinant structure between 
the two genotyping methods, but little agreement on breakpoint location (Table 
3_9). The SCUEAL breakpoint, which was used for the cluster analysis, was 
approximately 250 nucleotides distant from the jpHMM breakpoint, indicating that 
sequencing of a longer region additional was necessary to enable precise 
breakpoint identification.  
Overall, 2/4 sequences had associated demographic data; both were white male 
MSM. The geographic region associated with these sequences was Northwest 
England. The HIV BLAST search did not identify any similar recombinant structures. 
These results suggested a novel G/B recombinant circulating among white MSM; 
however, longer sequence lengths were required to confirm the genotyping of the 
putative subtype B region.    
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No. jpHMM 
GT 
jpHMM 
breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 G/B 2759 G/B G/B  3049 
(2998-
3100) 
 
2 G/B 2772 
(2760-2784) 
G/B G/CRF03  3049 
(3033-
3045) 
 
3 G/B 2778 G/B G/B/B 2885 
(2875-
2895) 
3001 
(2996-
3006) 
 
4 G/B 2886 G/B G/B/B  3049 
(3044-
3054) 
3378 
(3368-
3388) 
Table 3_9. Full breakpoint results for Cluster 5. Both jpHMM and SCUEAL 2012 results 
show consistent predicted recombinant structures. The SCUEAL 2012 breakpoint at 3049 
was approximately 250 nucleotides distant from the jpHMM breakpoints.   
 
3.2.4.6 Cluster 6 (G/F/B) 
Cluster 6 had three members and a maximum genetic distance of 0.5%. Alignment 
slices were placed at HXB2 2500 and 2968. All three sequences clustered together 
consistently in each slice with posterior probabilities of 1 (Figure 3_13a, 3_13b, 
3_13c). Slice 1 clustered with subtype G and related CRFs (posterior probability = 
1), slice 2 clustered with subtype F1 (posterior probability = 0.99) and slice 3 
clustered with subtype B (posterior probability = 1). 
The full breakpoint results showed consistent recombinant structure and breakpoint 
locations between both genotyping methods, which were consistent with the results 
shown in the trees (Table 3_10). 
 
 
 
71 
 
 
Figure 3_13. Cluster 6: G, F and B fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoints were placed at HXB2 2500 and 2968. Sequences 
exhibiting monophyletic clustering with a posterior probability of >0.7 are highlighted in red. 
a) Slice 1; b) Slice 2; c) Slice 3.      
 
No. jpHMM 
GT 
jpHMM breakpoint (95% 
CI) 
SCUEAL 
GT (S) 
SCUEAL GT 
(D) 
SCUEAL breakpoints (95% 
CI) 
1 G/F1/B 2495 
(2426-2564) 
2968 
(2955-2981) 
Complex CRF25/F1/B 2369 
(2352-2386) 
2975 
(2974-2976) 
2 G/F1/B 2503 
(2426-2580) 
2968 
2955-2981) 
Complex CRF25/F1/B 2444 
(2443-2445) 
2975 
(2973-2976) 
3 G/F1/B 2500 
(2426-2574) 
2967 
(2955-2979) 
Complex CRF14/F1/B 2450 
(2438-2462) 
2977 
(2976-2978) 
Table 3_10. Full breakpoint results for Cluster 6. Both jpHMM and SCUEAL results show 
consistent predicted recombinant structures and breakpoint locations. The highest sequence 
position for the first SCUEAL is HXB2 2450; the second predicted breakpoint is at HXB2 
2975.  
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The HIV BLAST search identified nine sequences that matched to all three cluster 
members. Two sequences were G/F/B recombinants from Spain and Macau, and 
seven sequences were F1/B recombinants from Argentina. jpHMM analysis of the 
breakpoints showed one G/F/B sequence with breakpoints at HXB2 2813 and 2968, 
and eight F/B sequences with 5/8 breakpoints at HXB2 2992, two breakpoints at 
HXB2 2990, one breakpoint at 2979 and one breakpoint at 3034. A time-scaled 
phylogeny including these sequences was attempted; inadequate mixing between 
the chains and subsequent low ESS were observed. This indicated that further 
analysis without full-length sequencing of the genome was unlikely to yield 
satisfactory results.  
There were 2/3 sequences with demographic information available; 1/3 sequences 
was from a white woman and 1/3 was from a white male. Both were IVDU. The 
geographic location for all three sequences was East Anglia.  
These results suggested a novel CRF circulating in IVDU in East Anglia. Some 
evidence was identified that suggests these sequences may be related to 
sequences isolated in Spain and Argentina, but sequencing of a longer genomic 
region is required for confirmation. 
3.2.4.7 Cluster 7 (F/B) 
Cluster 7 had four members and a maximum genetic distance of 4.9%. The 
alignment slice was placed at position HXB2 2963. When split into component 
subtype regions, none of the four sequences clustered together, indicating that 
these sequences did not share a common evolutionary path, and therefore did not 
comprise a novel CRF. 
3.2.4.8 Cluster 8 (F/B) 
Cluster 8 had 14 members and a maximum genetic distance of 5.9%. Of these, 7/14 
sequences had a breakpoint located at HXB2 2486 and the alignment slice was 
placed at this position; 4/7 sequences clustered consistently with CRF44 in both 
trees; 1/7 sequences did not cluster with any other sequences, and 2/7 sequences 
clustered as a pair in both trees. 
There were 3/14 sequences (Cluster 8a) that clustered in both trees with a posterior 
probability of 1. These sequences clustered weakly with subtype F1 in tree 1 
(posterior probability = 0.44) and subtype CRF29 in tree 2 (posterior probability = 1). 
Demographic information was available for 2/3 sequences; both sequences 
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belonged to white MSM. The geographic location was the south coast of England 
and Wales for all three sequences. 
There were 4/14 sequences (Cluster 8b) that clustered in both trees with posterior 
probabilities of 0.83 and 1, respectively. These sequences clustered closest to 
subtype CRF29 in tree 1 and subtype B/CRF28/CRF29 in tree 2 (with weak 
support).  
Both trees were very weakly supported in the subtype F and CRF29 branches of 
tree one and the subtype B and CRF29 branches of tree two. Combined with the 
position of the likely breakpoint at HXB2 2486, only 86 nucleotides distant from the 
F/B breakpoint of CRF29, the most likely explanation was that these strains were 
closely related to CRF29 rather than a true novel CRF. 
3.2.4.9 Cluster 9 (D/A) 
After excluding obvious CRF50 sequences, Cluster 9 had eight members and a 
maximum genetic distance of 6.0%. The alignment slice was placed at HXB2 2545. 
All eight sequences clustered with CRF50 sequences. These results did not suggest 
a further novel CRF, but instead sequences related to CRF50.  
3.2.4.10 Cluster 10 (D/A) 
Cluster 10 had 12 members and a maximum genetic distance of 5.2%. Overall, 6/12 
sequences had a jpHMM breakpoint at HXB2 2610 and the alignment slice was 
placed here. All 12 sequences clustered consistently with CRF50 sequences in both 
slices.   
3.2.4.11 Cluster 11 (D/A/B) 
Cluster 11 had three members and a maximum genetic distance of 1.6%. The 
sequences had jpHMM breakpoints at HXB2 2553 and 3298; the second breakpoint 
would have resulted in a too-short fragment for analysis so the end of the alignment 
was trimmed to HXB2 3298 and the alignment slice was placed at HXB2 2553. All 
four sequences clustered with CRF50 in both trees. 
3.2.4.12 Cluster 12 (CRF01/B) 
Cluster 12 had five members and a maximum genetic distance of 6.5%. The 
alignment slice was placed at position HXB2 2945. The sequences did not cluster 
monophyletically in either tree.  
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3.2.4.13 Cluster 13 (A/B) 
Cluster 13 had eight members and a maximum genetic distance of 6.5%. Of these, 
4/8 sequences had a breakpoint at HXB2 2716 and the alignment slice was placed 
here; 6/8 sequences clustered monophyletically in trees 1 and 2 with posterior 
probabilities of 1 (Figure 3_14a and 3_14b). In tree 1 the sequences clustered 
strongly with subtype A1 (posterior probability = 0.97) and in tree 2 the sequences 
clustered with subtype B (posterior probability = 0.87). Restricting the cluster to 
these sequences reduced the maximum genetic distance of the cluster to 0.87%. 
Figure 3_14. Cluster 13: A and B fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoint was placed at HXB2 2716. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red; sequences 
that do not cluster monophyletically are shown in green.  a) Slice 1; b) Slice 2 
 
The full breakpoint results showed consistent predictions in jpHMM and SCUEAL 
results (Table 3_11); 6/6 recombinant structures were classified as A1/B by jpHMM, 
as were 4/6 sequences by SCUEAL. The remaining 2/6 sequences were classified 
by SCUEAL as complex, due to the prediction of a subtype D fragment in 1/6 
sequences and subtype K and CRF12 fragments in 1/6 sequences. The SCUEAL-
predicted breakpoint at HXB2 2738 was consistent with the jpHMM-predicted 
breakpoint of 2716 in 4/6 sequences.   
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Overall, 5/6 sequences were MSM and 1/6 was of an unknown risk group; 3/6 were 
white, 2/6 were Black-African and 1/6 was Black-Caribbean. The geographic 
location of all six was London and Southeast England. The time scaled phylogeny 
showed a tMRCA of 2005.52 in the UK, indicating a novel recombinant located 
primarily in white and Black-African MSM (Figure 3_15). No evidence was found to 
indicate a geographic origin of the recombinant outside the UK. 
No. jpHMM 
GT 
jpHMM 
breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL GT 
(D) 
SCUEAL breakpoints (95% CI) 
1 A1/B 2689 
(2617-2761) 
Complex A1/B/D  2738 
(2729-2747) 
3457 
(3456-3458) 
2 A1/B 2716 
(2654-2778) 
Complex K/A1/B/CRF12 2354 
(2351-2357) 
2738 
(2737-2739) 
3428 
(3425-3431) 
3 A1/B 2705 (2624-
2786) 
A1/B A1/B/CRF12  2771 
(2749-2793) 
3428 
(3420-3436) 
4 A1/B 2716 
(2654-2778) 
A1/B A1/B/B  2738 
(2730-2746) 
3452 
(3436-3468) 
5 A1/B 2716 
(2654-2778) 
A1/B A1/B/B  2738 
(2737-2739) 
3337 
(3314-3360) 
6 A1/B 2716 
(2654-2778) 
A1/B A1/A1/B/CRF12 2389 
(2388-2390) 
2752 
(2747-2756) 
3428 
(3427-3429) 
Table 3_11. Full breakpoint results for Cluster 13. 4/6 predicted recombinant structures 
were identical in both jpHMM and SCUEAL 2012 results. The jpHMM results showed 
consistent breakpoint predictions across all six sequences; the SCUEAL breakpoint in 4/6 
sequences was HXB2 2738. 
 
 
Figure 3_15. Time scaled phylogeny of Cluster 13, a MSM cluster of mixed ethnicity. 
MCMC analysis of a novel subtype A1/B recombinant cluster. Sequences from the UK are 
shown in red. Subtype reference A1 and B sequences are shown in black.  
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3.2.4.14 Cluster 14 (B/A/J/G) 
Cluster 14 had six members and a maximum genetic distance of 2.3%. All six 
sequences were designated 'complex' by SCUEAL 2012 and the suggested 
recombinant structure contained three breakpoints in the 1301bp pol fragment 
analysed. Overall, 5/6 sequences had a first breakpoint at HXB2 2354; subsequent 
breakpoints were located at HXB2 2815 and HXB2 3093, respectively. Owing to the 
short length of fragment 1, the first two sequence regions were analysed as one 
fragment; slices 3 and 4 were analysed separately. 
In all three phylogenetic trees (slices 1+2, slice 3, slice 4, Figure 3_16a, 3_16b and 
3_16c, respectively), all six sequences clustered together monophyletically with a 
posterior probability of 1. In the tree of slices 1 and 2 the sequences were clustered 
closest to subtypes CRF01_AE and CRF22 (posterior probability = 0.93), in the tree 
of slice 3 the sequences were clustered closest to subtype J (posterior probability = 
1), and in the tree of slice 4 the sequences were clustered closest to subtypes K 
and CRF18 (posterior probability = 0.72). 
The full breakpoint results showed relatively consistent breakpoint locations in both 
the jpHMM and SCUEAL 2012 results, but no clear consensus as to the predicted 
recombinant structure (Table 3_12). Although the simplified SCUEAL results 
designated all six sequences as complex, the detailed subtype results showed no 
consensus either within the other SCUEAL results, or between the SCUEAL and 
jpHMM results.  
Demographic information was available for 6/6 sequences. All six individuals were 
heterosexual Black-African; 4/6 were female and 2/6 were male. The geographic 
location was London and Southeast England for 5/6 sequences and Southwest 
England and Wales for 1/6 sequences. The HIV BLAST search returned two 
sequences that were present in 6/6 closest sequence matches: DQ886038, an 
A/K/U recombinant from the USA and GQ241034, a CRF45 sequence from Spain. 
These results suggest these sequences form a novel recombinant, however due to 
the complexity of the putative recombinant structure further work to confirm this is 
needed. No clear evidence was present to suggest that this recombinant is 
circulating in regions other than the UK.  
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Figure 3_16. Cluster 14: B, A, B, J, G recombinant fragments. Maximum clade credibility 
trees of putative pure subtype regions.  Breakpoints were placed at HXB2  2354, 2815 and 
3093, respectively.  Owing to the short length of the first fragment, slices 1 and 2 were 
analysed in a single tree. Sequences exhibiting monophyletic clustering with a posterior 
probability of >0.7 are highlighted in red. a) Slices 1 and 2; b) Slice 3; c) Slice 4.      
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No. jpHMM 
GT 
jpHMM breakpoint (95% CI) SCUEAL GT (S) SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 U/A1/J/G 2305 
(2253-2357) 
2815 
(2790-2840) 
3110 Complex U/AE/A1/J/B/J   2420 
(2419-2421) 
2669 
(2668-2670)  
2791 
(2790-2792) 
3118 
(3117-3119) 
3217 
(3216-3218)  
2 J/A1/J/G 2356 
(2326-2386) 
2808 
(2782-2834) 
3092 
(3074-3110) 
Complex B/AE/J/CRF18  2354 
(2353-2355) 
 2806 
(2790-2832) 
3118 
(3117-3119) 
 
3 B/A1/J/B 2370 
(2313-2427) 
2815 
(2790-2840) 
3093 
(3070-3116) 
Complex B,A,AE,CRF22,J,CRF18  2354 
(2353-2355) 
2512 
(2508-2516) 
2613 
(2604-2622) 
2791 
(2790-2792) 
3113 
(3112-3114) 
4 B/A1/J/G 2369 
(2313-2425) 
2810 
(2783-2837) 
3110 Complex B/AE/J/K/J  2354 
(2353-2355) 
 2806 
(2804-2808) 
3118 
(3117-3119) 
3223 
(3222-3224) 
5 01/J/G 2503 
(2253-2753)  
2795 
(2754-2836) 
3110 Complex B/AE/J/J/J  2354 
(2353-2355) 
 2756 
(2755-2757)  
3056 
(3055-3057)  
3167 
(3055-3279) 
6 01/J/G  2782 
(2754-2810) 
3092 
(3070-3114) 
Complex B/A/AE/J/B/J  2354 
(2353-2355) 
2485 
(2484-2486) 
2789 
(2788-2790) 
3124 
(3121-3125) 
 3223 
(3222-3224) 
Table 3_12. Full breakpoint results for Cluster 14. The predicted results show a complex recombinant structure, with no clear consensus as to the 
constituent subtypes. The breakpoint locations in jpHMM are relatively consistent. Breakpoints appear consistently in SCUEAL at positions 2354 (5/6 
sequences), 2789-2806 (5/6 sequences) and 3113-3124 (5/6 sequences). 
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3.2.4.15 Cluster 15 (B/C) 
Cluster 15 had five members and a maximum genetic distance of 0.3%. All five 
recombinant structures had a jpHMM breakpoint at HXB2 2589. The  MCMC tree of 
slice 1 showed monophyletic clustering, closest to subtype B, with a posterior 
probability of 1; the support for subtype B was moderate, with a posterior probability 
of 0.54 (Figure 3_17a). The tree of slice 2 also showed monophyletic clustering with 
a posterior probability of 1; this was closest to subtype C (Figure 3_17b). 
 
 
Figure 3_17. Cluster 15: B and C fragments. Maximum clade credibility trees of putative 
pure subtype regions.  The breakpoint was placed at HXB2 2589. Sequences exhibiting 
monophyletic clustering with a posterior probability of >0.7 are highlighted in red. a) Slice 1; 
b) Slice 2.      
 
The full breakpoint results showed identical recombinant structure predictions from 
both jpHMM and SCUEAL 2012 (Table 3_13). The SCUEAL breakpoint was placed 
at HXB2 2523, only 66 nucleotides distant from the jpHMM predicted breakpoint of 
HXB2 2589.  
Demographic information was available for 4/5 sequences and showed 4/4 white 
men; 3/4 were heterosexual and 1/4 was MSM. Geographic data was available for 
5/5 sequences and showed 3/5 from London and Southeast England and 2/5 from 
Northwest England. 
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The time scaled phylogeny showed a cluster with a tMRCA of 2004.86 (95%HPD = 
2003.36-2007.34) (Figure 3_18). This cluster contained sequences from the UK, 
Spain, and Paraguay; all sequences shared identical breakpoints and recombinant 
structures. No close relationship seen with the sequences from Brazil. The branch 
containing sequences from the UK contained sequences from Spain and Paraguay, 
suggesting co-circulation of this recombinant structure in three countries. 
 
No. jpHMM 
GT 
jpHMM 
breakpoint (95% 
CI) 
SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 B/C 2589 
(2464-2714) 
B/C B/C  2523 
(2512-
2534) 
 
2 B/C 2589 
(2464-2714) 
B/C B/C/CRF31  2522 
(2521-
2523) 
3432 
(3424-
3440) 
3 B/C 2589 
(2464-2714) 
B/C B/B/C 2376 
(2366-
2386) 
2522 
(2521-
2523) 
 
4 B/C 2589 
(2464-2714) 
B/C CRF39/B/C/CRF31 2418 
(2417-
2419) 
2522 
(2521-
2523) 
3432 
(3424-
3440) 
5 B/C 2589 
(2464-2714) 
B/C B/C  2520 
(2505-
2535) 
 
Table 3_13. Full breakpoint results for Cluster 15. Both jpHMM and SCUEAL show a B/C 
predicted recombinant structure; the breakpoint was at 2589 in all jpHMM results and 
between HXB2 2520 and 2523 in all SCUEAL results.  
 
Figure 3_18. Time scaled phylogeny of Cluster 15, a mixed MSM/heterosexual cluster. 
MCMC analysis of a novel subtype B/C recombinant cluster, plus strains showing identical 
recombination profiles from Spain, Paraguay and Brazil. Sequences from the UK are shown 
in red, sequences from Spain are shown in blue, sequences from Brazil are shown in orange 
and sequences from Paraguay are shown in lavender. Subtype reference B, C, and F1 
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sequences are shown in black. Clustering of the Spanish, UK and Portuguese sequences 
indicates co-circulation of this recombinant strain in three distinct geographic locations.  
 
3.2.4.16 Cluster 16 (B/C) 
Cluster 16 had four members and a maximum genetic distance of 5.0%. The 
breakpoint was placed at HXB2 3079 (shared by 2/4 sequences). The tree of slice 1 
showed monophyletic clustering with a posterior probability of 0.97, closest to 
subtype CRF07 (posterior probability = 0.99, Figure 3_19a). The tree of slice 2 also 
showed monophyletic clustering with a posterior probability of 0.93; this was in 
subtype C (posterior probability = 0.99, Figure 3_19b). 
 
Figure 3_19. Cluster 16: CRF07 and B recombinant fragments. Maximum clade 
credibility trees of putative pure subtype regions.  The breakpoint was placed at HXB2 3079. 
Sequences exhibiting monophyletic clustering with a posterior probability of >0.7 are 
highlighted in red. a) Slice 1; b) Slice 2.      
 
The full breakpoint results showed a predicted B/C structure in 3/4 jpHMM results 
and 3/4 SCUEAL 2012 results (Table 3_14). There was a jpHMM-predicted 
breakpoint at HXB2 3077-3079 in 3/4 sequences; these sequences all had a 
SCUEAL-predicted breakpoint at HXB2 3077-3083. 
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No jpHMM 
GT 
jpHMM 
breakpoint 
(95% CI) 
SCUEAL 
GT (S) 
SCUEAL 
GT (D) 
SCUEAL breakpoints (95% CI) 
1 B/C 3079 
(3068-3090) 
B/C B/B/C/ 
CRF03 
2611 
(2597-2625) 
3083 
(3082-3084) 
3245 
(3244-3246) 
2 B/C 3079 
(3068-3090) 
B/C B/C/B/C/ 
CRF03 
2611 
(2597-2625) 
2710 
(2709-2711) 
3083 
(3082-3084) 
3259 
(3258-3260) 
3 B/C 3077 
(3068-3086) 
Complex B/C/B/D 2564 
(2563-2565) 
2719 
(2718-2720) 
 2918 
(2917-2919) 
3077 
(3076-3079) 
 
4 B/C/B 2607 
(2560-2654) 
3404 
(3390-3421) 
B/C B/C/B 2611 
(2597-2625) 
 3394 
(3386-3402) 
Table 3_14. Full breakpoint results for Cluster 16. Both the jpHMM and the SCUEAL 
results showed consistent breakpoint prediction in 3/4 sequences. The SCUEAL-predicted 
breakpoint at HXB2 3077-3083 is consistent with the jpHMM-predicted breakpoints. 
 
Demographic information was available for 3/4 sequences; 4/4 were white MSM. 
Geographic location was available for 4/4 sequences; this showed 3/4 in East 
Anglia and 1/4 in London and Southeast England.  
The HIV BLAST search showed seven sequences that appeared in at least 75% of 
the closest sequence match lists. They were: JN223163, a B/C recombinant from 
Myanmar; GQ303845 and HM468715, subtype B sequences from Canada; 
JN944923, a subtype B sequence from the USA; JX299665, a subtype B sequence 
from Germany; GQ399355, a subtype B sequence from Portugal, and EU611261, a 
subtype B sequence from an unrecorded location. jpHMM analysis of the BC 
recombinant sequence showed a  pure subtype B sequence. 
These results suggested these sequences form a novel recombinant located in 
white MSM. No evidence indicated this recombinant had extra-UK circulation. 
3.2.4.17 Cluster 17 (B/G/B) 
Cluster 17 had seven members and a maximum genetic distance of 3.0%. Both 
jpHMM and SCUEAL showed relatively consistent breakpoint location results 
(jpHMM: HXB2 2409/2952/3110; SCUEAL 2377/2578/3212). Owing to the short 
fragment length that would result from slicing the sequences at HXB2 3212, a single 
slice was made at HXB2 2954. Both trees showed all seven sequences clustering 
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together consistently, however in both instances the clustering was with CRF02_AG 
sequences.   
3.2.4.18 Cluster 18 (B/CRF01) 
Cluster 18 had three members and a maximum genetic distance of 2.1%. The 
jpHMM and SCUEAL analyses showed conflicting results regarding these 
sequences: jpHMM returned results of B, B/U and A1/B, respectively, whilst 
SCUEAL gave 3/3 results of B/AE with a breakpoint at HXB2 3145 (Table 3_15). 
The slice was placed here for the phylogenetic analysis.  
 
No. jpHMM 
GT 
jpHMM 
breakpoint (95% 
CI) 
SCUEAL GT (S) SCUEAL GT (D) SCUEAL 
breakpoints (95% 
CI) 
1 B/U 3203 
(3155-3251) 
B/AE B/AE 3145 
(3128-3162) 
2 B  B/AE B/AE 3145 
(3129-3161) 
3 A1/B 3122 B/AE B/AE 3145 
(3096-3200) 
Table 3_15. Full breakpoint results for Cluster 18. No clear agreement existed between 
the jpHMM and SCUEAL-predicted results. The SCUEAL results show clear concordance. 
 
The tree from slice 1 showed all three sequences clustering together with a 
posterior probability of 1 (Figure 3_20a).  The sequences clustered with subtype B 
with a posterior probability of 0.64; the posterior probability for the B branches was 
0.97. The tree from slice 2 also showed clustering with a posterior probability of 1; in 
this fragment the sequences clustered with subtype A1 (posterior probability = 0.52, 
Figure 3_20b). The query sequences did not cluster near the CRF01 sequences. 
The region of the slice 2 tree containing the A1, CRF01, CRF15, CRF33 and CRF34 
sequences was not well-supported; a longer fragment length than 146 nucleotides 
may have shown a clearer relationship between the query sequences and the 
reference sequences. 
Demographic information was available for 3/3 sequences. This showed 3/3 
sequences belonging to MSM; 2/3 were white and 1/3 was Black-African. The 
geographic region was Southwest England and Wales for 2/3 sequences and the 
Midlands for 1/3 sequences.  
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The HIV BLAST search showed four sequences that were present in at least 75% of 
the closest sequences matches. Three of these were subtype B submissions from 
the UK HIV DRD (JN101126, JN101698, JN101327) and one was a subtype B 
sequence from the Netherlands (JQ650838).    
These results indicated that these sequences comprise a novel CRF circulating in 
the UK only.       
 
Figure 3_20. Cluster 18: B and A1 recombinant fragments. Maximum clade credibility 
trees of putative pure subtype regions.  The breakpoint was placed at HXB2  3145. 
Sequences exhibiting monophyletic clustering with a posterior probability of >0.7 are 
highlighted in red. a) Slice 1; b) Slice 2.      
 
3.2.4.19 Cluster 19 (C/B/C) 
Cluster 19 had seven members and a maximum genetic distance of 3.2%. 
Breakpoints were placed at HXB2 2726 and 3089, which was consistent with both 
the jpHMM and SCUEAL subtyping results (Table 3_16). The tree for slice 1 
showed monophyletic clustering of all seven sequences closest to subtype C with a 
posterior probability of 1 (Figure 3_21a); the posterior probability of the clustering 
with subtype C was 0.73. The tree for slice 2 showed 5/7 sequences clustering 
monophyletically with subtype B (Figure 3_21b, posterior probability = 1, posterior 
probability of clustering with subtype B = 0.25), and the remaining 2 sequences 
continuing to cluster closer to subtype CRF31  (posterior probability = 0.99, 
posterior probability of clustering with CRF31 = 0.23). This tree was very poorly 
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supported, with only the subtype C, D, F1 and G branches showing strong support 
for the tree topology.   
The tree for slice three showed all seven sequences clustering monophyletically 
with subtype C (Figure 3_21c, posterior probability = 1).  
 
Figure 3_21. Cluster 19: C and B recombinant fragments. Maximum clade credibility 
trees of putative pure subtype regions.  Breakpoints were placed at HXB2 2726 and 3089. 
Sequences exhibiting monophyletic clustering with a posterior probability of >0.7 are 
highlighted in red. a) Slice 1; b) Slice 2; c) Slice 3.      
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No. jpHMM 
GT 
jpHMM breakpoint (95% CI) SCUEAL 
GT (S) 
SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
1 C/B/C 2716 
(2692-2740) 
3089 
(3072-3106) 
B/C CRF31/CRF31/B/C 2573 
(2528-2618) 
2723 
(2722-2724) 
3100 
(3099-3101) 
 
2 C/D/C 2726 
(2712-2740) 
3095 
(3087-3103) 
C/U CRF31/CRF31/U/C/C 2573 
(2571-2575) 
2743 
(2742-2744) 
3100 
(3095-3105) 
3209 
(3208-3210) 
3 C/B/C 2716 
(2692-2740) 
3089 
 (3072-3106) 
B/C CRF31/CRF31/B/C 2573 
(2540-2606) 
2723 
(2720-2726) 
3100 
(3098-3101) 
 
4 C/B/C 2720 3099 
(3092-3106) 
B/C CRF31/CRF31/B/C/CRF31 2573 
(2561-2585) 
2723 
(2720-2726) 
3100 
(3099-3101) 
3208 
(3207-3209) 
5 C/B/C 2723 3100 
(3092-3108) 
B/C CRF31/B/C/CRF31  2743 
(2742-2744) 
3087 
(3086-3088) 
3373 
(3343-3403) 
Table 3_16. Full breakpoint results for Cluster 19. The jpHMM results show consistent predictions for breakpoint locations within a 10 nucleotide interval. 
The SCUEAL breakpoints at HXB2 2723-2743 and HXB2 3087-3100, which are present in 5/5 sequences, are consistent with the jpHMM results. 
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Demographic information was available for 4/5 sequences; 4/4 were from men, 3/4 
were MSM, 3/4 were white, 1/3 were from UK, 1/3 from Denmark, 1/4 Black-African 
from Nigeria.  The geographic location of the 5 sequences showed 4/5 in London 
and Southeast England and 1/5 in Southwest England. 
The time scaled phylogeny included seven sequences with identical breakpoints 
and recombinant structures, all from Italy (Figure 3_22). The tMRCA for the branch 
containing the UK sequences was 2003.19 (95% HPD = 1998.98-2009.40). The 
Italian sequences were interspersed with the UK sequences, indicating co-
circulation of this recombinant in the UK and Italy, and possible export from the UK 
to Italy of this recombinant. 
 
 
Figure 3_22. Time scaled phylogeny of Cluster 19, a MSM cluster of mixed ethnicity. 
MCMC analysis of a recombinant C/B/C cluster. Sequences from the UK are shown in red. 
Sequences from Italy are shown in blue. Later tMRCAs of the Italian sequences relative to 
the UK sequences indicate possible export from the UK to Italy, and subsequent co-
circulation of this strain.  
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3.2.4.20 Cluster 20 (B/C/B) 
Cluster 20 had five members and a maximum genetic distance of 1.5%. Breakpoints 
were placed at HXB2 2386 and 2704. The tree for slice 1 showed 4/5 sequences 
clustering weakly in subtype C (posterior probability of 0.51) and 1/5 sequences 
clustering elsewhere in subtype C. The tree for slice 2 showed all five sequences 
clustering together in subtype B with a posterior probability of 1, and the tree for 
slice 3 also showed monophyletic clustering with a posterior probability of 1, in this 
case closest to subtype C. The fragment length of slice 1 was very short (133 bp), 
which may account for the weak clustering behaviour. However, the jpHMM result 
for these sequences showed 2/5 as having B/C/B structures, 2/5 as C/B structures 
and 1/5 as B only. It is more likely that these differences are the source of the weak 
clustering in slice 1 and that these sequences are somewhat related in terms of 
transmission, but not representative of a novel CRF. 
3.2.4.21 Cluster 21 (B/U) 
Cluster 21 had four members and a maximum genetic distance of 1.1%. 3/4 
sequences showed an identical SCUEAL breakpoint at sequence position 212 
(HXB2 2465) and the breakpoint was placed here to slice the alignment. The tree 
for slice 1 showed monophyletic clustering with a posterior probability of 1; this was 
weakly associated with subtype D (posterior probability of 0.40). The tree for slice 2 
also showed 4/4 sequences clustering monophyletically, in this case closest to 
subtype B. All four sequences were from MSM located in southeast England. 
Although the sequences exhibited monophyletic clustering throughout, the tree for 
slice 1 showed the sequences located in a mixed subtype D, B, CRF21 region of the 
tree. It seems more likely that these sequences may be related in terms of 
transmission, but not a novel CRF. 
3.2.4.22 Cluster 22 (B/A) 
Cluster 22 had four members and a maximum genetic distance of 4.4%. The 
breakpoint was placed at HXB2 2558. The sequences did not exhibit monophyletic 
clustering in either tree, making it unlikely that they comprise a novel CRF.  
3.2.4.23 Cluster 23 (B/A) 
Cluster 23 had three members and a maximum genetic distance of 3.6%. The 
breakpoint position was placed at HXB2 3099. The sequences did not exhibit 
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monophyletic clustering in either tree, making it unlikely that they comprise a novel 
CRF.  
3.2.4.24 Cluster 24 (B/A) 
Cluster 24 had five members and a maximum genetic distance of 1.5%. The 
breakpoint was placed at HXB2 2615. All five sequences exhibited clustering 
closest to CRF50_A1D sequences in both trees, making it likely that these 
sequences are related to CRF50 rather than a novel CRF. 
3.2.4.25 Cluster 25 (B/A/B) 
Cluster 25 had 21 members and a maximum genetic distance of 8.1%. Owing to 
conflicting breakpoint analysis results, the alignment was sliced three different ways 
for analysis. Method 1 placed breakpoints at HXB2 positions 2555 and 3048 (Figure 
3_23), method 2 placed breakpoints at 2545 and 2941 (Figure 3_24), and method 3 
placed breakpoints at 2632 and 2943 (Figure 3_25; Table 3_17). The clustering 
displayed in the three groups of trees showed that, rather than one large cluster, 
there were three distinct groups of sequences, each potentially comprising a novel 
CRF. Cluster 25a contained 10 sequences and had breakpoints at HXB2 2555 and 
3048, Cluster 25b contained seven sequences and had breakpoints at HXB2 2545 
and 2941, and Cluster 25c contained three sequences and had breakpoints at 
HXB2 2632 and 2943. One sequence did not cluster with any other query sequence 
in any of the phylogenetic analyses. 
Tree 1 for Cluster 25a showed all 10 sequences clustered together with a posterior 
probability of 1 (Figure 3_23a). The sequences clustered closest to subtype B 
(posterior probability = 0.95). Tree 2 (Figure 3_23b) showed well supported 
posterior probabilities. All ten sequences clustered together (posterior probability = 
1), closest to CRF50 sequences (posterior probability = 1). Tree three (Figure 
3_23c) showed all ten sequences clustered together (posterior probability = 1) 
closest to subtype B (posterior probability = 0.89).  
Restricting the cluster to these 10 sequences gave a maximum genetic distance of 
2.1%. The geographic location of Cluster 25a showed 9/10 sequences in London 
and Southeast England and 1/10 sequences in Northeast England. 
Demographic information was available for 10/10 sequences; this showed that all 
sequences came from white MSM. 
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No. jpHMM 
GT 
jpHMM breakpoint (95% CI) SCUEAL GT (S) SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
Cluster 25a 
1 B/A1/B 2555 
(2519-2591) 
3048 
(3035-3061) 
A1/B CRF05/B/A1/CRF17 2438 
(2437-2439) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
2 B/A1/B 2555 
(2519-2591) 
3048 
(3035-3061) 
A1/B CRF05/B/A1/B 2438 
(2437-2439) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
3 B/A1/B 2555 
(2519-2591) 
3048 
(3035-3061) 
A1/B CRF05/B/A1/B 2360 
(2359-2361) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
4 B/A1/B 2555 
(2518-2592) 
3048 
(3035-3061) 
Complex D/A1/B  2540 
(2539-2541) 
 3034 
(3024-3046) 
5 B/A1/B 2555 
(2518-2592) 
3048 
(3035-3061) 
A1/B B/A1/B  2540 
(2539-2541) 
 3034 
(3024-3046) 
6 B/A1/B 2555 
(2518-2592) 
3048 
(3035-3061) 
Complex B/G/A1/A1/B  2552 
(2551-2553) 
2722 
(2712-2732) 
2890 
(2888-2891) 
3034 
7 B/A1/B 2568 
(2540-2596) 
3048 
(3035-3061) 
A1/B CRF05/B/A1/B 2362 
(2361-2363) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
8 B/A1/B 2562 
(2519-2605) 
3048 
(3035-3061) 
A1/B B/A1/B  2540 
(2497-2583) 
 3034 
(3033-3035) 
9 B/A1/B 2557 
(2519-2595) 
3048 
(3035-3061) 
A1/B CRF39/B/A1/B 2418 
(2411-2425) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
10 B/A1/B 2567 
(2540-2594) 
3048 
(3035-3061) 
Complex CRF05/U/A1/B 2437 
(2425-2449) 
2540 
(2539-2541) 
 3034 
(3033-3035) 
Cluster 25b 
1 B/A1/B 2545 
(2538-2552) 
2941 
(2911-2971) 
B B     
2 B/A1/B 2545 
(2538-2552) 
2941 
(2911-2971) 
Complex B/B/A1/U/B 2354 
(2353-2355) 
2540 
(2539-2541) 
2671 
(2647-2695) 
3016 
(3013-3020) 
3 B/A1/B 2545 
(2538-2552) 
2941 
(2910-2972) 
B/U B/U/B  2540 
(2539-2541) 
 3016 
(3004-3028) 
4 B/U/B 2530 2974 B/U U/CRF03    3033 
(2951-3117) 
5 B/U/B 2554 2932 Complex B/A1/F1/A1/B  2555 2671 2918 
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No. jpHMM 
GT 
jpHMM breakpoint (95% CI) SCUEAL GT (S) SCUEAL GT (D) SCUEAL breakpoints (95% CI) 
(2556-2558) (2670-2772) 
2819 
(2818-2820) 
(2917-2919) 
6 B/A1/B 2592 
(2553-2631) 
2922 
(2907-2937) 
B B     
7 B/U/B 2520 2924 A1/B B/A1/B   2818 
(2816-2820) 
2917 
(2916-2918) 
Cluster 25c 
1 B/A1/B 2653 
(2612-2694) 
2923 
(2909-2937) 
B B 2434 
(2430-2438) 
2540 
(2539-2541) 
  
2 B/A1/B 2632 
(2612-2652) 
2923 
(2909-2937) 
A1/B B/A1/B/B   2729 
(2727-2731) 
2924 
(2923-2925) 
3184 
(3166-3202) 
3 B/A1/B 2648 
(2612-2684) 
2923 
(2909-2937) 
A1/B B/B/A1/CRF03 2371 
(2367-2373) 
2612 
(2601-2623) 
 2924 
(2923-2925) 
Table 3_17. Full breakpoint results for Cluster 25a,b,c. In Cluster 25a, the jpHMM results show near-identical breakpoint predictions for all ten sequences. 
The most commonly SCUEAL-predicted breakpoints are at HXB2 2540 and HXB2 3035. In Cluster 25b, the first jpHMM breakpoint has a similar placement to 
cluster 25a, but the second breakpoint is approximately 100 nucleotides distant from the second breakpoint identified for that cluster. The SCUEAL results 
show little consistency. In Cluster 25c, the jpHMM results indicate a B/A1/B structure for these sequences, but the phylogenetic results indicate a CRF50/B 
recombinant. CRF50 is not included at present in the jpHMM algorithm, which accounts for the seemingly discrepant results. The only SCUEAL breakpoint 
that is present in 2/3 sequences, HXB2 2924, is consistent with the second predicted jpHMM breakpoint.   
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The HIV BLAST search showed 10 sequences that appeared in at least 75% of the 
closest sequence matches. Four of these sequences were submissions from the UK 
HIV DRD, and the remaining six were A1/B sequences from Canada. jpHMM 
analysis of the six Canadian sequences showed that all sequences had a single 
breakpoint only; 3/7 were B/A1 recombinants and 4/7 were D/A1 recombinants.  
 
Figure 3_23. Cluster 25a: B and CRF50 recombinant fragments. Maximum clade 
credibility trees of putative pure subtype regions.  Breakpoints were placed at HXB2 2555 
and 3048 (Method 1). Sequences exhibiting monophyletic clustering with a posterior 
probability of >0.7 are highlighted in red. Sequences that do not exhibit monophyletic 
clustering are highlighted in green. a) Slice 1; b) Slice 2; c) Slice 3.      
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Tree 1 for cluster 25b showed all seven sequences clustering monophyletically, with 
a posterior probability of 1 (Figure 3_24a). The sequences clustered with subtype B, 
however the support for this was weak (posterior probability = 0.38).  
Tree 2 showed all seven sequences clustered closest to CRF50 sequences, with 
moderate support (posterior probability = 0.60), and strong support once subtype A1 
was included (posterior probability=1; Figure 3_24b). Tree 3 showed all seven 
sequences clustered close to sequences from cluster 25c, and closest to subtype B 
(posterior probability = 0.83, Figure 3_24c). Restricting the cluster to these seven 
sequences reduced the maximum genetic distance to 1.5%.  
The predicted structure for cluster 25b was B/CRF50/B, with breakpoints at 
breakpoints at 2545 and 2941. The geographic location showed 6/7 sequences in 
Scotland and 1/7 sequences in Northwest England. Demographic information was 
available for 1/7 sequences, which was a white MSM. 
The HIV BLAST search showed eight sequences that appeared in at least 75% of 
the closest sequence matches. 5/8 were sequences that were submissions from the 
UK HIV DRD, 2/8 were subtype B sequences from Sweden and 1/8 was a subtype 
B sequences from the USA. 
Trees 1 and 2 from cluster 25c showed the three sequences clustering with CRF50 
sequences, with relatively strong support in both trees (Figure 3_25a, 3_25b). The 
tree from slice 3 showed all three sequences clustering with subtype B sequences 
(posterior probability = 0.82, Figure 3_25c). Restricting the cluster to these 
sequences gave a maximum genetic distance of 0.4%. The geographic location 
showed that 2/3 sequences came from London and Southeast England and 1/3 
sequences came from Scotland. Demographic information was available for 2/3 
sequences; both sequences came from white MSM. The country of origin for one 
sequence was the USA. 
The HIV BLAST search showed seven sequences that were present in at least 75% 
of the closest sequence matches. Two of these were subtype B sequences from the 
UK (not submitted from the UK HIV DRD), two were subtype B sequences from 
Sweden, and three were D/A1 recombinant sequences from Canada. jpHMM 
analysis of the recombinant sequences showed a breakpoint located between HXB2 
2550 and 2561, similar to the D/A1 breakpoint in CRF50. 
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Figure 3_24. Cluster 25b: B and CRF50 recombinant fragments. Maximum clade 
credibility trees of putative pure subtype regions.  Breakpoints were placed at HXB2 2545 
and 2941 (Method 2).Sequences exhibiting monophyletic clustering with a posterior 
probability of >0.7 are highlighted in red; sequences that do not exhibit monophyletic 
clustering are highlighted in green.  a) Slice 1; b) Slice 2; c) Slice 3.      
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Figure 3_25. Cluster 25c: CRF50 and B recombinant fragments. Maximum clade 
credibility trees of putative pure subtype regions.  Breakpoints were placed at HXB2 2632 
and 2943 (Method 3). Sequences exhibiting monophyletic clustering with a posterior 
probability of >0.7 are highlighted in red; sequences that do not exhibit monophyletic 
clustering are highlighted in green.  a) Slice 1; b) Slice 2; c) Slice 3.      
 
 A time-scaled phylogeny including all 72 identified CRF50_A1D strains showed that 
Cluster 25a had a tMRCA of 1997.60 (95% HPD = 1994.26-2001.14) in the UK 
(Figure 26).  MCMC analysis showed a tMRCA for Cluster 25b of 1999.14 (95% 
HPD = 1995.95 – 2002.48). Three of the sequences were in a sub-branch 
containing subtype B sequences from the UK and Sweden. The remaining four 
sequences formed their own branch with a tMRCA of 2005.07 (95% HPD = 
2004.59-2005.94). The time scaled phylogeny for Cluster 25c showed a tMRCA of 
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1999.55 (95% HPD = 1997.54-2001.82) and contained a sequence from the UK 
showing identical recombinant structure and breakpoints. 
 
Figure 3_26. Time scaled phylogeny of Clusters 25a, b, and c, white MSM clusters. 
MCMC analysis of three CRF50_A1D/B recombinant clusters. CRF50_A1D sequences are 
contained in the collapsed node. Canadian sequences showing almost identical 
recombination breakpoints as CRF50 are shown in purple; the later tMRCA of this cluster 
indicates possible export of CRF50 from the UK to Canada. Cluster 25a is shown in green, 
cluster 25b is shown in lavender and cluster 25c is shown in blue.  
 
3.2.4.26 Cluster 26 (C/B/C) 
Cluster 26 had four members and a maximum genetic distance of 6.4%. 
Breakpoints were placed at HXB2 2572 and 3026. The sequences did not cluster 
together in any of the three trees, indicating that these sequences were not a novel 
CRF. 
3.2.4.27 Cluster 27 (C/B/C) 
Cluster 27 comprised five members and had a maximum genetic distance of 4%. 
Overall, 3/5 sequences had identical SCUEAL breakpoints at HXB2 equivalent 2377 
and 2719, respectively (Table 3_18), accordingly, the alignment was sliced in these 
positions. 5/5 sequences clustered together in all three trees (posterior probabilities 
= 0.79, 1 and 1, respectively). Slice 1 showed the sequences clustering closest to 
subtype C sequences (Figure 3_27a), slice 2 showed the sequences clustered with 
subtype B (Figure 3_27b) and slice 3 showed clustering closest to subtype C 
97 
 
(Figure 3_27c). No demographic information was available. The geographic location 
showed 2/5 in Southwest England and Wales, 1/5 in Northeast England, 1/5 in 
Northwest England and 1/5 in Scotland. 
The HIV BLAST search showed two sequences that were consistently present in 
the closest sequence matches. Both were subtype C sequences; one from 
Zimbabwe and one from South Africa. 
The trees indicate that these sequences may comprise a novel CRF that is 
circulating in an unknown population. 
No. jpHMM 
GT 
jpHMM breakpoint (95% 
CI) 
SCUEAL 
GT (S) 
SCUEAL 
GT (D) 
SCUEAL breakpoints (95% CI) 
1 C/B/C 2379 
(2323-2435) 
2703 
(2688-2719) 
Complex C/B/C/U 2377 
(2376-
2378) 
2716 
(2718-
2720) 
3142 
(3140-
3148) 
2 C/B/C 2381 
(2322-2440) 
2703 
(2688-2719) 
B/C C/B/B/C/C 2398 
(2397-
2399) 
2501 
(2500-
2502) 
2710 
(2709-
2711) 
3058 
(3051-
3065) 
3 C/B/C 2389 
(2346-2432) 
2704 
(2688-2720) 
Complex C/B/C/G 2377 
(2376-
2378) 
2719 
(2714-
2725) 
3142 
(3141-
3143) 
4 C/B/C 2385 
(2335-2435) 
2712 
(2689-2735) 
Complex C/B/C/U 2377 
(2376-
2378) 
2719 
(2718-
2720) 
3142 
(3138-
3146) 
5 C/D/A2/
C 
2349 
(2340-2358) 
2443 
(2358-2528) 
2706 
(2685-2727) 
C C    
Table 3_18. Full breakpoint results for Cluster 27. The jpHMM results show consistent 
breakpoint predictions in 4/5 sequences; the SCUEAL breakpoints at positions 124 and 466 
are equivalent to HXB2 2377 and 2719, respectively. The predictions for the fifth sequence 
are different between jpHMM and SCUEAL and different from the predictions for the other 
four sequences. 
 
3.2.4.28 Cluster 28 (G/complex) 
Cluster 28 had 23 members and a maximum genetic distance of 9%. The predicted 
recombinant structures were comprised of complex structures based around 
subtype G. Although the sequences appeared related, there was no consensus 
regarding breakpoint locations in either of the two genotyping results; consequently 
the alignment was sliced using four different sets of breakpoints and analysed 
multiple times. The first set of breakpoints was placed at HXB2 2369, 2737 and 
3297, respectively, the second at 2429, 2542, 3033, the third at 2655, 2768, 3094 
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and the final set at 2671 and 3192. Consistent clustering was not observed in any of 
the trees.  
 
 
Figure 3_28. Cluster 27: C and B recombinant fragments. Maximum clade credibility 
trees of putative pure subtype regions.  Breakpoints were placed at HXB2 2377 and 2719. 
Sequences exhibiting monophyletic clustering with a posterior probability of >0.7 are 
highlighted in red. a) Slice 1; b) Slice 2.      
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Chapter 4: Identification of potentially recombinant HIV-1 
sequences and development of a near full-length single 
genome sequencing protocol 
4.1 Phylogenetic screening of pol gene sequences in the UK HIV DRD (2007 
and 2010 downloads)  
A screen of the pol gene (RT and PR) population sequences present in the 2007 
anonymised download of the UK HIV DRD was performed using the REGA tool 
developed by the REGA Institute in Leuven, Belgium. This process identified five 
mosaic sequences that were unable to be assigned to a definite subtype. All five 
sequences shared a similar recombination profile, which was a single breakpoint 
between subtype D and A1 between nucleotides HXB2 2603-2703. Alignments of 
subtype D and sub-subtype A1 sequences of the same genomic region were 
generated and used to confirm the subtype classifications, using the 100 closest 
BLAST matches in the UK HIV DRD.  
The five putative A1/D recombinant specimens were all from white MSM diagnosed 
with HIV infection between 2000 and 2003. This part of the work was done in 
collaboration with our collaborators at the REGA Institute. Following the REGA 
investigation, stored samples from four of the subjects  were subsequently retrieved 
and transferred to the Royal Free Hospital for near full-length, single genome 
sequencing (NFL-SGS).  
In 2011, following sequencing of the four specimens, an additional screen of the 
2010 download of the database was performed to expand the previous analysis. 
The single genome sequences were used as reference sequences for a BLAST 
search of the 2010 UK HIV DRD, and the top 400 matches were genotyped using 
SCUEAL to identify sequences sharing the same D/A1 breakpoint. 42 sequences 
sharing the same pol D/A1 breakpoint were identified, of which 16/42 were located 
in clinics in London and southeast England and 26/42 were located in clinics in 
northwest England. As the original four specimens that were sequenced were from 
clinics in London and Southeast England, two additional samples from clinics in 
Northwest England were obtained and sequenced. 
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4.1.1 Sample retrieval 
In order to preserve patient anonymity, we elected to characterise samples from 
clinics with large numbers of patients. Furthermore, when retrieving samples for 
testing we used the MRC-CTU (who held the linked database and clinic patient 
identifiers) as an intermediate between the laboratory (holding database identifiers 
only) and the clinic, thereby ensuring we remained fully blinded to the patients’ 
personal details. Finally, the aliquots of plasma were anonymised before transfer to 
the Royal Free Hospital.    
4.2 Development and validation of a near full-length, single genome 
sequencing (NFL-SGS) protocol for plasma HIV-1 RNA  
Although protocols for HIV-1 NFL-SGS were available in published literature, the 
majority of these were for amplification of viral DNA extracted from peripheral blood 
cells (PBMC); few published data were available for the amplification of near full-
length HIV-1 genomes from plasma HIV-1 RNA. Additionally, there were particular 
challenges related to the development of this technique. Firstly, although two of the 
samples retrieved from storage were less than one year old, four samples were 
between six and ten years old;  all samples had been stored at -80oC under routine 
conditions and the viral RNA may have undergone a degree of deterioration. 
Secondly, the volume of plasma available varied according to the storage protocols 
at each centre; sample volumes received were between 270µl and 1.5ml. Finally, 
the plasma HIV-1 RNA (“viral”) load ranged between 9,148 and 500,000 copies/ml, 
meaning that the number of viral copies available for amplification was generally low 
(see Table 5_1 in the next chapter for further details of viral loads). Obtaining extra 
stored samples was not possible under the terms of the ethics agreement. 
Therefore, a robust protocol was optimised for low sample volumes and viral load. 
Additionally, because the ultimate aim was single genome amplification of 
recombinant specimens, a two-step, nested protocol using a single set of primers 
per PCR round was required. The two-step approach allowed for dilution of cDNA 
following reverse transcription, and therefore amplification of single genomes, and 
the single set of primers per PCR round eliminated the possibility that multiple sets 
of primers were amplifying a mixed, rather than recombinant, viral population. 
The plasma specimens used for the validation process were left over samples from 
the virology diagnostic department at the Royal Free Hospital.  These samples had 
been previously genotyped to determine the presence of drug resistance, as part of 
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routine care. Once retrieved from storage, samples were identified by laboratory 
number only and not linked to patient identifiable information.  
4.2.1 Preliminary protocols 
Development of an NFL-SGS system commenced with an attempt to optimise a 
protocol published by Nadai et al. in 2008. The protocol involved amplification of the 
HIV-1 genome between HXB2 nucleotides 769 and 9181 in either two or three 
overlapping fragments of sizes 2.6kb (HXB2 769 - 3477), 3.3kb (HXB2 5861 -  
9181), 3.7kb (HXB2 2483 - 6352), and 7.0kb (HXB2 2166 - 9181), respectively. The 
reported success rate for the 2.6kb fragment (which was used in both 2- and 3- 
fragment strategies) was 100% for viral loads greater than 750,000 copies/ml, 75% 
for viral loads between 100,000 and 200,000, 40% for viral loads between 10,000 
and 100,000 copies/ml  and 0% for viral loads less than 10,000 copies/ml. 
Therefore, an attempt was made to optimise the protocol for specimens with low 
viral loads. The protocol was designed for the amplification of subtype B specimens, 
and therefore the initial optimisation attempts were made using clinical subtype B 
plasma specimens. 
4.2.1.1 Amplification of the 2.6kb fragment  
The amplification of the 2.6kb fragment was the first step of the optimisation 
process. HIV-1 RNA was extracted using the Biomerieux easyMAG automated 
extractor using 1ml of plasma as the input in a generic on-board lysis protocol, with 
a final elution of 25µl. cDNA synthesis was trialled using both gene-specific and 
Oligo dT priming during reverse transcription (RT) with Superscript III Reverse 
Transcription reagents (Life Technologies). A total of 3µl RNA, 500µM dNTPs, and 
2.5µM of either Oligo dT or primer UNINEF 7’ 5’-
GCACTCAAGGCAAGCTTTATTGAGGCTT-3’ were combined and heated at 65°C 
for 5 minutes. Subsequently, PCR reactions were removed from the thermal cycler, 
and a mastermix of 2µl RT Buffer, 25mM MgCl2, 0.1M DTT, 1µl RNaseOUT, 2µl 
Superscript III and 3µl nuclease-free H2O added for a combined reaction volume of 
20µl. Reverse transcription was performed at 50°C 2 hours, 85°C 5 minutes, 
followed by addition of 1µl RNase H, and then 37°C 20 minutes, 70°C 15 minutes. 
These conditions (except for priming with Oligo dT) were identical to the conditions 
detailed in Nadai et al.   
To amplify the cDNA, the Expand Long Template PCR Kit (Roche Diagnostics, 
Sussex, UK) was used. The 50µl first-round PCR reaction mixture comprised 5µl 
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10x PCR Buffer, 350µM dNTPs, 0.4µM each of forward primer msf12b 5’-
AAATCTCTAGCAGTGGCGCCCGAACAG and reverse primer RT347R 5’-
GAATCTCTCTGTTTTCTGCCAGTTC, 5U enzyme, 29.3µl nuclease-free H2O and 
10µl cDNA. Cycling conditions were 94°C 2 minutes, followed by 10 cycles of 94° 
10 s, 60°C 30 s, 68°C 3 m, then 20 cycles of 94°C 10s, 55°C 30s, 68°C 3 m; the 
final extension was 68° C 10 minutes. The second round of PCR used forward 
primer f2nst 5’-GCGGAGGCTAGAAGGAGAGAGATGG and reverse primer proRT 
5’-TTTCCCCACTAACTTCTGTATGTCATTGACA. 5µl of first-round PCR product 
was used as the reaction template, and the volume of nuclease-free H2O was 
34.3µl. All other reaction components and conditions remained the same. The PCR 
was performed without the physical wax barrier used in the Nadai et al. paper.  This 
approach failed to yield an amplified product with both gene-specific and Oligo dT 
approaches.   
Subsequently, the PCR protocol was attempted using a physical wax barrier 
(AmpliWax PCR Gem 50, Life Technologies) as described in the Nadai et al. paper. 
Briefly, 350µM dNTPs, 0.4µM of each primer (msf12b and RT3473R in the first 
round and f2nst and proRT in the nested round) and 20µl of nuclease-free H2O 
were combined and placed in a thin-walled PCR reaction tube with a wax bead. 
PCR reactions were heated to 85°C for 5 minutes, and then placed on ice to re-
solidify the wax and create a physical barrier that would prevent premature primer 
hybridisation during the enzyme activation stage. Following this, 5µl 10x PCR 
Buffer, 5U of enzyme, 9.3µl of nuclease-free H2O (14.3 µl in the nested round) and 
either 10 (first round) or 5 (nested round) µl template was combined and added to 
the PCR reaction. The cycling conditions were identical to those detailed above. 
Unfortunately, the addition of the wax barrier also failed to yield any amplified PCR 
product when using both gene-specific and Oligo dT priming.  
At this stage, three subtype B clinical specimens were extracted in parallel using the 
easyMAG system and Viroseq manual extractions, and tested using an already-
validated HIV-1 pol PCR. Only the Viroseq extracts amplified, and so the easyMAG 
extraction protocol was discarded. All subsequent testing was performed using 
Viroseq extractions. 
A new RT approach using random hexamers (Qiagen) with Promega reagents 
(London, UK) was adopted. The reaction mixture comprised 4µl 5xRT Buffer, 1µl 
25mM dNTPs, 1.25µl random hexamers, 400U RNAseIn, 50U MMLV RT, 1.75µl 
nuclease-free H2O and 10µl RNA. The RNA, dNTPs and random hexamers were 
103 
 
combined and heated to 65°C for 30 seconds, followed by 42°C for five minutes. 
Following this, the remaining reagents were added, and reverse transcription was 
performed at 42°C 60 minutes, followed by 99°C for 5 minutes.  The subsequent 
PCR amplification was performed with the wax barrier as detailed above. This 
approach resulted in the successful amplification of the 2.6kb fragment of three 
subtype B clinical specimens (Figure 4_1a). 
Although the fragment amplification was successful, the gel showed smears of DNA 
in 2/3 specimens, indicating an unoptimised methodology. To optimise the reaction, 
the annealing temperature was increased by 2°C, to 57°C, in the second round of 
cycles in the nested PCR, and amplification was repeated using the same three 
clinical specimens. This resulted in both smears of DNA and evidence of mispriming 
(smaller, incorrectly-sized products) (Figure 4_1b), and so the annealing 
temperature was returned to 55°C, and a further subtype B specimen was amplified 
in triplicate. When this showed clean bands in 2/3 replicates (Figure 4_1c), the 
decision was made to delay final optimisation of each fragment until successful 
amplification was achieved across the entire HIV genome. 
 
Figure 4_1. Amplification of the 2.6kb fragment  spanning gag-pol (HXB2 769 - 3477) 
from the Nadai et al. protocol for near full-length sequencing of HIV-1 from plasma.  
a)  Amplification of the 2.6kb fragment using three clinical HIV-1 subtype B stored plasma 
specimens.  Lane 1 contained Hyperladder I, lanes 3, 5 and 7 contained one replicate each 
of a clinical HIV-1 subtype B specimen. Lane 9 contained the negative control. Although the 
DNA bands were of the correct size, DNA smears were present, indicating an unoptimised 
methodology. b) Optimisation of the second round PCR annealing temperature. The same 
clinical specimens as in Figure 4_1a were amplified using an annealing temperature of 57°C 
in the second round of cycles in the nested PCR. Lane 1 showed Hyperladder I, and lanes 3, 
5 and 7 contained one replicate each of a clinical HIV-1 subtype B specimen. Lane 9 
contained the negative control. Increasing the annealing temperature in this step did not 
optimise the method, as DNA smears were still present, and mispriming occurred in the 
second specimen. c) Triplicate amplification of a single subtype B specimen at the original 
annealing temperature of 55°C. Hyperladder I is in lane 1; lanes 2 - 4 show triplicate 
replicates of a single specimen. Although 1 replicate failed to amplify, the other two 
replicates showed clean DNA bands. 
 
104 
 
4.2.1.2 Amplification of the 3.3kb and 3.7kb fragments 
Following the successful amplification of the 2.6kb fragment, amplification of the 
remaining two fragments in the three fragment protocol (3.3kb (HXB2 5861-9181), 
3.7kb (HXB2 2483-6352)) was attempted. Owing to the consistent failure of the 
extraction and RT steps from the Nadai et al. paper, the Viroseq extraction and 
random hexamer RT were retained. The PCR reactions comprised the same 
components as for the 2.6kb amplicon; primers for the 3.3kb fragment were 
ENVoutF1 5’-AGARGAYAGATGGAACAAGCCCCAG and UNINEF 7’ in the first 
round, and ENVinF1 5,-TGGAAGCATCCRGGAAGTCAGCCT and nefyn05 5’-
GTGTGTAGTTCTGCCAATCAGGGAA in the nested round; primers for the 3.7kb 
amplification were POLoutF1 5’-CCTCAAATCACTCTTTGGCARCGAC  and VIF-
VPUoutR1 5’-GGTACCCCATAATAGACTGTRACCCACAA in the first round 
reaction, and POLinF1 5’-AGGACCTACRCCTGTCAACATAATTGG and VIF-
VPUinR1 5’-CTCTCATTGCCACTGTCTTCTGCTC in the nested round. The cycling 
conditions for each were the same as for the 2.6kb fragment, except that the 
extension time in each stage was increased from 3 minutes to 4 minutes. These 
conditions were identical to those in Nadai et al. 
Although the new RT strategy resulted in consistently successful amplification of the 
2.6kb fragment, when this approach was applied to amplification of the 3.3 and 
3.7kb fragments, the results showed either products of incorrect size (for the 3.7kb 
fragment reaction), or complete failure of amplification (for the 3.3kb reaction) 
(Figure 4_2 a). This was most likely due to the use of random hexamers at the RT 
stage, which produces many shorter fragments of cDNA rather than the single 
fragment gained from using gene-specific or Oligo dT priming, but, as this was the 
only RT strategy that had been successful, further attempts at optimising the 
reactions for these fragments were made. 
The Expand Long Template kit came equipped with three different reaction buffers 
containing differing concentrations of MgCl2. Amplification of both fragments was 
subsequently attempted using both Buffer 2 and Buffer 3, using a single clinical 
specimen from which the 2.6kb fragment was successfully amplified. The reactions 
with Buffer 2 resulted in failed amplification for the 3.3kb fragment, and amplification 
at the incorrect size for the 3.7kb fragment (Figure 4_2b). One faint band of the 
correct size was amplified for the 3.7kb fragment, however this was of insufficient 
intensity for use in any downstream analyses. The reactions using Buffer 3 also 
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resulted in failure of amplification of the 3.3kb fragment and amplification of 
incorrectly-sized products for the 3.7kb fragment (Figure 4_2c).     
 
Figure 4_2. Optimisation of the 3.3kb and 3.7kb fragments from the Nadai et al. 
protocol.  
a) Typical results from attempted subtype B amplification of the 3.3kb and 3.7kb fragments 
of the Nadai et al protocol.  Lanes 1-2 and 3-4 contained duplicate reactions of two clinical 
subtype B specimens using the 3.7kb amplification protocol. Incorrectly sized product was 
present in 3/4 reactions; the remaining reaction failed to amplify. Lanes 5-6 and 7-8 
contained duplicate reactions of the same two subtype B clinical specimens, amplified using 
the 3.3kb protocol. All reactions failed to amplify. Lanes 9 and 10 contained the negative 
control reactions, and lane 11 contained Hyperladder I. b) Results from attempted 
amplification of the 3.3kb and 3.7kb fragments using Buffer 2. Lane 1 contained Hyperladder 
I, lanes 2-4 contained triplicates of a subtype B clinical specimen amplified using the 3.7kb 
fragment protocol, lanes 5-7 contained triplicates of the same subtype B specimen amplified 
using the 3.3kb fragment protocol, and lane 8 contained the negative control. There was one 
faint band of the correct size for the 3.7kb fragment (lane 3); all other replicates for both 
fragments failed. c) Results from attempted amplification of the 3.3kb and 3.7kb fragments 
using Buffer 3 and the same subtype B clinical specimen used in 4-b. Lane 1 contained 
Hyperladder I, lanes 2-4 contained triplicates of the subtype B clinical specimen amplified 
using the 3.7kb protocol, lanes 5-7 contained triplicates of the same subtype B specimen 
amplified using the 3.3kb fragment protocol, and lanes 8-9 contained the negative controls. 
Some very faint products of the correct size were observed for the 3.7kb fragment; no 
products were present for the 3.3kb amplicon. DNA smears and evidence of mispriming was 
widespread across all reactions. 
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Given the consistent failure of the 3.3kb fragment, it was decided to focus on 
amplifying this region of the genome successfully before proceeding to further 
optimisation of other genomic regions. A new strategy of splitting the 3.3kb fragment 
into two smaller, overlapping fragments (HXB2 6813-8817 and 5514-7374) was 
adopted, with a view to extending this strategy to the 3.7kb fragment if successful. 
The primers for this fragment were sourced from the list of sequencing primers in 
Nadai et al. (see Appendix 2_4 for the full list). The HXB2 co-ordinates and melting 
temperatures of primers were compared, and a nested PCR was designed using 
first round primers ZFF 5’-GGGATCAAAGCCTAAAGCCATGTGTAA and JL89 5’-
TCCAGTCCCCCCTTTTCTTTTAAAAA, and second round primers 793SEQ1 5’-
AACACCTCAGTCATTACACAGGCC and JL71 5’-TTTTGACCACTTGCCACCCAT. 
The HXB2 co-ordinates of this fragment were 6813-8817. 
Amplification of the new fragment was attempted using triplicates of a single 
subtype B clinical specimen that had previously successfully amplified. Owing to the 
size of the fragment (2.0kb), the PCR mastermix components and cycling conditions 
used were as for the 2.6kb fragment. Each of the three buffers in the Expand Long 
Template PCR kit was trialled simultaneously, and the best results were achieved 
using Buffer 3 (Figure 4_3 a).  Following this, a further fragment (fragment 4) was 
designed using the first-round primers ACC1 5’-
TTCAGAAGTATACATCCCACTAGG and JL102 5’-GATGGGAGGGGCATACAT, 
and second round primers VIFC 5’-GAYAAAGCCACCTTTGCCTAGTGTT and JL98 
5’-AGAAAAATTCCCCTCCACAATTAA (HXB2 co-ordinates 5514 - 7374; fragment 
size 1.8kb). This was amplified using the same conditions as fragment 3, but using 
Buffer 3 only (Figure 4_3b).     
Given the success of splitting the 3.3kb fragment into two, smaller, fragments, the 
same approach was now attempted for the 3.7kb fragment. Accordingly, the 
fragment was split into regions amplified by the following primers: fragment 2a used 
first round PoloutF1 5’-CCTCAAATCACTCTTTGGCARCGAC and SP1AS 5’-
GGATGAATACTGCCATTTGTACTGC, and PolinF1 5’-
AGGACCTACRCCTGTCAACATAATTGG and POLT- 5’-
GCAGTCTACTTGTCCATGCATGGC in the nested round (HXB2 co-ordinates 
2483-4397; fragment 2b used first round POLP 5’-
GGATGGGATATGAACTCCATCC and VIF-VPUinF1 5’-
CTCTCATTGCCACTGTCTTCTGCTC, and POLU 5’-
ACTTTCTATGTAGATGGGGCAGC and ACC8R 5’-
TCTCCGCTTCTTCCTGCCATAG in the nested round (HXB2 co-ordinates 3864 - 
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5989). These new fragments were trialled using Buffer 3, and the same PCR 
reaction components and cycling conditions as the 2.6kb fragment. Although 
fragment 2a amplified (Figure 4_3 c), fragment 2b failed to amplify. 
 
Figure 4_3. Optimisation of newly designed fragments.  
a) Amplification of triplicates of a clinical subtype B specimen for the newly designed 
fragment 3, spanning HXB2 6813 - 8817. Each of the three buffers in the Expand Long 
Template PCR kit was trialled simultaneously. Lane 1 contained Hyperladder I and Lanes 2 -
10 contained amplification products. Lanes 2 - 4 contained the fragment using Buffer 1, and 
lanes 5 - 7 and 8 - 10 contained the products from using Buffers 2 and 3, respectively.  
Consistent  amplification without mispriming was achieved using Buffer 3 only. b) 
Amplification of the subsequently designed fragment 4, spanning HXB2 5514 - 7374, using 
Buffer 3.  Lane 1 contained Hyperladder I.  Lanes 2 - 4 contained amplification of a clinical 
HIV-1 subtype B specimen. c) Amplification of fragment 2a using triplicates of a subtype B 
clinical specimen. Lane 1 contained Hyperladder I, and lanes 2 - 4 contained the subtype B 
specimen. Amplification of the correct size was achieved in all three replicates.  
 
 
4.2.1.3 Filling in the gaps 
At this stage, a total of 6.9kb of the genome had been amplified successfully using 
subtype B clinical specimens (Figure 4_4). However, there were two regions of the 
genome that showed consistent amplification failure. Two sets of primers were 
designed using Primer3 to cover these regions. The primer sets were designed to 
cover the missing regions with sufficient overlap to allow for subsequent sequence 
assembly, and with melting temperatures that should allow for use of the same PCR 
conditions as the other fragments. The primers for fragment pol-vif were Pol2fwd 5’-
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AATACAGAAGCAGGGGCAAG and Pol2rev 5’-GCAATGAAAGCAACACTTTTT in 
the first round (HXB2 3533 - 5932), and Pol2nestedfwd 5’-
AGGAAACATGGGAAACATGG and Pol2nestedrev 5’-
TCGACACCCAATTCTGAAAA (HXB2 3733 - 5790). Unfortunately, both of the 
newly-designed fragments failed to amplify. 
Following this, a final attempt was made to amplify the pol-vif region using a 
combination of the primers POLP 5’-GGATGGGATATGAACTCCATCC and Pol2rev 
in the first round, and POLU 5’-ACTTTCTATGTAGATGGGGCAGC and 
Pol2nestedrev in the nested round. Unfortunately, this combination of primers also 
failed to amplify. Additionally, there was concern regarding splitting the HIV-1 
genome into too many fragments, especially when the identification of a 
recombinant structure was the ultimate goal of the analysis. Therefore, a renewed 
attempt to amplify the 3.7kb fragment in a single reaction was made using two new 
long-range PCR systems. 
 
Figure 4_4. Regions of the HIV-1 genome successfully amplified using conditions and 
primers adapted from the Nadai et al. protocol. A modified schematic of the HIV-1 
genome shows regions successfully amplified using modified primers sets and conditions 
from the Nadai et al. protocol.  Genomic regions that had successfully been amplified are 
shown in red. Although approximately 2/3 of the genome was covered, the two missing 
regions showed consistent amplification failure. The original genome schematic is available 
from http://dx.doi.org/10.1016/S0966-842X(00)01816-3. 
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4.2.1.4 Amplification of the 3.7kb fragment using two long-range PCR systems
   
Two new long-range PCR systems were used in a final attempt to amplify the 3.7kb 
fragment: the New England Biolabs Phusion PCR Kit (Hitchen, UK), and the Qiagen 
Long Range PCR Kit (Hilden, Germany). The Phusion PCR kit strategy was 
attempted according to the manufacturer’s instructions, both with and without the 
addition of DMSO. Per reaction components without DMSO comprised 25µl Phusion 
Mastermix, 2.5µl each of forward primer POLoutF1 and reverse primer VIF-
VPUoutR1, 15µl nuclease-free H2O and 5µl template DNA. The per reaction 
components for the reactions with DMSO comprised 25µl Phusion Mastermix, 2.5µl 
each of forward primer POLoutF1 and reverse primer VIF-VPUoutR1, 13.5µl 
nuclease-free H2O, 1.5µl DMSO and 5µl template DNA.  The nested round was 
identical to the first round except for the use of forward and reverse primers 
POLinF1 and VIF-VPUinR1. 5µl of first round product was used as the template for 
the nested PCR.  Cycling conditions for both reactions were 98°C 30s, followed by 
35 cycles of 98°C 10s, 68°C 30s, 72°C 2m, and a final extension of 72°C 10m. Both 
these reactions failed to amplify.  
Following amplification failure, a gradient PCR using annealing temperatures of 
69.0°C, 69.5°C, 70°C, 71.5°C and 72°C was performed to optimise the annealing 
temperature, and the primer concentration was titrated in concentrations of 0.2µM, 
0.25µM, 0.3µM and 0.35µM per reaction. Unfortunately, no amplified product was 
observed at any stage. An attempt was made to amplify the 2.6kb fragment 
amplifiable with the Expand Long Template Kit; after this fragment did not amplify in 
the correct size, the kit was abandoned. 
Next, the Qiagen Long Range PCR kit was trialled. This kit contained a proprietary 
RT step, which was trialled using parallel testing with the random hexamer RT 
protocol. Per reaction components for the Qiagen RT were: 4 µl RT Buffer, 2µl 
dNTP mix, 1µl Oligo dT, 0.2µl RNasIn, 1µl RT enzyme, 1.8µl nuclease-free H2O and 
10µl RNA. Cycling conditions were 42°C 90m, followed by 85°C. The per reaction 
components for the PCR protocol were: 5µl 10xBuffer, 2.5µl dNTPs, 2µl each of 
forward and reverse primers POLoutF1 and VIF-VPUoutR1, 0.4µl enzyme, 33.1µl 
nuclease-free H2O and 5µl cDNA. Cycling conditions were 93°C 3m, followed by 35 
cycles of 93°C 15s, 62°C 30s, 68°C 3 m; the final extension was 68°C 10m. The 
nested PCR protocol was the same as the first round but with the use of primers 
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POLinF1 and VIF-VPUinR1. The PCR reactions using the proprietary RT and the 
random hexamer RT failed to amplify.  
After amplification failure, a gradient PCR with annealing temperatures of 60°C, 
62°C, 66°C and 68°C was performed, followed by experimentation using both 
touchdown PCR and cycle elongation of 20 successive cycles. After these 
modifications still failed to yield products of the correct size, the protocol was 
discarded. 
Subsequently, a protocol was successfully adapted from one developed in Beatrice 
Hahn’s laboratory at the Centre for HIV/AIDS Vaccine Immunology (CHAVI) 
(unpublished, CHAVI-MBSC-2). This protocol involved the amplification of HIV-RNA 
in a single 9kb fragment.  
4.2.2 Optimisation of the CHAVI protocol 
Optimisation of the CHAVI protocol was performed at each of the following steps: 
4.2.2.1 RNA extraction 
To lessen the labour associated with performing manual nucleic acid extractions, 
RNA extraction was trialled using the QiAmp Viral RNA Mini Kit (Qiagen) as detailed 
in the CHAVI protocol, and the automated BioMerieux Nuclisens easyMAG system 
(BioMerieux, Basingstoke, UK). 22/65 (33.8%) reactions using the automated 
extractor showed evidence of mispriming and PCR products of the incorrect size 
(~2-3kb) (Figure 4_5a). This was most likely due to the automated extractor 
shearing the RNA during the extraction process. In contrast, when the QiAmp Viral 
RNA Mini Kit was used, PCR products of the correct ~9kb size were amplified. 
The putative recombinant samples were not only limited in volume, but were 
potentially of poor quality and may therefore have contained fewer RNA copies than 
suggested by the viral load result. Therefore, extraction of RNA using theoretical 
quantities of 20,000 and 40,000 copies was compared (Figure 4_5b). However, 
RNA extraction using double the amount of theoretical viral copies (40,000 copies 
instead of 20,000) proved counterproductive, as a higher number of reactions failed 
when using the increased copy number.  Extraction of 20,000 copies was retained 
for the standard protocol, with the reservation that an extraction of 40,000 copies 
remained an option in specimens of sufficient volume, but poor quality.  
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Figure 4_5. Optimisation of a near full-length, single genome sequencing protocol. 
a) Optimisation of the RNA extraction method. A clinical subtype B specimen was extracted 
at 20,000 copies and 40,000 copies using the automated easyMAG system, transcribed, and 
amplified using neat cDNA and a 1:2 cDNA dilution as the template input. 16 replicates of 
each extraction/dilution combination were run. Top row: Lane 1 contained Hyperladder I; 
lanes 2 - 17 contained neat cDNA from the 20,000 copies extraction; lanes 18 - 34 contained 
the 1:2 cDNA dilution from the 20,000 copies extraction. Bottom row: lanes 1 contained 
Hyperladder I; lanes 2 - 16 contained neat cDNA from the 40,000 copies extraction; lanes 18 
- 34 contained the 1:2 cDNA dilution from the 40,000 copies reaction; lane 35 contained the 
NTC control. The circled lanes indicate amplified PCR product of the correct size. There was 
widespread evidence of mispriming across both the 20,000 copies and 40,000 copies 
extractions and the two cDNA dilutions (22/65 wells).  b) Optimisation of copy number 
extraction.  Extraction of 20,000 copies and 40,000 copies of RNA was trialled using 5 
replicates of two clinical HIV-1 subtype B (top lanes) and C (bottom lanes) plasma samples.  
Lane 1 in each row contained Hyperladder I, Lanes 2 - 6 contained 5 replicates of a clinical 
subtype B (row 1) or C (row 2) specimen extracted at 20,000 RNA copies, and lanes 7 - 11 
contained 5 replicates of the same subtype B and C specimens extracted at 40,000 RNA 
copies. Successful amplification was achieved more consistently when 20,000 RNA copies 
were extracted (lanes 2-6, top and bottom, success rate 5/5 and 3/5, respectively), then 
when 40,000 copies were extracted (lanes 7 - 11 top and bottom, success rate 3/5 and 2/5, 
respectively).  
 
4.2.2.2 cDNA synthesis 
The CHAVI protocol used Life Technologies’ Superscript III Reverse Transcription 
reagents. However, these reagents had been previously trialled during the 
optimisation of the Nadai et al. protocol, and were found to be unsatisfactory. 
Therefore, the Superscript III First-Strand Synthesis Supermix Kit (Life 
Technologies) was selected for optimisation instead. This kit was chosen for trial 
due to the reduction in RNase H activity that is provided by the M-MLV-RT enzyme 
in the enzyme mix. As RNase H activity can promote strand transfer during minus 
strand DNA synthesis (Shriner et al., 2004), the selection of a system with reduced 
RNase H activity that could minimise any in vitro recombination events was 
desirable. The initial reaction conditions were identical to the manufacturer’s 
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instructions; however, a modified protocol using an additional 2µl of Superscript III 
RT enzyme (not included in the kit) added to each reaction following the initial 90 
minute RT step at 50°C was selected. The extra enzyme circumvented enzyme 
exhaustion due to both the product size and the length of the RT protocol. 
4.2.2.3 Nested PCR protocol 
As the primers obtained from the CHAVI protocol were originally designed for use 
with subtype C viruses, the optimisation process commenced using subtype B and 
C clinical samples. Subtype B was chosen as the second subtype because the 
genetic distance of subtype B from subtype C would potentially give a good 
indication of the likelihood of the primers working with a range of HIV-1 subtypes. 
Although the CHAVI protocol used the same Expand Long Template PCR Kit as the 
Nadai et al. protocol, these reagents had already been trialled extensively, and so 
the Life Technologies Platinum PCR Supermix High Fidelity Kit was trialled 
alongside the Expand Long Template Kit. Using extracts from subtype B and C 
clinical samples, parallel PCR reactions were run using the Roche Diagnostics kit 
and the Life Technologies kit, using the manufacturer’s recommendations for each 
set of reagents. The Life Technologies reaction components and conditions were as 
follows: 45µl PCR Supermix, 0.2µM each of forward primer 1.U5.B1F and reverse 
primer 1.R3.B3R, 1µl nuclease-free H2O and 2µl cDNA were combined and used 
under the cycling conditions 94°C 2m, followed by 35 cycles of 94°C 15s, 55°C 30s, 
68°C 9.5m, with a final extension of 68°C 20m. The nested round used the same 
components save forward primer 2.U5.B4F and reverse primer 2.R3.B6R were 
used, and 2µl of the first round reaction was used as the reaction template. The 
number of cycles was increased to 45 for this round. 
The Expand Long Template Kit reactions were run using a wax barrier. The reaction 
conditions were the same as for the 2.6kb fragment from the Nadai et al. protocol, 
but with an extension time of four minutes.  The specimen input for these reactions 
was one subtype B and one subtype C clinical specimen that was extracted at both 
20,000 and 40,000 copies and was tested in five replicates per extraction for each 
of the two PCR systems.  
 All reactions using the Roche kit failed to amplify, whereas the reactions using the 
Life Technologies kit amplified at the correct size of 9kb in 2/5 (40%) cases using 
the subtype B and C specimens extracted at 20,000 copies, 4/5 (80%) cases using 
the subtype B specimen extracted at 40,000 copies, and 1/5 (20%) using the 
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subtype C specimen extracted at 40,000 copies (Figure 4_6). Accordingly, the Life 
Technologies kit was selected for use. 
 
Figure 4_6. Comparison of the Life Technologies Platinum PCR Supermix High 
Fidelity and the Roche Expand Long Template PCR System.  One subtype B clinical 
specimen and one subtype C clinical specimen were extracted at 20,000 copies and 40,000 
copies. Following reverse transcription, cDNA was diluted 1:2 and used as the input into 
parallel testing of both PCR systems. Each extract was amplified in 5 replicates. Lane 1 of 
each row contained Hyperladder I. Lanes 2 - 11 of the top row contained the subtype B 
specimen extracted with 20,000 copies, of which lanes 2 - 6 show the Life Technologies 
protocol, and lanes 7 - 11 show the Roche protocol. 2/5 replicates of the Life Technologies 
protocol and no replicates using the Roche protocol successfully amplified. Lanes 12 - 16 of 
the top row and lanes 2 - 6 of the middle row contain the subtype B specimen extracted at 
40,000 copies; lanes 12 - 16 show the Life Technologies protocol and lanes 2-6 show the 
same Roche protocol. 4/5 replicates of the Life technologies protocol amplified; no replicates 
of the Roche protocol amplified. Lanes 7 - 16 in the middle row contained the subtype C 
specimen extracted at 20,000 copies, of which lanes 7 - 11 show the Life Technologies 
system and lanes 12 - 16 show the Roche system. 2/5 Life Technologies replicates have 
amplified; none of the Roche replicates were successful. Lanes 2 - 6 of the bottom row 
contain the subtype C specimen extracted at 40,000 copies, and show the Life Technologies 
replicates only . 1/5 of the Life Technologies replicates amplified; none of the Roche 
replicates amplified (not shown). 
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4.2.2.3.1 Optimisation for subtype A amplification 
Having selected the Life Technologies PCR system, the reaction conditions needed 
optimisation such that subtypes A, B, C and D were amplified with comparable 
efficiency. The multiple subtype optimisation was begun using a subtype A clinical 
specimen, using the same reaction conditions used during the Roche/Life 
Technologies comparison. Although these conditions amplified subtype A, the 
highest amplification achieved was 31% using the 1:2 cDNA dilution (Figure 4_7a). 
As this dilution equated to a total input of 100 template molecules per reaction, the 
reaction efficiency was clearly suboptimal. The reaction conditions were therefore 
optimised to increase the efficiency of subtype A amplification. 
Firstly, the primer concentration was increased to 0.30µM per reaction, and 8 
replicates of a clinical specimen extracted at 20,000 and 40,000 copies were run 
(Figure 4_7b). 7/8 (75%) of the 20,000 copies reactions showed amplification at the 
correct size, although 1 of these also showed evidence of mispriming. The 40,000 
copies reactions showed 5/8 (63%) positive reactions, of which 2/5 (40%) also 
showed mispriming. 3/8 (38%) of reactions were negative. These conditions clearly 
improved the subtype A reaction efficiency, however could potentially negatively 
impact the reactions for other subtypes, so at this stage reactions using subtype A, 
B, C and D specimens were run at primer concentrations of 0.30 and 0.35µM per 
reaction. 
Figure 4_7c shows the results from the primer titration reactions. Overall, 16 
replicates of each of subtype A, B, C and D were performed using a primer 
concentration of 0.35µM per reaction, and eight replicates of each subtype were 
performed using a primer concentration of 0.30µM per reaction. At 0.35µM, there 
were 4/16 (25%) positive reactions for subtype A, 6/16 (38%) positive reactions for 
subtype B, 12/16 (75%) positive reactions for subtype C and 9/16 (56%) positive 
reactions for subtype D. The reactions for subtypes A and D showed widespread 
mispriming (11/16, 69% and 7/16, 44%, respectively). The best results were for 
subtype C. The reactions using a primer concentration of 0.30µM showed 3/8 (38%) 
positive reactions for subtypes A and B, 7/8 (88%) positive reactions for subtype C 
and 5/8 (63%) positive reactions for subtype D. Mispriming was still evident in the 
subtype A and D reactions (5/8, 62% and 2/8, 25%, respectively), however, this was 
reduced. 
 
115 
 
 
Figure 4_7. Optimisation of PCR reactions to work successfully with subtypes A, B, C 
and D. a) Initial amplification of a subtype A clinical specimen. 16 reactions each using 
undiluted cDNA and cDNA dilutions of 1:2, 1:4 and 1:10 were performed. Lane 1 of each row 
contained Hyperladder I. Lanes 2-17 of the top row contained neat cDNA (3/16 positive, 
19%); lanes 18-34 contained the1:2 cDNA dilution (5/16, 31% positive). In the middle row, 
lanes 2-17 contained the 1:4 cDNA dilution (2/16 positive,13%) and lanes 18-34 contained 
the 1:10 cDNA dilution (1/16, 6%). The highest number of positive reactions (5/16, 31%) was 
gained from using a 1:2 cDNA dilution. Lane 35 contained the negative control. This low rate 
of successful reactions indicated suboptimal reaction conditions for the amplification of 
subtype A specimens. b) Optimisation of subtype A reaction conditions. 8 replicates of a 
subtype A clinical specimen extracted at both 20,000 and 40,000 copies were amplified 
using an increased primer concentration of 0.35µM per reaction. Lane 1 in each row 
contained Hyperladder I. Lanes 2-9 in the top row contained the amplified products from the 
20,000 copies extraction. Lanes 2-9 in the bottom row contained the products from the 
40,000 copies extraction, and lane 10 contained the negative control.  7/8 of the 20,000 
copies reactions showed amplification at the correct size; 5/8 of the 40,000 copies extraction 
showed amplification at the correct size. c) Optimisation of primer concentrations across 
subtypes A, B, C and D. 16 reactions using a primer concentration of 0.35µM each primer 
per reaction and 8 reactions using a primer concentration of 0.3µM each primer per reaction 
were performed using extracts from clinical specimens of subtypes A, B, C and D. Lane 1in 
each row contained Hyperladder I; The top and second rows contained the subtype A and B 
reactions using 0.35µM (top row) and 0.30µM (second row). The third and bottom rows 
contained the subtype C and D reactions using 0.35µM (third row) and 0.30µM (bottom row). 
Top and second rows: lanes 2-17 contained subtype A reactions; lanes 18-34 contained 
subtype B reactions. Third and bottom rows: lanes 2-17 contained subtype C reactions and 
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lanes 18-34 contained subtype D reactions. Although the reactions across both 
concentrations were generally robust when using the subtype C extract, the higher primer 
concentration caused multiple mispriming events across all four subtypes, particularly 
subtypes A and D. The lower primer concentration of 0.3µM produced fewer mispriming 
events. 
 
 
Further testing showed that a primer concentration at 0.25µM per reaction reduced 
the degree of mispriming, but also reduced the overall reaction efficiencies for 
subtypes A and D. The number of PCR cycles in the first round was increased from 
35 to 40 to help alleviate this. 
The annealing temperature was optimised across subtypes A, B, C, and D. A 
preliminary gradient PCR was performed using annealing temperatures of 50°C, 
53°C, 56°C, 59°C, 62°C, 65°C and four replicates each of clinical specimens with 
20,000 RNA copies extracted . The reactions for subtypes B and C viruses were 
robust over a range of temperatures, but the reactions for subtypes A and D were 
not. On this basis, the gradient PCR was repeated using eight replicates of 
subtypes A and D only, in order to perform a more rigorous assessment for these 
subtypes. The results showed that, whilst mispriming was still occurring with 
subtype A, the best temperature was between 59°C and 62°C for both subtypes.  
Based on the results from both gradient PCRs, an annealing temperature of 60°C 
was chosen.  
Two final checks were performed to ensure that the selected reaction conditions 
were optimal. Firstly, 16 replicates each of a subtype A specimen with 20,000 
copies extracted were amplified as neat cDNA, and dilutions of 1:2 and 1:4 at primer 
concentrations per reaction of both 0.25 and 0.30µM. The results showed 
comparable amplification success at neat cDNA (10/16, 63%) for both primer 
concentrations, but better success at the 1:4 cDNA dilution when using the 0.25µM 
concentration (7/15, 47% vs. 3/14, 21%). In terms of mispriming, the 0.25µM 
reactions showed generally less mispriming (7/16, 44%, 8/16, 50%, 3/16, 19% for 
neat cDNA, 1:2 and 1:4, respectively) than the 0.3µM reactions (12/16, 75%, 7/16, 
44%, 4/16, 25% for neat cDNA, 1:2 and 1:4, respectively). These results suggested 
that mispriming was related as much to the template concentration as the primer 
concentration. 
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One of the potential recombinant specimens that had a high viral load and a large 
sample volume available (500,000 copies/ml and 1500µl, respectively) was 
amplified using eight replicates each at the following cDNA dilutions: neat, 1:4, 1:10, 
1:50 and 1:100. The degree of mispriming found in these reactions was 7/8 (88%) 
using neat cDNA, 3/8 (38%) using the 1:4 dilution, 2/8 (25%) using the 1:10 dilution, 
0/8 using 1:50, and 0/8 using 1:100, respectively. Given that the aim of the 
optimisation was to optimise for low numbers of template molecules, these results 
suggested that the assay was optimised sufficiently.    
The final reaction conditions chosen represented the best available combination that 
achieved consistent amplification across all four validation subtypes. These 
conditions differed from the original protocol, in that the optimised assay used a 
different PCR system, different primer concentrations, a different annealing 
temperature and a different number of PCR cycles. Table 4_1 summarises the main 
features of the finalised protocol compared with the Nadai et al. and unadapted 
CHAVI protocols. 
 
 Nadai et al. (2008) CHAVI (2009) Final protocol 
Template Plasma RNA  Plasma RNA Plasma RNA 
No. of fragments to 
amplify HIV-1 genome 
2 - 3 1 1 
Genomic coverage 
(HXB2) 
623 - 9636 552 - 9636 552 - 9636 
Optimum HIV-1 RNA 
copies (input) 
50,000 - 375,000 20,000 - 40,000 10,000 - 20,000 
Optimised HIV-1 
subtypes  
B B, C A, B, C, D 
Method 2-step, nested RT-PCR 2-step, nested RT-PCR 2-step, nested RT-PCR 
cDNA synthesis method Oligo dT or gene-specific 
priming (UNINEF 7') 
Gene-specific priming 
(1.R3.B3R) 
Gene-specific priming 
(1.R3.B3R) 
PCR Reagents Expand Long Template 
PCR kit (Roche 
Diagnostics) 
Expand Long Template 
PCR kit (Roche 
Diagnostics) 
Platinum PCR 
Supermix High Fidelity 
(Life Technologies) 
Forward and Reverse 
Primer concentrations 
(µM) 
0.4 0.3 0.25 
Number of PCR cycles 
first round 
30 35 40 
Number of PCR cycles 
second round 
30 35 45 
Annealing Temperature 
(⁰C) 
60 55 60 
Table 4_1. Comparison of the final optimised RT-PCR protocol for near full-length 
HIV-1 amplification with the unadapted Nadai et al. and CHAVI protocols. 
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4.2.2.4 Dilution of cDNA and DNA sequencing for single genome analysis 
Following the optimisation of reaction conditions, the final procedural aspect 
requiring optimisation was the manner in which a single template molecule would be 
amplified. The limiting dilution of cDNA into a PCR reaction such that it is assumed 
that only one copy of cDNA is present in each amplified reaction is based on 
Poisson’s distribution. In a situation where cDNA has been diluted such that only 
30% of reactions are positive, then Poisson’s distribution states that there is only a 
single amplified copy of DNA in 80% of cases (Simmonds et al., 1990). 
However, in long range PCR, the efficiency of a reaction decreases dramatically 
with the length of the template (Dittmar et al., 1997). Therefore, even in an 
optimised reaction, the possibility exists that even at cDNA dilutions that produce 
only 30% positive reactions, there may still be more than one molecule of template 
DNA present.  Additionally, the reaction conditions were a set of ‘best fit’ conditions 
chosen to work across a range of subtypes, rather than a set of conditions 
optimised for a single subtype at maximum efficiency. To test that the Poisson 
distribution for single template amplification still applied for this particular set of 
reaction conditions, three specimens were sequenced at a range of dilutions below 
30% positivity required, up to a dilution of 1:200, which is the theoretical limit where 
one molecule of cDNA was input into each reaction (20,000 copies of RNA 
transcribed into 200µl of cDNA = 100 copies per/µl, input into PCR reaction = 2 µl, 
therefore, a 1:200 dilution = 0.5 copies/µl, which gives an input of one copy into the 
reaction) (Table 4_2). During sequence analysis, dilutions for each specimen were 
analysed in parallel, and assessed for the presence of mixed bases that might 
indicate a mixed population. Any differences in individual bases between dilutions 
were assessed by examining the raw electropherogram data for that primer. No 
differences were found in individual bases that could not be explained by either low 
quality sequence or a low sequencing signal. Where evidence of low quality signal 
was found, these primers were repeated to obtain a higher quality sequence. In all 
cases, this resulted in the difference between nucleotides, or the presence of mixed 
bases, being resolved. Nevertheless, in order to circumvent the possibility of more 
than one molecule being amplified in a reaction, the highest dilution that still 
produced a number of wells that could be sequenced (≥4) was used for single 
genome analysis. This represented a final departure from the methodology of the 
CHAVI protocol which used a traditional limiting dilution to produce single molecule 
amplification. 
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Study number cDNA dilution  cDNA copies/µl cDNA 
copies/reaction 
Positive reactions 
at this dilution (%) 
33365 1:80 1.25 2.5 26 
 1:100 1 2 12 
 1:200 0.5 1 6 
8179 1:10 10 20 12 
 1:20 5 10 4 
40534 undiluted 22 44 40 
 1:4 5.5 11 7 
Table 4_2. Comparison of full-length sequences at different cDNA dilutions. Three 
study specimens were sequenced at 6 dilutions below the 30% positive rate suggested by 
Poisson’s distribution as producing an amplicons from one amplified copy of cDNA 80% of 
the time, and one dilution above the 30% positive rate, in order to analyse whether the 
decreased sensitivity of long-range PCR had an impact on the sequences from these 
specimens. No differences between sequences were found, indicating that decreased 
sensitivity did not change the statistical distribution of mixed populations. Nevertheless, 
sequences at the highest dilution that produced ≥4% positive reactions per plate were used 
for single genome analysis. 
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Chapter 5: Identification of CRF50_A1D 
 
5.1 Single genome amplification and sequencing of 6 patients with 
recombinant HIV-1 
5.1.1 Normalisation of plasma to contain 20,000 copies of vRNA and 
amplification of 6 near full-length genomes 
All of the study samples obtained were frozen plasma taken between 2000 and 
2011. The viral load range was 9,148 - 500,000 copies/ml and the range of sample 
volumes was 270 - 1500µl (Table 5_1). Owing to low viral loads, 20,000 copies 
could not be extracted in 3/6 samples.  
Relatively consistent amplification was observed across all specimens; differences 
in reaction efficiency were most likely due to specimen age and routine storage 
conditions, and the freeze-thaw cycle required to separate aliquots for transfer 
between centres. Only one genome amplified successfully at the theoretical cDNA 
dilution of one molecule/reaction; a further specimen amplified at 1.37 
molecules/reaction.  Each of the remaining four specimens showed amplification 
lower than the 30% Poisson distribution set point. One specimen (11762) only 
amplified with an undiluted cDNA input. This specimen was re-extracted, however 
still only amplified when using undiluted cDNA (Appendix 5_1).  
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Study 
number 
Sample date Viral load 
(copies/ml) 
Volume 
received 
(µl) 
Volume required 
to extract 20,000 
copies (µl) 
Copies 
extracted 
Final concentration 
undiluted cDNA 
(copies/µl) 
Final cDNA concentration used 
for single genome analysis 
(copies/µl) 
Positive 
reactions (%) 
33365 28/04/2003 500,000 1500 40 20,000 100 0.5 6 
8179 25/07/2000 150,380 500 133 20,000 100 5 4 
40534* 23/04/2003 31,111 500 643 4,356 22 5.5 7 
34567 27/03/2003 11,893 270 1682 3,211 16 16 8 
11762† 12/03/2011 74,595 410 268 20,000 100 100 19 
12792* 06/07/2010 9,148 610 550 548 2.74 0.685 13 
Table 5_1. Characteristics of the study samples received.  Four specimens were received from two London centres (33365, 8179, 40534, 34567), and 
two specimens were received from one Northwest centre (11762, 12792). The amount of plasma received varied depending on storage protocols at each 
centre. 20,000 RNA copies were extracted where the plasma volume received/viral load allowed, and amplification was performed at the highest dilution 
resulting in 4% success or higher.   
*These specimens were originally extracted at a volume for 20,000 vRNA copies. However, the amplification of these extractions failed. The value in the 
‘copies extracted’ column reflects subsequent, successful extractions. 
†This sample only amplified as undiluted cDNA. A subsequent extraction of 10,443 extracted vRNA copies also only amplified undiluted. Please see 
Appendix 5_1 for further details 
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5.2 Recombination analysis of near full-length sequences 
5.2.1 RIP analysis 
RIP analysis of the six recombinant specimens showed a putatively identical A1/D 
structure for 5/6 specimens (33365, 8179, 40534, 11762, 12792), and a complex 
A1/B/D structure for the remaining specimen (34567) (Figure 5_1). In all six plots 
the lowest region of similarity was between positions approximately located at 5,900 
– 6,700; when translated back to HXB2 numbering, this region corresponds to the 
hypervariable region of env coding for the V1-V3 loops, and is, as such, a region 
where lower similarity to subtype demarcations is expected. Each of the A1/D plots 
suggested a recombinant structure with approximately three breakpoints in gag, one 
breakpoint in pol, along with a possible region of uncertainty; one breakpoint in the 
accessory genes, and a further three breakpoints in env. The plot for the complex 
A1/B/D structure switched between subtypes A1, B and D for the first 3000 
nucleotides, with no clear regions of identity. This plot showed a clear region of 
subtype B between positions 3000 and 5000; after this point, the plot showed the 
same A1/D structure as the other five plots. 
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Figure 5-1. Simplified Recombinant Identification Program (RIP) scans of 6 putatively 
recombinant specimens. The Los Alamos program RIP was used to scan six near full-
length recombinant HIV-1 sequences.  The settings used were a window size of 400bp, gap 
stripped and a step size of 20bp. RIP performs a similarity scan and reports results 
graphically using the closest subtype match from its own set of subtype reference 
sequences. The x axis is numbered according to the nucleotide position of the query 
sequence. The bar at the top of the scan shows the most likely subtype for that region of the 
sequence.  In plots, a), b), e) and f), subtype A1 is represented in red, subtype B in green, 
and subtype D in blue. In plots c) and c) subtype A1 is represented in red, subtype B in 
green, subtype C in blue and subtype D in  purple. In plot e), subtype F2 is represented in 
purple. Five of the six plots (a - c), e) and f)) showed near-identical A1/D structures; plot d) 
showed a complex A1/B/D structure. a) 33365, b) 8179, c)40534 d) 34567 e)11762 f)12792.   
 
 
5.2.2 jpHMM analysis 
The RIP analysis gave a basic ‘working’ structure of the recombinant specimens, 
but did not designate breakpoint locations; these were initially defined using jpHMM.  
The jpHMM analysis of the six specimens also showed five specimens with largely 
identical structures (33365, 8179, 40543, 11762, 12792) and one specimen with a 
complex A1/A2/D/B/U structure (34567) (Figure 5_2).The breakpoint locations and 
confidence intervals for the five A1/D specimens are summarised in Table 5_2.  
Generally, the jpHMM breakpoint locations and subtype classifications showed a 
good level of consistency among the five A1/D specimens, and the structure 
suggested by the RIP screening. However, there were three structural differences 
observed in the jpHMM plots among the five A1/D specimens. Firstly, specimen 
11762 (Figure 5_2 e) showed a region of subtype D uncertainty in the p2-p7 regions 
of the gag gene which was classified as subtype A1 in the other four A1/D 
specimens. However, as the limits of the region of uncertainty corresponded to the 
confidence intervals of the subtype A1 region (Table 5_2*), this was considered an 
area for further investigation rather than a true structural difference. 
 The second structural difference was the location of the pol breakpoint in specimen 
12792 (Figure 5_2 f), Table 5_2†). The breakpoint location for this specimen was 
set 109 -111 nucleotides distant from the corresponding breakpoint in the other four 
specimens. However, the plot indicated that the breakpoint was in the same location 
as the other four specimens, but there was an area of A1/D uncertainty adjacent to 
it. In these cases, the jpHMM algorithm sets the ‘breakpoint’ location as the central 
point of the uncertainty region; this was therefore considered an area for further 
analysis rather than a true structural difference. 
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The final difference in the jpHMM plots concerned specimens 33365 and 12792 
(Figure 5_2a and f). These two specimens showed a region of subtype D 
uncertainty in the env gene (confidence intervals 7320 - 7496 and 7314 - 7496, 
respectively). Again, these were considered areas for further investigation. 
The jpHMM analysis of specimen 34567 (Figure 5_2 d) provided a clearer picture of 
this complex specimen than the RIP analysis. Whereas the RIP plot indicated that 
the first 3000 nucleotides of the sequence did not clearly correspond to any 
particular subtype, the jpHMM plot showed two clear regions in the genome with the 
same structure as the five A1/D specimens. These regions were the very beginning 
of gag, which had an identical A1/D breakpoint (1162 ±8), and from the breakpoint 
in tat/rev (5983 ±23) to the end of the genome. This raised the possibility for the first 
time that this specimen may be the result of a further recombination event between 
the A1/D structure seen in the five A1/D specimens, and another infection.      
The remaining regions of 34567 were not so clearly defined. While there were clear 
regions of subtype B, including a B/A1 breakpoint that largely corresponded with the 
D/A1 breakpoint in pol (2535 ±16 c.f. 2489 ±26), there were areas of subtype A 
uncertainty in pol, and a region of gag (1479-1625) that could not be assigned to 
any known subtype. 
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Figure 5_2. jpHMM analysis of six recombinant HIV-1 sequences. Putative recombinant 
HIV-1 sequences were submitted to the online implementation of jpHMM at the GOBICS 
server.  The program used its own stored reference alignment and statistical algorithm to 
determine subtype classifications, breakpoint locations and 95% confidence intervals.  
Breakpoint locations and confidence intervals are marked on each plot and are equivalent to 
HXB2 numbering. In each plot, subtype A1 is represented in red, subtype A2 in coral, 
subtype D in lavender and subtype B in blue. Areas of subtype uncertainty are grey.  The 
plots show the same structure as identified by the RIP scanning, that is, five A1/D 
recombinants (a-c, e and f) and one complex structure (d). The jpHMM result for d) shows a 
more complex structure than that elucidated by RIP, with regions of subtype A2 and one 
extra region of subtype B. a)33365. b)8179. c) 40534. d)34567. e)11762. f)12792.  
 
Breakpoint Specimen ID Gene/region 
33365 8179 40534 11762 12792 
1 1162 
(1154-1170) 
1159 
(1147-1171) 
1167 
(1148-
1186) 
1177 
(1154-1200) 
1156 
(1141-1171) 
gag p24 
2 1843 
(1809-1877) 
1844 
(1809-1879) 
1844 
(1809-
1879) 
1958* 
(1811-2105) 
1828 
(1809-1847) 
gag p24 
3 2089 
(2047-2131) 
2078 
(2046-2110) 
2078 
(2046-
2110) 
 2056 
(2002-2110) 
gag p1 
4 2489 
(2463-2515) 
2489 
(2465-2515) 
2489 
(2465-
2515) 
2487 
(2475-2499) 
2598† 
(2463-2733) 
pol Protease 
5 5981 
(5951-6011) 
5979 
(5953-6005) 
5976 
(5951-
6001) 
5985 
(5973-5997) 
5998 
(5989-6007) 
tat/rev - 
6 6551 
(6543-6559) 
6551 
(6543-6559) 
6551 
(6543-
6559) 
6551 
(6539-6563) 
6551 
(6543-6559) 
env gp120 
7 7247 
(7234-7260) 
7246 
(7231-7261) 
7249 
(7232-
7266) 
7483 
(7471-7495) 
7214 
(7171-7257) 
env gp120 
8 8679 
(8664-8694) 
8672 
(8651-8693) 
8679 
(8663-
8695) 
8674 
(8662-8686) 
8678 
(8663-8693) 
env gp41 
Table 5_2. jpHMM-assigned breakpoint locations and confidence intervals for the five 
A1/D recombinant sequences. Breakpoint locations with confidence intervals as 
determined by jpHMM (HXB2 numbering). Confidence intervals are indicated in parentheses 
under each breakpoint. The gene/region column indicates the position of each breakpoint in 
relation to the genetic structure of HIV-1. The breakpoint locations were generally consistent 
across all five specimens, indicating that the same A1/D recombinant structure is shared.   
*This corresponds to a region of subtype D uncertainty. Refer to Figure 5_2. 
†This corresponds to a region of subtype A uncertainty. Refer to Figure 5_2. 
Please note that specimens 33365 and 12792 had a region of subtype D uncertainty in env 
(confidence intervals 7320 - 7496 and 7314 - 7496, respectively). 
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5.2.3 Sliding window and maximum likelihood analysis  
5.2.3.1 Sliding window analysis of specimens 33365, 8179, 40534, 11762, 
12792 
The RIP and jpHMM results from the six sequenced specimens suggested that five 
of the specimens were of a putatively identical A1/D recombinant structure, and that 
the remaining specimen was a unique A1/B/D/U structure. However, these results 
contained regions of structural uncertainty that required a third method to both 
confirm previous results and refine the genomic areas that were not definitively 
classified. Accordingly, sliding window analysis was performed using each of the six 
recombinant specimens as a query sequence.  
Figure 5_3 shows bootscan plots for specimens 33365, 8179, 40534, 11762 and 
12792. The bootscanning further confirmed the A1/D structure indicated by the RIP 
and jpHMM analyses and resolved areas of structural uncertainty suggested by the 
other two algorithms. The first area of structural uncertainty indicated by the jpHMM 
analysis was an uncertain area of subtype classification in the p2-p7 region of the 
gag gene in specimen 11762. The bootscan plot for this specimen (Figure 5_3 e, 
nucleotide positions 1400 - 1700) classified this region as a clear subtype A1 match 
with >70% of all permuted trees containing this specimen with subtype A1.    
The second region of uncertainty concerned the uncertain region of subtype A1 in 
specimen 12792 immediately adjacent to the pol breakpoint. Figure 5_3 f showed 
that, firstly, the pol  breakpoint for this specimen was in the same location as in the 
other four A1/D specimens (approximately position 2250), and that the region 
directly following this (nucleotide positions 2250-2600) was a clear subtype A1 
region with a near-100% match to subtype A1 across the region.  
The final structural difference suggested by jpHMM was the area of uncertainty in 
the env gene in specimens 33365 and 12792. Figure 5_3a and f shows this region 
for both specimens. In both cases, this area (Figure 5_3a and f, nucleotide positions 
7,200-7,500) showed a definitive subtype D classification, with >85% of all trees 
matching this subtype.   
The bootscanning analysis also showed some uncertain areas not shown by jpHMM 
and RIP. These were in specimens 33365 (dip in identity in env Figure 5_3a), and 
40534 (dip in identity in env Figure 5_3c). However, these were not present in the 
jpHMM or RIP analyses.    
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Figure 5_3. Bootscanning plots for the A1/D recombinant specimens (33365, 8179, 
40534, 11762, 12792). Bootscanning plots from Simplot sliding window analysis using a 
window size of 400bp, a step size of 20bp and 100 bootscanning replicates. The y axis 
shows the percentage of permuted trees that the query sequence clustered with the closest 
subtype match from the reference alignment. The x axis shows the nucleotide position of the 
sequence (not HXB2 numbering). Subtype A is represented in red, subtype D in lavender, 
and subtype F (outgroup) in grey.  All five specimens show identical  bootscanning plots, 
with five subtype A1 regions and four subtype D regions. a) Specimen 33365; b) Specimen 
8179; c) Specimen 40534; d) Specimen 11762; e) Specimen 12792 
 
Figure 5_4 shows the same bootscan plots as Figure 5_3, but with informative sites 
analysis added. The informative sites plots show the breakpoint positions that 
maximised the x2 score around the 50% crossover point between subtypes. All 
positions showing a subtype crossover, or a region of <70% identity, e.g. nucleotide 
positions 4575 - 4625 in specimen 33365 (Figure 5_4a), had putative breakpoint/s 
placed, and the statistical significance of the informative sites at that location was 
assessed using Fisher’s exact test.  The breakpoints remaining on the plots were 
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those that showed statistical significance of <0.05. The areas of uncertainty 
introduced by Simplot were not replicated in jpHMM and RIP and were not 
statistically significant.  
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Figure 5_4. Bootscanning plots with informative sites analysis for the A1/D 
recombinant specimens 33365, 8179, 40534, 11762 and 12792. Bootscanning plots with 
informative sites analysis. The x and y axes are labelled as for Figure 5_3, as are the 
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colours representing each subtype. The vertical red lines represent putative breakpoint 
locations. Reference sequences used for informative sites analysis are shown in red at the 
left of the plot. Red numbers in the plot show the number of informative sites between the 
reference sequence, the query sequence and the outgroup sequence for that section of the 
alignment.  The total x
2
 sum across the whole genome is shown on the right. Breakpoints 
were positioned to maximise the x
2
 at each location around the 50% crossover point 
between subtypes. The statistical significance of each breakpoint was checked using 
Fisher’s exact test. These breakpoints were used to create alignment slices that were used 
for downstream phylogenetic analyses. a) Specimen 33365; b) Specimen 8179; c) 
Specimen 40534; d) Specimen 11762; e) Specimen 12792. 
 
Table 5_3 summarises the breakpoint locations for specimens 33365, 8179, 40534, 
11762 and 12792. Breakpoint locations were consistent across all three specimens, 
and were similar to those identified by jpHMM; minor differences in these can be 
attributed to differences between the jpHMM and sliding window algorithms. 
 
Breakpoint Specimen ID 
33365 8179 40534 11762 12792 
1 1273 
(0.0007) 
1272 
(<0.0001) 
1272 
(<0.0001) 
1275 1284 
(0.0176) 
2 1883 
(0.0011) 
1851 
(<0.0001) 
1875 
(<0.0001) 
1854 1874 
(0.0032) 
3 2100 
(0.0048) 
2100 
(0.005) 
2097 
(0.0001) 
2097 
(0.0194) 
2069 
(0.0018) 
4 2503 
(<0.0001) 
2503 
(<0.0001) 
2493 
(<0.0001) 
2523 
(<0.0001) 
2553 
(0.0001) 
5 6007 
(<0.0001) 
6004 
(<0.0001) 
6007 
(<0.0001) 
6009 
(<0.0001) 
6003 
(<0.0001) 
6 6611 
(<0.0001) 
6602 
(<0.0001) 
6621 
(<0.0001) 
6585 
(0.0008) 
6614 
(0.0006) 
7 7417 
(<0.0001) 
7440 
(<0.0001) 
7407 
(<0.0001) 
7400 
(0.0001) 
7363 
(<0.0001) 
8 8567 
(<0.0001) 
8573 
(<0.0001) 
8562 
(<0.0001) 
8596 
(<0.0001) 
8548 
(<0.0001) 
Table 5_3. Sliding window breakpoint locations and statistical significance for the five 
A1/D specimens. Breakpoint locations determined using bootscanning analysis for the five 
A1/D recombinant specimens. Breakpoint locations are displayed in HXB2 numbering. The 
statistical significance of each breakpoint was assessed using informative sites analysis and 
Fisher’s exact test and is shown in parentheses under each breakpoint. Breakpoints were 
consistent among the five specimens. 
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Three A1/D specimens (33365, 8179 and 40534) were taken forward for maximum 
likelihood analysis of the putative subtype A1 and D regions of the genome. The 
identified breakpoints in the alignment were used to create ‘slices’ of the alignment 
that corresponded to the putative pure subtype regions of the recombinant genome. 
These slices were then used for subsequent downstream phylogenetic analysis. 
Each specimen was sliced and analysed separately, according to the breakpoints in 
Table 5_3. Therefore, nine slices of the alignment were made, corresponding to 
HXB2 coordinates 552 - 1272 (slice 1), 1273 - 1851 (slice 2), 1852 - 2100 (slice 3), 
2101 - 2503 (slice 4), 2504 - 6004 (slice 5), 6005 - 6602 (slice 6), 6603 - 7440 (slice 
7), 7441 - 8573 (slice 8), and 8574 - 9636 (slice 9), respectively (using specimen 
8179 as reference coordinates).  
Likelihood mapping to assess phylogenetic signal was performed on each slice of 
each specimen. Table 5_4 shows the likelihood mapping of each slice for 
specimens 3365, 8179 and 40534. There was a high percentage of unresolved 
quartets for slice 3 across all three specimens (10.3, 9.8, 10.6 for specimens 33365, 
8179 and 40534, respectively); slice 4 also showed a uniformly high proportion of 
unresolved quartets (4.3, 4.4, and 4.8, respectively). Slice 1 also showed uniformly 
moderately high unresolved quartets of 2.1, 2.5, and 2.3, respectively. These high 
proportions of unresolved quartets indicated that any downstream phylogenetic 
analysis would need to be interpreted with caution, given the low phylogenetic 
signal for these regions.  This lack of signal was attributable to the short length of 
the slices (248 and 402 nucleotides, respectively), and, in the case of slice 4, the 
highly conserved nature of the region of pol that this slice covered. No other slice 
showed a uniform percentage of unresolved quartets greater than 2.0; no individual 
figure was greater than 2.5%. 
Entropy testing between subtypes B and D for the region covered by alignment slice 
4 showed that the number of informative sites present between the two subtypes 
was only six. This indicated that downstream phylogenetic analyses would 
potentially be weak at distinguishing between subtypes B and D in this genomic 
region. 
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Slice Study number 
 33365 8179 40534 
 HXB2 coordinates 
(length) 
Unresolved 
quartets 
(%) 
Partly 
resolved 
quartets 
(%) 
HXB2 coordinates 
(length) 
Unresolved 
quartets 
(%) 
Partly 
resolved 
quartets 
(%) 
HXB2 coordinates 
(length) 
Unresolved 
quartets (%) 
Partly 
resolved 
quartets 
(%) 
1 552-1273 
(721) 
2.1 5.6 552-1272 
(720) 
2.5 5.7 552-1272 
(720) 
2.3 5.7 
2 1274-1883 
(609) 
1.6 5.1 1273-1851 
(578) 
1.5 4.8 1273-1875 
(602) 
1.5 4.5 
3 1884-2100 
(216) 
10.3 6.0 1852-2100 
(248) 
9.8 6.3 1876-2097 
(221) 
10.6 6.0 
4 2101-2503 
(402) 
4.3 6.2 2101-2503 
(402) 
4.4 6.0 2098-2493 
(395) 
4.8 6.2 
5 2504-6007 
(3503) 
0.1 1.3 2504-6004 
(3500) 
0.1 1.8 2494-6007 
(3513) 
0.1 1.6 
6 6008-6611 
(603) 
2.0 4.4 6005-6602 
(597) 
2.3 4.8 6008-6621 
(613) 
1.9 4.8 
7 6612-7417 
(805) 
2.1 4.4 6603-7440 
(837) 
1.9 5.0 6622-7407 
(785) 
2.0 4.2 
8 7418-8567 
(1149) 
0.3 2.6 7441-8573 
(1132) 
0.3 2.6 7408-8562 
(1154) 
0.3 2.5 
9 8568-9636 
(1068) 
0.6 3.8 8574-9636 
(1062) 
0.7 3.7 8563-9636 
(1073) 
0.6 3.6 
Table 5_4.Likelihood mapping of three A1/D specimens. Alignment slice numbers, HXB2 co-ordinates and nucleotide length, and likelihood 
mapping results for specimens 33365, 8179 and 40534. Likelihood mapping results are expressed as the number of unresolved and partly resolved 
quartets in each slice. A high percentage of un- and partly-resolved quartets indicates a lack of phylogenetic signal in the alignment. Slices 3 and 4 
showed the highest percentages of un- and partly-resolved quartets, which was potentially due to them being the shortest alignments.
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Following likelihood mapping, PhyML maximum likelihood analysis was performed. 
Figure 5_5 shows the PhyML maximum likelihood trees for specimens 33365, 8179 
and 40534; Table 5_5 summarises the bootstrap support for each slice of each 
query specimen.  Each fragment of each query specimen clustered with the pure 
subtype (A1 or D) indicated by the bootscanning analysis. As expected, the 
maximum likelihood trees for the slices with the highest consistent percentage of 
unresolved quartets returned the lowest bootstrapping support, i.e. slices 1 
(Specimen 33365: 2.1% unresolved, 48% bootstrapping support; Specimen 8179: 
2.5% unresolved, 62% bootstrapping support, Specimen 40534: 2.3% unresolved, 
51% bootstrap support), 3 (Specimen 33365: 10.3% unresolved, 39% bootstrap 
support; Specimen 8179: 9.8% unresolved, 38% bootstrap support; Specimen 
40534: 10.6% unresolved, 22% bootstrap support), and 4 (Specimen 33365: 4.3% 
unresolved, 58% bootstrap support; Specimen 8179: 4.4% unresolved, 57% 
bootstrapping support; Specimen 40534: 4.8% unresolved, 33% bootstrap support), 
respectively. To confirm the subtype classification for these fragments, the regions 
were first analysed using a higher range of subtypes from the reference alignment. 
When this did not substantially improve the bootstrap support (owing to the low 
phylogenetic signal), the posterior probabilities for these regions from the jpHMM 
analysis were examined. These results, in conjunction with the results from the 
entropy testing for slice 4, were sufficiently high to confirm the final subtype 
classification. 
The final A1/D structure was predominantly subtype A1 in pol and the accessory 
genes, subtype D in env, and was fairly evenly split between subtype A1 and D in 
gag.  There were three breakpoints in gag, one in pol, one in tat/rev and three in 
env, respectively. In gag, a breakpoint was located at either end of p24, suggesting 
that the entire coding region for the antigen was swapped in a recombination event. 
Similarly, the third breakpoint was located at the junction of the p7/p1 regions, again 
suggesting that entire coding regions were swapped in the formation of this 
recombinant. The distribution of subtypes in gag by protein were A1 (p17, p2, p7) 
and D (p24, p1, p6).   
The single D/A1 breakpoint in pol was located approximately 250bp from the start of 
the protease. The remainder of the pol gene was subtype A1, as was vif and vpr. 
The breakpoint located at HXB2 6007 fell in the overlap of tat and rev, meaning that 
both of these genes were A1/D mosaics. Vpu was solely subtype D. Although the 
envelope gene was largely subtype D, three of the hypervariable regions, V1-V3 
were subtype A1. 
137 
 
 
 
 
 
 
138 
 
 
 
 
 
 
 
139 
 
 
 
 
 
 
 
 
 
140 
 
 
 
 
 
 
 
 
141 
 
 
 
 
 
 
 
 
 
142 
 
 
 
 
 
 
 
143 
 
 
 
 
 
144 
 
 
 
 
 
 
 
145 
 
 
Figure 5_5. Maximum likelihood analysis of the A1/D recombinant (specimens 33365, 
8179 and 40534). 
Maximum likelihood trees of putative non-recombinant fragments from specimens 33365, 
8179 and 49534 drawn using PhyML with PAUP-defined parameters. Subtypes used for 
analysis were A1, D, B and K (outgroup). Blue boxes indicate the genomic region analysed. 
Numbers indicate bootstrapping support from 1000 replicates (excepting slice 5; 100 
replicates). 70% support was the cut-off for acceptable clustering. For each fragment, trees 
from specimen 33365 are shown in the upper left, specimen 8179 the upper right and 40534 
lowermost. a) Fragment 1. This fragment clusters with subtype A1, with low to moderate 
bootstrap support across all three specimens (48%, 62% and 51%, respectively); b) 
Fragment 2. This fragment clusters strongly with subtype D across all three specimens 
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(78%, 90% and 73% support, respectively); c) Fragment 3. This fragment clusters with 
subtype A1 in specimens 33365 and 8179, although bootstrap support is low (39%, and 
38%, respectively). However, the length of this fragment is short,  and likelihood mapping for 
all three specimens showed a high percentage of unresolved quartets, which suggested a 
lack of phylogenetic signal for analysis. Specimen 40534 clusters with the K outgroup in this 
fragment. However, the bootstrap support is very low at 22%; d) Fragment 4. This highly 
conserved region of pol shows a low bootstrap support (58%, 57% and 33%, respectively), 
but clear clustering with subtype D; e) Fragment 5. This region, which encompasses the 
majority of the pol  gene, shows strong support for subtype A1 across all three specimens 
(98%, 96%, 100%, respectively); f) Fragment 6. Strong support for subtype D is seen across 
the accessory genes and initial region of gp120 (100%, 77%, 100%, respectively); g) 
Fragment 7. This region, which codes for the V1-V3 regions, clusters strongly with subtype 
A1 (98%, 100%, 99%, respectively); h) Fragment 8. This subtype D region codes for the V4 
and V5 loops and gp41 (100%, 97%, and 100%, respectively); i) Fragment 9. The end of 
gp41 and nef cluster strongly with subtype A1 (83%, 82% and 81% support, respectively). 
 
Slice Study number 
33365 8179 40534 
 Subtype Bootstrap 
support (%) 
Subtype Bootstrap 
support (%) 
Subtype Bootstrap 
support (%) 
1 A1 48 A1 62 A1 51 
2 D 78 D 90 D 73 
3 A1 39 A1 38 A1 22 
4 D 58 D 57 D 33 
5 A1 98 A1 96 A1 100 
6 D 100 D 77 D 100 
7 A1 98 A1 100 A1 99 
8 D 100 D 97 D 100 
9 A1 83 A1 82 A1 81 
Table 5_5. Bootstrap support from PhyML maximum likelihood analyses for each 
alignment slice of specimens 33365, 8179 and 40534. 1000 bootstrapping replicates were 
performed for each slice*. 70% support was the cut-off for subtype classification. Slices 2, 5, 
6, 7, 8, and 9 showed sufficient support across all three specimens for subtype classification. 
Slices 1, 3 and 4 showed lower support values, but still clustered with the subtypes indicated 
by the preceding analyses.  These slices were analysed using a greater range of subtypes 
before final subtype classification was assigned.  
*Excepting slice 5 (100 replicates only)   
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5.2.3.2 Analysis of specimen 34567 
The RIP and jpHMM analyses of specimen 34567 showed a unique, complex 
recombinant structure.  The initial Simplot bootscanning analysis of this specimen 
showed an A1/B/D structure, with three substantial regions with no clear subtype 
(Figure 5_6a). Repeated scanning with the full range of pure HIV-1 subtypes did not 
improve the subtype designations (Figure 5_6b). However, all three analysis 
methods had suggested that specimen 34567 included some A1/D regions with 
identical breakpoints as the three London specimens.   Bootscanning analysis of 
specimen 34567 against the A1/D specimen 33365 showed three clear regions of 
A1/D identity and two subtype B regions (Figure 5_6c). With this in mind, two 
downstream analyses of this specimen were performed: informative sites, alignment 
slicing and subsequent downstream PhyML analyses, and alignment slicing and 
downstream PhyML analyses according to the breakpoints identified for the A1/D 
specimens. 
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Figure 5_6. Bootscanning analysis of specimen 34567. Bootscanning plots for specimen 
34567. The y axis shows the percentage of permuted trees that the query sequence 
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clustered with the closest subtype match from the reference alignment. The x axis shows the 
nucleotide position of the sequence (not HXB2 numbering). a) Bootscanning plot of 
specimen 34567 against subtypes A1, B, D and F (outgroup).Subtype A is represented in 
red, subtype B in blue, subtype D in lavender, and subtype F in grey.  Although the majority 
of the genome shows clear subtype identity, there are three regions (800-1,300, 1,700-2250, 
2750-3250) that have no clear subtype classification. b) Bootscanning plot of specimen 
34567 against all HIV-1 pure subtypes.  Subtype A is represented in red, subtype B in Blue, 
subtype C in light green, subtype D in lavender, subtype F in purple, subtype G in dark 
green, subtype H in burgundy, subtype K in light brown and subtype J in dark brown.  
Despite the larger range of reference subtypes, the unclassified regions from A) are still 
present. c) Bootscanning plot of specimen 34567 against specimen 33365, and reference 
subtype A1, B, D and F specimens. Specimen 33365 is represented in red, subtype A1 in 
grey, subtype B in blue, subtype D in yellow, and subtype F in purple. Three regions of 
identity with 33365, and two regions of subtype B, are present, indicating that this specimen 
is a recombinant of the A1/D recombinant.  
 
 
Figure 5_7 shows the bootscanning plot with informative sites for specimen 34567. 
The informative sites analysis showed a structure similar to that shown by the 
jpHMM and RIP analyses, especially in those regions of the genome judged to be 
identical to the A1/D recombinant. However, the region between positions 770 and 
2284 showed no clear subtype identity, and the x2 was maximised when there were 
no breakpoints placed in this region. When extra slices of the alignment were 
created to explore this region more closely, no breakpoints placed within this region 
were statistically significant. Those breakpoints that were statistically significant are 
summarised in Table 5_6. 
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Figure 5_7. Bootscanning and informative sites analysis of specimen 34567. 
Bootscanning and informative sites analysis of specimen 34567 was performed using 
subtypes A1, A2, B, D and F2. Subtypes A1, A2, B and D were indicated from the jpHMM 
analysis of the specimen, and subtype F2 was included as an outgroup. The x axis shows 
the nucleotide position of the sequence (not HXB2 numbering. The y axis shows the 
percentage of permuted trees that the query specimen clustered with the subtype reference. 
Subtype A1 is shown in red, subtype A2 in grey, subtype B in blue, subtype D in lavender 
and subtype F2 in brown. Breakpoints are indicated by vertical red lines. The breakpoints 
shown on this plot were those that were subsequently shown to be statistically significant.  
 
Breakpoint jpHMM 
breakpoint 
Sliding window 
breakpoint 
Gene  Region p 
1 1162 (±8) 1196 gag p24 <0.001 
2 1479 (±7) 1688 Extra slices created to explore region of 
uncertainty more closely – not supported by 
statistical significance 
3 1625 (±27) 2070 
4  2257 
5 2535 (±16) 2622 pol RT 0.0143 
6 3296 (±23) 3095 pol RT 1.0* 
7 3488 (±30) 3471 pol RT 0.0670 
8 3866 (±31) 3875 pol RNase <0.001 
9 5785 (±25) 5746 vpr - <0.001 
10 5983 (±27) 6014 tat/rev - 0.0017 
11 6551 (±8) 6664 env gp120 0.0011 
12 7359 (±128) 7314 env gp120 0.0011 
13 8674 (±21) 8655 env gp41 <0.0001 
Table 5_6 jpHMM and sliding window breakpoints for specimen 34567. Breakpoints for 
specimen 34567 identified by jpHMM and sliding window analyses. Sliding window 
nucleotide positions have been converted into HXB2 numbering for ease of comparison. 
Statistical significance was assessed using informative sites analysis and Fisher’s exact test. 
Breakpoints 2 - 4 (HXB2 1688 - 2257) correspond to the uncertain B/D region in the sliding 
window analysis.   
*This corresponds to the unclassified region in the jpHMM analysis 
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The results from the informative sites analysis were used to create a tentative 
schematic of specimen 34567’s structure (Figure 5_8). This structure recognised 
that areas of the gag and pol genes could not be reliably distinguished between 
subtypes B and D. The alignment was sliced according to the breakpoints in Figure 
5_7, and PhyML analysis was performed to confirm the subtype of each region 
(Figure 5_9). Some of the trees were poorly supported, especially those shown in 
Figures 5_9c, 5_9d and 5_9g. This was most likely due at least partly to the short 
length of the fragments under analysis. Paraphyletic clustering of Specimen 34567 
was seen in Figures 5_9b, 5_9c and 5_9d (HXB2 1196-3471), which corresponded 
to the uncertain B/D region seen in the jpHMM analysis. Despite not resolving the 
uncertain B/D region sufficiently, the maximum likelihood analysis did confirm the 
tentative structure seen in Figure 5_8, pending further analysis of the uncertain B/D 
region.  
 
 
Figure 5_8. RDT schematic of specimen 34567. The results from the informative sites 
analysis were used to create a tentative structure for specimen 34567.  This structure shows 
clear similarities to the A1/D recombinant specimens in the latter half of the genome, but 
recognised that the gag and pol genes cannot be clearly distinguished between subtypes B 
and D.   
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Figure 5_9. Maximum likelihood analysis of specimen 34567. Maximum likelihood 
analysis of slices of specimen 34567 was performed to classify pure subtype regions using 
the breakpoints identified in the information sites analysis (Figure 5_7). a) Slice 1. This 
regions showed strong support for subtype A (>90%), and weak support for sub-sutype A1 
(23.8%); b) Slice 2. This region corresponds to the uncertain B/D region from the 
bootscanning analysis (HXB2 1688 - 2257). Specimen 34567 clusters paraphyletically with 
subtypes B and D, regardless of the number of sub-regions into which it is split. It was 
therefore classified as B/D uncertain; c) Slice 3 was eventually classified as subtype A1, 
despite the low bootstrapping support. The region showed statistically significant breakpoints 
differentiating it from the adjacent uncertain regions d) Slice 4 did not show significant 
clustering with any subtype, and was classified as unknown; e) Slice 5 showed 72% 
bootstrapping support for subtype A1, which was sufficient for subtype classification; f) Slice 
6, which corresponds to the end region of pol, vpu and the beginning region of vpr, clustered 
with 99% support for subtype B; g) Slice 7 shows strong support for subtype A1;  h)-k) 
Slices 8-11 show clustering and bootstrap support consistent with the corresponding regions 
seen in the five A1/D recombinant specimens.  
 
 
In order to confirm the similarities between specimen 34567 and the five A1/D 
recombinant specimens that were seen in the bootstrap analysis (Figure 5_6c), 
slices of the alignment containing specimens 33365, 8179, 40534 and 34567 were 
made according to the A1/D recombinant breakpoints and submitted for PhyML 
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analysis. The trees from this analysis showed that the complex 34567 clustered with 
the A1/D recombinant in 7/9 genomic regions (Figure 5_10). In the remaining 2/9 
regions (slices 3 and 5), specimen 34567 clustered with subtype B (Figures 5_10c 
and e, respectively), although both trees showed low bootstrap support of 
approximately 44%. In the case of slice 3, the entire tree was poorly resolved, which 
was at least in part due to the short fragment length and low phylogenetic signal of 
the slice, and was similar to the trees of this slice seen in Figure 5_5c. In the case of 
slice 5, however, the poor bootstrap support seen for the clustering with subtype B 
was most likely due to the presence of a subtype-unresolved region within specimen 
34567 in this slice (HXB2 3097 - 3473). This region was seen consistently 
throughout the analysis of this specimen and was present in the jpHMM analysis 
(Figure 5_2d) as a region of uncertain subtype A1/B and the sliding window analysis 
(Figure 5_8) as a subtype-unresolved region.  
The results from the maximum likelihood analysis were sufficiently robust to confirm 
the structure for specimen 34567 that was suggested by the bootscan analysis 
(Figure 5_6c). This largely resolved the subtype B/D uncertain regions seen in 
earlier stages of the analysis and resulted in the structure seen in Figure 5_11, 
which shows the structure in relation to its similarity with the A1/D recombinant 
strain. This confirmed that specimen 34567 was either a recombinant arising from 
the strain shared by the five A1/D specimens, or that this structure was a precursor 
of the A1/D recombinant strain.  
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Figure 5_10. Maximum likelihood analysis of specimen 34567 with A1/D recombinant 
specimens 33365, 8179 and 40534. Following bootscanning analysis of the complex 
specimen 34567 against the A1/D recombinant specimen, specimen 34567 was cut into 
alignment slices according to the A1/D recombinant breakpoints, and maximum likelihood 
analysis performed to see if it clustered with the A1/D recombinant across the HIV-1 
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genome. 1000 bootstraps were performed, excepting slices 5 and 8, in which 100 bootstraps 
were performed to ease computational requirements. The A1/D specimens are highlighted in 
red, and 34567 is highlighted in blue. Partial trees are shown for easier visualisation. 
Relevant bootstrap values have been enlarged. Specimen 34567 clustered with the A1/D 
recombinant specimens in slices 1,2,4,6,7,8,and 9 (Figures 5_10a, b, d, f, g, h, and i, 
respectively). In slices 3 and 5 (Figures 5_10c and e), 34567 clustered with subtype B. Low 
bootstrap values (44%) were observed in slice 5 for the clustering with subtype B; this is 
most probably due to the presence of a subtype-unclassified region within this slice a) Slice 
1; b) Slice 2; c) Slice 3; d) Slice 4; e) Slice 5; f) Slice 6; g) Slice 7; h) Slice 8; i) Slice 9. 
 
 
Figure 5_11. Confirmed structure of the complex recombinant 34567. The confirmed 
structure of the complex A1/B/D/U recombinant specimen 34567 following maximum 
likelihood analysis with the five A1/D specimens (Figure 5_10). The regions that correspond 
to the structure seen in the A1/D recombinants are shown in green, and subtype B regions 
are shown in blue. The region HXB2 3097 - 3473 was unable to be definitively resolved. 
 
 
5.3 Confirmation of the new recombinant as a novel circulating recombinant 
from and registration as a new CRF. 
The analysis performed to confirm the structure of 34567 also suggested that the 
A1/D recombinant was a new circulating recombinant form. To register a new CRF 
with the Los Alamos database, satisfaction of three criteria was required: a) that the 
recombinant was novel, b) that it clustered with itself across the whole genome and 
c) that it be identified in three epidemiologically unlinked patients. The three patients 
that were fully characterised (33365, 8179 and 40534) were from London centres, 
but were epidemiologically unlinked, thus criteria c was satisfied. Criteria b was 
satisfied during the clustering analysis of specimen 34567, as the A1/D recombinant 
specimens demonstrated clustering across the entire genome; an extra analysis 
was performed including specimens 11762 and 12792 using approximate maximum 
likelihood trees to see whether all five patients were infected with the same CRF. As 
all five specimens clustered together across the genome, we were satisfied that 
these five recombinant specimens were a shared strain. With two criteria satisfied, 
the final criteria, that of novelty, was assessed.   
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5.3.1 Global BLAST of sequence 
Two checks of the A1/D recombinant were performed to ensure that the 
recombinant structure was novel. Firstly, the full-length sequence and pol gene 
sequence of specimen 33365 were submitted to BLAST to search for similar 
structures. This search returned no matches with the same recombinant structure 
as the A1/D structure for either the full-length sequence or the pol region.  
5.3.2 Comparison with registered HIV-1 CRF list 
The final check for novelty was to compare the recombinant structure with the 
published list of HIV-1 CRFs at the Los Alamos website. No matches were found. 
Accordingly, three A1/D sequences (specimens 33365, 8179 and 40534) were 
submitted to Los Alamos for registration as a new CRF. Following checks by Los 
Alamos, the recombinant was duly registered as CRF50_A1D, and can be found on 
the Los Alamos list of published CRFs (available at 
http://www.hiv.lanl.gov/content/sequence/HIV/CRFs/CRFs.html). The official 
breakpoints for the recombinant were the breakpoints set using the jpHMM analysis, 
and the reference sequence for the strain was that of specimen 8179. All six full-
length sequences were submitted to GenBank (accession numbers: JN417236-
JN417241; reference sequence: JN417236). 
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Chapter 6: Emergence, distribution and likely origin of 
CRF50_A1D 
 
Following the registration of CRF50_A1D as a new CRF, an investigation was 
performed into the origin of this recombinant. There were three goals for this 
investigation: 1) to identify how many cases of CRF50_A1D infection were present 
in the UK HIV DRD in order to assess the spreading potential of the novel strain; 2) 
to investigate the geographic origin of the component subtype  A1 and D strains, in 
order to determine whether CRF50_A1D emerged from a recombination event in 
the UK or was imported as a formed recombinant; 3) to investigate the tMRCA of 
CRF50_A1D in the UK and the geographic and exposure group distribution across 
the country.   
6.1 Identification of additional CRF50_A1D cases in the UK HIV DRD 
 6.1.1 BLAST, SCUEAL and jpHMM  analysis of the UK HIV DRD 
The original cluster analysis identified six potential cases of CRF 50_A1D, of which 
five were CRF50_A1D and the sixth a CRF50_A1D/B recombinant.  Additional 
cases of CRF50_A1D present in the UK HIV DRB that were not captured during the 
original analysis were captured using local BLAST searches of the UK HIV DRB and 
genotyping using SCUEAL and jpHMM.  
Summarised results for SCUEAL genotyping are in Table 6_1. In each of the three 
closest sequence match lists, the majority of sequences indentified as close genetic 
matches were pure subtype A1 sequences (305/500 (61.0%) for specimen 33365, 
332/500 (66.4%) for specimen 8179 and 338/500 (67.6%) for specimen 40534, 
respectively). This was an expected result owing to the large proportion of subtype 
A1 in the pol gene of CRF50_A1D (~1kb in the 1302bp that was captured by the UK 
HIV DRB). In the remaining one third of sequences that were not subtype A1, A1/D 
recombinant results were the most numerous, with 90/500 (18.0%) A1/D 
recombinant results for specimen 33365, and 82/500 (16.4%) for specimens 8179 
and 40534, respectively.  The next largest fraction of results was A1/B recombinant 
sequences; overall 6.6% of tests produced an A1/B recombinant result.   
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 Reference sequence 
 33365 8179 40534 Overall 
Subtype Count Proportion Count Proportion Count Proportion Count Proportion 
A,A1 recombinant 2 0.40 2 0.40 3 0.60 7 0.47 
A-ancestral 1 0.20 0 0 0 0 1 0.07 
A-ancestral,A1 
recombinant 3 0.60 4 0.80 6 1.20 13 0.87 
A1 305 61.00 332 66.40 338 67.60 975 65.00 
A1,A2 recombinant 3 0.60 2 0.40 2 0.40 7 0.47 
A1,A4 recombinant 2 0.40 1 0.20 0 0.00 3 0.20 
A1,AE recombinant 5 1.00 7 1.40 6 1.20 18 1.20 
A1,B recombinant 35 7.00 38 7.60 26 5.20 99 6.60 
A1,C recombinant 2 0.40 2 0.40 2 0.40 6 0.40 
A1,D recombinant 90 18.00 82 16.40 82 16.40 254 16.93 
A1,G recombinant 3 0.60 0 0 1 0.20 4 0.27 
A1,J recombinant 1 0.20 0 0 1 0.20 2 0.13 
A1,U recombinant 5 1.00 1 0.20 2 0.40 8 0.53 
A3 1 0.20 1 0.20 1 0.20 3 0.20 
AE 2 0.40 3 0.60 4 0.80 9 0.60 
B 18 3.60 4 0.80 1 0.20 23 1.53 
CRF02-like 1 0.20 0 0 0 0.00 1 0.07 
CRF15 0 0 0 0 1 0.20 1 0.07 
CRF22 1 0.20 1 0.20   2 0.13 
Complex 19 3.80 20 4.00 24 4.80 63 4.20 
D 1 0.20 0   0 0  0  1 0.07 
Total 500  500  500  1500 100 
Table 6_1. Summary of SCUEAL subtyping results.  Three CRF50_A1D sequences 
(33365, 8179, 40534) were used as the reference sequence in three local BLAST searches 
of the UK HIV DRB. The 500 closest matches to each sequence were genotyped using 
SCUEAL. This method engendered a high degree of overlap between the three sequence 
lists, but allowed the entire range of genetic information contained in the three sequences to 
be used to capture additional cases of CRF50_A1D.  The highest proportion of genotyping 
results were pure subtype A1, followed by A1/D recombinants and A1/B recombinants. 
 
All A1/D and A1/B sequences from each list were also genotyped using jpHMM 
(Table 6_2). All sequences identified by SCUEAL as A1/D or A1/B were also 
identified as A1/D or A1/B by jpHMM. The jpHMM results show that the majority of 
sequences in the sequence lists had breakpoints located in a 20 nucleotide region 
between HXB2 2485 and 2505 (specimen 33365 71/90 (78.9%); specimen 8179 
63/82 (76.8%); specimen 40534 70/91 (76.9%)). This 20 nucleotide region 
contained the jpHMM-identified breakpoint for CRF50_A1D of HXB2 2489, 
confirming that the closest sequence matches were likely to be additional cases of 
CRF50_A1D.  
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 Reference sequence 
 33365 8179 40534 
Total sequences 
analysed 
90 82 91 
Subtype Count Proportion Count Proportion Count Proportion 
A1/B 50 55.6 43 52.4 17 18.7 
A1/D 40 44.4 39 47.6 74 81.3 
Breakpoint Count Proportion Count Proportion Count Proportion 
2385 0 0 1 1.2 0 0 
2485-2490 22 24.4 19 23.2 56 61.5 
2491-2495 3 3.3 4 4.9 8 8.8 
2496-2500 4 4.4 4 4.9 1 1.1 
2501-2505 42 46.7 36 43.9 5 5.5 
2506-2510 2 2.2 1 1.2 7 7.7 
2511-2515 2 2.2 3 3.7 2 2.2 
2516-2520 0 0 0 0 1 1.1 
2521-2525 0 0 0 0 0 0 
2526-2530 1 1.1 1 1.2 3 3.3 
2530-3115 14 15.5 13 15.9 8 8.8 
Table 6_2. jpHMM subtyping results for A1/D and A1/B recombinant sequences. All 
A1/D and A1/B sequences identified by SCUEAL genotyping were further subtyped using 
jpHMM.  Results are summarised first by subtype result (A1/D or A1/B) and then by 
breakpoint location. The majority of sequences had breakpoints located between HXB2 
2485 and 2505.  
 
All sequences with a breakpoint location which either matched the SCUEAL (HXB2 
2465) or jpHMM (HXB2 2489) CRF50 breakpoint, or contained one of these 
breakpoint positions in the 95% confidence interval produced with breakpoint 
predictions (e.g. a breakpoint of HXB2 2505 with a 95% confidence interval of HXB2 
2485-2525, which contains HXB2 2489) were classified as CRF50_A1D cases. 
Following removal of duplicate sequences from the same patient, 72 sequences 
remained (Appendix 6_1). 
 
6.1.2 Addition of demographic information to the 72 CRF50_A1D sequences. 
Where available, demographic information collected by UK CHIC was matched to 
the 72 CRF50_A1D patients.  Of 72 patients, 53/72 (74%) had sex available, 51/72 
(71%) had risk group available, and 49/72 (68.0%) had ethnicity information 
available (Table 6_3). All 53 patients with sex available were men.  In terms of 
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exposure route, 47/51 (92.1%) were MSM, 2/51 (3.9%) were heterosexual and 2/51 
(3.9%) were IDU. The ethnicity results showed that 47/49 (95.9%) were white and 
2/49 (2.0%) were Black-African and Indian/Pakistani, respectively. The 
overwhelming majority of cases were found in white MSM (46/51, 90%); however, 
the instances in heterosexual men and IVDU were significant. It should be noted, 
however, that the data capturing algorithms in UK CHIC only allow one risk group to 
be entered per individual, and that a risk group of IVDU is considered to be of higher 
priority than a risk group of MSM. Therefore, it is possible that the identified IVDU 
instances were also MSM. Finally, it should also be noted that risk groups are self-
identified by the infected individuals, and that social and cultural pressures can 
influence self-reporting. Therefore, it is also possible that the sole heterosexual 
male also belonged to the MSM risk group.   
 
Demographic characteristic Classifier Number of sequences 
Sex Male 53 
Female 0 
Unknown 19 
Exposure group MSM 47 
Heterosexual 2 
IDU 2 
Unknown 21 
Ethnicity White 47 
Black-African 1 
Indian/Pakistani 1 
Unknown 22 
Table 6_3. Demographic breakdown of CRF50 patients. Where available, demographic 
data collected by UK CHIC was matched to the CRF50_A1D sequences. Approximately one 
third of patients had no demographic information available. Sequences with available 
demographics showed an exclusively male profile, with the overwhelming majority of 
sequences coming from white MSM. Two heterosexuals and two IDU were identified, and 
the majority of sequences came from white patients. 
 
All sequences had associated geographic data. Most cases were located in NW 
England (39/72, 54.2%) and London/SE England (27/72, 37.5%). Three cases 
(4.2%) were located in SW England, one (1.4%) in NE England, and two (2.8%) in 
the Edinburgh region of Scotland. 
6.2 Geographic origin of parental subtype A1 and D strains  
The global BLAST search performed in Chapter 5 as part of the CRF50_A1D 
registration process identified no other recorded cases of the CRF50_A1D 
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recombinant structure. In order to investigate the origin of this recombinant, the 
origin of the parental component subtype A1 and D strains was sought.  
6.2.1 Construction of global alignments. 
The alignments of subtype A and D sequences constructed for regions of gag, pol 
and env genes were analysed both in their entirety and following filtering by genetic 
distance. Although sequences were collected from any country with a proportion of 
subtype A or D sequences that exceeded 10%, in practice filtering the sequences 
using genetic distance resulted in alignments composed almost exclusively of 
sequences from East Africa and the UK (Tables 6_ 4, 6_5). 
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Gene 
gag pol env 
No. of sequences  
pre-screening 
No. of sequences 
post-screening 
No. of sequences  
pre-screening 
No. of sequences 
post-screening 
No. of sequences  
pre-screening 
No. of sequences 
post-screening 
1261 385 486 251 536 185 
Countries 
 pre-screening 
Countries in final 
alignment 
Countries  
pre-screening 
Countries in final 
alignment 
Countries 
 pre-screening 
Countries in final 
alignment 
Belarus Belarus Belarus Kenya Burundi Kenya 
Cameroon Latvia Burundi Rwanda DRC Rwanda 
DRC Kenya Cameroon Uganda Kenya Tanzania 
Georgia Rwanda DRC UK Tanzania Uganda 
Kenya Tanzania Gabon  Rwanda  
Latvia Uganda Georgia  Uganda  
Russia  Kazakhstan    
Rwanda  Kenya    
Tanzania  Moldova    
Uganda  Russian Federation    
Ukraine  Rwanda    
  Tanzania    
  Uganda    
  Ukraine    
  UK    
Table 6_4. Composition of global subtype A alignments. Sequences were obtained from public repositories of HIV-1 sequences, and were collected from 
any country where the proportion of either subtype A or subtype D sequences was >10%. Filtering by genetic distance using CRF50 sequences as the 
reference resulted in alignments composed almost exclusively of sequences from East Africa and the UK. 
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Gene 
gag pol env 
No. of sequences  
pre-screening 
No. of sequences 
post-screening 
No. of sequences 
 pre-screening 
No. of sequences 
post-screening 
No.  of sequences  
pre-screening 
No.  of sequences 
post-screening 
1091 138 360 216 375 215 
Countries  
pre-screening 
Countries in final 
alignment 
Countries  
pre-screening 
Countries in final 
alignment 
Countries  
pre-screening 
Countries in final 
alignment 
Chad Chad Botswana Kenya Chad Chad 
DRC DRC Chad Tanzania DRC DRC 
Kenya Kenya DRC Uganda Kenya Kenya 
Rwanda Tanzania Ethiopia UK Tanzania Tanzania 
Tanzania Uganda India  Uganda Uganda 
Uganda UK Kenya    
UK  Sudan    
  Tanzania    
  Uganda    
  UK    
Table 6_5. Composition of global subtype D alignments. Sequences were obtained from public repositories of HIV-1 sequences using the conditions 
detailed in Table 6_4. In common with the subtype A alignments, filtering the subtype D alignments by genetic distance also resulted in alignments composed 
almost exclusively of sequences from East Africa and the UK. 
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6.2.2 FastTree analysis  
6.2.2.1 Subtype A1. 
Although the majority of sequences in the unfiltered gag alignment came from East 
Africa, a limited number of sequences from Central African countries (DRC, 
Cameroon) and Eastern Europe (Russia, Latvia, Belarus, Ukraine) were also 
available (Table 6_4). The FastTree analysis of the unfiltered alignment showed all 
CRF50_A1D specimens clustered together with an approximate maximum 
likelihood support value of 0.99 (Figure 6_1a).  The sequences that the 
CRF50_A1D sequences clustered most closely with were from East Africa, with a 
support value of 0.97; support for the whole branch was 0.84. The closest sequence 
was from Rwanda in 1992 (accession number U86548), followed by a sequence 
from Kenya in 2000 (accession number AF457067, support value 0.74). All of the 
Eastern European sequences clustered closely with sequences from Central Africa, 
with a branch support value of 0.87. 
The filtered alignment for gag contained almost exclusively sequences from East 
Africa, apart from two sequences from Eastern Europe, one from Belarus and one 
from Latvia (Table 6_4). The CRF50_A1D sequences also clustered together in this 
tree, with a support value of 0.99 (Figure 6_1b). The topology of the FastTree tree 
did not show clear grouping of sequences by country; however, the CRF50_A1D 
sequences clustered closest to the same sequence from Rwanda as in the 
unfiltered tree (support value 0.97). The next closest sequence was the same 
sequence from Kenya as in the unfiltered tree, however the support value for this 
branch was low (0.062). Overall, although the branch containing the CRF50_A1D 
sequences had high support (0.96) the internal branch support values for the 
topology were low, excepting the CRF50_A1D sequences.  
In terms of international sequences, the unfiltered alignment for pol predominantly 
contained sequences from East Africa, although a limited number of sequences 
were also available from Central Africa, West Africa, Eastern Europe and Central 
Asia  (Table 6_4). Pure subtype A1 sequences from the UK HIV DRB were 
available, and all of these were initially included. The FastTree analysis of this 
alignment showed that the CRF50_A1D sequences still formed a single cluster of 
sequences (support value = 1), even within the background of extensive sequences 
from the UK (Figure 6_1c). The CRF50_A1D sequences were clustered closest to 
East African sequences, particularly sequence AF457067, an A1 sequence from 
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Kenya (support value = 0.77). The overall tree was well supported and showed high 
branch support values throughout.  
The filtered alignment contained sequences from East Africa and the UK only (Table 
6_4). In order to evaluate the relationship between the CRF50_A1D sequences, the 
East African sequences and the UK sequences, all 72 CRF50_A1D sequences 
were included in the analysis. The FastTree analysis showed that, even with all 72 
sequences included, the CRF50_A1D sequences clustered in a monophyletic group 
(support value = 0.99; Figure 6_1d). The closest sequence to the CRF50_A1D 
sequences was sequence AF457067 (support value = 0.82) similar to the unfiltered 
analysis.  
The subtype A1 region of env in CRF50_A1D was not a genetic region for which 
sequences have been collected from a wide variety of geographic regions. Even in 
the unfiltered alignment, almost all of the sequences were from East Africa, with the 
exception of three sequences from the DRC  (Figure 6_1e). The CRF50_A1D 
sequences did not cluster with the DRC sequences. The CRF50_A1D sequences 
clustered  together with a strong support value of 0.99. The closest sequences to 
the CRF50_A1D sequences were a cluster of 19 sequences from Kenya; 12 were 
from 1996 and collected as part of a mother-to-child transmission study, 2 were 
from 1997 and collected as part of a superinfection study (accession numbers 
EU164115 - EU 164116), and 5 were from 1997 and collected as part of a viral 
evolution study (accession numbers FJ641711 - FJ641715). The support value for 
this branch with CRF50_A1D was 0.88; support for the entire branch was 0.74 
(Piantadosi et al., 2007, 2009).  
The filtered alignment contained sequences from East Africa only (Table (6_4). The 
FastTree analysis showed the CRF50_A1D sequences clustered together with a 
support value of 1 (Figure 6_1f). The closest sequences were a cluster of 
sequences from Kenya made up of sequences from the superinfection  and 
evolution studies mentioned in the paragraph above (support value = 0.87). The 
support value for the whole branch was 0.77. In this analysis, the branch containing 
the sequences from the mother-to-child transmission study were no longer located 
close to the CRF50_A1D sequences.  In common with the trees for the subtype A1 
gag region, the filtered tree did not display clear grouping of sequences into specific 
countries; however, almost all of the sequences from Tanzania grouped in a tight 
cluster. This was also seen in the filtered tree for gag, where nearly all of the 
sequences from Tanzania apart from two clustered together (Figure 6_1b).    
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Overall, the analysis of the subtype A global alignments showed that the 
CRF50_A1D sequences were most closely related to sequences from East Africa. 
This was the case even when an extensive background of sequences from the UK 
were included in the analysis. 
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Figure 6_1. Approximate maximum likelihood trees for subtype A1 gag, pol and env 
regions of CRF50_A1D. Analysis was performed using unfiltered alignments containing all 
identified sequences and alignments filtered using genetic distance screening. In the 
unfiltered trees (a, c and e) sequences are coloured by geographic region, where East Africa 
= green, West Africa = purple, Central Africa = blue, Eastern Europe  = orange, Central Asia 
= turquoise, UK = yellow. In the filtered trees for gag and env (b and f), sequences are 
coloured by country, where Kenya = green, Uganda = blue, Rwanda  = orange, Tanzania = 
purple, Latvia = yellow. In the filtered tree for pol (d) sequences are coloured by country, 
where Kenya = green, Uganda = blue, Rwanda  = orange, UK = purple.  CRF50 sequences 
are shown in red all trees. Numbers represent approximate maximum likelihood support 
values. a) Unfiltered tree for gag.  The CRF50_A1D sequences cluster closest to sequences 
from East Africa (support value for CRF50_A1D clustering = 0.99, support value for closest 
sequences = 0.97). The support for the branch containing the CRF50_A1D sequences and 
the closest East African sequences is 0.84. Sequences from Eastern Europe cluster closest 
to sequences from Central Africa (support value = 0.87); b) Filtered tree for gag. The 
CRF50_A1D sequences cluster together (support value = 0.99), and closest to a sequence 
from Rwanda (support value = 0.97). The support value for the branch containing 
CRF50_A1D and Rwanda sequences was 0.96; c) Unfiltered tree for pol. The CRF50_A1D 
sequences clustered closest to a sequence from Kenya (support value for CRF50_A1D 
sequences = 1, support value for branch with Kenyan sequence = 0.77, support value for 
entire branch = 0.93); d) Filtered tree for pol. This tree contains all 72 CRF50 sequences. 
The CRF50_A1D sequences form a monophyletic cluster with a support value of 0.99. The 
closest sequence is the same Kenyan sequence seen in the unfiltered tree; the support 
value for this branch is 0.82; e) Unfiltered tree for env. The CRF50_A1D sequences cluster 
together with a support value of 0.99. The closest sequences were a cluster of 19 
sequences from Kenya; the support value for this was 0.88. The support value for the 
branch containing the CRF50_A1D and Kenyan sequences was 0.74; f) Filtered tree for env. 
The CRF50_A1D sequences cluster together with a support value of 1. The closest 
sequences were a cluster containing 12 of the same Kenyan sequences as seen in the 
unfiltered tree (support value = 0.87). The support value for the branch containing the 
CRF50_A1D sequences and the Kenyan sequences was 0.77.  
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6.2.2.2 Subtype D. 
The unfiltered alignment for the gag subtype D region contained mainly sequences 
from East Africa, but also contained a good proportion of sequences from Central 
African countries (Table 6_5, Figure 6_2a). In the FastTree analysis, the pure 
CRF50_A1D sequences clustered together with a support value of 0.98; however 
the sequence from the URF, specimen 34567, clustered in a close, but separate, 
branch (Figure 6_2a). The closest sequence to the URF was from Uganda from 
1995 (accession number K21221A6). This branch had weak support of 0.38. The 
support value for the branch containing the CRF50_A1D sequences, the Ugandan 
sequence and the URF was 0.26. The closest sequence to this branch was a 
sequence from the UK in 2000 (accession number FJ712794) and a sequence from 
Uganda in 1995 (accession number A12410A1). The support value for this branch 
was 0.87. 
The filtered alignment contained sequences from both East and Central African 
countries (Table 6_5). The FastTree analysis also showed the pure CRF50_A1D 
sequences clustered together (Figure 6_2b, support value = 0.93). The closest 
sequence was a sequence from Uganda from 1994 (accession number A00336A1); 
the branch support was 0.71. In the filtered tree, the URF sequence clustered much 
further away from the CRF50_A1D sequences than in the unfiltered tree (Figure 
6_2b). The URF was located in a branch that contained the sequence from the UK 
from 2000 with a support value of 0.79 (accession number FJ712794). The support 
value for the whole branch was 0.82.  
The region of gag from the URF that was contained in this alignment was located in 
one of the subtype B regions of the URF genome. The clustering with the UK 
sequence in the filtered tree indicated that the subtype B regions of the URF came 
from a different geographic region than the subtype D regions of the URF, further 
indicating that the event that recombined the URF with a CRF50_A1D sequence 
took place in a different geographic region than the recombination event that 
resulted in CRF50_A1D.   
In common with the subtype A alignments, the unfiltered and filtered alignments for 
pol contained almost equal numbers of sequences from East Africa and the UK 
(Table 6_5). The FastTree analysis for the unfiltered alignment showed the 
CRF50_A1D sequences clustered together with a support value of 0.77. The closest 
sequences to the CRF50_A1D sequences were a cluster of five sequences from 
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Uganda. The support value for the branch containing the CRF50_A1D sequences 
and the Ugandan sequences was 0.94 (Figure 6_2c). 
The filtered alignment for pol was comprised predominantly of sequences from 
Uganda (Figure 6_2d). This alignment contained all 72 CRF50_A1D sequences. 
The CRF50_A1D sequences clustered together with a support value of 0.77. The 
closest sequence was a sequence from Uganda dated 1997; the branch containing 
this sequence and the CRF50_A1D sequences had a support value of 0.81. 
Both the unfiltered and filtered alignments for env contained sequences from East 
Africa, and Central Africa (Table 6_5). The FastTree analysis for the unfiltered 
alignment showed the CRF50_A1D sequences clustering together with a support 
value of 1 (Figure 6_2e). The closest sequence was a sequence from Kenya dated 
1997; the support value for the branch containing this sequence and the 
CRF50_A1D sequences was 0.91. The filtered alignment contained predominantly 
sequences from Tanzania and Kenya (Figure 6_2f). The support value for the 
CRF50_A1D sequences was 1. The closest sequences were the same sequence 
from Kenya seen in the unfiltered tree and a sequence from Tanzania dated 1995. 
The support value for the branch containing these sequences and the CRF50_A1D 
sequences was 0.96.  
Overall, each of the subtype A1 and D gag, pol, and env regions of CRF50_A1D 
showed strongly supported clustering with sequences from East Africa; 
unfortunately, we were not able to more precisely define the geographic region 
when using sequences from publicly available repositories. The CRF50_A1D 
sequences displayed monophyletic clustering in all of the 12 analyses. Monophyletic 
clustering in the pol trees, which contained all of the pure subtype A1 and D 
sequences from the UK HIV DRD, supports the assertion that this recombinant was 
imported into the UK as an existing recombinant strain rather than arising from an 
in-country recombination event. The exception to this is the URF sequence, 
specimen 34567. This sequence clustered monophyletically with CRF50_A1D in all 
trees apart from the subtype D gag trees, where it was located on a separate 
branch. That the closest sequence to this branch was a sequence from the UK 
supports the assertion that this CRF50_A1D/B recombinant arose from a UK 
recombination event with a subtype B strain. 
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Figure 6_2. Approximate maximum likelihood trees for subtype D gag, pol and env 
regions of CRF50_A1D. Analysis was performed using unfiltered alignments and filtered 
alignments that had been filtered by genetic distance. In the unfiltered trees sequences are 
coloured by geographic region, where East Africa = green, West Africa = purple, Central 
Africa = blue, North Africa = turquoise, Southern Africa = Lavender, Eastern Europe  = 
orange, India = teal,  UK = yellow. In the filtered trees, sequences are coloured by country, 
where Kenya = green, Uganda = blue, Rwanda  = Orange, Tanzania = purple, Chad = 
turquoise, DRC = Lavender, UK = yellow. Numbers represent approximate maximum 
likelihood support values. The trees for pol contain all 72 CRF50_A1D sequences. a) 
Unfiltered tree for gag.   The pure CRF50_A1D sequences cluster closest to sequences from 
East Africa (support value = 0.98). Specimen 34567 (the URF) is located in a close, but 
separate branch; b) Filtered tree for gag. The CRF50_A1D sequences cluster together with 
a support value of 0.93. The closest sequence is a sequence from Uganda (support value = 
0.71). The URF is located on a separate branch which contains a specimen from the UK 
(support value = 0.79); c) Unfiltered tree for pol. The CRF50_A1D sequences (support value 
= 0.77)  cluster closest to sequences from Uganda (support value = 0.94); d) Filtered tree for 
pol. The CRF50_A1D sequences (support value (0.77) cluster closest to sequences from 
Uganda (support value = 0.81); e) Unfiltered tree for env. The CRF50_A1D sequences 
(support value = 1) cluster closest to a sequence from Kenya (support value = 0.91); f) 
Filtered tree for env. The CRF50_A1D sequences (support value = 1) cluster closest to a 
sequence from Kenya and a sequence from Tanzania (support value = 0.96).  
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6.3 Emergence and distribution of CRF50_A1D in the UK. 
Having established that the parental subtype A1 and D strains of CRF50_A1D were 
related to strains from East Africa, and that CRF50 itself was likely to have been 
imported into Britain as a recombinant, an investigation was performed into the time 
of introduction of CRF50_A1D in Britain and its distribution throughout the UK. This 
was performed using the six full-length sequences (five CRF50_A1D plus one 
URF), the additional 67 CRF50_A1D pol sequences identified from the UK HIV 
DRB; from the full-length sequences, subtype A1 and D regions of gag, pol and env 
genes, and the concatenated A1/D pol gene region were investigated 
independently. 
 
6.3.1 Model selection. 
6.3.1.1 Alignments containing all 72 CRF50_A1D sequences (pol gene) 
6.3.1.1.1 A/D concatenated alignment. 
The FindModel results for the concatenated A1/D pol alignment were summarised in 
Table 6_6. The nucleotide substitution model with the lowest AIC score (and 
therefore the best fit for the data) was GTR plus gamma. Similar AIC scores were 
also seen for the HKY plus gamma and the Tamura-Nei plus gamma models, 
respectively. 
Nucleotide substitution model AIC score 
 A1 D A1/D 
Jukes-Cantor 87904.25 10628.46 125603.07 
Jukes-Cantor plus gamma 5133.67 1855.31 7065.46 
Felsenstein 1981 5320.99 4577.41 7340.82 
Felsenstein 1981 plus gamma 5105.41 1731.40 7021.76 
Kimura 2-parameter 5150.97 1768.25 7134.52 
Kimura 2-parameter plus gamma 4933.75 1690.54 6816.78 
Hasegawa-Kishino-Yano 5117.20 1766.59 7093.91 
Hasegawa-Kishino-Yano plus gamma 4893.00 1686.11 6762.24 
Tamura-Nei 5099.32 1768.02 7093.91 
Tamura-Nei plus gamma 4869.08 1687.51 6745.54 
GTR 5090.09 1763.93 7061.83 
GTR plus gamma 4858.38 1685.00 6726.42 
Table 6_6. FindModel results for 72 CRF50_A1D pol sequences. FindModel best fit 
results for subtype A1, subtype D, and A1/D concatenated sequences for all 72 CRF50_A1D 
sequences. The nucleotide substitution model with the lowest AIC score was considered the 
best fit. The lowest AIC score for each alignment was the GTR plus gamma substitution 
model (highlighted in grey). 
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Following the FindModel testing, the GTR plus gamma model and HKY plus gamma 
models were selected for further comparison using BEAST. GTR plus gamma and 
HKY plus gamma models were compared using both strict molecular clocks and 
uncorrelated lognormal relaxed molecular clocks, and Bayes factors calculated for 
each permutation. Table 6_7 showed the log10 Bayes factors for the model 
comparisons. The model with the best fit was the GTR plus gamma substitution 
model with a relaxed uncorrelated lognormal molecular clock; this had a log10 Bayes 
factor of 226.56 compared to a HKY plus gamma model with a strict molecular 
clock, 201.28 compared to the HKY plus gamma model with a relaxed uncorrelated 
lognormal molecular clock and 23.14 compared to the GTR plus gamma model with 
a strict molecular clock. The GTR plus gamma model with a relaxed uncorrelated 
lognormal molecular clock was selected as the best model to analyse the 
concatenated A1/D pol gene alignment.  
 
Model HKY strict clock HKY relaxed clock GTR relaxed clock GTR strict clock 
HKY strict clock - -25.28 -226.56 -203.42 
HKY relaxed clock 25.28 - -201.83 -178.15 
GTR relaxed clock 226.56 201.28 - 23.14 
GTR strict clock 203.42 178.15 -23.14 - 
Table 6_7. log10 Bayes factors for A1/D segment. GTR and HKY nucleotide substitution 
models were compared using both strict and relaxed molecular clocks. The Bayes factor of 
each combination of models is shown; models listed vertically are compared to models listed 
horizontally. A score of >20 is considered to be significantly more in favour of the model in 
question. The GTR with a relaxed molecular clock had the highest Bayes factor in each 
comparison. 
 
6.3.1.1.2 Subtype A1 and subtype D alignments 
In common with the concatenated A1/D alignment, the FindModel results for the 
component subtype A1 and subtype D regions showed that the GTR plus gamma 
model had the best predicted fit (Table 6_6). This model was compared to the HKY 
plus gamma model using a relaxed uncorrelated molecular clock, and Bayes factors 
were calculated to compare the results (Table 6_8).  For both A1 and D regions of 
the pol gene, the GTR plus gamma model with a relaxed uncorrelated lognormal 
molecular clock was the best model; Bayes scores were 141.01 and 39.50 for 
subtypes A1 and D, respectively when compared to the HKY plus gamma model. 
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Therefore, the GTR plus gamma model with a relaxed uncorrelated lognormal 
molecular clock was selected as the best model to use. 
 
Model GTR relaxed HKY relaxed 
Subtype A   
GTR relaxed - 141.01 
HKY relaxed -141.01 - 
Subtype D   
GTR relaxed - 39.50 
HKY relaxed -39.50 - 
Table 6_8 log10 Bayes factors for subtype A1 and subtype D segments of CRF50_A1D 
pol gene. GTR and HKY nucleotide substitution models were compared using relaxed 
molecular clocks. In both cases, the GTR model had the highest Bayes factor.  
 
6.3.1.2 Alignments containing CRF50_A1D full-length sequences only (gag, 
pol, env genes; full-length sequences) 
Although the alignment that contained all 72 sequences was the most apposite 
alignment to use in terms of giving enough genetic information to estimate a 
tMRCA, it was restricted by only having a partial pol gene. Therefore, estimates for 
tMRCA were also calculated using the full-length sequences, and the gag, pol and 
env genes. Subtype A1 and D regions were analysed separately in order to confirm 
that the genes and subtypes had a shared evolutionary path. Alignments were 
analysed both with and without the URF (specimen 34567) in order to ascertain 
whether this sequence represented a precursor of CRF50_A1D or an onward 
recombination event. 
6.3.1.2.1 Full-length sequences 
The FindModel results for the alignment containing the full-length CRF50_A1D 
sequences indicated that the GTR plus gamma model was the best fit (Table 6_9). 
This model was compared with both strict and relaxed uncorrelated molecular clock 
models; the Bayes factor for the strict clock compared with the relaxed uncorrelated 
lognormal clock was 0.26. This result was not consistent with a significant difference 
in the molecular clock chosen, and so for reasons of consistency the relaxed 
molecular clock was selected for use. 
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6.3.1.2.2 Subtype A1 and D gag, pol  and env alignments 
Unlike the preceding alignments, the FindModel results for the subtype A1 and 
subtype D regions of the gag, pol and env genes were not uniformly in agreement 
(Table 6_9). The GTR plus gamma model was the predicted best fit in 5/12 (41.7%) 
cases, the HKY plus gamma model in 4/12 (33%) of cases, the Tamura Nei plus 
gamma model in 2/12 cases (16.7%) and the Tamura Nei model in 1/12 (8.3%) of 
cases. Accordingly, analysis began using the GTR plus gamma model. However, for 
those alignments in which GTR plus gamma was not the preferred substitution 
model, it proved difficult to achieve consistent ESS >200, even when combining 
multiple runs and using a strict molecular clock. Therefore, the decision was made 
to use the simpler HKY plus gamma model for all of the alignments, so that the 
results were comparable across each gene. The HKY plus gamma model was used 
with a relaxed uncorrelated lognormal molecular clock. 
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Model Full-length 
sequences 
Subtype A1 genes Subtype D genes 
gag pol env gag pol env 
  Pure 
CRF50 
With 
34567 
Pure 
CRF50 
With 
34567 
Pure 
CRF50 
With 
34567 
Pure 
CRF50 
With 
34567 
Pure 
CRF50 
With 
34567 
Pure 
CRF50 
With 
34567 
Jukes-Cantor 33865.69 1802.76 2377.20 2575.86 1496.59 31137.71 4265.84 2110.36 2236.75 914.09 1068.85 2504.66 3183.13 
Jukes-Cantor 
plus gamma 
33694.28 1803.21 2369.06 2566.93 1488.97 3116.70 4196.05 2102.99 2224.20 915.43 1066.85 2505.50 3162.11 
Felsenstein 
1981 
33194.72 1756.70 2322.92 2494.65 1451.58 3071.53 4196.19 2075.80 2204.21 896.86 1051.38 2469.13 3142.88 
Felsenstein 
1981 plus 
gamma 
33020.53 1756.90 2313.03 2489.55 1443.81 3049.80 4120.66 2068.21 2190.92 898.03 1048.63 2469.94 3120.73 
Kimura-2 
parameter 
33531.00 1788.48 2333.84 2543.99 1465.09 3092.69 4203.30 2089.82 2187.63 902.72 1043.04 2490.16 3141.60 
Kimura-2 
parameter 
plus gamma 
33348.91 1788.60 2325.65 2534.75 1456.64 3070.83 4131.31 2082.04 2173.30 903.87 1040.50 2490.82 3120.34 
HKY 32883.23 1744.60 2284.67 2466.23 1419.57 3020.86 4122.69 2056.55 2158.27 886.26 1026.89 2455.95 3104.69 
HKY plus 
gamma 
32699.73 1744.41 2273.90 2456.49 1408.02 2998.84 4048.25 2048.61 2143.86 887.44 1024.20 2456.46 3081.25 
Tamura-Nei 
93 
32884.69 1745.63 2282.87 2466.29 1415.94 3018.36 4121.58 2058.47 2160.14 884.09 1025.30 2457.12 3105.97 
Tamura-Nei 
93 plus 
gamma 
32701.47 1745.45 2272.59 2456.63 1406.18 2995.82 4047.63 2050.54 2145.62 885.53 1023.84 2457.74 3082.92 
GTR 32886.29 1745.19 2276.97 2470.71 1419.81 3018.46 4115.25 2063.46 2164.54 884.63 1022.40 2455.22 3096.53 
GTR plus 
gamma 
32683.43 1745.10 2267.49 2461.06 1410.34 2996.03 4040.82 2055.46 2149.88 886.25 1020.86 2455.64 3071.82 
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Table 6_9. FindModel AIC scores for subtype A1 and D alignments for gag, pol and env genes. The reduced set of substitution models were 
considered for each alignment, and the model with the lowest AIC score was considered the best fit (highlighted). Please note that the results for the 
subtype A1 alignment that included specimen 34567 appeared inconsistent with the results for the alignment containing pure CRF50_A1D 
sequences only. This is not a discrepancy; in the region of pol that was analysed, specimen 34567 is not pure subtype A1, and therefore the 
alignment area was trimmed to ensure only subtype A1 genetic evolution was analysed.  
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6.3.2 Time scaled phylogenies 
6.3.2.1 MCMC analysis of all 72 CRF50_A1D sequences 
Time scaled phylogenies were performed for pol using the subtype A1 region of the 
genome, the subtype D region of the genome and the concatenated A1/D region 
(Figure 6_3). Summarised tMRCA results are shown in Table 6_10.  
6.3.2.1.1 A1/D concatenated alignment. 
MCMC analysis of the A1/D concatenated alignment showed a tMRCA of 1992.46 
(95% HPD 1987.47-1998.57) (Table 6_10, Figure 6_3a). The sequences from the 
full-length sequencing were distributed evenly across the CRF50_A1D cluster. The 
tree had consistent strong support for the topology throughout.   
6.3.2.1.2 Subtype A1 and subtype D alignments 
The tMRCA for subtype A1 was 1994.88 (95% HPD 1990.78-2000); the tMRCA for 
subtype D was 1994.36 (1989.80-2000.37) (Table 6_10). In both trees the 
sequences from the full length sequencing were distributed evenly across the 
CRF50_A1D cluster (Figure 6_3b, c). In the subtype D tree the CRF50_A1D cluster 
was split into two branches. The smaller of the two branches contained 25 
sequences, but had very low topological support (posterior probability =0.02). 
The A1 tree showed fairly consistent strong support across the tree. The D tree 
showed strong support for a uniform cluster of CRF50_A1D (posterior probability 
=0.89) but generally weak support for the topology within the CRF50_A1D cluster. 
This is not unexpected as the fragment of subtype D was very short and in a highly 
conserved area of the genome, resulting in a limited amount of variable genetic 
information.  
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Figure 6_3. Time scaled phylogenies of all 72 CRF50_A1D sequences. Subtype A1 
reference sequences are shown in blue. Subtype D sequences are shown in lavender. 
Sequences for which there was a full-length sequence available are shown in red. Posterior 
probabilities are displayed at nodes. The outgroup (subtype C) is shown in black. a) A1/D 
time scaled phylogeny. CRF50_A1D sequences have a tMRCA of approximately 1992; b) 
Subtype A1 region of pol. The topology of the tree is similar to that of the A1/D tree and 
shows CRF50_A1D with a tMRCA of approximately 1993; c) Subtype D region of pol. The 
topology of this tree is different to that of the A1/D and A1 trees, and the tree as a whole 
shows weaker support.   
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6.3.2.2 Demographic reconstruction 
Demographic reconstruction of the number of effective CRF50_A1D infections, 
which estimates the number of infections contributing to new transmissions,  grew 
exponentially in the period 2001-2002 (Figure 6_4). The reconstruction showed that 
aside from a small increase in the mid-1990s when CRF50_A1D first came to the 
UK, the number of effective infections remained stable until 2001-2002. Following 
the increase during this year, the number of effective infections returned to a more 
stable state. As of 2010, the number of effective infections was estimated at greater 
than 100, higher than the 72 instances identified in the UK HIV DRD.  This indicated 
that a number of CRF50_A1D infections potentially remained uncaptured by current 
routine screening protocols.  
 
Figure 6_4. Bayesian Skyline reconstruction of the demographic history of 
CRF50_A1D in the UK. The black line represents the median; blue lines represent the 95% 
lower and upper HPD estimates of the effective population size. The plot shows an 
exponential increase in the number of effective infections between 2001 and 2002. As of 
2010, the number of effective CRF50_A1D infections in the UK was estimated at greater 
than 100. 
 
6.3.2.3 MCMC analysis of alignments containing CRF50_A1D full-length 
sequences and associated regions only (gag, pol, env genes; full-length 
sequences) 
6.3.2.3.1 Full-length sequences 
The tMRCA for the BEAST analysis of the full-length sequences was 1995.56 
(1990.91-1999.60), consistent with the tMRCA of the trees using all 72 sequences 
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(Figure 6_4). There was strong support for the branches connecting 40534 and 
8179 (posterior probability = 0.98) and for the branch connecting these sequences 
to 12792 (posterior probability = 0.88), but weak support for the branch connecting 
specimens 11762 and 33365 (posterior probability = 0.52).  The branch lengths for 
specimens 12797 and 11762 were much longer than the branch lengths connecting 
the other sequences; this was as expected owing to the recent sampling date of 
these specimens compared to the specimens. 
 
Figure 6_5. Time-scaled phylogeny using full-length CRF50_A1D sequences. The 
tMRCA using full-length sequences was 1995.56 (95% HPD 1990.91-1999.60), consistent 
with tMRCA from the A1/D pol analysis of 1992.46. 
 
6.3.2.3.2 gag , pol and env alignments 
The analysis of the gag subtype A1 alignment showed a tMRCA of 2000.76 (95% 
HPD 1998.84 – 2004.86) (Table 6_10). The tree showed generally weak support, 
with only one branch exceeding posterior probability support of 0.7 (Figure 6_6a). 
The corresponding tree containing specimen 34567 showed tMRCA of 1996.05 
(95% HPD 1987.21-2010.49). This tree showed consistently strong support >0.7 
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except for the branch containing specimen 34567 (Figure 6_6b). The branch 
containing specimen 34567 showed that the sequence had a later divergence date 
than the pure CRF50_A1D sequences. 
The subtype D trees for gag had similar topologies as the subtype A1 trees (Figure 
6_6c, d). The tMRCA for the tree containing the pure CRF50_A1D sequences was 
1997.83 (95% HPD 1991.69 – 209.60). Stronger support for the subtype D tree in 
general was shown compared to the subtype A1 tree. The tree containing specimen 
34567 showed a later tMRCA than the pure CRF50_A1D specimens, but the branch 
had weak support. 
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Figure 6_6. Time scaled phylogenies for CRF50_A1D gag regions. a) Subtype A1 region 
(pure CRF50_A1D sequences only) b) Subtype A1 region (including specimen 34567; c) 
Subtype D region (pure CRF50_A1D sequences only); d) Subtype D region (including 
specimen 34567).  
 
Analysis of the subtype A1 pol alignment showed a tMRCA of 2001.33 (95%HPD 
2000.22 – 2003.88) (Table 6_10). All branches in this tree had support values <0.7 
(Figure 6_7a).  The corresponding tree containing specimen 34567 showed 
stronger support but showed specimen 34567 with a divergence date prior to the 
pure CRF50_A1D sequences (Figure 6_7b). 
The subtype D pol tree showed a tMRCA of 1998.83 (95% HPD 1994.46 – 2006.72) 
(Table6_10). There was good support throughout the tree (Figure 6_7c). The tree 
containing specimen 34567 showed a tMRCA of 2001.16 (95% HPD 1999.73 – 
2004.64) (Table 6_9). The branch containing 34567 had weak support but  showed 
a later divergence date than the pure CRF50_A1D sequences (Figure 6_7d). 
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Figure 6_7. Time scaled phylogenies for CRF50_A1D pol regions. a) Subtype A1 region 
(pure CRF50_A1D sequences only) b) Subtype A1 region (including specimen 34567; c) 
Subtype D region(pure CRF50_A1D sequences only); d) Subtype D region (including 
specimen 34567).  
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The subtype A1 env tree had a tMRCA of 1999.64 (95% HPD 1996.47 – 2005.68). 
This tree was very weakly supported and contained negative branch lengths (Figure 
6_8a). The tree containing specimen 34567 had consistent strong support 
especially for 34567 (posterior probability = 1) and showed a later divergence date 
of the URF compared to the pure CRF50_A1D sequences (Figure 6_8b). 
The subtype D env trees also showed negative branch lengths and very weak 
support (Figure 6_8c). In this case, the tree containing specimen 34567 also 
showed weak support throughout (Figure 6_8d).  
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Figure 6_8. Time scaled phylogenies for CRF50_A1D env regions. a) Subtype A1 region 
(pure CRF50_A1D sequences only) b) Subtype A1 region (including specimen 34567); c) 
Subtype D region (pure CRF50_A1D sequences only); d) Subtype D region (including 
specimen 34567).  
 
Overall, the median tMRCA for the individual gene analysis was 2000.76 for the 
pure CRF50_A1D sequences and 1999.31 for the alignments containing specimen 
34567, respectively. The standard deviation of the tMRCA for the pure sequences 
was 1.32 and the standard deviation for alignments with 34567 was 2.58. The 
standard deviation over all individual gene dates was 2.15. The tMRCA dates from 
the individual gene analyses were consistent with those for the full-length 
sequences and for the alignments containing all 72 CRF50_A1D sequences. The 
divergence date of the URF specimen was consistently later than the divergence 
date of the pure CRF50_A1D sequences, confirming that this strain was the product 
of an onward recombination event between a CRF50_A1D strain and a subtype B 
strain. 
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Gene A1 D 
 Pure CRF50 With 34567 Pure CRF50 With 34567 
gag 2000.76 
(1998.84 – 2004.86) 
1996.05 
(1987.21-2010.49) 
1997.83 
(1991.69 – 209.60) 
1994.82 
(1986.43 – 2005.27) 
pol 2001.33 
(2000.22 – 2003.88) 
1998.83 
(1994.46 – 2006.72) 
2001.16 
(1999.73 – 2004.64) 
2000.07 
(1997.73 – 2003.10) 
env 1999.64 
(1996.47 – 2005.68) 
1999.79 
(1995.59 – 2009.53) 
2000.76 
(1999.63 – 2003.31) 
2001.57 
(2000.94 – 2003.91) 
Table 6_10. CRF50_A1D tMRCA dates. Time to most recent common ancestor for each 
subtype A1 and subtype D region of the CRF50_A1D genome that was analysed 
independently. Each separate region was analysed both with and without the URF specimen 
(34567) in order to ascertain whether the URF was precursor of CRF50_A1D or the product 
of an onward recombination event with a subtype B strain. 
 
6.3.3 Phylogeographic analysis 
The phylogeographic analysis was performed using all 72 UK sequences identified 
as CRF50_A1D infections i.e. five sequences that were obtained from full-length 
sequencing and the additional 67 sequences identified in the UK HIV DRD. Only pol 
sequences were used for this analysis. The phylogeographic analysis investigated 
the spread of CRF50_A1D throughout the UK following emergence in 1992 and was 
captured using video 6_1. Briefly, the video showed emergence of CRF50_A1D in 
Northwest England in 1992, followed by travel to London/Southeast England in 
approximately 1995; in 1998 independent spread in  London/Southeast England 
and Northwest England was seen, followed by travel from Northwest England to 
Southwest England  in approximately 2000. Also in 2000 was travel from Northwest 
England back into London/Southeast England and more accelerated spread within 
London/Southeast England followed by spread from London/Southeast England 
back into Northwest England. By 2003 there was spread into three areas of 
London/Southeast England, followed by transmissions from London into a new 
region of Northwest England, transmission from London and the Northwest to a new 
area of Southwest England followed by spread from Northwest England to 
Northeast England and Scotland.  
The plotted inferences were coloured by rate; the rate of transmission from 1993 to 
1998 remained stable, followed by slightly faster transmissions in 1999-2001, and 
then much faster transmissions from 2002 onward. The rate of spread was fastest 
within London and between London and Northwest England; the fastest rate seen 
was from Northwest England to Scotland in approximately 2007. The faster 
transmissions seen from 2002 onward correlate with the Bayesian Skyline 
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reconstruction, which showed the number of effective infections increasing 
exponentially in the period 2001-2002. 
The plotted inferences in the video showed CRF50_A1D emerging in Northwest 
England prior to travelling to London/Southeast England. Subsequent transmissions 
of the strain and further travel between London/Southeast England and Northwest 
England occurred before the video showed spread from Northwest England to 
Southwest England, Northeast England and Scotland. This indicated that the 
primary epicentre of CRF50_A1D was located in Northwest England, and that 
transmission of this strain was driven by repeated migration of the strain out of this 
region, rather than transmission to new regions creating new epicentres for 
subsequent transmissions to extra geographic regions.    
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Chapter 7: Influence of CRF50_A1D on disease pathogenesis 
 
7.1 Obtainment of CD4 cell count data from CRF50_A1D patients captured by 
the UK CHIC database 
Anonymised CHIC IDs for 16 CRF50_A1D patients that had UK CHIC identification 
numbers were transferred to the MRC-CTU for retrieval of CD4 cell count data 
stored in the UK CHIC database. CD4 cell count data was available for 15/16 
patients; 2/15 (13.3%) patients had no pre-ART CD4 cell counts recorded; a further 
1/15 (6.7%) had only one pre-ART count available (Table 7_1). The mean time 
range for pre-ART counts was 1.53 years; the range covered was 0 - 7.48 years.  
The median number of total CD4 cell counts available was 16, and the median 
number of post-ART CD4 cell counts was 10.  The median number of pre-ART CD4 
cell counts available was five and the median time range of pre-ART CD4 cell 
counts was 0.7 years. 
Patients with less than three pre-ART CD4 cell counts and/or less than two months 
between available pre-ART counts were excluded from further analysis; 6/15 (40%) 
of patients were excluded. The remaining nine patients were taken forward for 
further analysis. 
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Patient number CD4 cell count measurements 
Total  Pre-ART  Duration pre-ART (years) Post-ART  
37829 8 0 0 8 
22720 12 3 0.7 9 
27497 40 26 4.6 14 
15732 34 5 0.7 29 
5033 32 8 1.3 24 
20545 16 5 0.7 11 
27082 25 23 7.5 2 
15846 17 7 2.5 10 
27797 7 1 0 6 
31 17 3 0.1 14 
29820 16 0 0 16 
20893 22 6 0.6 16 
33119 2 2 0.7 0 
40107 12 2 0 10 
25529 5 5 3.5 0 
Table 7_1. CD4 cell counts for CRF50_A1D patients. Anonymised CD4 cell count data 
were obtained from the UK CHIC database. CD4 cell count data were available for 15 
patients. The length of pre-ART follow-up ranged from 0 to 7.5.   
 
7.2 Linear regression analysis of CD4 slopes 
Figure 7_1 shows the linear regression slopes for the nine remaining patients. 
There was no uniform pattern apparent across the patients. The regression slope 
for each of the nine patients is shown in Table 7_2. The median slope was -0.52. 
When the data was restricted to those patients for whom the time range of CD4 cell 
counts was greater than one year, the median slope was also -0.52.  
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Figure 7_1. Pre-ART CD4 cell count slopes for 9 CRF50_A1D patients. Linear 
regression slopes a)  Patient 22720. b)  Patient 27497. c)  Patient 15732. d) Patient 5033. e) 
Patient 20545. f) Patient 27082 g) Patient 15846 h) Patient 20893 i) Patient 25529 
 
CHIC ID CD4 cell count slope r2 
22720 -0.08 0.30 
27497 -0.49 0.07 
15732 -4.76 0.35 
5033 -3.66 0.72 
20545 -0.64 0.01 
27082 -0.51 0.24 
15846 -0.93 0.39 
20893 0.68 0.01 
25529 -0.14 0.02 
Table 7_2. Linear regression slopes for CRF50_A1D patients.  Pre-ART CD4 cell slope 
results for each of the 9 patients eligible for analysis.  
 
 
7.3 Comparison to subtype B slopes 
Linear regression slopes for patients infected with subtype B strains of HIV-1 were 
obtained from Dr. Marina Klein at McGill University Health Centre, Montreal. The 
mean slope for subtype B patients screened to exclude early and late presenters 
was -1.22 (95% CI -1.26, -1.18); the slope for unselected patients was -1.33 (95% 
CI -1.37, -1.29). A CD4 cell decline slope was also available for subtype A1, which 
was -0.61 (95% CI -0.79, -0.43) (Klein et al., 2010, CROI 2011 abstract B-131). 
Slopes for subtype D were not available. 
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The mean CD4 cell decline slope for the nine CRF50_A1D patients was -1.17 
(Range -0.08, -4.76; 95% CI -2.29, -0.05). When the slopes were restricted to those 
patients for whom the time range of CD4 cell counts was greater than one year, the 
mean CD4 decline was -1.15 (Range -0.49, -3.66; 95% CI not calculated due to low 
number of measurements available).  When compared to the slopes for subtype B 
and subtype A1 infections, the CRF50_A1D patients appear to experience CD4 cell 
decline in a manner more similar to subtype B than subtype A1 infections. 
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Chapter 8: Discussion 
Traditionally, HIV-1 infections in the UK displayed a pattern of parallel epidemics: a 
subtype B epidemic, which affected almost exclusively MSM and IVDU 
(predominantly acquired in-country), and a heterosexual epidemic, which showed a 
diverse range of non-B subtypes and was dominated by infections acquired whilst 
abroad (Geretti, 2006; HPA, 2012). However, these infection dynamics have 
changed in recent years, and the number of indigenously acquired infections 
currently exceeds the number of imported infections (HPA, 2012). This, coupled 
with new increases in rates of infection in both MSM and heterosexuals following 
years of decline, raised the question of whether these new infection dynamics would 
lead to the emergence of new population networks that had the potential to change 
the genetic landscape of HIV-1 infections in the UK.  
This study was therefore designed to investigate the emergence of such networks, 
using subtype- unclassified strains of HIV-1 as a proxy for newly emerging 
population dynamics. We sought to answer the following questions: is the 
composition of the UK HIV-1 landscape changing on a genetic level? Are there 
novel HIV-1 CRFs circulating in Britain, and, if so, what are the origin and likely 
pathogenesis of these novel strains? 
The study was performed using sequences collected from routine HIV care and 
captured by the UK HIV DRD and sequences generated using an in house protocol 
for full length, single genome analysis of HIV-1.  
1. Is the composition of the UK HIV-1 landscape changing on a genetic 
level? 
Constant intermixing of HIV-1 strains within and between regions and populations 
has resulted in an epidemic that is continually increasing in genetic complexity 
(Geretti, 2006; Vidal et al., 2009). This presents an unending challenge to existing 
phylogenetic classification systems, which is reflected in the number of sequences 
that are considered “untypeable” by these programs (Gifford et al., 2007). 
Accordingly, the method of genotyping chosen in this investigation was crucial, 
given variation between different methods and the unclassified nature of the 
sequences under investigation.   
Genotyping complex recombinant sequences is necessarily a difficult task; different 
genotyping methods use different algorithms to identify the component genotypes of 
210 
 
recombinant sequences. The UK HIV DRB was customarily genotyped using two 
methods: Rega and SCUEAL. Rega has high specificity but low sensitivity for 
recombination detection, and therefore was not considered a suitable screening 
method for this investigation (Abecasis et al., 2013). SCUEAL was designed to 
detect subtype recombination and evolutionary relationships, and was chosen as 
the primary screening method (Kosakovsky Pond et al., 2009). Owing to the lack of 
recombinant breakpoint locations in the data held by the UK HIV DRD for 
unclassified sequences, repeat genotyping of sequences of interest using SCUEAL 
was performed (referred to as SCUEAL 2012 in text). As breakpoints identified by 
SCUEAL were considered invitations for further analysis rather than confirmed 
breakpoints (Pond et al., 2006), the jpHMM program was also used to genotype 
unclassified strains and predict recombinant breakpoint locations.  
The results from each iteration of SCUEAL (2010 and 2012) and jpHMM were very 
different. Greater agreement was seen between the SCUEAL 2012 results and the 
jpHMM results than the SCUEAL 2010 and SCUEAL 2012 results or the SCUEAL 
2010 and jpHMM results. Differences between the SCUEAL 2010 and SCUEAL 
2012 results were partially explained by a change in the background sequences 
comprising the reference alignment for the program, which resulted in the reference 
alignment more accurately reflecting genetic variation within subtypes (conversation 
with S. Frost, 2013; Gifford et al., 2006). The differences between the SCUEAL 
2012 results and the jpHMM results could be investigated in more depth by running 
each program locally using the same background reference alignment; this 
approach will be considered for further investigations of this nature.   
By stratifying the number of subtype unassigned sequences by year, and comparing 
them to the number of pure and recognised CRF strains, we found a statistically 
significant increase in the number of unassigned sequences between the years of 
1997-2008 (0-1140, respectively, p=<0.001) and the total number of recombinant 
records (0-1,377, respectively, p=<0.001). During this period the proportion of 
unassigned sequences increased from 0% in 1996 to 12.6% in 2008 and the 
proportion of CRFs increased from 0% in 1996 to 2.6% in 2008, showing that the 
unassigned sequences increased at a faster rate than the recognised CRF 
sequences.  
There were two caveats to these numbers. Firstly, SCUEAL rarely classified CRF02 
sequences as such, meaning that the number of unclassified sequences might be 
artificially inflated. However, the proportion of CRF02 infections in the UK is 
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comparatively small, and therefore the numbers of these infections was not 
considered to substantially affect the overall figures. Second, the overall numbers 
were calculated using the SCUEAL simplified subtype field. This is a more 
conservative classification than the detailed subtype field, and as such, the numbers 
of recombinant strains identified were likely to be an under- rather than over-
estimate.    
Given evidence that the proportion of unassigned strains in the UK was increasing, 
the transmission networks within these strains was investigated. Subtype B-
containing recombinants were selected for this due to their traditional constraint by 
exposure group. Using the detailed subtype field in SCUEAL 2010, 2,030 
sequences were identified as potential B-recombinant strains. Although it became 
apparent upon genotyping using SCUEAL and jpHMM that only 444 - 699 of these 
sequences were true B-recombinants, the results from the two genotyping methods 
were sufficiently different such that the entire 2,030 putative B-recombinant 
sequences were used as input into an approximate maximum likelihood tree. As 
genetic interpatient variability is less when infection comes from a common source, 
the maximum likelihood tree was screened for clusters using genetic distance 
measurements; this identified 28 potential transmission clusters (Simmonds et al., 
1990). As the presence of recombination can affect the accuracy of phylogeny 
estimation (Posada and Crandall, 2002), confirmation of transmission clusters was 
performed by analysing each putative pure region separately, in order to confirm 
clustering, before concatenating sequences and performing the time scaled 
phylogenies. 
The BEAST cluster analysis found 15/28 (53.6%) confirmed clusters. Of the 15 
clusters, the smallest clusters contained 3 members (4 clusters) and the largest 
contained 23 members (1 cluster). 5/15 (33.3%) were mixed male and female, of 
which one was exclusively heterosexual black-African with six members, one was 
heterosexual white with four members, one was IVDU with three members, one was 
mixed IVDU and heterosexuals with five members and one was mixed IVDU, 
heterosexual and MSM with 23 members (all white); 20% of clusters overall showed 
mixed exposure profiles. 
There was one all male cluster with mixed heterosexual/MSM with five members, 
and one all male MSM/IVDU cluster with three members. Eight clusters were 
exclusively MSM, of these five were all white, one was white/black-African/black-
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Caribbean with six members and two were mixed white black-African with 3 and 5 
members respectively. 
In terms of geographic location, seven clusters were located exclusively in 
London/Southeast England, two in East Anglia, one in London/Southeast England 
and Northwest England, one in Northwest England, one in Scotland/Northwest 
England, and three in Southwest England/Wales. Overall, 75% of clusters showing 
mixed ethnicities were located in London/Southeast England and the only cluster 
involving exclusively black Africans was located in London/Southeast England. 
Time-scaled phylogenies were performed on clusters showing potential extra-UK 
geographic involvement, including the largest cluster (Cluster 1) which contained 23 
members. Geographic matching identified a number of sequences from Portugal 
and Spain displaying identical recombination profiles; the more recent tMRCA of the 
UK cluster relative to these sequences indicates possible import of this strain during 
the late 1990s, consistent with accepted geographic distribution of G/B 
recombinants, which have traditionally been found in Spain and Cuba (Thomson et 
al., 2012). Interestingly, subtype G in Portugal has been associated with indigenous 
transmission in heterosexual and IVDU populations (Abecasis et al., 2013); this 
pattern was continued in 1/3 G/B recombinant clusters identified in this study 
(Cluster 2, four heterosexual members), but MSM involvement  was present in 2/3 
clusters (Cluster 1, Cluster 5, four MSM members). The high number of G/B 
recombinant clusters found, and the links to Portugal, support data from Gifford et 
al., who also identified UK-Portugal transmission networks (2007).  
Cluster 15, which also contained mixed exposure profiles, showed an identical 
recombinant profile to sequences previously identified in Spain, Paraguay and 
Brazil. Evolutionary analyses showed no linkage to the Brazilian sequences, but co-
circulation of this novel strain in three distinct geographic regions (UK, Spain and 
Paraguay).  Co-circulation in multiple countries was also found in Cluster 2, a B/G 
recombinant circulating exclusively in heterosexuals in the UK. Co-circulation of this 
strain was identified in the UK, Portugal and Luxembourg. 
Evidence of three further novel circulating strains formed from onward 
recombination of CRF50 strains with subtype B strains was found. The tMRCAs of 
two of these strains indicated that onward recombination with subtype B infections 
took place relatively quickly following the emergence of CRF50_A1D in the UK 
(1997.60 and 1999.55 vs. 1992.46). Evolutionary analysis that included Canadian 
strains showing nearly identical recombination profiles showed a closer relationship 
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with the pure CRF50 sequences, indicating that CRF50 may have given rise to at 
three further CRFs and been exported from the UK to North America during the 
period 1992-2007. 
The final cluster exhibiting extra-UK linkages was Cluster 19, which showed a B/C 
recombinant circulating in White and Black-African MSM in the UK. The evolutionary 
analyses showed a tMRCA during the early 2000s, followed by probable export from 
the UK to Italy in approximately 2008. Non-B subtypes in Italy have been estimated 
to comprise 2.4-19.4% of all HIV-1 infections, but to date this has been dominated 
by B/F genetic forms from introduction events associated with South America 
(Ciccozzi et al., 2012; Lai et al., 2012). This is the first report of novel strains from 
the UK being imported into Italy. 
Crucially, of the eight clusters with time scaled phylogenies, 5/8 (62.5%) show 
tMRCAs in 2004-2005, a period in which there was a statistically significant year-on-
year increase in the number of unassigned sequences in the UK HIV DRD. Cluster 
1, which had a tMRCA of 1999.72, showed short branch lengths around 2004-2006, 
indicating that the greatest number of transmissions took place during this time. This 
confirms that periods of increasing genetic diversity are the periods in which novel 
circulating strains are generated. 
Overall, 66.7% of the UK clusters contained sequences from MSM. Given that this 
analysis focussed on B-containing recombinants, the high proportion of MSM 
sequences in not surprising; what is surprising is the 33.3% of clusters that were 
composed of B-containing recombinants that did not contain sequences from MSM. 
This shows parallel diversification of the UK epidemic whereby the non-MSM 
epidemic has been incorporating B-strains at the same time as the MSM epidemic 
has been incorporating strains more commonly associated with heterosexual 
infections.  
Significantly higher proportions of males, IVDUs and people of white ethnicity were 
found to be associated with clusters of novel recombinants when compared to the 
proportion of individuals in the UK HIV DRD infected with pure subtypes and 
recognised CRFs. These figures indicate that emerging transmission of HIV-1 in the 
UK is being driven by new transmission patterns and is an area that would benefit 
from further study. 
Finally, 33.3% of clusters were found to be imported into the UK or have evidence of 
co-circulation in other countries; however, 60% showed no geographic linkages 
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outside of the UK, confirming that as the number of indigenous transmissions within 
the UK increases, so too does the number of new CRFs generated in-country.  
2. Are there novel HIV-1 CRFs circulating in the UK? 
The main limitation of the cluster study was that in any study using only one 
genomic region the presence or absence of recombination outside of the sequenced 
region remains unknown (Abecasis et al., 2013; Sanabani et al., 2009). 
Confirmation of a new circulating recombinant form of HIV-1 required 
characterisation of substantial regions of the genome (Robertson et al., 2000). 
Following the analysis that identified a potential novel A1/D CRF in the UK, full-
length HIV-1 sequencing was performed on six specimens that were retrieved from 
routine storage from three centres. Although identification of novel CRFs can be 
performed using viral DNA from PBMC samples, plasma sampling was selected in 
this case in order to characterise the circulating, rather than the archived, virus. 
To develop the protocol used for the full length sequencing, a protocol from Nadai et 
al. was selected for adaptation. Ultimately, adaptation of this protocol was not 
successful, and a protocol was developed using primers from CHAVI-MSBNC. The 
final protocol was optimised to work with subtypes A, B, C and D and specimens 
with low viral loads or reduced sample volume, unlike the original protocol which 
was optimised for use with subtypes B and C only. A number of modifications were 
trialled and adopted, including an increase in the number of cycles during the first 
round of PCR from 35 to 40; an optimised annealing temperature of 60⁰C, and a 
primer concentration of 0.25µm.  
Due to the age of the specimens, the likelihood of poor quality viral RNA was 
substantial. Automated nucleic acid extractions were trialled; however, these 
resulted in PCR template fragments of incorrect lengths. It is likely that the 
automated extraction process sheared the RNA, resulting in mis-priming and shorter 
fragments than desired. An RT enzyme with engineered reduced RNase H activity 
was selected for use to counteract an increase in in vitro errors due to RT strand 
switching during minus strand DNA synthesis, which is especially likely if the original 
RNA is of poor quality (Jansen and Ledley, 1990; Marton et al., 1991; Meyerhans et 
al., 1990; Shriner et al., 2004).  
In order to detect the existence of Taq polymerase-incorporated errors in the 
amplified specimens, two specimens were sequenced at more than one cDNA 
dilution beyond that required by Poisson’s distribution. One specimen was 
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sequenced at the theoretical dilution of 0.5 copies/µl (1 copy/reaction) given 
circumstances of no viral RNA degradation during 7 years of storage, and perfect 
extraction and RT results. The specimen amplified at a rate of 6% positive 
reactions, which is below the 30% required for Poisson’s distribution, but still 
sufficient to achieve full genome sequencing. Only one specimen amplified 
successfully at this dilution, but a combination of low volume and low viral load 
made this testing impractical for the other recombinant specimens. No differences 
were seen between the sequences obtained at any dilution below 30% positive, 
demonstrating the success of the optimised protocol. 
The protocol was also optimised to work with samples of low viral load and volume. 
Of the study samples received, the range of viral loads was 9,148-500,000 
copies/ml and the range of samples volumes was 270-1500ul. Conversely, the 
sample with the highest viral load was also the sample with the most volume 
available.  Although the protocol called for 20,000 copies of viral RNA to be 
extracted, this was only possible for 3/6 specimens, owing to the low sample 
volumes available. The number of viral RNA copies extracted per specimen ranged 
from 548 – 20,000. 
PCR amplification of the specimens showed relatively consistent amplification 
across all six specimens. One specimen amplified when using a cDNA dilution such 
that only one copy of cDNA was present in each well; a further specimen amplified 
at 1.37 copies per well. Each of the remaining four specimens were able to be 
sequenced at dilutions lower than that producing the Poisson distribution result, 
demonstrating the robustness of the optimised protocol with these specimens. The 
highest input into a reaction was for specimen 11762, which had a theoretical input 
of 200 copies/reaction well. However, this is based on the viral load at the time of 
sample, not a measurement of the sample once received; as this sample did not 
amplify at all at any dilution, and only amplified with 19/90 (21.1%) positive wells 
when tested undiluted, we have concluded that the specimen was degraded during 
storage and/or transport. Overall, given that sample ages ranged from 10 years old 
(specimen 8179), to seven years old (specimens 33365, 40534, 34567) to two years 
old (specimen 12792) to one year old (specimen 11762), the procedure was 
remarkably successful at amplification. That the most recent specimen was used at 
the lowest dilution of cDNA adds weight to the argument that this specimen in 
particular was somehow degraded.    
216 
 
Following sequencing, the recombination analysis of the six full-length genomes 
showed identical putative A1/D structures and one genome that was an A1/D/B/U 
recombinant.  The five identical structures showed a genome containing eight 
breakpoints, three in the gag gene, one in the pol gene, one in the accessory genes 
and a further three in the env gene. 
There were regions of the putative pure subtype components that initially defied 
easy subtype classification. This was due to three main factors. The first was the 
low number of genomes and the high similarity between them. This resulted in low 
phylogenetic signal in some of the fragments, which was shown in the likelihood 
mapping results of three of the specimens (33365, 40543 and 8179). This was 
particularly evident in fragments three (HXB2 co-ordinates 1884-2100, fragment 
length 216 nucleotides, gag p2, p7) and four (HXB2 co-ordinates 2101 -2503, 
fragment length 402 nucleotides, gag p1, p6, pol protease amino acids 1-84). Whilst 
the short fragment length of 216 nucleotides was the most probable explanation for 
the low phylogenetic signal for fragment three, the low signal for fragment 4 was 
explained by something different, namely the remarkable similarity of subtypes B 
and D in this region. The entropy analysis of this region showed that the number of 
informative sites between the two subtypes was only six, thus explaining the poor 
likelihood mapping results.   
Maximum likelihood analysis was used to genotype the putative pure subtype 
regions in the six genomes. Following this analysis, the genome was confirmed as 
an A1/D recombinant where the genome starts as subtype A1 through the 5’ LTR 
and gag p17, and part of p24 and then has breakpoints at HXB2 1272 (within p24) , 
1851 (end of p24, p2, p7), 2100 (gag p1, p6, pol protease amino acids 1-81), 2489 
(pol RT, RNase, Integrase, vif, vpr, beginning of tat/rev), 6004 (tat/rev, vpu, env 
CDS, gp120), 6602 (env gp120, V1- V4 loops), 7440 (env gp120, V5 loop, gp41, 
tat/rev exon), 8573 (tat/rev exon, gp41, nef, 3’LTR).  
Limited selective advantage is provided by the majority of HIV-1 recombination 
breakpoint locations, with the exception of breakpoints falling within regions 
associated with viral fitness such as the env gene (Archer et al., 2008; Palmer et al., 
2005; Quiñones-Mateu and Arts, 2002; Tee et al., 2009; Troyer et al., 2009). The 
tendency of breakpoints in env  to cluster around the 5’ and 3’ ends of the gene, has 
indicated a tendency for either the entire gene, or at least the gp120 coding region, 
to be preserved intact (Archer et al., 2008; Simon-Loriere et al., 2009). The env 
breakpoints in the identified A1/D recombinant structure fell within the recombination 
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hot-spots for env identified by Simon-Loriere et al., in 2009, in regions 1 and 3, 
respectively. As the recombination hot zone 3 has been associated with a high 
probability of loss of functionality (Simon-Loriere et al., 2009), further research on 
this particular recombinant structure could be performed, in order to ascertain 
whether a breakpoint location within this narrow zone constrains onwards viral 
evolution and affects the phenotypic properties of the viral strain. Such studies could 
consider the position of the recombination breakpoint with regards to the boundaries 
of protein folds, as this can influence functionality; another aspect to consider is  the 
degree of similarity between the parental subtype A1 and D strains around each 
breakpoint location, as the degree of local sequence similarity has been found to be 
crucial in determining the frequency and pattern of genetic recombination (Archer et 
al., 2008; Hu and Temin, 1990; Simon-Loriere et al., 2009, 2010; Zhang et al., 
2010).  
The final specimen sequenced was a URF specimen with a CRF50_A1D/B 
structure, where the subtype B regions were gag p2, p7 and pol RNase, Integrase, 
vif, vpr, and the beginning of the tat/rev intron. Given that data have indicated that 
recombination between genetically distinct HIV strains may not be an immediate or 
common outcome to dual infection in vivo and suggest critical roles for viral and 
host factors such as viral fitness, viral diversity and host immune responses (Powell 
et al., 2010), and that the URF specimen preserved the env breakpoints seen in 
CRF50_A1D, it is possible that breakpoints at these positions possess fitness 
determinants that favoured the preservation of the CRF50_A1D structure over a 
structure incorporating subtype B in env.   
There were limitations involved in performing full-length sequencing in the manner 
undertaken in this study. Amplification of HIV-1 in a single ~9kb fragment meant that 
shared nucleotide polymorphisms and mixed bases can be detected more 
frequently than when methods involving shorter fragments are used (Salazar-
Gonzalez et al., 2009). To control for this, additional safeguards were added to the 
sequencing protocol to ensure that the PCR template fragments were not subject to 
PCR-mediated recombination. These were: to sequence each specimen below the 
point of Poisson’s distribution and to pool the DNA from the positive PCR wells 
before sequencing. 
Pooling product from positive PCR wells was performed because the 50µl product 
from a single positive well was not sufficient to sequence the entire genome, even 
after dilution. Pooling of positive wells prior to sequencing therefore allowed the 
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detection of potential chimeric products across the length of the entire genome.  Any 
partial sequence that looked as if it came from a mixed source i.e. showed evidence 
of ambiguous bases that could not be explained by poor sequencing signal were 
repeated.  In addition, proof-reading enzymes and high fidelity PCR kits were used 
throughout to reduce the chance of PCR-mediated recombination. 
Instead of performing full-length sequencing using a single fragment, there was the 
option of developing a protocol that involved amplification of multiple overlapping 
fragments. However, we did not choose to take this approach. Although the 
sensitivity of the PCR would have been increased, other drawbacks made this an 
unattractive option. The drawbacks included the unknown structure of the 
recombinant, and therefore the risk that breakpoints fell within or close to the end of 
the overlapping fragments, clouding the downstream analyses. 
Following the phylogenetic confirmation of the five A1/D structures, further instances 
of this strain were sought by performing global BLAST searches in both NCBI and 
the Los Alamos National HIV Database. When no matches for this structure were 
found, the structure was registered as CRF50_A1D.   
Additional interrogation of the UK HIV DRD using three of the CRF50_A1D 
sequences as reference sequences found an additional 67 instances of this 
recombinant in the UK, leading to a total of 72 confirmed cases. Investigation of 
demographic information (where available) showed 46 cases in white MSM and 
transmission to two IVDU and two heterosexuals. Ethnicity results showed 
transmission to one black-African MSM and to one white heterosexual male; the 
IVDU’s were white; there was one Indian-Pakistani MSM. The range of country of 
origins showed cases from patients originating from UK, Ireland, Norway, the 
Philippines, and the US. 
All 72 sequences had associated aggregated centre data to indicate geographic 
origin; this showed that most cases were located in Northwest England (39/72, 
54.2%) and London/Southeast England (27/72, 37.5%). There were three cases in 
Southwest England, one in Northeast England and two in the Edinburgh region of 
Scotland.  
3. What are the origin and likely pathogenesis of these novel strains? 
The investigation into the geographic origin of the component subtype A1 and D 
parental strains showed that the strains were most closely related to strains from 
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East Africa. The analysis was unable to determine a specific country of origin with 
the East African region; further studies that might address this could include 
reconstruction of the ancestral subtype A1 and D sequences in order to more 
precisely determine the geographic origin of the component CRF50_A1D subtypes. 
Epidemic origins can be difficult to pinpoint if the source is geographically or 
temporally remote (Pybus and Rambaut, 2009); more extensive sampling of these 
strains, in the right genetic region, would also assist in arriving at a more precise 
determination. Speculation regarding likely candidate countries would involve 
Kenya, as the predominant circulating subtype is A1, but a high recombination rate 
is evident and the country borders others where other subtypes are prominent 
(Dowling et al., 2002; Hué et al., 2012; Land et al., 2008). 
The analysis of the pol gene global trees showed that the CRF50_A1D sequences 
clustered closet to the East African strains even in the presence of subtype A1 and 
D sequences from the UK, demonstrating that CRF50_A1D was most likely 
imported into the UK as a fully-formed recombinant, rather than arising from 
recombination events in the UK itself.  
Phylogeographic analysis of the emergence and spread of CRF50_A1D showed 
emergence in Northwest England, followed by subsequent spread to London and 
Southeast England. Northwest England remained the epicentre of the strain’s 
spread, as spread to Southeast England, Northeast England and Scotland all 
occurred from this region. The analysis showed that the spread of CRF50_A1D was 
fastest within London/Southeast England. It is important to note that the likelihood of 
every person in the UK infected with CRF50 being included in the analysis is 
extremely low, meaning that the time between transmissions has almost certainly 
been overestimated (Lewis et al., 2008). Similar patterns of spread of CRFs have 
been reported in China, particularly the exchange of CRF01_AE circulating in MSM 
in the geographically close regions of Liaoning and Beijing (An et al., 2012).  The 
phylogeography was modelled using discrete transitions; using continuous 
diffusions could allow a more nuanced description of the geographic emergence of 
CRF50_A1D (Lemey et al., 2010).  
Time scaled phylogenies were performed in order to determine the time to most 
recent common ancestor of CRF50_A1D in the UK.  Multiple methods were used in 
order to ensure that the date arrived at was robust. The five full-length sequences 
were split into component subtype A1 and D regions in the gag, pol, and env genes, 
with subsequent analysis of each component; the full-length sequences were 
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analysed as a whole, and the pol region for all 72 UK CRF50_A1D cases was 
analysed as both component subtype A1 and D regions and as a concatenated 
A1/D region. 
Results for all 72 CRF50_A1D cases showed a tMRCA of 1992.46 (95%HPD 
1987.47-1998.57), which was consistent with the tMRCAs for the component A1 
and D regions of 1994.88 and 1994.36, respectively. Low topological support was 
seen in parts of the subtype D tree, but this was due to the region being highly 
conserved, as previously noted, and also the short length of the fragment under 
analysis.  
In general, the results for the individual gene subtype A1 and D regions showed low 
posterior probabilities. However, the results for the tMRCA across the regions were 
consistent overall, with a standard deviation across all genes of 2.15. The tMRCA 
when using the full-length sequences was 1995.56 (95% HPD 1990.91-1999.60), 
which was also consistent with the other dates. Conclusions drawn from small and 
local samples will underestimate dynamic complexity (Pybus and Rambaut, 2009). 
This explains why later dates of divergence are seen when using the genetic 
regions of the full-length sequences only. Therefore, we are confident that the 
predicted tMRCA for CRF50_A1D is robust.  
Gifford et al. predicted that a novel subtype A recombinant was circulating in MSM 
in the UK, with an origin date of the late 1980s/early 1990s (2007). Given the results 
of this analysis, we are confident that CRF50_A1D is the predicted novel 
recombinant. The period of origin was the period during which the HIV epidemic in 
Africa was growing particularly quickly, and is, crucially, prior to the introduction of 
HAART in the UK (Gifford at al., 2007). This period also saw a doubling of 
prevalence of HIV-1 in MSM in London, along with multiple transmissions of clusters 
(Lewis et al., 2008).  
The final sample characterised using full-length sequencing proved to be a 
B/CRF50_A1D URF. This recombinant structure was substantially more complex 
than the A1D recombinant. However, the complexity was evident outside the region 
of pol that is routinely sequenced for the evaluation of drug resistance. This further 
indicates that the proportion of recombinant specimens circulating in the UK may be 
much higher than previously suspected, and also highlights the inherent difficulties 
in resolving recombinant HIV-1 sequences to parental strains. 
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 The time-scaled analyses including the URF showed that the URF was the product 
of onward recombination between a CRF50_A1D infection and a subtype B strain. 
The index CRF50_A1D case for this recombination was not identified during this 
study, indicating that additional instances of this strain exist in the UK. This was 
supported by the Bayesian skyline analysis, which predicted a number of effective 
infections in the low hundreds. This, in addition to the evidence for CRF50_A1D 
creating further novel CRFs and the possible export to Canada of CRF50_A1D that 
was discovered during the cluster analysis, demonstrates that newly recombinant 
strains can rapidly become established and significantly change the genetic 
landscape of HIV-1 infections.  
It has been suggested that the ever-growing number of CRFs will be become 
blurred and unmanageable to the HIV research community, and that a 
nomenclature system that recognises recombination ‘families’ would more 
accurately reflect the dynamic reality of HIV-1 evolution (Zhang et al., 2010). The 
data uncovered during the course of this study supports this suggestion. This study 
was conducted using the current CRF nomenclature, which requires all sequences 
to have near-identical breakpoints. However, there were approximately 200 A1/D 
recombinant sequences in the UK HIV DRD that were very similar to CRF50_A1D, 
but did not meet the strict nomenclature criteria. As A1/D recombinants have been 
described in Europe and the UK for nearly two decades (Leitner et al., 1995), it 
seems probable that ongoing evolution has created a family of similar A1/D 
recombinants and that full elucidation of the various lineages present would be 
better understood following an investigation concentrating on the entirety of A1/D 
recombinants rather than a single group that meets the current CRF nomenclature 
criteria.     
Thorough analysis of the process by which new CRFs become established in 
communities cannot be considered complete without an investigation into the 
phenotypic properties of the recombinant virus, as mentioned above. The process of 
recombination may disrupt linked compensatory point mutations that have evolved 
to preserve viral fitness (Drummond et al., 2002; Simon-Loriere et al., 2010; Voigt et 
al., 2002), meaning that recombinants may be more, or less, fit than the sum of 
fitness of the parental strains. The final aspect of this study was a preliminary 
investigation into the likely pathogenesis of CRF50_A1D infections. Pre-ART CD4 
cell counts were obtained for 9 patients and linear regression of the CD4 decline 
slopes showed that the mean CD4 cell decline was -1.17 sq root cells/year (95% CI 
-2.29 - -0.05). When compared to the decline slopes for subtype B (-1.22, 95% CI -
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1.26 - -1.18) and subtype A (-0.61, 95% -0.79, -0.43) infections, it appeared that 
CRF50_A1D patients experience disease progression in a manner more akin to a 
subtype B infection than a subtype A infection.  
The scarcity of the data available to make this calculation was reflected in the wide 
95% CI for the mean CD4 cell decline, which meant that the data must be 
interpreted with caution. Additionally, no slopes were available for subtype D for 
comparison. Therefore, although it appears that CRF50_A1D patients experience 
disease progression in a manner more similar to subtype B than subtype A 
infections, we were unable to make any comparisons as to whether this is faster or 
slower than progression with a subtype D infection, although the current data tends 
toward agreement with that from earlier studies (Baeten et al., 2007; Huang et al., 
2007; Kaleebu et al., 2002; Kiwanuka et al., 2010). Of interest was the specific 
structure of CRF50_A1D in the env gene, which was subtype A1 in the 
hypervariable loop region. This region has specific fitness determinants, and so data 
indicating CRF50_A1D infections behave more similarly to subtype A1 than subtype 
D would be expected (Fouchier et al., 1992). 
The unusual structure of CRF50_A1D in the env  gene further indicated that this 
recombinant structure may possess interesting phenotypic or functional properties 
associated with specific breakpoint locations. This could be investigated using 
growth competition assays and other assays designed to measure specific 
determinants of viral fitness. This work was beyond the scope of the current 
investigation, but should be considered for the future.  
Another aspect for further investigation is whether the structure of CRF50_A1D 
(particularly in env) possesses properties that elicit unique host immune responses, 
such as particular adaptive mutations driven by early cytotoxic T-cell responses 
(Salazar-Gonzalez et al., 2009). Again, this work was outside the scope of the 
current study, but should be considered for the future. 
The UK HIV DRD collects nearly all sequences identified in the course of routine 
HIV care in the UK. The coverage of the database is estimated at approximately 
80% of the known HIV infected population in the UK. However, a natural limitation of 
this type of work is that only the sequences that are available can be used, i.e. there 
are inevitable gaps in the data from those who are infected and know it but have not 
been captured by routine care (or have been but have not had sequences submitted 
to the database), but more importantly, those who are infected but not yet 
diagnosed, which is still estimated as a third of the UK HIV population (HPA, 2012).  
223 
 
Therefore, work such as mapping the networks of populations or of estimating how 
many people are infected with a particular strain of HIV are necessarily incomplete. 
As universal genotyping at diagnosis increases (particularly when closer to the time 
of infection), the genotypic coverage contained in the database will improve, and 
some of the caveats that still remain in Bayesian analysis will be resolved (Brenner 
et al., 2013).  
Finally, it is important to note that in performing this type of analysis, corrections for 
the presence of drug resistance mutations in sequences is necessary, as ART leads 
to suppression of quasispecies evolution (Redd et al., 2012). Although ART history 
was not available for all patients in the UK HIV DRD, we controlled for the presence 
of ART-associated drug resistance mutations by using only the earliest sequence 
available for each patient. All downstream analyses such as full-length sequencing 
and the CD4 decline slopes were performed using confirmed pre-ART data and 
samples. 
8.1 Final conclusions 
This study reported a comprehensive investigation into emerging population 
dynamics in HIV-1 infections in the UK, using the molecular epidemiological 
analysis of subtype-unclassified HIV-1 strains captured by the UK HIV DRD. 
Investigations of this nature have the potential to have significant impacts on public 
health interventions to reduce the incidence of HIV-1 transmission. Mathematical 
modelling of HIV-1 transmission has shown that the resurgence in HIV infections 
among MSM in the UK and Europe is the result of continuing risky sexual 
behaviour, and that long term reductions in incidence will require increased and 
sustained uptake of effective interventions (van Sighem et al., 2012). However, 
interventions can be effective at either the community or the individual level, and a 
systematic review of infections in MSM in Western Europe, the US and Australia 
concluded that the mean incidence rate of 2.5% per year remained stable during 
1998-2008, indicating that interventions that are effective at the individual level are 
not having an effect at the population level (DeGruttola et al., 2010; Stall et al., 
2009). Phylogenetic analyses can elucidate the longitudinal phylodynamic structure 
of a local epidemic  and help to identify potential targets for interventions, for 
example targeted Treatment as Prevention programmes (DeGruttola et al., 2010; 
Hughes et al., 2009; Lewis et al., 2008; von Wyl et al., 2011). Integrating these 
analyses with epidemiological, clinical and demographic data will be crucial in 
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delineating the role of linkage to care, behaviour, socioeconomic factors and 
migration on transmission dynamics (Brenner et al., 2013).  
The potential for phylogenetic analyses to improve the impact of public health 
interventions is particularly relevant in the UK, where the transmission network 
among UK MSM is characterised by preferential association such that a randomly 
distributed intervention would not be expected to stop the epidemic (Leigh Brown et 
al., 2011). Many countries, including the UK, currently perform routine surveillance 
of HIV-1 prevalence and drug resistance, however phylogenetic analyses have an 
added value above these existing methods, in that phylogeographic modelling can 
identify the source of continued transmission to new geographic areas. For 
example, the phylogeographic analysis of CRF50 showed that, although the 
greatest number of transmissions were occurring in London and Southeast England, 
the source of geographic spread to London and Southeast England, Southwest 
England, Northeast England, and Scotland was Northwest England in each 
instance, even after transmission to London had occurred. This implies that an 
effective public health intervention targeting Northwest England could have 
prevented the spread of CRF50_A1D to other areas of the UK. It is this information 
that is not captured by existing surveillance programmes, but which would be 
invaluable in designing effective public health interventions.  
The spread of newly recombinant strains has implications beyond that of providing 
insights into population dynamics. Analysis of the SPREAD programme showed that 
MSM infected with a subtype B virus were significantly more likely to be infected 
with drug-resistant HIV-1 (Vercauteren et al., 2009). Increased transmission of 
newly recombinant strains, especially strains that recombine readily with subtype B, 
such as CRF50_A1D, could therefore potentially increase the rate of transmitted 
drug resistance in HIV-1 populations. There is the potential for newly recombinant 
strains to exhibit differing response profiles to newer HIV-1 drugs in development, or 
to accumulate drug resistance mutations at a faster rate than other subtypes 
(Schader et al., 2012; Soares et al., 2007); however, the evidence for this is weak 
as HIV-1 antiretroviral drugs are designed to work across the entire spectrum of 
HIV-1 genotypes, and clinical evidence suggests no genotype-based difference in 
the accumulation of drug resistance mutations. 
In addition to the opportunities for further investigations that have been detailed 
above, there are two obvious further investigations regarding the transmission and 
progression of CRF50_A1D (or other newly recombinant) infections that could be 
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performed. Firstly, next-generation sequencing to characterise the viral 
quasispecies in combination with replicative capacity assays could be used to 
incorporate a population model into an assessment of the fitness of this viral strain 
(Lauring and Andino, 2010). This approach has the advantage of combining directly 
observed phenotypic behaviour with factors such as immune escape, 
transmissibility and cellular tropism (Lauring and Andino, 2010). Quantitative 
assessment of HIV-1 evolution can be determined by measuring HIV sequence 
diversity and comparing it to a reference point e.g. the founder virus (Gall et al., 
2013). Therefore, longitudinal deep sequencing would also provide a method of 
tracking the dynamic evolution of the HIV-1 quasispecies and, ultimately, viral 
progression (Tsibris et al., 2009). 
The second investigation is an assessment of whether the burden of transmission of 
these novel recombinant strains is due to recent or established infections. Acute 
infections are particularly important in determining the evolutionary course of the 
HIV-1 epidemic, as the viruses present in acute infection are stored and 
"preferentially" transmitted (Lythgoe and Fraser, 2012). Until now, the temporal 
spread of clustered transmissions has been evaluated exclusively with respect to 
chronology and geography to improve our understanding of transmission dynamics 
in the UK (Brenner et al., 2013). The next stage to evaluate the data from this study 
would be to look at the stage of infection in of each sequence, in order to ascertain 
whether transmissions were occurring primarily between recent or established 
infections. This could be done using ambiguous nucleotides within sequences as a 
marker for viral diversity and therefore the age of infection (Kouyos et al., 2009).  
This study proposed using newly recombinant strains of HIV-1 as a proxy for the 
changing landscape of HIV-1 infection in the UK. We identified CRF50_A1D, a 
subtype A1/D recombinant that emerged in the UK in approximately 1992 from East 
African origins. The study of the extent of recombination in the UK found one year, 
2004-2005, in which a statistically significant increase in subtype-unclassified 
infections occurred. Further study of transmission clusters within these unassigned 
sequences found that 5/8 (62.5%) of clusters had a tMRCA in this time period. 
Additionally, the cluster study identified probable co-circulation of a number of 
unassigned strains in countries outside of the UK, and export of an unassigned 
strain from the UK to Italy. This, in combination with the finding that majority of 
unassigned strains investigated contained mixed ethnicities and exposure routes 
within Britain, suggests that indigenous HIV-1 transmission in the UK is of 
increasing importance, and that previous compartmentalised transmission patterns 
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will continue to blur. Continuing detailed characterisation of local epidemics will 
enable the design of public health interventions suited to responding effectively to 
these changed dynamics.      
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Chapter 9: Appendices 
 
Appendix 2-1: UK HIV DRD proposal for the analysis of unassigned 
sequences 
 
 
 
 
Analysis Proposal 
1. Title of proposal 
Analysis of the subtype unassigned sequences within the UK HIV Drug Resistance 
Database. 
 
2. Study team 
Please list all collaborators (lead investigator named first). 
Geraldine Foster (UCL/University of Liverpool) 
John Ambrose (UCL/University of Liverpool) 
Anna Maria Geretti (UCL/University of Liverpool) 
 
3. Background  
The UK HIV-1 epidemic is becoming increasingly complex in terms of the subtypes 
involved1,2,3.  This is largely due to increased immigration, especially from sub-
Saharan Africa4, but there is evidence that onward transmission of non-B subtypes 
is now occurring in the UK5 and that they may be spreading in the MSM 
population3,6. 
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The sequences in the UK HIV DRB have traditionally been subtyped using the Rega 
subtyping software tool.   This is a conservative tool that returns many 
complex/unassigned sequences. More recently, the subtyping tool SCUEAL7 has 
been used to subtype database sequences. Although it is common for different 
subtyping methodologies to exhibit discrepant classifications for a proportion of 
sequences8,9, the results from using SCUEAL have been shown to be more 
accurate than Rega when characterising complex recombinant isolates10.  However, 
even this method returns a significant proportion of unassigned sequences, which 
functions as an indicator of the increasing complexity of the epidemic, and may 
conceal unidentified circulating recombinant forms (CRFs). 
 
CRF50_A1D, which is circulating in the Men who have Sex with Men (MSM) 
community, has been recently identified11 from within the unclassified sequences in 
the UK HIV DRB, and has been shown to be contained within a sub-cluster of 
subtype A1 specimens analysed as part of the phylogeography of subtype A1 in the 
UK12.  The identification of this CRF appears to confirm the hypothesis of Gifford et 
al. in 2007 that a novel subtype A recombinant is spreading within the UK via the 
MSM community13.   
 
Ongoing monitoring of the UK HIV epidemic is an important part of the battle against 
the disease.  Knowledge of which subtypes are in circulation may inform vaccine 
design in the future14, whilst a greater understanding of transmission dynamics and 
possible differences between risk groups will feed into decision making on 
prevention and intervention strategies within different populations. 
 
References: 
1. Arnold et al. (1995) AIDS Research and Human Retroviruses 11:427-429 
2. Parry et al. (2001) Journal of Acquired Immune Deficiency Syndromes 26: 381-
388 
3. Gifford et al. (2007) Journal of Virology 81:13050-13056 
4. Health Protection Agency (2009), HIV in the United Kingdom: 2009 report 
5. Aggarwal et al. (2006). Journal of Acquired Immune Deficiency Syndromes; 
41:201-209 
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6. Ambrose et al. 17th Conference on Retroviruses and Opportunistic Infections, 
San Francisco, February 2010, Abstract 98 
7. Pond et al. (2009) PLoS Computational Biology 5 (11): e1000581  
8. Gifford et al. (2006) AIDS 20: 1521-1529 
9. Ntemgwa et al. (2008) AIDS Research and Human Retroviruses; 24 (7): 995-
1002 
10. Foster et al. 14th Annual Resistance Meeting: ‘New Directions, New 
Challenges’, London, September 2010, Abstract 
11. Foster et al. 18th Conference on Retroviruses and Opportunistic Infections, 
Boston, February 2011, Abstract 456 
12. Hue et al. Conference on Retroviruses and Opportunistic Infections, Boston, 
February 2011, Abstract 457 
13. Gifford et al. (2007). Journal of Virology; 81: 13050-13056 
14. Thomson et al. (2002). Lancet Infectious Diseases, 2:461-471 
  
4. Proposed analysis 
 
The SCUEAL analysis has indentified approximately 1400 unassigned and complex 
sequences in the UK HIV DRB.   
 
In this proposal we wish to analyse the unassigned sequences in the database, in 
order to determine whether the proportion of unassigned sequences is increasing 
relative to 2007.  Further questions will address whether the unassigned sequences 
represent the generation of new CRFs or the increasing complexity of the epidemic 
into complex URFs. The study population will be composed of people with 
complex/unassigned sequences in the UK HIV DRB.  
 
The 4 main questions we hope to address are: 
 Of the ~1400 patients with complex/unassigned sequences, what proportion of 
these can be said to represent new CRFs? 
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 When relating people with complex/unassigned infections to the whole UK HIV 
Drug Resistance Database population, can we identify further clusters or a trend 
towards the mixing of subtypes into complex URFs? 
 Is there any evidence that these complex subtypes are transmitted preferentially 
to ‘pure’ infections? 
 Is the contribution of recombination to the UK epidemic greater now than in 
2007? 
 
Our analysis will be based upon methods detailed in Gifford et al. 2007, and will 
focus on two aspects: 1) characterising the complex/unassigned sequences; 2) 
mapping these sequences to previously identified ‘pure’ subtype clusters, in order to 
assess the hitherto undetected contribution of recombination to the epidemic as a 
whole.   
1. Sequences from patients with complex/unassigned subtypes by SCUEAL from 
both the 2007 and 2010 downloads will be requested from the UK HIV Drug 
Resistance Database (UKHDRD). In the case of patients with multiple 
sequences in the database, all sequences will be requested.  
2. Where patients have multiple sequences in the database, the sequence closest 
to the time of infection will be used in the phylogenetic analysis.  
3. Sequences will be analysed for recombination subtypes and breakpoints using 
jpHMM and Simplot, using a reference alignment comprised of sequences from 
the Los Alamos HIV Database that has been screened for recombination using 
GARD. 
4. Phylogenetic analysis by maximum likelihood and Bayesian analysis will be 
used to identify any sets of complex sequences that cluster together.    
5. Sets of complex sequences that cluster together will be split into subtype-
specific fragments together with randomly selected subset of control sequences 
and all cohort and new sequences (ensuring duplicates are removed) will be 
analysed using maximum likelihood or Bayesian analyses. 
6. Sequences that cluster together with apparently identical breakpoint locations 
will be requested and characterised using full-length, single genome analysis.  It 
is our intention to request no more than 9 specimens in total, in order to comply 
with our current ethics approval that limits our total number of characterised 
specimens to 15. Specimens will only be requested if there appears to be a 
previously unidentified CRF amongst the unidentified sequences.  
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7. The number of complex sequences will be compared to the number of complex 
sequences from the 2007 download.  
8. Next, a Bayesian Monte Carlo Markov Chain approach will be used to analyse 
reduced sets of sequences (those identified by the previous analyses as 
potentially linked in transmission clusters, together with selected control 
sequences).  
9. BEAST (Drummond and Rambaut, BMC Evolutionary Biology 2007;7:214) will 
be used to construct time-scaled phylogenies of clusters, using sample dates to 
help date the tree. 
10. Major sources of complex infections within the United Kingdom will be mapped 
using grouped centre data. 
 
5. Intended start date and completion date 
12 months from approval 
6. Variables required 
Variables required from UK HIV Drug Resistance Database: 
Variable 
Name Variable Label 
id Internal patient ID 
labsampid Test identifier 
sampleno Local sample identifier 
centreid Clinic requesting test (MRC coding) 
dbsample Date of blood sample 
dob Date of birth 
lastcd4  
lastvl  
lastdate  
lastaids  
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group Treatment status when sample taken 
dupsamp Number of tests per sample 
idcheck Flag to indicate if sequence indicates wrongly matched patient 
subtype  
method Subtyping Method - (R)ega or (S)tar 
 
Further variables required (some of which may need to come from UKCHIC): 
1. pol sequences for all patients included in the database with date of 
sample/sequence (multiple sequences from the same patient to be included but 
identifiable as such) 
2. Date of HIV diagnosis 
3. Risk group 
4. Ethnic group 
5. Date of arrival in UK  
6. Suspected country of infection 
 
7. Feasibility assessment 
 
Database scanning of the 2007 UK HIV DRB download identified 5 patients that 
appeared to contain a novel recombinant.  4 patients seen at clinics in London were 
characterised using full-length single genome analysis; 3 were found to be infected 
with a novel CRF, CRF50_A1D, and 1 was infected with a recombinant of 
CRF50_A1D and subtype B1.  Geographic mapping identified a further 74 patients 
who appeared to be infected with the same recombinant.  32 of these patients were 
present in a putative subtype A cluster analysed by S. Hue. 
 
Although the size of the cohort used in this study is relatively small, the results of 
the analysis allow us to tentatively suggest a number of conclusions.  Firstly, 
unidentified CRFs can be located in the subtype unassigned sequences in the 
database. Secondly, sequences with a short recombinant fragment can be 
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misclassified as ‘pure’, indicating that the contribution of recombination to epidemic 
diversity is likely to have been underestimated.  Thirdly, non-B subtypes appear to 
be spreading within the MSM population.   
 
References: 
1. Foster et al. 18th Conference on Retroviruses and Opportunistic Infections, 
Boston, February 2011, Abstract 457 
 
8. Resource required 
We require support from the MRC-CTU and possibly UK CHIC for handling of the 
dataset. 
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Appendix 2_2: UK CHIC proposal for the analysis of CD4 decline in 
CRF50_A1D patients 
Title: Investigating the pathogenesis of CRF50_A1D. 
Submission Date: 04.05.2012 
Study Team: Geraldine Foster, Anna Maria Geretti 
 
Background: 
We recently identified CRF50_A1D, a novel HIV recombinant circulating 
predominately in the UK MSM population1. Our research suggests that this 
recombinant currently infects 72 people in the UK, who are located almost 
exclusively in north west and south east England2. 17 of these patients have data 
held in UK CHIC.  
Research from the Rakai cohort in Uganda has indicated that recombinant A/D 
infections progress faster than those with ‘pure’ A or D infections3,4,5. We would like 
to investigate the pathogenesis of CRF50 in the UK population, and propose to 
begin this analysis by analyzing the CD4 decline of the 17 patients with data in UK 
CHIC. This will be a preliminary analysis to allow us to decide whether to collect 
data from those patients who are not in CHIC. 
Aims: 
 To assess the rate of CD4 decline in CRF50 patients by mapping CD4 
slopes onto the CD4 decline slopes presented at CROI 20116  
Inclusion/Exclusion criteria: Inclusion: Infected with CRF50_A1D 
Variables required: 
 CD4 counts; Viral loads; ART history 
Possible limitations/issues that should be considered when interpreting the 
findings: 
This analysis will only involve 17/72 (23.6%) CRF50 patients, and, as such, should 
be considered preliminary. 
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Proposed time scale for analysis: 3 months from proposal approval 
Resources required: No extra resources will be required 
References 
1. Foster et al. http://www.retroconference.org/2011/Abstracts/40621.htm 2011  
2. Foster et al. Oral presentation 19th International HIV Dynamics and 
Evolution, 2012 
3. Baeten et al. J. Infect Dis 2007 
4. Kaleebu et al. J.Infect Dis 2002 
5. Kiwanuka et al. J AIDS 2010 
6. Klein et al. http://www.retroconference.org/2011/PDFs/463.pdf 2011
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Appendix 2-3: Sequencing primers used for near full-length HIV-1 single genome sequencing 
Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
Forward Primers 
1 2.U5.B4F AGTAGTGTGTGCCCGTCTGTTGTGTGACTC 552-581 CHAVI-MBSC, 2009, unpublished 
2 msf12b(+) AAATCTCTAGCAGTGGCGCCCGAACAG 623-649 Nadai et al., 2008  
3 KVL066 TCTCTAGCAGTGGCGCCCGAACAG 626-649 Van Laetham et al., 2006 
4 f2nst(+) GCGGAGGCTAGAAGGAGAGAGATGG 769-793 Nadai et al., 2008 
5 DD GTATGGGCAAGCAGGGAGCTAGAA 892-915 Nadai et al., 2008 
6 HH ATGAGGAAGCTGCAGAATGGG 1406-1426 Nadai et al., 2008 
7 II ATAATCCACCTATCCCAGTAGGAGAAAT 1544-1571 Nadai et al., 2008 
8 pro5F(+) AGAAATTGCAGGGCCCCTAGGAA 1966-2018 Nadai et al., 2008 
9 POLCLO1- GAGAGACAGGCTAATTTTTTAGGGAA 2071-2096 Nadai et al., 2008 
10 pro3F(+) AGANCAGAGCCAACAGCCCCACCA 2143-2166 Nadai et al., 2008 
11 POLoutF1(+) CCTCAAATCACTCTTTGGCARCGAC 2253-2277 Nadai et al., 2008 
12 BJPOL1 ACAGGAGCAGATGATACAGTA 2328-2348 Nadai et al., 2008 
13 POLinF1 AGGACCTACRCCTGTCAACATAATTGG 2483-2509 Nadai et al., 2008 
14 AZT3 CCAGGAATGGATGGACCAA 2589-2607 Nadai et al., 2008 
15 SP4S GGGCCTGAAAATCCATACAATACT 2700-2723 Nadai et al., 2008 
16 AZT9 TGGATGTGGGTGATGCATA 2875-2893 Nadai et al., 2008 
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Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
17 SP5S GGATTAGATATCAGTACAATGTGC 2971-2994 Nadai et al., 2008 
18 AZT6 CAATACATGGATGATTTGTATGTAGG 3093-3118 Nadai et al., 2008 
19 POLP GGATGGGATATGAACTCCATCC 3235-3256 Nadai et al., 2008 
20 DGPOLF7 GGAATATATTATGACCCATCAAAAGAC 3495-3521 Nadai et al., 2008 
21 POLU ACTTTCTATGTAGATGGGGCAGC 3864-3886 Nadai et al., 2008 
22 POLI GAGCAGTTAATAAAAAAGGAA 4116-4136 Nadai et al., 2008 
23 POLJ GAAGCCATGCATGGACAAGTAGA 4371-4393 Nadai et al., 2008 
24 POLK ACGGTTAAGGCCGCCTGTTGGTGG 4602-4625 Nadai et al., 2008  
25 POLSEQ2 CGGGTTTATTACAGGGACAGC 4899-4919 Nadai et al., 2008 
26 VIF1 GGGTTTATTACAGGGACAGCAGAG 4900-4923 CHAVI-MBSC, 2009, unpublished 
27 ACC1 TTCAGAAGTATACATCCCACTAGG 5196-5219 Nadai et al., 2008 
28 KVL008 GGTCAKGGRGTCTCCATAGAATGGA 5284-5308 Van Laetham et al., 2005 
29 VIFB ATATAGCACACAAGTAGACCCT 5319-5340 Nadai et al., 2008 
30 AV317 TCAAGCAGGACATAAYAAGGTAGG 5445-5468 Van Laetham et al., 2005 
31 VIFC GAYAAAGCCACCTTTGCCTAGTGTT 5514-5538 Nadai et al., 2008 
32 ENVoutF1 (+) AGARGAYAGATGGAACAAGCCCCAG 5550-5574 Nadai et al., 2008 
33 ACC5 TGAAACTTAYGGGGATACTTGG 5699-5720 Nadai et al., 2008 
34 ENVinF1 TGGAAGCATCCRGGAAGTCAGCCT 5861-5884 Nadai et al., 2008 
35 ENVA GGCTTAGGCATCTCCTATGGCAGGAAGAA 5954-5982 CHAVI-MBSC, 2009, unpublished 
36 ED3 TTAGGCATCTCCTATGGCAGGAAGAAGCGG 5957-5986 Nadai et al., 2008 
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Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
37 GP1205- AGAGCAGAAGACAGTGGCAATGA 6206-6228 Nadai et al., 2008 
38 Z1F TGGGTCACAGTCTATTATGGGGTACCT 6327-6353 Nadai et al., 2008 
39 ENVSEQ22 GTGTACCCACAGACCCCAGCCCACAAG 6445-6471 Nadai et al., 2008 
40 ZFF GGGATCAAAGCCTAAAGCCATGTGTAA 6559-6585 Nadai et al., 2008 
41 793SEQ1 AACACCTCAGTCATTACACAGGCC 6813-6836 Nadai et al., 2008 
42 E16 CCAATTCCCATACATTATTGTG 6858-6879 Nadai et al., 2008 
43 AV318 TGCTGYTRAATGGCAGTCTAGCAGA 7000-7024 Van Laetham et al., 2005 
44 E15 GTAGAAATTAATTGTACAAGACCC 7098-7121 Nadai et al., 2008 
45 OFM54 TTTAATTGTGGAGGGGAATTTTTCT 7350-7374 Nadai et al., 2008 
46 E13 ACAAATTATAAACATGTGGCAGG 7487-7509 Nadai et al., 2008 
47 JL109 GTGAATTATATAAATATAAAGTAG 7668-7689 Nadai et al., 2008 
48 TUG GTCTGGTATAGTGCAACAGCA 7859-7879 Nadai et al., 2008 
49 ZLF GGGATAACATGACCTGGATGCAGTGGG 8092-8118 Nadai et al., 2008 
50 JL104 GGAGGCTTGATAGGTTTAAGAATA 8292-8315 Nadai et al., 2008 
51 JL106 TTCAGCTACCACCGCTTGAGAGACT 8520-8544 Nadai et al., 2008 
52 NEF7 TAAGATGGGTGGCAAGTGGTCCAAAA 8793-8818 Nadai et al., 2008 
53 NEF6 AGCAGCAGATGGGGTGGGAGCAG 8871-8893 Nadai et al., 2008 
54 LTR2 TTTGGATGGTGCTACAAGCTA 9211-9231 Designed using Primer3 
Reverse primers 
55 JL19 CTTCTATTACTTTTACCCATGC 1249-1270 Nadai et al., 2008 
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Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
56 JL17 CATTCTGCAGCTTCCTCATTGAT 1402-1424 Nadai et al., 2008 
57 SP2AS GGTGGGGCTGTTGGCTCTG 2147-2165 Nadai et al., 2008 
58 SP3AS CCTCCAATTCCCCCTATCATTTTTGG 2382-2407 Nadai et al., 2008 
59 KVL067 GGCCATTGTTTAACYTTTGGDCCATCC 2597-2623 Van Laetham et al., 2006 
60 SP4AS AGTATTGTATGGATTTTCAGGCCC 2700-2723 Nadai et al., 2008 
61 KVL065 TCCTAATTGAACYTCCCARAARTCYTGAGTTC 2797-2828 Van Laetham et al. 
62 POLC- CTAGGTATGGTAAATGCAGTATA 2928-2950 Nadai et al., 2008 
63 AZT10 CCTACATACAAATCATCCATGTATTG 3093-3118 Nadai et al., 2008 
64 AZT5 TCAGATCCTACATACAAATCATCCATGTATTG 3093-3124 Nadai et al., 2008 
65 AZT4 TATAGGCTGTACTGTCCATTT 3261-3281 Nadai et al., 2008 
66 POLEE- TGTATGTCATTGACAGTCCAGCTG 3299-3322 Nadai et al., 2008 
67 proRT TTTCCCCACTAACTTCTGTATGTCATTGACA 3308-3338 Nadai et al., 2008 
68 RT3473R (-) GAATCTCTCTGTTTTCTGCCAGTTC 3453-3477 Nadai et al., 2008 
69 POLSEQ3 GATATGWCCACTGGTCTTGCCC 3546-3567 Nadai et al., 2008 
70 DGPOL3R GTATTGACAAACTCCCAGTCAGGAAT 3780-3805 Nadai et al., 2008 
71 POLI- TTTGTGTGCTGGTACCCATGCCAG 4146-4169 Nadai et al., 2008 
72 POLT- GCAGTCTACTTGTCCATGCATGGC 4374-4397 Nadai et al., 2008 
73 SP1AS GGATGAATACTGCCATTTGTACTGC 4752-4776 Nadai et al., 2008 
74 DGPOL2R CACTATTGTCTTGTATTACTAC 4974-4995 Nadai et al., 2008 
75 ACC2 AGGGTCTACTTGTGTGYTATAT 5319-5340 Nadai et al., 2008 
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Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
76 ACC6 GCTTGTTCCATCTRTCYTCTGTYAG 5545-5569 Nadai et al., 2008 
77 ACC4 CCAAGTATCCCCRTAAGTTTCA 5699-5720 Nadai et al., 2008 
78 ACC8R TCTCCGCTTCTTCCTGCCATAG 5968-5989 Nadai et al., 2008 
79 VIF-VPUinR1 CTCTCATTGCCACTGTCTTCTGCTC 6207-6231 Nadai et al., 2008 
80 ES33 CATTGCCACTGTCTTCTGCTC 6207-6227 Nadai et al., 2008 
81 VIF-VPUoutR1 (-) GGTACCCCATAATAGACTGTRACCCACAA 6324-6352 Nadai et al., 2008 
82 JL99 TTTAGCATCTGATGCACAAAATAG 6378-6401 Nadai et al., 2008 
83 AENVSEQ4 CAAGCTTGTGTAATGGCTGAGG 6817-6838 Nadai et al., 2008 
84 TUE3 TCCTTCTGCTAGACTGCCATTTA 7006-7028 Nadai et al., 2008 
85 JL98 AGAAAAATTCCCCTCCACAATTAA 7351-7374 Nadai et al., 2008 
86 JL102 GATGGGAGGGGCATACAT 7509-7524 Nadai et al., 2008 
87 EDS8 CACTTCTCCAATTGTCCCTCA 7648-7668 Nadai et al., 2008 
88 AV323 CTGCTCCYAAGAACCCAA 7783-7800 Van Laetham et al., 2005 
89 TUH GCCCCAGACTGTGAGTTGCAACAGATG 7914-7940 Nadai et al., 2008 
90 FM116 CAGAGATTTATTACTCCAACTA 8060-8081 Nadai et al., 2008 
91 ENVSEQ6 CCTGCCTAACTCTATTCAC 8337-8355 Nadai et al., 2008 
92 E8 CTCTCTCTCCACCTTCTTCTTC 8424-8445 Nadai et al., 2008 
93 JL71 TTTTGACCACTTGCCACCCAT 8797-8817 Nadai et al., 2008 
94 AV319 GCTSCCTTRTAAGTCATTGGTCT 9025-9047 Van Laetham et al., 2005 
95 JL89 TCCAGTCCCCCCTTTTCTTTTAAAAA 9064-9089 Nadai et al., 2008 
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Number Primer Name Sequence 5’-3’ HXB2 co-ordinates Source 
96 KVL009 GCCAATCAGGGAAGWAGCCTTGTGT 9145-9169 Van Laetham et al., 2005 
97 nefyn05 (-) GTGTGTAGTTCTGCCAATCAGGGAA 9157-9181 Nadai et al., 2008 
98 UNINEF 7’ (-) GCACTCAAGGCAAGCTTTATTGAGGCTT 9605-9632 Nadai et al., 2008 
99 OFM19 GCACTCAAGGCAAGCTTTATTGAGGCTTA 9604-9632 CHAVI-MBSC, 2009, unpublished 
100 2.R3.B6R TGAAGCACTCAAGGCAAGCTTTATTGAGGC 9607-9636 CHAVI-MBSC, 2009, unpublished 
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Appendix 5_1: Amplification of specimen 11762 
Although sufficient volume of specimen 11762 to extract 20,000 copies was 
received, the specimen did not amplify in a manner suggesting near-ideal 
extraction/RT success. 
 
 
a) Initial amplification. 20,000 RNA copies were extracted and reverse 
transcribed. The specimen was amplified using 16 replicates of neat 
cDNA, 32 replicates of cDNA diluted 1:20 and 46 replicates of a 1:100 
cDNA dilution. Two ntc wells were run. Lane 1 of each row contains 
Hyperladder I. Top row: lanes 2 - 17 contain the neat cDNA, lanes 18-33 
contain 1:20 dilution. Middle row: lanes 2 - 17 contain the 1:20 dilution, and 
lanes 18 - 33 contain the 1:100 dilution. Bottom row: Lanes 2 - 31 contain 
the 1:100 dilution and lanes 32 - 33 contain the ntc replicates. Only one 
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reaction using neat cDNA is positive; no other positive reactions are 
present. 
b) Subsequent amplification. The remaining plasma was used to extract 
10,443 RNA copies. Following reverse transcription, the specimen was 
amplified using 16 replicates of neat cDNA, 32 replicates of 1:4 diluted 
cDNA, and 32 replicates of 1:20 diluted cDNA. 16 replicates of the original 
extraction amplified in a) was amplified in parallel. Lane 1 of each row 
contains Hyperladder I. Top row: lanes 2 - 17 contain the original neat 
cDNA; lanes 18 - 33 contain the new neat cDNA. Middle row: lanes 2 - 33 
contain the 1:4 diluted cDNA. Bottom row: lanes 2 - 33 contain the 1:100 
dilution.  3/16 positive reactions are seen using the original cDNA 
extraction, 3/16 positive reactions are present using the new neat cDNA, 
and no positive reactions using the 1:4 or 1:20 dilution are present.   
Subsequent Sanger sequencing was performed using the positive 
reactions from the original extraction.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
259 
 
Appendix 6_1: CRF50 sequences, genotyping results and breakpoint 
location 
ID Sample 
date 
jpHMM 
result 
jpHMM 
breakpoint 
SCUEAL 
result 
SCUEAL 
breakpoint 
33365 2003.29 A1/D 2489 A1/D 2465 
8179 200.54 A1/D 2489 A1/D 2465 
40534 2003.29 A1/D 2489 A1/D 2465 
11762 2010.21 A1/D 2487 A1/D 2465 
12792 2010.54 A1/D 2498 A1/D 2465 
129767 2000.79 A1/B 2496 A1/D 2465 
118019 2002.04 A1/D 2504 A1/D 2465 
92050 2003.29 A1/B 2505 A1/D 2465 
141509 2003.38 A1/B 2489 A1/D 2465 
133564 2003.54 A1/D 2504 A1/D 2465 
108052 2003.54 A1/B 2490 A1/D 2489 
110018 2004.04 A1/D 2489 A1/D 2465 
134946 2004.71 A1/D 2504 A1/D 2465 
97391 2005.13 A1/B 2515 A1/D 2465 
102936 2005.21 A1/D 2504 A1/D 2465 
93054 2005.54 A1/B 2489 A1/D 2473 
142422 2005.71 A1/B 2505 A1/D 2484 
100178 2005.71 A1/B 2505 A1/D 2484 
102174 2005.71 A1/D 2489 A1/D 2479 
138730 2006.04 A1/D 2504 A1/D 2465 
125935 2006.04 A1/B 2505 A1/D 2465 
141321 2006.13 A1/D 2504 A1/D 2465 
103799 2006.21 A1/B 2505 A1/D 2474 
107137 2006.29 A1/B 2505 A1/D 2465 
91340 2006.46 A1/B 2489 A1/D 2465 
109054 2006.54 A1/B 2489 A1/D 2465 
134450 2006.54 A1/B 2513 A1/D 2484 
141058 2006.63 A1/B 2490 A1/D 2484 
143060 2006.63 A1/B 2505 A1/D 2465 
107838 2006.63 A1/D 2485 A1/D 2484 
145478 2006.71 A1/B 2491 A1/D 2465 
99870 2006.79 A1/B 2505 A1/D 2465 
106138 2006.79 A1/B 2489 A1/D 2465 
107730 2006.79 A1/B 2491 A1/D 2465 
127533 2006.88 A1/B 2490 A1/D 2465 
118453 2007.04 A1/B 2489 A1/D 2465 
144994 2007.04 A1/B 2505 A1/D 2484 
140410 2007.04 A1/D 2504 A1/D 2465 
121724 2007.04 A1/B 2505 A1/D 2465 
145903 2007.04 A1/D 2489 A1/D 2465 
132904 2007.13 A1/B 2490 A1/D 2465 
110110 2007.21 A1/B 2505 A1/D 2484 
108721 2007.21 A1/D 2504 A1/D 2465 
103364 2007.38 A1/B 2505 A1/D 2465 
92971 2007.38 A1/D 2504 A1/D 2465 
138786 2007.46 A1/B 2489 A1/D 2465 
109993 2007.46 A1/B 2497 A1/D 2465 
91853 2007.54 A1/B 2489 A1/D 2465 
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ID Sample 
date 
jpHMM 
result 
jpHMM 
breakpoint 
SCUEAL 
result 
SCUEAL 
breakpoint 
135349 2007.63 A1/D 2504 A1/D 2465 
129432 2007.71 A1/B 2496 A1/D 2465 
102695 2007.79 A1/B 2489 A1/D 2465 
114465 2007.79 A1/B 2489 A1/D 2465 
96930 2007.79 A1/B 2505 A1/D 2465 
141595 2007.88 A1/D 2504 A1/D 2465 
135766 2007.96 A1/D 2504 A1/D 2465 
103741 2008.04 A1/D 2504 A1/D 2465 
111029 2008.13 A1/D 2504 A1/D 2465 
102569 2008.21 A1/D 2489 A1/D 2473 
125047 2008.38 A1/B 2491 A1/D 2465 
122007 2008.46 A1/D 2534 A1/D 2465 
120030 2008.54 A1/B 2505 A1/D 2465 
134766 2008.63 A1/D 2489 A1/D 2465 
110602 2008.63 A1/D 2489 A1/D 2473 
123511 2008.71 A1/B 2490 A1/D 2465 
119404 2008.79 A1/D 2489 A1/D 2465 
114012 2008.88 A1/B 2494 A1/D 2465 
115813 2008.88 A1/B 2505 A1/D 2465 
121059 2008.96 A1/B 2490 A1/D 2484 
103294 2008.04 A1/B 2505 A1/D 2465 
137893 2008.38 A1/B 2489 A1/D 2465 
103571 2006.79 A1/B 2505 A1/D 2465 
114916 2012.21 A1/D 2489 A1/D 2465 
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Abstract
Background: An increase in non-B HIV-1 infections among men who have sex with men (MSM) in the United Kingdom (UK)
has created opportunities for novel recombinants to arise and become established. We used molecular mapping to
characterize the importance of such recombinants to the UK HIV epidemic, in order to gain insights into transmission
dynamics that can inform control strategies.
Methods and Results: A total of 55,556 pol (reverse transcriptase and protease) sequences in the UK HIV Drug Resistance
Database were analyzed using Subtype Classification Using Evolutionary Algorithms (SCUEAL). Overall 72 patients shared
the same A1/D recombination breakpoint in pol, comprising predominantly MSM but also heterosexuals and injecting drug
users (IDUs). In six MSM, full-length single genome amplification of plasma HIV-1 RNA was performed in order to
characterize the A1/D recombinant. Subtypes and recombination breakpoints were identified using sliding window and
jumping profile hidden markov model approaches. Global maximum likelihood trees of gag, pol and env genes were drawn
using FastTree version 2.1. Five of the six strains showed the same novel A1/D recombinant (8 breakpoints), which has been
classified as CRF50_A1D. The sixth strain showed a complex CRF50_A1D/B/U structure. Divergence dates and
phylogeographic inferences were determined using Bayesian Evolutionary Analysis using Sampling Trees (BEAST). This
estimated that CRF50_A1D emerged in the UK around 1992 in MSM, with subsequent transmissions to heterosexuals and
IDUs. Analysis of CRF50_A1D/B/U demonstrated that around the year 2000 CRF50_A1D underwent recombination with a
subtype B strain.
Conclusions: We report the identification of CRF50_A1D, a novel circulating recombinant that emerged in UK MSM around
1992, with subsequent onward transmission to heterosexuals and IDUs, and more recent recombination with subtype B.
These findings highlight the changing dynamics of HIV transmission in the UK and the converging of the two previously
distinct MSM and heterosexual epidemics.
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Introduction
The dynamics of the HIV epidemic are changing in the United
Kingdom (UK). By the end of 2010, approximately 91,500 people
were estimated to be living with HIV, including 40,100 men who
have sex with men (MSM), 47,000 heterosexual men and women
and 2,300 injecting drug users (IDUs) [1]. In previous years,
heterosexual infections, which were mostly imported, had over-
taken infections in MSM, 81% of which are indigenously
acquired. However, the trend has now reversed, reflecting a
decline in the number of infections acquired abroad, and a
corresponding increase in the number of infections acquired in the
UK [1]. These changes have considerable potential to modify
established epidemic patterns.
Mapping the molecular epidemiology of HIV infection can
provide valuable insights into transmission networks and thereby
inform prevention and containment strategies.
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As seen in other Western countries, including Italy and the
United States [2,3], in the UK the HIV epidemic among MSM
was traditionally composed of nearly uniformly subtype B
infections, contrasting with the variety of non-B subtypes found
in heterosexual infections, which are predominantly imported
from sub-Saharan Africa [4,5]. Non-B infections have been
increasing in recent years in MSM [2,6,7]. Under favorable
conditions such as those found in populations at risk of multiple
HIV exposures, novel recombinant strains can emerge and
become established, supplanting previous patterns of infection.
The emergence of recombinant HIV-1 strains among UK MSM
was proposed by Gifford et al. in 2007, based upon the detection of
a potentially novel subtype A recombinant in phylogenetic
analyses of pol gene sequences [6].
The aim of this study was to seek firmer evidence that novel
recombinant forms of HIV are emerging in the UK MSM
population. Through the screening of a large national database
containing reverse transcriptase and protease sequences from
patients undergoing drug resistance testing in routine care, and
subsequent near full-length, single genome sequencing (SGS) of
clinical isolates, we identified a novel A1/D circulating recombi-
nant form, now registered as CRF50_A1D, which first emerged in
the UK around 1992. We show that over time, CRF50_A1D
spread geographically and entered heterosexual and IDU trans-
mission networks, followed by recombination with a subtype B
strain and emergence of the unique recombinant form (URF)
CRF50/B/U. These findings indicate that the two previously
distinct HIV epidemics in MSM and heterosexuals have started to
converge in the UK, creating opportunities for greater HIV
genetic diversification.
Methods
Study population
The UK HIV Drug Resistance Database (HIV-DRD) (http://
www.hivrdb.org.uk/) and Public Health England (previously the
Health Protection Agency) provided access to pol sequences and
demographic and clinical data. The HIV-DRD is a national
repository of protease and reverse transcriptase sequences
obtained by Sanger sequencing in patients undergoing drug
resistance testing in routine care. At the time of the analysis, there
were 55,556 sequences in the database from both antiretroviral
treatment (ART)-naı¨ve and ART-experienced patients. Based
upon data from Gifford et al. indicating that a potentially novel
subtype A (sub-subtype A1) recombinant was circulating among
MSM in the UK [6], sequences from patients infected with sub-
subtype A1 were selected from the database for further analysis.
The REGA Subtyping tool and bootscanning analysis using
Simplot v3.5.1 were used to subtype recombinant sequences [8].
Subsequent subtyping was performed using Subtype Classification
Using Evolutionary Algorithms (SCUEAL) [9]. Stored plasma
samples from six selected patients were retrieved for further
sequence analysis.
Ethics statement
The Ethics Committee of the Royal Free Hospital in London
approved the anonymized use of stored plasma samples collected
during routine care. Personnel from the HIV-DRD selected
patients with different identifiers that attended centers with more
than 1000 patients in follow-up and were not known to be related,
and communicated the HIV-DRD identifier to the center of care
to allow sample retrieval from storage. Samples were anonymized
prior to shipment to the laboratory for sequencing.
Near full-length single genome sequencing
Near full-length SGS was performed using a protocol adapted
from the Centre for HIV/AIDS Vaccine Immunology (CHAVI-
MBSC 2009, unpublished) and optimised for plasma specimens
with low HIV-1 RNA levels. Briefly, 140 ml of plasma was adjusted
through either dilution or centrifugation to contain 20,000 HIV-1
RNA copies. RNA was extracted using the QiAmp Viral RNA
Mini kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions, with a final elution volume of 65 ml. All
extracted RNA was immediately transcribed with Superscript III
First Strand Synthesis Supermix (Life Technologies, Paisley, UK)
using the following protocol per reaction: 0.25 mM of reverse
primer 1.R3.B3R 59-ACTACTTGAAGCACTCAAGGCAAGC-
TTTATTG (CHAVI-MBSC 2009, unpublished), 1.87 ml nuclease
free water, 2.5 ml annealing buffer and 15 ml (5,000 copies) RNA
template were denatured at 65uC for 5 minutes. Reactions were
placed on ice for at least 1 minute before adding 25 ml of reaction
mixture and 5 ml of enzyme mixture. Reverse transcription was
performed at 50uC 90 minutes, 55uC 90 minutes, 85uC 5 min-
utes. An extra 2 ml of Superscript III RT Enzyme was added prior
to increasing the temperature to 55uC.
A two-step protocol was used to ensure single genome
amplification. The first step was a limiting dilution to assess that
cDNA was amplifying at rates suggesting near-ideal extraction and
reverse transcription conditions, i.e. that the undiluted cDNA
contained 100 copies/ml. Following this, cDNA was amplified
using a 1:200 cDNA dilution (a theoretical input of 1 copy/
reaction). In circumstances where the extracted number of HIV-1
RNA copies was below 20,000 copies, or the limiting dilution plate
suggested that the sample was amplifying suboptimally, dilutions
were adjusted accordingly.
Both first round and nested PCR reactions used the Platinum
PCR Supermix High Fidelity Kit (Life Technologies, Paisley, UK).
First round reactions comprised 45 ml PCR supermix, 0.25 mM
each forward primer 1.U5.B1F 59CCTTGAGTGCTTCAAG-
TAGTGTGTGCCCGTCTGT and reverse primer 1.R3.B3R,
0.5 ml nuclease free water and 2 ml cDNA. Cycling conditions
were 94uC 2 minutes, followed by 40 cycles of 94uC 15 s, 60uC
30 s, 68uC 9.5 m, and a final extension at 68uC 20 minutes.
Nested PCR reactions were identical to the first round reactions,
excepting the use of forward primer 2.U5.B4F 59-AG-
TAGTGTGTGCCCGTCTGTTGTGTGACTC, reverse primer
2.R3.B6R 59-TGAAGCACTCAAGGCAAGCTTTATTGAGGC,
and 45 cycles of PCR. The resulting 9 kb product spanned HXB2
nucleotides 552–9636.
Positive nested PCR reactions were identified using 1% agarose
gel electrophoresis. Filtered PCR products were directly sequenced
using fluorescently labeled dideoxy chain terminators (BigDye
Terminator v3.1 Cycle Sequencing Assay, Life Technologies) and
an automated ABI 37306l sequencer. Sequencing primers were
either sourced from the in-house protocols of the Molecular
Biology and Sequencing Core at the Centre for HIV/AIDS
Vaccine Immunology or protocols available in published literature
[10–12], or designed using Primer3 version 4.0 (http://frodo.wi.
mit.edu/primer3) (Supplementary information 1). Sequencing
reactions were repeated until near full bi-directional coverage
was obtained, and sequences were assembled using SeqScape
version 2.6 software (Life Technologies). Fragment sequences from
individual sequencing primers were examined for mixed bases;
where evidence of amplification of .1 target molecule was found,
amplification and sequencing was repeated.
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Phylogenetic and recombination analyses
Recombination analyses and subtype assignation was performed
using the Recombinant Identification Program (RIP) (http://
www.hiv.lanl.gov/content/sequence/RIP/RIP.html), jpHMM
(http://jphmm.gobics.de) and Simplot [13]. For RIP and Simplot
analyses, a window size of 400 bp and a step size of 20 were used.
Sequences were gap-stripped and genetic distances were calculated
using Kimura 2-p parameters. Simplot analyses were performed
using a full-length reference alignment of 78 pure subtype
sequences. Bootscanning of the query sequence was performed
using subtypes A1, B, D, and F2 with informative sites analysis.
Recombination breakpoints were set using the highest statistically
significant X2 value around the 50% crossover point between
subtypes. The statistical significance of the identified breakpoints
was assessed using Fisher’s exact test. Following breakpoint
assignment, slices of the alignment corresponding to putative pure
subtype regions between each breakpoint were created and saved
for downstream analyses. Likelihood mapping of each slice was
used to assess phylogenetic signal prior to maximum likelihood
analysis and was performed using TreePuzzle [14].
Likelihood parameters for each putatively pure subtype region
of the HIV genome were estimated using PAUP version 4.0
(Sinauer Associates, Massachusetts, USA). Maximum likelihood
analysis was performed using the PhyML implementation housed
at the ATGC server (http://www.atgc-montpellier.fr/phyml/).
1000 bootstrapping replicates were performed, with the exception
of alignment slices 5 and 8, which were restricted to 100 replicates
to limit computational requirements.
Phylogenetic trees were visualized using Dendroscope version
2.3 (available from http://ab.inf.uni-tuebingen.de/data/software/
dendroscope3/download/welcome.html) and FigTree v1.3.1
(http://tree.bio.ed.ac.uk/software/figtree/). Schematics of final-
ized recombinant structures were drawn using the Recombinant
HIV-1 Drawing Tool (RDT), available from the Los Alamos
website (http://www.hiv.lanl.gov/content/sequence/DRAW_CRF/
recom_mapper.html).
Beyond full-length sequencing, further instances of
CRF50_A1D infections were identified using BLAST to compare
three representative CRF50_A1D sequences (33365, 8179, 40534)
to the sequences contained in the HIV-DRD. The top 500 hits for
each sequence were analyzed for recombination profiles and
breakpoints using jpHMM and SCUEAL. Sequences with
identical subtype classifications and with a jpHMM breakpoint
that fell within the SCUEAL 95% confidence interval were
considered CRF50_A1D matches for further investigation.
The likely global origin of the parental subtype A1 and D strains
of CRF50 was investigated using global subtype alignments
containing subtype A1 or D sequences from every country in
the Los Alamos National HIV Database with a greater than 10%
representation of either subtype. These sequences were selected by
geographical region only and no further data was sought. One
alignment for each subtype was generated for partial gag, pol, and
env genes. The pol gene trees were supplemented with pure subtype
A and D sequences from the HIV-DRD. Approximate maximum
likelihood analysis was performed using FastTree 2.1 using a
GTR+CAT model (http://meta.microbesonline.org/fasttree/).
The emergence and distribution of identified CRF50_A1D
sequences in the UK was analyzed using time-scaled analyses
implemented in BEAST. The 72 putative CRF50_A1D sequences
were aligned with 8 reference A1 and D sequences from East
Africa, the 4 closest sequence matches in the NCBI database, and
4 subtype C sequences as an outgroup. A total of 36MCMC runs
of 16108 states were performed and combined for each analysis.
The GTR+C nucleotide model was used with a relaxed, log-
normal molecular clock and a Bayesian skyline coalescent with a
constant population distribution and 10 skyline groups. For
discrete phylogeographic analyses phylogeographic operators as
detailed in (http://beast.bio.ed.ac.uk/Discrete_Phylogeographic_
Analysis) were used with a resampled time-scaled tree as input. In
order to preserve patient anonymity, the locations of individual
clinics were not used as inputs into the phylogeographic analysis.
Instead, the geographic location for patients was determined using
aggregated center data which groups clinics together in approx-
imate locations; the central latitude/longitude point of each
aggregate was used as patient location. Following BEAST analysis,
phylogeographic trees were converted to .kml format and
visualized in Google Earth.
The A1/D recombinant structure was registered with the Los
Alamos National Database as CRF50_A1D. All six full-length
sequences were submitted to Genbank (accession numbers:
JN417236-JN417241); the reference sequence for CRF50_A1D
is JN417236.
Results
Identification and amplification of putative novel
recombinant sequences
Following screening of 55,556 HIV-1 pol gene sequences in the
HIV-DRD, sequences from eight subjects were identified that
appeared to share a novel recombinant structure. Stored plasma
samples from six of these eight subjects were retrieved from three
centers in the UK. The samples had been collected between 2000
and 2011 and stored at 280uC under routine conditions. The
HIV-1 RNA load measured at the time of sample collection
ranged from 9,148 to 500,000 copies/ml and the available sample
volumes ranged from 270 to 1500 ml. The optimal 20,000 HIV-1
RNA copies for sequencing were recovered from three of the six
samples; all six specimens, however, were successfully amplified at
lower than the 30% Poisson distribution set-point for single
genome amplification following limiting dilution.
Recombination analyses
RIP analysis of six specimens showed a putatively identical A1/
D structure with five of the six clinical isolates analyzed (33365,
8179, 40534, 11762, 12792); the sixth isolate (34567) showed a
complex A1/B/D structure (data not shown). jpHMM analysis
similarly identified five isolates with largely identical A1/D
structures (33365, 8179, 40543, 11762, 12792) and one isolate
with a complex A1/A2/D/B/U structure (34567) (Figure 1). The
Figure 1. jpHMM analysis of six recombinant HIV-1 sequences. Putative recombinant HIV-1 sequences were submitted to the online
implementation of jpHMM at the GOBICS server. The program used its own stored reference alignment and statistical algorithm to determine
subtype classifications, breakpoint locations and 95% confidence intervals. Breakpoint locations and confidence intervals are marked on each plot
and are equivalent to HXB2 numbering. In each plot, subtype A1 is represented in red, subtype A2 in coral (plot d only), subtype D in lavender, and
subtype B in blue (plot d only). Areas of subtype uncertainty are grey. Five specimens (a, b, c, e, and f) showed largely identical A1/D structures,
whereas one specimen (d) showed a complex A1/A2/D/B/U structure. a) Specimen 33365; b) Specimen 8179; c) Specimen 40534; d) Specimen 34567;
e) Specimen 11762; f) Specimen 12792.
doi:10.1371/journal.pone.0083337.g001
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breakpoint locations for the five A1/D specimens are summarized
in Table 1. Generally, the jpHMM breakpoint locations and
subtype classifications showed a good level of consistency among
the five A1/D specimens, and with the structure suggested by the
RIP screening. Two potential structural discrepancies were
suggested by jpHMM. With specimen 11762, the p2–p7 regions
of gag showed a lower degree of subtype A1 identity than observed
with the other four A1/D specimens; however, overlapping
confidence intervals indicated that the uncertainty was unlikely
to reflect a true structural difference. With specimens 33365 and
12792, two regions of env were designated as subtype D/uncertain
in the jpHMM plots; however bootscanning of these regions
confirmed the subtype D classification (Figure 2).
Breakpoints identified using bootscanning and informative sites
analyses were consistent with those identified using jpHMM. All
five A1/D specimens (33365, 8179, 40534, 11762, 12792) showed
identical bootscanning plots, with five subtype A1 regions and four
subtype D regions.
The jpHMM analysis of specimen 34567 further clarified the
recombinant structure of this complex isolate. Two clear regions
with the same structure as the five A1/D specimens were
identified, at the very beginning of gag, which had an identical
A1/D breakpoint (116268), and from the breakpoint in tat/rev
(5983623) to the end of the genome. This suggested that this
specimen resulted from a further recombination event between the
A1/D recombinant and a subtype B strain.
Maximum likelihood analyses
Maximum likelihood trees of putative non-recombinant frag-
ments drawn using PhyML with PAUP-defined parameters
showed that each fragment of each specimen clustered with the
pure subtype (A1 or D) indicated by the bootscanning analysis.
Results obtained with A1/D specimens 33365, 8179, and 40534,
and complex specimen 34567 are shown in Figure 3. The A1/D
structure was predominantly subtype A1 in pol and the accessory
genes; subtype D in env; and fairly evenly split between subtype A1
and D in gag. Three breakpoints were located in gag, one in pol, one
in tat/rev, and three in env, respectively. In gag, a breakpoint was
located at either end of p24, suggesting that the entire coding
region for the antigen was swapped in the recombination event.
Similarly, the third breakpoint was located at the junction of the
p7/p1 regions, suggesting that entire coding regions were swapped
in the recombination event. The distribution of subtypes in gag by
protein was A1 (p17, p2, p7) and D (p24, p1, p6).
The single D/A1 breakpoint in pol was located approximately
250 bp from the start of the protease; the remainder of the pol gene
was subtype A1, as were vif and vpr. The breakpoint located at
HXB2 6007 fell in the overlap of tat and rev; both of these genes
were A1/D mosaics. Vpu was solely subtype D. Although env was
largely subtype D, three of the hypervariable regions (V1–V3)
were subtype A1.
The maximum likelihood analysis confirmed that the A1/D
isolates clustered monophyletically across the entire genome
(Figure 3). The complex isolate 34567 clustered with the A1/D
isolates in 7/9 genomic regions; in 2/9 regions this specimen
clustered with subtype B reference sequences, confirming that this
specimen was a recombinant of the A1/D structure and a subtype
B infection (Figures 3 and 4).
Emergence and distribution of CRF50_A1D
Analysis of the UK HIV-DRD identified a further 67 sequences
showing a recombination profile that matched that of
CRF50_A1D. The global approximate maximum likelihood trees
were built using sequences from East Africa (Kenya, Tanzania,
Rwanda, Uganda, Burundi), Central Africa (DRC), Western
Africa (Cameroon), Eastern Europe (Latvia, Belarus, Georgia,
Russia) and the UK, due to the prevalence of subtypes A and D in
these regions. In the approximate maximum likelihood analysis of
global alignments of gag, pol and env gene subtype A and D
sequences the CRF50 sequences clustered monophyletically with
Figure 2. Bootscanning plots for five A1/D recombinants. Bootscanning plots from Simplot sliding window analysis using a window size of
400 bp, a step size of 20 bp and 100 bootscanning replicates. The y axis shows the percentage of permuted trees that the query sequence clustered
with the closest subtype match from the reference alignment. The x axis shows the nucleotide position of the sequence (not HXB2 numbering).
Subtype A is represented in red, subtype D in lavender, and subtype F (outgroup) in grey. All five specimens (33365, 8179, 40534, 11762, 12792)
showed identical bootscanning plots, with five subtype A1 regions and four subtype D regions. A) Specimen 33365; b) Specimen 8179; c) Specimen
40534; d) Specimen 11762; e) Specimen 12792.
doi:10.1371/journal.pone.0083337.g002
Table 1. jpHMM-assigned breakpoint locations (with 95% confidence intervals) for five HIV-1 A1/D recombinant sequencesa.
Break point Study number Gene Region
33365 8179 40534 11762 12792
1 1162 (1154–1170) 1159 (1147–1171) 1167 (1148–1186) 1177 (1154–1200) 1156 (1141–1171) gag p24
2 1843 (1809–1877) 1844 (1809–1879) 1844 (1809–1879) 1958* (1811–2105) 1828 (1809–1847) gag p24
3 2089 (2047–2131) 2078 (2046–2110) 2078 (2046–2110) 2078 (2046–2110) 2056 (2002–2110) gag p1
4 2489 (2463–2515) 2489 (2465–2515) 2489 (2465–2515) 2487 (2475–2499) 2598{ (2463–2733) pol PR
5 5981 (5951–6011) 5979 (5953–6005) 5976 (5951–6001) 5985 (5973–5997) 5998 (5989–6007) tat/rev
6 6551 (6543–6559) 6551 (6543–6559) 6551 (6543–6559) 6551 (6539–6563) 6551 (6543–6559) env gp120
7 7247 (7234–7260) 7246 (7231–7261) 7249 (7232–7266) 7483 (7471–7495) 7214 (7171–7257) env gp120
8 8679 (8664–8694) 8672 (8651–8693) 8679 (8663–8695) 8674 (8662–8686) 8678 (8663–8693) env gp41
aBreakpoint locations as determined by jpHMM with HXB2 numbering. The breakpoint locations are generally consistent across the five specimens, indicating that the
same A1/D recombinant structure is shared.
*This corresponds to a region of subtype D uncertainty;
{This corresponds to a region of subtype A uncertainty; refer to Figure 1. PR = Protease.
doi:10.1371/journal.pone.0083337.t001
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the East African sequences in both the subtype A and subtype D
trees (data not shown). No clustering was observed with subtype
A1 or D sequences from the UK. This suggested that CRF0_A1D
probably originated in East Africa and was possibly introduced to
the UK as a recombinant, rather than emerging from subtype A1
and D strains circulating in the UK.
Figure 3. Recombinant map of CRF50_A1D and maximum likelihood phylogenetic trees of non-recombinant fragments. Maximum
likelihood trees of putative non-recombinant fragments from specimens 33365, 8179, 40534 and 34567 drawn using PhyML with PAUP-defined
parameters. HIV-1 subtypes used for analysis were A–D, F, G, H, J, K. Numbers indicate bootstrapping support from 1000 replicates (excepting slice 5;
100 replicates). 70% bootstrap support and monophyletic clustering were the criteria for subtype classification. The recombinant map was drawn
using the RDT program at Los Alamos. Component subtype fragments are labeled 1–9 on the genome map, corresponding with numbered
phylogenetic trees. The genomic regions in which the URF specimen 34567 did not cluster with the CRF50_A1D specimens are indicated in the
appropriate trees.
doi:10.1371/journal.pone.0083337.g003
Figure 4. Confirmed structure of the complex recombinant. The confirmed structure of the complex A1/B/D/U recombinant specimen 34567
following maximum likelihood analysis with the CRF50_A1D specimens. CRF50_A1D regions are shown in green and subtype B regions are shown in
blue.
doi:10.1371/journal.pone.0083337.g004
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Time-scaled analysis dated the emergence of CRF50_A1D in
the UK to 1992 [95% highest posterior density (HPD) 1966–2007;
posterior probability 0.9933] (Figure 5). Phylogeographic analysis
showed probable emergence in northwest England followed by
spread to London and southeast England, with further, limited
transmission events in southwest and northeast England and
Scotland. Demographic information was available for 51/72
patients infected with CRF50_A1D. Of these, 45 (88.2%) were
MSM, 3 (5.9%) were heterosexual males, and 2 (3.9%) were IDUs.
Analysis including the CRF50/B/U unique recombinant form
(URF) sequence showed a median divergence date of 2000,
indicating an onward recombination event between CRF50_A1D
and a subtype B strain. The CRF50_A1D/B/U sequence came
from an MSM.
Discussion
The HIV epidemic in MSM in the UK continues to diversify,
creating opportunities for the emergence of novel recombinant
forms. By scanning a large national sequence repository, we
identified 72 patients who all appeared to be infected with the
same novel A1/D recombinant. Near full-length SGS of plasma
HIV-1 RNA was performed to characterize the structure of the
recombinant. Five patients were found to carry the same A1/D
recombinant, which was classified as CRF50_A1D. Based on the
recombinant profile, we conclude that CRF50_A1D is the subtype
A recombinant that Gifford et al hypothesized was circulating
among MSM in 2007 [6]. It should be noted that some
recombination breakpoints were not identical among the five
CRF50_A1D isolates in the jpHMM plots. However, the
confidence intervals of the identity estimations and the subsequent
analyses indicated that the uncertainties were unlikely to reflect a
true alternative recombinant structure. We also found evidence of
further genetic evolution of CRF50_A1D through recombination
with subtype B, which is the predominant HIV-1 subtype
circulating among MSM in the UK. This complex URF was
classified as CRF50_A1D/B/U. Crucially, the estimated emer-
gence date of 1992 was both prior to the introduction of highly
active antiretroviral therapy and during a period when HIV
infections were spreading exponentially in African countries,
creating ideal conditions for the creation of novel HIV recombi-
nants which could move into the wider epidemic.
We found a relatively low number of patients infected with this
strain within a database that at the time of screening contained
55,556 sequences from 43,002 patients. This relatively modest
spread could reflect fitness properties of the CRF. We detected an
unusual structure of the env gene in this recombinant, in which
three out of the five hypervariable regions belonged to subtype A1,
whereas the remaining two regions belonged to subtype D.
Available data indicate that recombination events in env tend to
include either the entire gene or at least the entirety of gp120, and
this has been related to the functional impact of this protein on
viral fitness [15].
We found that CRF50_A1D was related to A1 and D strains of
East African origin. A1/D recombinants detected in East Africa
have been associated with a fast disease progression, which may
limit the number of infections in the community [16–19]. It should
be noted however that in a sub-analysis, the CD4 cell count slopes
before starting ART were similar in MSM infected with subtype B
or CRF50_A1D (data not shown). These considerations indicate
that CRF50_A1D has potentially interesting phenotypic proper-
ties, which would bear further investigation. Further studies are
required to indicate whether there is an influence on clinical
outcomes or treatment responses.
There are limitations to this study. Our phylogeographic
approach dated the emergence of CRF50_A1D in the UK to
mid-1992. This study had a limited number of sequences with
which to draw this inference. The prevalence of CRF50_A1D was
low in the dataset (72/43,002 or 0.17%) with no evidence for rate
increase over time. While the UK-DRB comprehensively collects
pol gene sequences from patients undergoing drug resistance in
routine care in the UK, not all HIV centers contribute to the
dataset. Furthermore, the database contains only protease and
reverse transcriptase sequences and there are similarity between
subtype B and subtype D in these genetic regions. Thus it may be
proposed that the 72 CRF50_A1D infections identified represent
an underestimate. This in turn may potentially bias the estimated
date of emergence. Evolutionary analysis of the individual gene
using the available full-length sequences and reconstruction of the
ancestral subtype A1 and D strains may yield a more precise
elucidation of the emergence date and help to determine whether
single or multiple introductions occurred in the UK. Furthermore,
given that the majority of 72 individuals infected with
CRF50_A1D had only partial pol sequences available for analysis,
it may be postulated that some of these cases may have shown a
more complex viral genomic structure if full-length genome
analysis had been performed.
The study of novel HIV variants such as CRF50_A1D and the
URF CRF50/B/U provides a tool for studying transmission
networks and interactions between populations and risk groups,
thus producing valuable epidemiological insights [20,21]. Al-
though in the early years of the HIV epidemic in Western Europe
it was rare to find non-B infections in MSM [22], more recent data
indicate that non-B infections are not only increasingly important,
but are being transmitted indigenously among this population
[23]. The use of molecular epidemiological techniques to map
these variants can add to our understanding of data gathered using
traditional epidemiological means and provides valuable insights
into the dynamics of the HIV epidemic that can be used to guide
control strategies.
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